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Abstract
 
 Telomere dysfunction is one mechanism of cellular and tissue ageing. 
Dysfunctional telomeres in fibroblasts are recognised as DNA double-strand 
breaks (DSBs) and trigger the DNA damage pathway of senescence. However, 
telomere uncapping in normal human epidermal keratinocytes, via expression 
of the dominant negative mutant of the telomere repeat-binding factor 2 
(TRF2!B!M), resulted in a senescent-like arrest without a significant DNA damage 
response (DDR). This suggests that either keratinocytes are unusually sensitive to 
telomere uncapping and the low DDR is sufficient to induce senescence or that 
dysfunctional telomeres may also be signalled through an alternative pathway. 
Subsequent analysis revealed genes HIST2H2BE, ICEBERG, S100A7 and HOPX as 
potential markers for telomere dysfunction-induced senescence (TDIS) since 
they were induced by telomere uncapping and seemed to be regulated by 
telomerase. The aim of this project was to assess the specificity of these 
candidate markers for TDIS and to select the most promising for use as a 
biomarker. To this end, keratinocytes were exposed to doses of ionising 
radiation, capable of generating transient or permanent damage to the DNA, 
or transduced with retroviral constructs expressing p14ARF, p16INK4a, p53 or 
TRF2!B!M and the gene expression levels of the candidates assessed after a 
recovery period or at the early stages of senescence. Whilst S100A7, HOPX or 
ICEBERG were not induced by a transient or persistent DDR or by p16INK4a, 
ICEBERG and HOPX were induced by p53 and p14ARF when these were 
ectopically expressed at higher levels. Thus, S100A7 seems to be the most 
specific early marker for telomere dysfunction in keratinocytes since it was 
selectively induced by telomere uncapping via expression of TRF2!B!M and not 
by DSBs or by over expression of p14ARF, p53 or p16INK4a. S100A7 may have the 
potential to identify cells with telomere dysfunction in human epithelia and 
body fluids.
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Chapter 1. General Introduction.
1.1. Introduction to Ageing
Definition of Ageing
 Ageing has been defined as, 
The collection of changes that render human beings progressively more likely to 
die (Medawar, 1952).
A universal, progressive, intrinsic and degenerative process, as it happens in all 
organisms within a species and is characterised by a continuous set of 
changes, which would occur even in a stress-free environment, and ultimately 
results in physiological failure and death (Strehler, 1962; Aspinall, 2003).
The intrinsic, inevitable, and irreversible age-related process of loss of viability 
and increase in vulnerability (Comfort, 1979).
 Although ageing does not occur in all species it is an event shared by 
most, which suggests that the ageing process provides some selective 
evolutionary advantage to those which experience it. Several explanations 
have been proposed for why organismal ageing occurs (Aspinall, 2003).
1
Evolutionary theories of ageing
 Evolutionary theories of ageing arose from the need of a unifying 
explanation for the incredible variation in ageing rates and longevity across 
species. They are all based on the observation that the force of natural 
selection declines with age and, until the first half of the twentieth century, were 
merely conjectured in a theoretical, non-experimental way (reviewed in 
(Gavrilov & Gavrilova, 2002)).
 The first theory of ageing was proposed by August Weismann in 1891 and 
it is known as the ‘theory of programmed death’. Weismann believed cells 
possessed a programmed death mechanism that would operate like a clock to 
count generations from the first stage of embryonic development. This would 
determine the lifespan of each generation of cells and, consequently, of the 
individual. He believed this mechanism was developed by natural selection to 
benefit the young in detriment of the old. His idea that somatic cells possess a 
cell division limit was challenged by the experimental work of Alexis Carrell in 
1912 which wrongly suggested that cells proliferated indefinitely in culture and 
were, therefore, intrinsically ‘immortal’. The concept of a cell division limit, 
known today as the ‘Hayflick Limit’, was experimentally confirmed just 50 years 
later by Hayflick and Moorhead (Hayflick & Moorhead, 1961). Weismann was 
also the author of the ‘germ-plasm theory’ which acknowledged the two main 
types of cells in the body, germ cells and somatic cells, and believed in the 
“perishable and vulnerable nature of the soma” in favour of the germ line. This 
idea relates to one of the modern theories of ageing, ‘the disposable soma 
theory’.
 Modern theories of ageing which are currently accepted were 
developed on the second half of the twentieth century. The ‘mutation 
accumulation theory’ postulated by Peter Medawar in 1952 (Medawar, 1952) 
argues against Weismann’s ‘programmed death theory’ and states that 
detrimental mutations acting in early life will be strongly selected against (not 
passed on to the next generation), whilst mutations deleterious for later life will 
prevail as the individual has already passed them on to the next generation. As 
a consequence, mutations detrimental for later life will passively accumulate 
and generate the panoply of changes characteristic of old age (ageing 
phenotype). 
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 The ‘antagonistic pleiotropy theory’ (Kirkwood & Austad, 2000), 
advanced by George Williams in 1957, proposes that the reason late-acting 
detrimental genes might not be selected against is because they provided a 
selective advantage in early life. Therefore, pleiotropic genes (genes with more 
than one effect) might be actively conserved in the gene pool because of their 
beneficial effect but, as a consequence, the organism would have to endure 
the antagonistic effect; this is also known as the ‘pay later theory’. 
 More recently, Thomas Kirkwood and Robin Holliday proposed an 
update on the antagonistic pleiotropy theory, called the ‘disposable soma 
theory’ (Kirkwood, 1977; Kirkwood & Austad, 2000). The authors refer to a 
special class of gene mutations with the purpose of saving energy for 
reproduction (positive early effect) by partially disabling molecular 
proofreading (repair mechanisms) in somatic cells (negative later effect). The 
idea is that higher organisms adopt an energy saving strategy for the 
maintenance of somatic cells with the purpose of accelerating development 
and reproduction which will, however, result in deterioration and death.
3
The genetic basis of ageing and lifespan 
 Following groundbreaking discoveries in cell biology and molecular 
pathways in the 1990‘s the original concept of ageing might be in need of 
revision. Research shows that ageing, like other biological processes, is 
regulated by classical signalling pathways and transcription factors (reviewed 
in (Kenyon, 2010)). Thus, although the process of ageing is in fact intrinsic, the 
question of whether it is ‘inevitable and irreversible’ (Comfort, 1979) might be 
debatable. 
 The first evidence that organismal lifespan can be manipulated came 
from a seminal study in C. elegans where a mutation (in the daf-2 hormone 
receptor) in the insulin/IGF-1 pathway more than doubled the lifespan of the 
worms (Kenyon et  al, 1993). This was followed by evidence that mutations in 
other metabolic pathways could also affect lifespan, which was interestingly 
accompanied by considerable improvements in healthspan, in various model 
systems. These include pathways signalled by the kinase target of rapamycin 
(TOR), AMP kinase (AMPK), sirtuins (SIRTs) and by insulin/IGF-1 receptors, through 
forkhead box O (FOXO) and other transcription factors. These nutrient and stress 
sensors mediate lifespan extension in response to environmental and 
physiological cues and caloric restriction (Fig. 1.1), for instance, has been 
shown to extend lifespan in species ranging from yeast to primates (Kenyon, 
2010). They do so by regulating processes such as autophagy (Kenyon, 2010), 
mitochondrial function and even the activity of the central tumour suppressor 
p53 (Sahin & DePinho, 2012).  
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Figure 1.1. Pathways that influence lifespan extension in response to caloric 
restriction in worms, flies and mice. Chronic dietary restriction extends lifespan by 
down-regulating TOR activity. In order for caloric restriction to extend lifespan in 
worms and flies via TOR inhibition it requires autophagy. whilst in flies and mice sirtuins 
are required instead. Legend: TOR = target of rapamycin; IIS = insulin/IGF-1 signalling 
(in (Kenyon, 2010)).
 In addition to metabolic pathways, telomere maintenance in particular 
and DNA integrity in general have a crucial role in ageing. Several studies 
underscore the importance of telomere dysfunction and of the main molecular 
effectors of cellular senescence as driving forces of the ageing process at the 
organismal level (Campisi & d'Adda di Fagagna, 2007; Sahin & DePinho, 2010; 
2012).
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1.2. Cellular senescence
Replicative senescence and the end-replication problem
 The concept of replicative senescence emerged in the 1960s from the 
work of Leonard Hayflick and Paul Moorhead (Hayflick & Moorhead, 1961). 
They meticulously documented the development and characterisation of 25 
strains of human fibroblasts, derived from organs such as skin, lung and kidney, 
all of foetal origin. Diploid cell strains shared a similar growth history which could 
be divided into three phases: Phase I, or early growth phase, from when cells 
were obtained from the original tissue until the primary cultures were 
established; Phase II, or rapid growth phase, when cells were serially sub-
cultivated and cultures exhibited high rates of cell division and metabolism; 
and Phase III, or terminal phase, characterised by accumulation of debris, 
altered cellular morphology and cell division arrest. Cells could remain in this 
phase for several months until they eventually died. These findings contradicted 
earlier work (Carrel, 1912), later shown to be experimentally flawed, which 
suggested that diploid cells were able to proliferate indefinitely. Thus, possible 
explanations for the 'Phase III phenomenon', such as the presence of virus, 
composition of the growth medium or metabolite depletion with subculture, 
were tested. However, experimental evidence strongly supported the 
occurrence of senescence at the cellular level (Hayflick & Moorhead, 1961). 
Firstly, the authors showed that the same pool of medium allowed for both 
growth and cellular degeneration; then, unless virus can distinguish between 
female and male cells they were also not a plausible cause for the Phase III 
phenomenon. This is because when two populations of cells with distinct 
doubling potential, an actively dividing female strain and a senescent male 
strain, were mixed and cultured for 17 doublings, the resulting population was 
composed solely of female cells. The results from this experiment and others 
showing that cells retain 'memory' of their passage number when frozen 
suggested that senescence is a process intracellularly determined and that its 
engagement is a function of cumulative cell doublings, not of calendar time 
(Hayflick & Moorhead, 1961; Hayflick, 1965). All cell strains exhibited a consistent 
maximum number of doublings, their 'passage potential'. This cell division limit, 
known as the ‘Hayflick Limit’, is the total number of population doublings (PDs) 
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a normal cell population can undergo in culture before reaching replicative 
exhaustion. Hayflick and Moorhead's work was pioneer in conclusively 
establishing that normal human diploid cells exhibit a finite lifespan in culture 
and challenged the incorrect notion of cellular 'immortality' which had 
prevailed for the previous 50 years. The authors argued that replicative 
senescence was the result of the gradual depletion, over generations in culture, 
of an intrinsic factor to a critical level that when surpassed became inconsistent 
with further cell division.
 The shortening of chromosome ends, or telomeres, consequence of the 
'end-replication problem', was first suggested as the intrinsic factor responsible 
for the limited doubling potential of clones of normal somatic cells by Alexey 
Olovnikov  in 1971 (Olovnikov, 1971). Olovnikov  theoretically predicted that the 
replication of linear genomes (as opposed to circular genomes) came with 
inherent loss of genetic material. James Watson reached a similar conclusion, 
independently, one year later (Watson, 1972) and this phenomenon became 
known as the end-replication problem. Basically, during each cell division, DNA 
replication is incomplete at the 5’ end of the lagging strand, due to the 
directional limitation of the DNA polymerase, resulting in loss of terminal DNA 
after each round. In his 'Theory of Marginotomy' (Olovnikov, 1973) Olovnikov 
suggested that either the existence of a catalytically inactive zone in the DNA-
polymerase or the need for an initiating RNA-primer would result in incomplete 
replication at the DNA ends. Therefore, a mechanism to maintain chromosome 
ends would be required or loss of terminal sequences would ensue. More 
importantly, Olovnikov  predicted the biological significance of this 
phenomenon. Gradual erosion of telomeric DNA could explain how cells were 
able to 'count' doublings. Also, since critical loss of the 'buffer' terminal regions 
would risk permanent loss of adjacent genes this could trigger senescence and, 
thus, explain the 'Hayflick limit'. He also suggested that germ line cells and 
tumour cells were able to avert telomere erosion by expression of a special 
form of polymerase, non-existent in normal somatic cells. This would ensure 
protection of important genetic information in germ cells and confer 
immortality to tumour cells. Olovnikov's theory was not adopted as an 
explanation for the 'Hayflick limit' due to lack of experimental validation. This 
became possible over the following decade with the discovery of both the 
telomeric DNA sequence and the enzyme telomerase, as well as the 
development of experimental methods to measure telomere length such as 
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telomere restriction fragment (TRF) analysis (Allshire et  al, 1988) and single 
telomere length analysis, or STELA (Baird et al, 2003).
 The structure of telomeric DNA was first characterised in the ciliated 
protozoan Tetrahymena thermophila (Blackburn & Gall, 1978). Restriction 
endonuclease digestion of Tetrahymena's extrachromosomal DNA revealed a 
terminal rDNA linear fragment composed of characteristic hexa-nucleotide 
TTGGGG repeats organised in tandem. A few years later Allshire et  al made the 
surprising discovery that the telomeric repeats of Tetrahymena cross hybridised 
with human telomeres, as well as with telomeres of several other eukaryotes 
including the mouse (Allshire et al, 1988). The authors used restriction 
endonucleases which can digest total genomic DNA, with the exception of the 
telomeric repeat tracts whose distinctive feature is their lack of restriction sites, 
fragments were separated by gel electrophoresis, blotted into a nylon 
membrane and finally incubated with a radio-labelled telomeric probe 
(containing Tetrahymena's TTGGGG repeats). Following exposure to 
autoradiographic film the long undigested telomeric fragments appeared as a 
DNA smear. This seem to be variable in size which was very interesting since it 
could be indicative of the heterogeneity in telomere length observed in 
different organisms. The ultimate confirmation that hybridisation was occurring 
at the telomeres was demonstrated by using a restriction enzyme, in addition to 
the other endonucleases, which can digest telomeric DNA. The smear 
completely disappeared after this treatment conclusively showing that it 
consisted of telomeric DNA. This was also supported by the observation that the 
smear was more homogeneous and of higher molecular weight in germline 
DNA than in somatic DNA (Allshire et al, 1988). Later it was shown to directly 
reflect the amount of TTAGGG repeats, and not other repeat types present in 
sub-telomeric regions, suggesting that TTAGGG was the telomeric DNA 
sequence in humans (Allshire et al, 1989). In addition, since TTAGGG probes 
were found to hybridise very strongly with telomeric smear in human and mouse 
DNA the two species apparently share the same telomeric sequence. These 
findings were very important as this technique could be used to assess telomere 
length and total amount of telomeric DNA by assessing the amount of probe 
that hybridises with the fragments and the size of the smear itself. Southern blot 
analysis using telomeric probes was the first technique used to measure 
average telomere length and became known as Telomere Restriction 
Fragment analysis.
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 Using TRF analysis Harley & Greider (Harley et al, 1990) were able to show 
for the first time that loss of telomeric DNA did in fact occur with serial passage 
in culture. They cultured human fibroblasts strains until terminal passage, an 
established method to assess in vitro ageing, and analysed both the size 
distribution and total amount of terminal restriction fragments (telomeres) by 
Southern blot analysis (TRF analysis). They observed a consistent 2Kb decrease 
in average telomere length with cumulative population doublings (PDs). This 
was accompanied by a decrease in the total amount of telomeric DNA as 
observed by the reduced intensity of the smear measured by densitometry and 
which is direct function of the amount of TTAGGG probe hybridising with 
telomeric DNA. This indicates true loss of DNA and not just rearrangement of 
telomeres in relation to restriction sites. Telomeric loss was also not a result of 
general DNA degradation or loss during preparation since other internal 
repetitive sequences remained unaltered in size and quantity. Authors also 
discarded loss as a function of growth stage. Making use of TRF analysis, Harley 
and Greider were able to establish that telomere loss was in fact a function of 
doublings in vitro whose rate was more consistent with incomplete copying of 
the template at the DNA ends rather than due to degradation of terminal 
regions, for example. These findings support Olovnikov's theory (Olovnikov, 1971; 
1973) that incomplete end replication and consequent telomere loss with each 
doubling is responsible for the Hayflick Limit. Similar findings were obtained in 
human skin, regarding decrease in mean telomere length as well as total 
telomeric DNA with donor age, and also based on TRF analysis, demonstrating 
that loss of telomeric repeats not only occurs with ageing in vitro but also in vivo 
(Lindsey et al, 1991).
 During the 1980s, the DNA polymerase capable of specifically 
elongating terminal DNA (telomerase) was finally discovered based on the 
ongoing work of Carol Greider and Elizabeth Blackburn in Tetrahymena. This 
was based on observations that telomeres in this model organism were 
dynamic structures which could actually increase in length. Given the known 
limitation of conventional DNA polymerases to fully replicate the ends of 
chromosomal DNA it was unlikely that these enzymes were responsible for 
telomere elongation in Tetrahymena. Greider and Blackburn (Greider & 
Blackburn, 1985) observed that Tetrahymena extracts contained telomere 
elongation activity with specific incorporation of dGTP and dTTP in a 
characteristic 6-base pattern, TTGGGG. They determined this by sequentially 
adding different combinations of radio-labelled and unlabelled nucleotides to 
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the extracts in presence of a synthetic single stranded DNA template 
composed of Tetrahymena's TTGGGG repeats. The DNA products obtained 
from each reaction were resolved in a sequencing gel and detected by 
autoradiography. A repeating pattern of two labelled dGTPs and four 
unlabelled dTTPs bands was obtained only for combinations of these two 
nucleotides and absent for all other combinations as well as in conditions 
where the telomeric template was absent or when DNA polymerase I was used 
instead of Tetrahymena extract. In all, this suggested that tandemly repeated 
TTGGGG sequences were being synthesised. This work presented the first 
evidence of a terminal transferase-like activity that specifically adds telomeric 
repeats onto a synthetic telomere template. This synthesis demonstrated 
characteristics of an enzyme-catalysed reaction such as high reaction 
efficiency and substrate affinity as well as susceptibility to heat and proteinase 
K treatment. Greider and Blackburn went on to show that telomerase from 
Tetrahymena can correctly add Tetrahymena telomeric repeats (TTGGGG) to 
template oligomers from yeast and other organisms so long as they contained 
G-rich telomeric sequences (Greider & Blackburn, 1985; 1987). Telomerase 
turned out to be a ribonucleoprotein enzyme whose protein component 
seemed necessary for template recognition whilst the RNA component seemed 
responsible for its specificity (Greider & Blackburn, 1987; 1989).
 Following the cloning of the human reverse transcriptase subunit of 
telomerase, hTERT (Nakamura et al, 1997), the opportunity to manipulate 
telomere length became available and finally allowed for the hypothesis that 
telomere shortening triggers senescence to be tested. Bodnar et al (Bodnar et 
al, 1998) found that expression of telomerase in normal cells corrected telomere 
length and, as a consequence, allowed cells to evade senescence and to 
acquire an extended replicative potential. This was demonstrated by 
ectopically expressing the catalytic component of telomerase, hTERT in two 
human strains, of foreskin fibroblasts and retinal pigment epithelial cells, using 
plasmid vectors. As expected, transfected clones showed telomerase activity, 
as assessed by the TRAP assay, in opposition to non-transfected controls. This 
was accompanied by an increase in mean telomere length, as measured by 
TRF analysis, and lifespan extension in the cells expressing telomerase. In 
contrast, controls arrested proliferation and engaged senescence as 
demonstrated by selective staining for the senescence associated "-
galactosidase marker to levels consistent with senescence. Therefore, 
correction of telomere loss by expression of the enzyme capable of elongating 
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telomeres seemed to allow these cells to evade or, at least, delay senescence. 
These findings strongly suggest that telomere loss, in the absence of telomerase, 
is the intrinsic property that controls the replicative potential of normal diploid 
cells and, thus, the number of cell divisions they can undergo until the onset of 
senescence. This work finally established a relationship of causality between 
telomere shortening and replicative senescence.
 Further investigation using mouse models revealed that the shortest 
telomere, and not average telomere length, was the determining factor in the 
engagement of senescence (Hemann et al, 2001). Hemann et al made use of 
the recently engineered late generation telomerase-null mice (Blasco et  al, 
1997) possessing a phenotype indicative of telomere dysfunction which is 
characterised by infertility accompanied by germ cell apoptosis and a high 
incidence of chromosome end-to-end fusions. When these animals, 
telomerase-deficient with short telomeres (mTR-/- G6) were crossed with 
animals heterozygous for telomerase activity and thus with long telomeres (mTR
+/-) they produced offspring with an equal amount of short and long telomeres 
and differing only in telomerase activity. This made it possible to distinguish 
between the cellular response elicited by the shortest telomere and the one 
triggered by decreased mean telomere length. The telomerase positive 
offspring (mTR+/- F1) displayed a wild-type phenotype, similar to the 
heterozygous parental mice. In contrast, the telomerase-null offspring (mTR-/- 
F1) showed increased germ cells apoptosis accompanied by a corresponding 
decrease in testis weight and a number of chromosome fusions similar to that 
found in the telomerase-null parental mice (mTR-/- G6). Since both offsprings 
have a similar number of short telomeres, the results indicate that the presence 
of telomerase (in mTR+/- F1) rescues the telomere dysfunction phenotype. The 
strong phenotype exhibited by telomerase-deficient mTR-/- F1 animals also 
suggests that the presence of critically short telomeres is sufficient to elicit a 
cellular response. To confirm this finding, the authors performed telomere length 
analysis in splenocytes of these animals using quantitative fluorescent in situ 
hybridisation (Q-FISH). They found that although average telomere length was 
very similar between the telomerase-proficient and telomerase-deficient 
offspring, the latter contained a significantly high number of telomeres 
completely lacking detectable telomeric repeats, which were specifically 
absent in the telomere length distribution of the heterozygous offspring. This 
suggested that in these animals telomerase was restoring telomere length by 
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adding repeats to the shortest telomeres, therefore preferentially rescuing 
them, rather than by increasing the mean telomere length of all telomeres.
 A couple of years later, with the development of STELA, an innovative 
molecular technique for analysis of individual telomere length, it was confirmed 
that at senescence there is almost complete loss of telomeric repeats (Baird et 
al, 2003). Single Telomere Length Analysis, or STELA, consists in applying single 
molecule PCR to accurately measure telomere length of the same 
chromosome end (XpYp, for example) in all cells (both dividing and non-
dividing) of a sample population. It exploits the fact that all telomeres end in a 
single stranded 3' G-rich overhang and makes use of an oligonucleotide linker 
which anneals and is ligated to the 5' end of the telomere using the overhang 
as a specific template. A linker-specific primer is then used in conjunction with a 
primer specific for a sub-telomeric region of a particular chromosome. This 
allows for amplification of an individual amplicon for each specific telomere 
which offers the distinct advantage of detecting subtle changes in telomere 
length and abruptly shortened telomeres. STELA analysis of XpYp telomeres in 
normal human diploid fibroblast strains (Baird et al, 2003) revealed that at 
senescence some telomeres showed almost no TTAGGG repeats (roughly 
45bp) indicating that telomere loss occurs from a subset of chromosomes. It 
also showed that the distribution of telomere lengths was bimodal, resulting 
from inter-allelic differences of up to 6.5Kb which shows large heterogeneity in 
telomere length between alleles. Further analysis of individual alleles during 
clonal expansion from a single cell of a particular strain revealed that, as for 
different strains, all subclones entered replicative senescence at different XpYp 
lengths, again with some showing almost complete loss of telomeric repeats. 
Since starting telomere length is the same, the unexpected heterogeneity 
observed between alleles suggests these differences are inherited. Also, as 
telomeres shorten gradually with each doubling independently of initial allele 
size and since rate of erosion seems consistent with loss due to incomplete end-
replication, other mechanisms possibly contribute to more substantial changes 
in telomere length. These data also point to a highly stochastic process rather 
than to a synchronised 'clock'-like event determining the engagement of 
senescence.
 This is consistent with classical studies which showed that the replicative 
potential of individual clones within a population of normal cells is highly 
variable (Smith & Hayflick, 1974) and that it is even distinct between daughter 
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cells in mitotic pairs (Smith & Whitney, 1980). The doubling potential of human 
foetal diploid fibroblasts was assessed after isolation from mass culture at 
different stages of its lifespan (Smith & Hayflick, 1974). Contrarily to earlier 
findings, where the limited number of clones selected happened to reflect the 
replicative potential of the culture (Hayflick, 1965), the wide range of individual 
cells tested showed a high extent of heterogeneity in their doubling potential 
when compared to the mass culture they derived from (Smith & Hayflick, 1974). 
More detailed and meticulous analysis (Smith & Whitney, 1980) revealed that 
this variation was intrinsic to each clone, since recloning of a clone with a high 
doubling potential originated subclones exhibiting varied division potential. 
Moreover, Smith and Whitney analysed the behaviour of two cells originating 
from the same mitosis and observed that their maximum replicative capability 
can differ by as many as 8PDs. Both the rapid occurrence of intraclonal 
variation and the large heterogeneity in daughter cells arising from the same 
mitotic event suggest that the doubling potential of human diploid cells is 
determined stochastically.
 These studies also pointed to a bimodal distribution of clones in a cell 
population which was consistent with findings obtained on bulk cultures. Clones 
obtained from human diploid fibroblast cultures seemed to originate from two 
distinct subpopulations, one capable of a maximum of 8 doublings and 
another with a much higher doubling potential. The group with limited doubling 
potential appeared to increase with incremental doublings of the mass culture 
at the time of cloning (Smith & Hayflick, 1974). The ability of cells to incorporate 
nucleotides or their analogues, such as 3H-thymidine or 5-bromodeoxyuridine 
(BrdU), into their DNA indicates that they are undergoing active DNA 
replication and are, therefore, in cycle. Thymidine incorporation was used to 
determine the fraction of cells entering S phase at each passage of the lifespan 
of cultures of human diploid fibroblasts (Cristofalo & Sharf, 1973). This analysis 
revealed that the fraction of unlabelled cells (non-dividing) increased with serial 
passage. This gradual reduction in the thymidine labelling index was shown not 
to be due to an increase in length of the cell cycle towards the culture's 
maximum lifespan. In addition, it was found that non-dividing cells were present 
in the culture at early passages and some actively dividing cells could also still 
be found at late passages (Cristofalo & Sharf, 1973; Grove & Cristofalo, 1977). 
This suggests that cells in a population do not divide synchronously, that there is 
a stochastic factor determining their exit decision from the cell cycle and finally 
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that cultures are bimodal mixtures of dividing and senescent cells the 
proportion of which changes with time in culture.
 Although telomere shortening provided the first molecular explanation 
for the replicative exhaustion of cells in culture or replicative senescence, other 
telomere-independent factors can also trigger senescence. Thus the general 
term cellular senescence being adopted instead.
Cellular senescence
 Whilst the term replicative senescence is applied to cells that cease to 
divide as a consequence of replicative exhaustion through telomere 
shortening, the term cellular senescence is more general and applies to all the 
situations where the senescent program can be activated. Several stimuli can 
induce senescence; these can be generally divided into factors that generate 
a DNA damage response (DDR) and factors that do not. Eroded or 
dysfunctional telomeres, non-telomeric DNA damage in the form of DSBs, 
chemicals that interfere with chromatin structure (histone deacetylase inhibitors 
(HDACIs), for example) and strong mitogenic signals (from oncogenes or 
proliferation genes) which cause DNA damage, are signalled through ATM or 
ATR and activate the tumour suppressor p53 with a sustained DDR. Additionally, 
physiological stress arising from inappropriate support layer in culture, lack of 
nutrients or growth factors, oxidative stress and mitogenic signals are signalled 
through the tumour suppressor p16INK4a and activate the retinoblastoma protein 
(pRb) or, alternatively, through ARF activating p53, without a DDR (reviewed in 
(Rodier & Campisi, 2011)). The senescence program is thus controlled by the 
p53 and p16INK4a-pRb pathways (Fig. 1.2).
 Senescence can be defined as a permanent block to further replication, 
however, cells that do not divide can also be quiescent, apoptotic or terminally 
differentiated. The distinction between senescence and quiescence, apoptosis 
or terminal differentiation has been demonstrated experimentally. For instance, 
keratinocytes prevented from terminally differentiating by being cultured in low 
levels of calcium engage senescence and are subsequently able enter the 
differentiation program once the calcium concentration is increased 
(Norsgaard et  al, 1996). In addition, whilst the proliferative capacity of human 
keratinocyte cultures decreases over time (Rheinwald & Green, 1975a), the 
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apoptotic rate remains constant throughout their lifespan (Norsgaard et  al, 
1996). Finally, quiescence in culture can be induced by serum starvation or by 
cell confluence but, as opposed to senescence, it is a transient growth arrest 
reversible by re-addition of serum to the growth medium or by sub-cultivation. 
Although longer periods of confluence do lead to the accumulation of p16INK4a 
and result in senescence (Munro et al, 2001).
Figure 1.2. Molecular pathways of senescence. p53 and pRb are the central 
effectors of senescence and control the p53 and p16INK4a/pRb pathways (in 
(Campisi & d'Adda di Fagagna, 2007)).
 Only mitotic cells are able to undergo senescence since post-mitotic 
cells have already lost their ability to divide due to terminal differentiation. 
Nevertheless, although most terminally differentiated cells are post-mitotic 
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some characteristically retain mitotic potential, as is the case of lymphocytes 
whose function is to undergo clonal expansion upon stimulation by the 
appropriate antigen. Mitotic cells can, therefore, remain quiescent in 
proliferative tissues and be promptly induced to divide in the presence of the 
appropriate stimuli, including oncogenic or mitogenic signals leading to 
cancer. One of the first features senescent cells acquire is resistance to 
mitogenic and apoptotic signals. This is accompanied by morphological and 
biochemical changes in addition to a distinct gene expression profile. These 
features, which characterise senescence, are generally known as the 
senescent phenotype (reviewed in (Campisi & d'Adda di Fagagna, 2007)).
The senescent phenotype
 Senescent cells are thought to arrest growth in phase G1 of the cell 
cycle (Grove & Cristofalo, 1977; Di Leonardo et  al, 1994; Serrano et al, 1997; 
Herbig et al, 2004), and are henceforth unable to resume DNA replication. The 
senescence growth arrest is permanent and irreversible under normal culture 
conditions (Fig. 1.3). Cells increase greatly in size (Hayflick, 1965) with a 
characteristic morphology and remain metabolically active despite being 
reproductively sterile. Senescent cells express a senescence-associated beta 
galactosidase (SA-"gal) which indicates "-galactosidase activity detectable at 
pH 6.0 (Dimri et  al, 1995) and is thought to reflect an increase in lysosomal mass 
(Lee et al, 2006). Increase in mitochondrial mass has also been reported in 
senescent cells (Passos et al, 2007b). Senescence is also accompanied by a 
series of drastic general changes in gene expression whose patterns tend to be 
cell-type specific (Shelton et al, 1999). 
 Most senescent cells express the two main cyclin-dependent kinase 
inhibitors (CDKIs) p21WAF1 (or CDKN1a) and p16INK4a (or CDKN2a) (Fig. 1.3), which 
are components of tumour-suppressor pathways governed by the 
transcriptional regulators p53 and pRb which activate senescence (Campisi, 
2001a). Expression of these cell cycle inhibitors results in pRb-directed 
inactivation of the transcription factor E2F and its target genes (cyclin A, PCNA, 
c-FOS, for example) involved in cell-cycle progression. These genes can also be 
silenced by pRb-mediated reorganisation of chromatin into senescence-
associated heterochromatic foci or SAHFs (Narita et al, 2003).
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 Many senescent cells also over-express genes that encode for secreted 
proteins which have the potential of altering the tissue microenvironment 
(Campisi & d'Adda di Fagagna, 2007; Rodier & Campisi, 2011). The senescence 
secretome includes, amongst others, matrix metalloproteinases (MMPs) and 
inflammatory cytokines, such as interleukines 6 and 8 (IL-6 and IL-8), secreted by 
dermal fibroblasts and keratinocytes (Shelton et  al, 1999; Kang et al, 2003; 
Coppé et  al, 2008) and growth factors, such as vascular endothelial growth 
factor (VEGF), secreted by fibroblasts (Coppé et al, 2006). These factors which 
have been defined as the senescence-associated secretory phenotype or 
SASP (Coppé et  al, 2008), are secreted as a consequence of persistent DDR 
signalling, possibly in an attempt from senescent cells to communicate their 
compromised state and request clearance by the immune system (Rodier et al, 
2009). However, they have also been associated with cell migration and 
invasiveness, characteristics which define tumour progression (Coppé et al, 
2010). 
 Finally, senescent cells harbour two main types of persistent nuclear foci, 
SAHFs and DNA-SCARS, which account for the irreversibility of the senescent 
state (Fig. 1.3). Senescence-associated heterochromatic foci, or SAHFs, are 
nuclear structures containing heterochromatin which have been associated 
with stable repression of E2F target genes through accumulation of pRb in their 
promoters. Activation of pRb is a requirement for SAHF formation and E2F target 
gene silencing and is thought to contribute to changes in gene expression 
associated with senescence (Narita et al, 2003). DNA segments with chromatin 
alterations reinforcing senescence, or DNA-SCARS, are persistent DNA foci, 
present in senescent cells with sustained DDR signalling, that associate with PML 
nuclear bodies and contain activated forms of DDR proteins such as p53 and 
CHK2. However, as opposed to transient foci, these lack the DNA repair proteins 
RPA and RAD51, single-stranded DNA and DNA synthesis. DNA-SCARS also 
associate with histone H2AX, which is responsible for their stabilisation and 
modulation of growth arrest and cytokine secretion associated with 
senescence. Although these dynamic structures require p53 and pRb to trigger 
the growth arrest, they can be formed independently of these cell cycle 
regulators (Rodier et al, 2011). A specialised type of DNA-SCARS are the 
persistent DNA damage foci that colocalise with telomeres, also known as 
telomere dysfunction–induced foci, or TIFs (d'Adda di Fagagna et al, 2003; 
Takai et al, 2003; Herbig et al, 2004).
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Figure 1.3. The senescent phenotype. Hallmarks of senescent cells include irreversible 
growth arrest, expression of SA-"gal and p16INK4a, secretion of growth factors, 
cytokines, proteases, and other proteins (SASP), and nuclear foci containing DDR 
proteins (DNA-SCARS/TIF) or heterochromatin (SAHF) (in (Rodier & Campisi, 2011)).
 
 None of the above features can be used in isolation as a specific 
indicator of cellular senescence. However, the combination of various of these 
features can be used to accurately identify senescent cells and distinguish 
them from their quiescent or terminally differentiated counterparts. Expression 
of p16INK4a is an important hallmark of senescence since it is not associated with 
quiescence or terminal differentiation (Hara et al, 1996; Serrano et  al, 1997). 
Also, p16INK4a-related organisation of heterochromatin into SAHFs, also does not 
occur in quiescent cells (Narita et  al, 2003). Finally, p16INK4a expression has been 
shown to increase in mouse and human tissues with age (Krishnamurthy et al, 
2004; Ressler et al, 2006) and to be an accurate indicator of physiological age 
(Waaijer et al, 2012).
 Hayflick’s early observations regarding senescence in culture (Hayflick & 
Moorhead, 1961) lead him to establish two important connections for which 
there is strong evidence today. First, the fact that tumour cells appear to 
undergo unlimited proliferation in culture might indicate that senescence, by 
permanently preventing it, evolved as a tumour-suppression mechanism. 
Second, the aged-like phenotype senescent cells presented in culture 
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prompted Hayflick to establish a connection between replicative senescence 
and organismal ageing. Senescence can contribute to ageing in vivo either by 
causing a decline in the regenerative capacity of the tissue by targeting the 
stem cell compartment (intrinsic ageing of stem cells) or by affecting the tissue 
microenvironment indirectly via the senescent secretome. Consequently, 
senescence is regarded as an example of antagonistic pleiotropy because it 
prevents tumourigenesis early in life but, due to accumulation of senescent cells 
in mitotic tissues, may promote cancer and ageing later in life (Campisi, 2005; 
Campisi & d'Adda di Fagagna, 2007).
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1.3. Senescence, tumour suppression and ageing.
Senescence as a tumour suppressor mechanism
 Several lines of evidence support the idea that senescence acts as a 
tumour-suppressor mechanism. The concept was first proposed by L. Hayflick in 
the 1960s (Hayflick, 1965) when he observed that normal diploid cells could only 
escape senescence by acquiring cancer-like properties. Thus, whilst one of the 
hallmarks of senescence is the establishment of permanent cell cycle arrest, the 
ability to divide indefinitely is characteristic of cancer (Hanahan & Weinberg, 
2000). In addition, most cancer cells harbour mutations in the p53 or the 
p16INK4a/pRb tumour suppressor pathways. This renders the main cell cycle 
regulators and effectors of senescence p53 and/or pRb dysfunctional, thus 
allowing cells to overcome the two main cell cycle checkpoints imposed by 
senescence (Campisi, 2001a; Finkel et al, 2007). Furthermore, neoplastic 
transformation by viral or cellular oncogenes requires the disruption of 
senescence checkpoints such as ATM and CHK2 (Gorgoulis et al, 2005; 
Bartkova et al, 2006).
 Expression of oncogenic Ras in human or murine cells results in 
oncogenic-induced senescence (OIS) via accumulation of p53 and p16INK4a 
(Serrano et al, 1997). It has been shown to promote DNA replication stress which 
contributes to stochastic telomere attrition and dysfunction (Suram et  al, 2012). 
It also results in mitochondrial dysfunction, characterised by increased 
mitochondrial mass and production of ROS, which leads to oxidative stress. This 
contributes to OIS and depends on functional p53 and pRb (Lee et  al, 1999; 
Moiseeva et  al, 2009). The use of inhibitors of mitochondrial function in human 
cells expressing activated Ras induces senescent arrest (Moiseeva et  al, 2009) 
which can be reversed by antioxidants (ROS scavengers) or by low oxygen 
treatment (Lee et  al, 1999). Also, inactivation of p53 or p16INK4a in mouse cells 
prevents Ras-induced G1 arrest allowing for transformation to occur (Serrano et 
al, 1997). Over-expression of other oncogenes (Mos and Cdc6) also results in 
induction of p16INK4a and increased replicative stress consequently activating a 
DNA damage checkpoint. However, whilst inactivation of ATM suppressed 
senescence p16INK4a depletion did not, suggesting variability in the response to 
different oncogenes (Bartkova et al, 2006).
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 Several in vivo studies corroborate these findings. Combined inactivation 
of tumour suppressors PTEN and p53 in mouse prostate results in invasive cancer 
and early death (Chen et  al, 2005), whilst inactivation of ATM in a mouse 
tumour model also led to increased tumour size and invasiveness (Bartkova et 
al, 2006). Additionally, in a mouse model of Burkitt’s lymphoma through Myc 
expression (Feldser & Greider, 2007) where animals were made Terc-deficient 
(mTR-/-) the formation of tumours is suppressed by telomere dysfunction-
induced senescence (TDIS). This response in animals with short telomeres was 
shown to be mediated by p53 since its deletion reversed the phenotype. 
Conversely, mouse models of p53 over-expression, either through a mutation 
that results in p53 activation (Tyner et  al, 2002) or through introduction of extra 
transgenic copies of the p53 gene (‘Super p53’ mice) (García-Cao et al, 2002), 
exhibit significant cancer-resistance however accompanied by an onset of 
ageing phenotypes. 
 Additionally, the fact that senescence is more common in pre-
malignancy than in malignancy also indicates that it may be a barrier to 
tumourigenesis. Senescent cells are abundant in pre-malignant lesions in mouse 
models of Pten deletion (Chen et al, 2005) and Myc expression (Feldser & 
Greider, 2007) but not in the cancers that arise from them. Evidence of 
senescence markers was also found in the early stages of human prostate 
(Chen et al, 2005), urinary bladder and breast (Bartkova et al, 2005), as well as 
in colon adenomas (Bartkova et  al, 2006), lung hyperplasias (Bartkova et  al, 
2005; Gorgoulis et  al, 2005) and dysplastic nevi (Michaloglou et al, 2005; 
Gorgoulis et  al, 2005; Suram et al, 2012). In colon adenomas and lung 
hyperplasias, for instance, there was strong evidence of DNA damage-induced 
senescence, such as activated histone H2AX and CHK2, p53 accumulation, 
and apoptosis (Bartkova et al, 2005; Gorgoulis et  al, 2005; Bartkova et al, 2006). 
In human nevi, colon and breast cancer precursor lesions, the majority of the 
DDR factors were found to associate with telomeres, indicating engagement of 
telomere dysfunction-induced senescence (Suram et al, 2012). Progression to 
cancer was associated with inactivation of p53 and 53BP1, and decreased 
apoptosis (Gorgoulis et al, 2005), whilst chemotherapy or reactivation of p53 in 
certain tumours caused tumour regression which was associated with 
senescence (Ventura et  al, 2007; Xue et  al, 2007; Coppé et al, 2008). All this 
body of work shows that oncogenic signalling contributes to replication stress 
and oxidative stress which leads to DNA DSBs, telomere dysfunction, genomic 
instability and selective pressure for p53 mutations, all factors that are 
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associated with the development of malignancy. Senescence (OIS, TDIS and 
DDR-induced) is activated at the early stages of transformation in an attempt 
to delay or prevent tumourigenesis and is, undoubtedly, a critical tumour 
suppressive response in vivo. This is underlined by the fact that several of the key 
molecules involved in senescence such as ATM  (Savitsky et  al, 1995), p53, CHK1 
and CHK2 (Malkin et al, 1990) and p16INK4a (Kamb et al, 1994) are all bone fide 
tumour suppressors.  
 Senescence, as it primarily entails permanent growth arrest, is thought to 
suppress tumourigenesis because cancer development requires cell 
proliferation (Hanahan & Weinberg, 2000). Surprisingly, senescence can also 
promote cancer (Rodier & Campisi, 2011). Senescent cells secrete various 
proteins, such growth factors, proteases, cytokines and other inflammatory 
factors, generally referred to as the SASP, which can contribute to development 
of malignancy (Coppé et al, 2008; 2010). Interleukines 6 and 8 (IL-6 and IL-8) 
induced pre-malignant epithelial cells to invade a basement membrane 
(Coppé et al, 2008) and VEGF, secreted by senescent fibroblasts, also 
stimulated endothelial cell migration and invasion which are changes 
associated with angiogenesis (Coppé et  al , 2006). Also, matr ix 
metaloproteinases which get secreted by senescent fibroblasts and 
keratinocytes were also associated with invasiveness (Kang et al, 2003; Coppé 
et al, 2010). Finally, this has also been observed in vivo, as senescent fibroblasts 
co-injected with pre-malignant or malignant epithelial cells induced tumours or 
accelerated tumour formation in mice (Krtolica et  al, 2001). Another example 
comes from areas of micro-invasion in advanced SCCs where p16INK4a-positive 
keratinocytes co-express the ɣ2 subunit of laminin 5, a basement membrane 
protein associated with increased directional mobility (Natarajan et  al, 2003). 
The same phenotype is observed in senescent keratinocytes and in 
keratinocyte migration during wound healing (Natarajan et  al, 2003; 2006). This 
suggests that although senescence prevents tumourigenesis it can also 
contribute to cancer later on, through changes it causes in the cellular 
microenvironment (Fig. 1.4). The paradoxical effect of senescence in cancer is 
one of the contexts in which it is an example of antagonistic pleiotropy; another 
is how senescence also contributes to ageing.  
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Figure 1.4. The paradoxical effects of senescence. Growth arrest is imposed by cell 
autonomous or intrinsic mechanisms (via p53 and p16INK4a/ pRb tumour suppressor 
pathways) and cell non-autonomous or extrinsic mechanisms (via the SASP). The 
growth arrest suppresses malignant transformation but can also contribute to the 
depletion of proliferative (stem/progenitor) cell pools. Additionally, components of 
the SASP can also promote tumour progression, wound healing, and, possibly, 
contribute to ageing (in (Rodier & Campisi, 2011)).
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The causal role of senescence in organismal ageing
 Several observations from early studies suggested that senescence in 
culture might be implicated in ageing in vivo. Interestingly, species lifespan 
seemed to directly correlate with replicative lifespan in culture (reviewed in 
(Campisi, 2001b; Aspinall, 2003)). More importantly, an inverse correlation was 
found between donor age and the maximum number of population doublings 
cells undergo in culture before entering senescence, which suggested that 
replicative potential decreases continually with organismal ageing. In human 
fibroblasts (Hayflick & Moorhead, 1961) and keratinocytes (Rheinwald & Green, 
1975a) the plating efficiency and lifetime in culture was found to be higher for 
cells obtained from young (fetal/newborn) donors than from older donors. In 
fact, cells originating from older donors give rise to a lower proportion of clones 
with high replicative potential (holoclones), which originate bigger colonies in 
culture. Conversely, clones displaying the lowest replicative potential 
(paraclones) and originating small colonies in culture are more abundant the 
older the donor (Barrandon & Green, 1987). However, this correlation has been 
questioned as it is not always observed and is also accompanied by some 
degree of variation (Cristofalo et al, 1998). Nevertheless, studies using cells 
derived from human with premature ageing conditions also support the idea 
that replicative potential in culture reflects ageing of the individual (Martin et  al, 
1970). Fibroblasts obtained from patients with Werner’s syndrome, for instance, 
exhibit a reduced lifespan in culture when compared to age-matched controls 
(Kill et al, 1994). Despite these indications, the matter remained controversial 
because evidence for the presence of senescent cells in vivo and their 
accumulation with age was still lacking.
 Until the 1990s, senescence in culture was identified on the basis of 
absence of DNA replication assessed through incorporation of synthetic 
nucleosides analogs of thymidine such as bromodeoxyuridine (5-BrdU) or 
tritiated thymidine (3H-thymidine) (Cristofalo & Sharf, 1973) into newly 
synthesised DNA, or later by immunostaining for PCNA or proliferation marker 
Ki67. Ki67 is a general marker for proliferation as it is associated not only with the 
S phase of the cell cycle but also with G1, G2 and M, whilst it is absent in G0 
when cells are not cycling (Brown & Gatter, 2002). However, this characteristic is 
not exclusive to senescent cells as their quiescent or terminally differentiated 
counterparts are also arrested in the cell-cycle. In 1995, Dimri and colleagues 
(Dimri et al, 1995) found that senescent cells, identified based on their inability 
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to incorporate 3H-thymidine, selectively exhibited "-galactosidase activity at 
pH6. This feature, designated senescence-associated "-galactosidase (SA-
"gal), correlated with replicative age in fibroblasts, keratinocytes and other cell 
types in culture, and was absent in immortal cells. More importantly, SA-"gal 
positive cells were present in human skin samples (in both dermal fibroblasts 
and epidermal keratinocytes) and showed an increase in frequency and 
intensity with donor age. SA-"gal staining was the first senescence biomarker to 
be established as it provided groundbreaking evidence for the existence of 
senescent cells in situ and their accumulation with age in vivo. Despite being a 
distinctive and more specific feature of senescent cells, SA-"gal presented a 
few limitations regarding its use and specificity (Severino et al, 2000; Cristofalo, 
2005). SA-"gal staining was found to increase not only as a function of 
replicative age in culture but also in response to environmental stressors such as 
exposure to H2O2 or cell density. Confluent cultures of immortal cells, for 
instance, showed increased frequency of SA-"gal staining as did confluent 
cultures of early passage diploid fibroblasts. Additionally, the utility of this marker 
in detecting senescent cells in vivo was also challenged as SA-"gal staining was 
reported in the lumen of hair follicles and glandular ducts regardless the age of 
the tissue donor (Severino et al, 2000). These limitations prompted the search for 
novel biomarkers of senescence.
 The major cell cycle regulator and effector of the pRb pathway of 
senescence, p16INK4a accumulates with senescence in various human cell types 
such as fibroblasts (Hara et  al, 1996) and keratinocytes (Loughran et al, 1996; 
Munro et  al, 1999), and in HSCs of old mice (Janzen et al, 2006). However, 
although most senescent cells express p16INK4a not all do, as for the case of BJ 
foreskin fibroblasts which consistently express very low levels of p16INK4a 
throughout their lifespan in culture (Beauséjour et al, 2003; Itahana et  al, 2003). 
In keratinocytes p16INK4a expression is exclusive to senescence and is not 
observed with terminal differentiation (Loughran et  al, 1996). Several in vivo 
studies have established p16INK4a as a robust senescence biomarker. p16INK4a 
expression was found to directly correlate with chronological age in almost all 
tissues in the mouse (Krishnamurthy et al, 2004), in human peripheral blood T-
lymphocytes (Liu et al, 2009) and in human skin, both epidermis and dermis, 
where it was accompanied by down-regulation of the INK4a  locus repressor 
Bmi-1 (Ressler et al, 2006). A recent study (Waaijer et  al, 2012) makes an 
interesting connection between p16INK4a expression in the skin and how well a 
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person ages. Offspring from long-lived families, who display indicators of 
younger biological age, such as a lower mortality rate, lower prevalence of 
cardiovascular diseases, beneficial glucose and lipid metabolism, preservation 
of insulin sensitivity and better resistance to cellular stress in vitro, show a 
significantly lower frequency of p16INK4a-positive cells in their skin, especially in 
the epidermis, than their age and environmentally matched partners. This 
suggests that p16INK4a expression in human skin can also be a predictor of 
biological age, as persons displaying fewer p16INK4a positive cells seem more 
likely to age better (Waaijer et  al, 2012). This is in line with recent evidence 
obtained in a mouse model that clearance of p16INK4a positive cells delays the 
onset of age-related diseases (Baker et al, 2011).
 p16INK4a signalling through the pRb tumour suppressor can establish self-
maintaining senescence-associated heterochromatic foci (SAHFs), due pRb-
induced changes in chromatin, that accumulate in senescent cells (Narita et 
al, 2003). SAHFs contain chromatin regulators (histone repressor A or HIRA and 
histone chaperone ASF1a) and heterochromatic proteins (histones H3 and 
macroH2A, HP1#, " and ɣ), which reflect the permanent changes in chromatin 
responsible for stably repressing the expression of genes involved in cell cycle 
progression associated with establishment of senescence. The formation of foci 
containing macroH2A seems to be driven by HIRA and ASF1a and to depend 
on flux of heterochromatic proteins through PML bodies (Zhang et  al, 2005; 
2007).
 Whereas the previously described markers associate with ageing driven 
by p16INK4a-dependent senescence, other changes occur which are 
associated with accumulation of DNA damage. Senescent cells accumulate 
molecular markers consistent with the presence of DNA DSBs; these include 
nuclear foci (DDR foci) containing activated H2AX (ɣ-H2AX) which colocalises 
with 53BP1 and other DDR proteins (d'Adda di Fagagna et al, 2003). These DNA 
damage foci are also found at dysfunctional telomeres with senescence, 
where they are designated telomere-dysfunction induced foci (TIFs) (Takai et  al, 
2003; d'Adda di Fagagna et al, 2003; Herbig et al, 2004). Persistent DDR foci 
mark unrepairable DNA lesions and have been recently characterised as DNA-
SCARS or ‘DNA segments with chromatin alterations reinforcing senescence’ 
because they contain ɣ-H2AX and activated forms of other DDR mediators, 
associate with PML bodies and localise with sites of modified chromatin (Rodier 
et al, 2011). DDR foci have been used to show that DNA damage in the form of 
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DSBs accumulates not only in senescent cells but also in mouse tissues with 
ageing (Sedelnikova et al, 2004; Wang et al, 2009). An age-dependent 
increase in TIFs frequencies, indicating accumulation of DNA damage at the 
telomeres, has also been reported in gut and liver of mice (Hewitt et al, 2012) as 
well as in terminally differentiated tissues of old primates (Fumagalli et al, 2012). 
 Finally, the combined use of these novel biomarkers of senescence, 
namely p16INK4a expression, telomere dysfunction (TIFs), activation of DDR (DDR 
foci) and heterochromatinisation of nuclear DNA (SAHFs), has been employed 
to demonstrate that senescent cells accumulate in vivo with age in primates. 
They can account for over 15% of the cell population in dermis of old animals 
therefore confirming that senescence is a physiological event (Herbig et al, 
2006; Jeyapalan et al, 2007). Nevertheless, expression of senescence markers 
does not establish a causal relationship between senescence and ageing. 
Conclusive evidence for the causal role of senescence in organismal ageing 
was obtained from genetic mouse models with manipulations in the major cell 
cycle regulators and effectors of the cellular senescence pathways. 
 Mice with a mutation that results in activation of p53 show increased 
resistance to spontaneous tumours accompanied with a reduction in lifespan 
and early ageing-related phenotypes (Tyner et  al, 2002). “Super p53” mice, 
however, exhibit similar tumour resistance but maintain a healthy lifespan and 
age normally. The authors argue that this may be because “super-p53” animals 
possess just an extra copy of the p53 which, like the additional normal p53 
alleles, is under normal regulatory control, as opposed to the mice with 
activated p53 which have total levels of constitutively activated p53 increased 
(García-Cao et al, 2002). In fact, increased p53 activity, under normal 
regulatory control, has been shown not to contribute to accelerated ageing in 
certain mouse models (García-Cao et al, 2006; Matheu et  al, 2007). A later 
study (Choudhury et al, 2007) showed that, at least in the context of telomere 
dysfunction, p21Waf1 is the effector responsible for the pro-ageing effects of p53 
activation. Deletion of p21Waf1 in telomerase-deficient mice prolongs lifespan 
and improves stem cell function in the epithelial and haematopoietic systems 
without increasing the incidence of cancer.  
 Similarly, expression of the tumour suppressors p16ink4a and Arf, products 
of the Ink4a/Arf locus, is attenuated in mouse kidney, ovary and heart by 
caloric restriction and correlates with decreased incidence of pathology in 
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these organs (Krishnamurthy et al, 2004). Expression of p16Ink4a is also associated 
with decreased haematopoietic (Janzen et  al, 2006) and pancreatic function 
(Krishnamurthy et al, 2006). However, deletion of p16Ink4a partially rescues age-
related defects in HSC proliferation and apoptotic rates and improves 
repopulating ability as well as the regenerative capacity of pancreatic "-cells 
(Janzen et al, 2006; Krishnamurthy et al, 2006). Consistently, mice with deletion 
of Bmi-1, a negative regulator of the Ink4a/Arf locus, exhibit compromised 
haematopoietic stem cell function, associated with impaired mitochondrial 
function and an increase in ROS level, and a shortened lifespan (Liu et al, 2009). 
 Whereas these studies (Janzen et al, 2006; Choudhury et al, 2007; Liu et 
al, 2009) attest to the contribution of intrinsic properties of senescent cells (cell-
intrinsic ageing) to organismal ageing, additional work corroborates the idea 
that the senescence secretome also contributes to ageing (cell-extrinsic 
ageing) via changes in the microenvironment of both mitotic and post-mitotic 
tissue (Fig. 1.4). For instance, muscle satellite cells from aged mice show a 
decline in tissue regenerative capacity that can be restored when cells are 
exposed to blood supply from young animals via heterochronic parabiosis. 
Similarly, haematopoietic stem cell dysfunction resulting from age-associated 
changes in the supportive niche can also be reversed by exposure to 
circulation from young animals in an equivalent system (Mayack, 2010).
 Stem cell numbers do not get depleted with age and actually increase 
in mouse intestine and skin (Martin et al, 1998a; Giangreco et  al, 2008). 
However, the regenerative clone size upon injury is reduced with age (Martin et 
al, 1998a; 1998b). The stem cell hypothesis of ageing (Fig. 1.5) proposes that this 
is due to senescence probably because it promotes a decline in the replicative 
function of adult stem cells (Charruyer et al, 2009) in tissues with both high and 
low turnover rates. The activation of tumour suppressor mechanisms, such as 
senescence or apoptosis, is thought to be in place to prevent expansion of 
clones which have acquired malignant potential (damage to the genome or 
oncogenes) but can unintentionally contribute to ageing and late life cancer 
by impairing stem cell function and by altering their supporting niches 
(Sharpless & DePinho, 2007). This is also consistent with the antagonistic 
pleiotropy theory of ageing.
28
Figure 1.5. The stem cell theory of ageing. Stem cell numbers do not get depleted 
with age as the ability to self-renew  (curved arrow) is maintained. Stem cell function 
however, measured as the ability to produce progenitors (blue) and differentiated 
effector cells (different colours), does decline (in (Sharpless & DePinho, 2007)).
29
1.4. Senescence, telomere dysfunction and ageing.
The telomere
 Most eukaryotes use a complex telomerase-based system to stabilise 
their chromosome ends which has been proposed to have evolved from 
conserved t-loop structures (de Lange, 2004). The telomere system consists of 
telomeric-repeat DNA (Blackburn & Gall, 1978), telomerase, a telomere-specific 
reverse transcriptase (Greider & Blackburn, 1985; 1987) and telomere-specific 
proteins which bind the latter (de Lange, 2005). Therefore, modern telomeres 
solve both problems associated with the transition to linear genomes; the end-
replication problem, where terminal DNA is lost after each round of replication, 
and the exposure of chromosome ends, where the open double-strand is at risk 
of being recognised and processed by the cell as a site of DNA damage (de 
Lange, 2004).  
 In mammals, telomeres are organised as a nucleoprotein complex (Fig. 
1.6 a) that is know to exhibit a t-loop configuration. The characteristic t-loop 
structure was first unveiled by electron microscopy following psolaren/UV 
treatment of nuclei, deproteinisation and isolation of telomeric DNA obtained 
from four different mammalian sources (Griffith et al, 1999). The proposed 
structure of the human telomeric complex is represented in figure 1.6. It consists 
of a long sequence of TTAGGG repeats arranged as double-stranded DNA that 
ends in a short single-stranded 3’ overhang. The telomeric DNA folds over itself 
forming a t-loop (telomeric loop) thus allowing the 3’ overhang to invade the 
duplex and create a D-loop (displacement loop) of TTAGGG repeats 
associated with the single-stranded telomeric DNA-binding protein POT1 
(protection of telomeres 1). The structure is further stabilised by two main protein 
complexes, TRF1 and TRF2 (Fig. 1.6 b), which bind the entire length of double-
stranded telomeric DNA (de Lange, 2004; 2005).
30
Figure 1.6. The human telomeric complex. a. Telomeres consist of telomeric DNA 
associated with a complex of protective and regulatory proteins (shelterin). 
Telomeric DNA is organised as an array of duplex  TTAGGG repeats folded into a t-
loop ending in a 100–200 nucleotide 3! single-stranded overhang which invades the 
telomeric duplex  forming a displacement loop. TRF1 and TRF2 associate with the 
duplex TTAGGG repeats whilst POT1 binds the single-stranded 3‘overhang. b. TRF2 
(left) and TRF1 (right) complexes. Legend: TRF = telomeric repeat-binding factor; 
PINX1 = PIN2-interacting factor-1; POT1 = protection of telomeres-1; TIN2 = TRF1-
interacting factor-2; WRN = Werner syndrome helicase (in (de Lange, 2004)).
 Chromosome ends evade DNA repair and interact with telomerase 
through association of telomeric DNA with protective and regulatory proteins 
(Fig.1.6). These are part of the protein complex generally known as shelterin 
which protects, shapes and associates exclusively with the telomere. Shelterin 
has six main subunits, TRF1, TRF2, TIN2, Rap1, TPP1 and POT1 which interact with 
one another and with other non-shelterin proteins (reviewed in (de Lange, 
2005)).
 TRF2 and TRF1 form homo-dimers containing homologous C-terminal 
Myb domains specifically capable of binding the double-stranded telomeric 
DNA. Whilst TRF1 possesses an N-terminal acidic domain TRF2’s motif is basic. 
TRF2 interacts specifically with Rap1 and both TRF2 and TRF1 have TIN2-binding 
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domains. TIN2 connects both telomeric repeat-binding factors, which 
contributes to the stabilisation of TRF2 on telomeres, and tethers TPP1/POT1 to 
TRF2 and TRF1. Several proteins involved in DNA repair associate with 
components of the shelterin complex. For instance, TRF2 is known to interact 
with the WRN and BLM helicases, the MRN complex (Mre11/Rad50/Nbs1) and 
Rad51 which are involved in homologous recombination (HR); ERCC1/XPF 
which is involved in nucleotide excision repair (NER) and cross-link repair; PARP 
which is involved in base excision repair (BER) and DNA-PKcs which is involved 
in non-homologous end-joining (NHEJ). TRF1, on the other end, interacts with 
tankyrases (1 and 2) known for their role in mitosis. 
 Shelterin’s protective function is mostly performed by TRF2 through 
stabilisation of the 3'-overhang and formation of the t-loop which is the 
protective conformation adopted by mammalian telomeres in vivo (Griffith et 
al, 1999). TRF2 is capable of remodelling linear telomeric substrates into t-loops 
in vitro. This was demonstrated by incubating a model of linear telomeric DNA 
with TRF2 and analysing the conformation of the resulting complexes using 
electron microscopy. It revealed the formation of lasso-like molecules (t-loops), 
the frequency of which dramatically decreased in the absence of TRF2. 
Assembly of the telomeric loop by TRF2 was also hindered upon removal of the 
3'-overhang by specific nuclease treatment (Griffith et  al, 1999). In addition, 
previous work had already revealed that deletion of TRF2 induced end-to-end 
chromosome fusions due to loss of the single-stranded G-tails, with no disruption 
of the duplex TTAGGG repeats (van Steensel et al, 1998). This suggests that the 
telomeric repeats alone are not sufficient to ensure telomere integrity and that 
TRF2 has an essential role in it by maintaining the correct configuration of the 3’-
overhang. Furthermore, disruption of the t-loop, by interfering with TRF2 function 
(van Steensel et  al, 1998) or with the integrity of the 3'-overhang (Li et al, 2003), 
has been shown to trigger senescence. Expression of TRF2 deletion mutants 
TRF2!B (lacking Myb domain only) and TRF2!B!M (lacking both its Basic and Myb 
domains) reduces or almost completely removes the endogenous full-length 
TRF2 from telomeres, respectively. In the human osteosarcoma tetracyclin-
inducible cell line, expression of these mutants is accompanied by growth arrest 
with characteristics of senescence, as measured by SA-"gal staining and 
characteristic morphological features, contrarily to what happens when full-
length TRF2 is over expressed instead (van Steensel et  al, 1998). Additionally, 
human neonatal early passage fibroblasts exposed to a T-oligo, an 
oligonucleotide homologous to the 3'-overhang sequence TTAGGG, showed a 
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similar senescent phenotype (Li et al, 2003). Cells treated with T-oligo, bearing 
an exposed telomere 3'-overhang, not only showed SA-"gal activity but also 
phosphorylation of p53, un-phosphorylation of pRb and elevation of p21WAF1 
and p16INK4a protein levels consistent with engagement of senescence 
pathways, as opposed to cells treated with a control bearing a complementary 
sequence (Li et  al, 2003). These studies provide evidence that disruption of the 
t-loop triggers senescence via exposure of the 3'-overhang and suggest that 
this happens through depletion of protective TRF2 from critically shortened or 
dysfunctional telomeres. As for TRF1, although it is also involved in the 
stabilisation of the t-loop its main role seems to be, alongside POT1, in the 
regulation of telomere length maintenance by controlling the access of 
telomerase to telomeric DNA via the 3’-overhang (reviewed in (de Lange, 
2005)).
Telomerase
 Telomerase is the enzyme responsible for maintaining telomere length 
(Greider & Blackburn, 1985; 1987) and although is it used by most eukaryotes it is 
just one of the solutions to the end-replication problem found through the 
course of evolution (de Lange, 2004). For instance, dipteran insects opted for 
retrotransposition whilst some telomerase-deficient yeast strains turned instead 
to rolling-circle replication or break-induced replication (BIR)/recombination-
dependent replication (RDR)-like pathways. Even some immortalised human 
cells have been found to use a mechanism of telomere maintenance that 
does not require telomerase, designated ‘alternative lengthening of telomeres’ 
or ALT (Fig. 1.7).   
 Human telomerase is composed of the telomerase reverse transcriptase 
enzyme (TERT) and the telomerase RNA component (TERC). TERT adds TTAGGG 
repeats to the telomere by using the 3’ overhang as a substrate and TERC as a 
primer for the DNA synthesis. This is known as the canonical function of 
telomerase which prevents telomere erosion as a consequence of cell division. 
However, telomerase also has non-canonical functions which can be divided 
into those that require telomerase activity but not telomere lengthening and 
those that require neither telomerase activity nor telomere lengthening 
(Parkinson et al, 2008).
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Figure 1.7. Different solutions to the end-replication problem. a. Telomerase, which 
uses an RNA template (TERC), part of the telomerase complex, for DNA synthesis; b. 
Retrotransposition, where a reverse transcriptase uses genomic RNA as a template 
(in dipteran insects); c. Rolling-circle replication, where the an extrachromosomal 
circular template is used (in telomerase-deficient Kluyveromyces lactis); d. BIR/RDR-
like pathways, where one telomere uses another telomere as template through 
strand invasion, and e. T-loop formation, by using terminal repeats and extension of 
the invaded 3‘ end (possible mechanism for ALT in human cells) (in (de Lange, 
2004)).
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 Average telomere length decreases gradually with cell divisions in vitro 
(Harley et  al, 1990) and in vivo with age in proliferative compartments (Lindsey 
et al, 1991; Sharpless & DePinho, 2007). Telomere attrition in normal human cells 
results in cellular senescence and can be averted by telomerase (Bodnar et al, 
1998). Ectopic expression of TERT in skin fibroblasts, retinal epithelial cells (Bodnar 
et al, 1998), keratinocytes (Dickson et al, 2000) and human skeletal muscle 
myoblasts (Wootton et  al, 2003) stabilises telomere length and facilitates cells to 
acquire unlimited replicative potential without neoplastic transformation 
(Ouellette et al, 1999; Jiang et  al, 1999). It also extends replicative lifespan of 
cultured fibroblasts obtained from patients with Werner’s syndrome(Wyllie et al, 
2000). Telomerase activity is low or undetected in normal human somatic cells, 
however certain stem cells, germ line cells, and most immortal and cancer cell 
lines are telomerase-positive (Kim et  al, 1994; Wright et al, 1996; Newbold, 1997). 
In fact, activation of telomerase is one of the events usually required for 
malignant transformation (Kim et  al, 1994; Soder et  al, 1997; Parkinson & Minty, 
2007). 
 The situation in the mouse is quite different. Mouse telomeres are, on 
average, many times longer than human telomeres and no significant 
reduction in average size is observed throughout their lifespan (Kipling & Cooke, 
1990). Telomerase activity is present in most somatic tissues in the mouse, 
especially those with high turnover, and its expression seems to be mainly 
determined by the rate of cell proliferation. This is exemplified in mouse tumours, 
where telomerase expression is increased with maintenance of basal average 
telomere length. Furthermore, murine cells increase their telomerase levels and 
tend to spontaneously immortalise in culture, whilst animals show an increased 
susceptibility to develop cancer (Kipling, 1997). As telomerase is actively 
expressed in proliferating tissues and telomeres maintain a constant great size, 
senescence due to telomere shortening was thought not to be relevant in the 
mouse. 
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Telomere dysfunction-induced senescence and ageing
 In order to assess the effect of telomere attrition on ageing in vivo and 
for lack of a mammalian-based model system that could mimic human ageing, 
a telomerase-deficient mouse model was devised. The telomerase knockout 
mouse (mTR-/- or Terc-/-) carries a deletion of the germline copy of the murine 
telomerase RNA gene (mTR) (Blasco et al, 1997). Not surprisingly, given the long 
murine telomere reserves, the lack of telomerase activity alone was not enough 
to generate significant ageing phenotypes in these animals (Rudolph et  al, 
1999; Lee et  al, 1998). However, consecutive generations (G2, G3, G4, G5 and 
G6) of mTR-/- mice resulting from successive matings of homozygous-null 
intercrosses exhibited increasingly limiting telomere length, comparable to what 
occurs naturally in a human setting (Blasco et al, 1997; Lee et al, 1998). 
 Late generation (G4 onward) telomerase-deficient mice (Terc-/-) exhibit 
an age-dependent telomere shortening that results in shortened lifespan and 
decreased regenerative capacity in the epithelial and haematopoietic systems 
(Blasco et al, 1997; Rudolph et al, 1999). Telomerase deficiency and 
consequent telomere shortening in this mouse model also results in genomic 
abnormalities, increased apoptosis and senescence, depletion of male germ 
cells and reduced proliferative capacity in the testes, bone marrow and spleen, 
suggesting an impairment in stem-cell function in the highly proliferative organs 
(Lee et al, 1998). Additionally it has been shown that Terc-null mice with 
shortened telomeres show an age-dependent dysfunction of the 
haematopoietic environment causing impairment of B lymphopoiesis and 
increased myeloid proliferation of transplanted wild-type HSCs from young 
mice, suggesting a role for telomere attrition also in cell-extrinsic ageing (Ju et 
al, 2007). Finally, recent work (Hewitt et  al, 2012) suggests that telomere length 
and integrity are compromised during ageing even in wild-type mice known for 
expressing telomerase and possessing long telomere reserves. This supports the 
idea, contrary to what was accepted so far, that telomere attrition and/or 
dysfunction might be relevant to the ageing process in the mouse after all. In 
addition to findings obtained in the telomerase-deficient mouse model, several 
conditions in humans implicate telomeric attrition in organismal ageing.
 Various inherited and acquired degenerative disorders suggest a causal 
role for telomere dysfunction in normal human ageing. Ataxia telangiectasia 
(AT), Werner’s syndrome (WS) and dyskeratosis congenita (DC) are examples of 
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genetic diseases caused by mutations in genes coding for proteins ATM, WRN 
and TERC/TERT, respectively, with functions related to DNA repair and/or to 
telomere function (Wyllie et  al, 2000; Vulliamy et al, 2001; Wong et  al, 2003; 
Vulliamy et  al, 2004; Chang et al, 2004). These conditions are classified as 
progeroid syndromes because they are characterised by a range of clinical 
manifestations that resemble accelerated ageing (Kipling et al, 2004; Kirwan & 
Dokal, 2009). Additionally, cells obtained from patients with DC and WS have 
shorter telomeres, show reduced replicative potential in culture and are 
rescued from senescence and readily immortalised following forced expression 
of telomerase. Neither the Wrn-null nor the Atm-null mouse models show the 
classic range of manifestations typical of Werner’s or AT. However, when these 
mice are created on a telomerase-deficient background they present 
degenerative pathologies associated with accelerated ageing (Wong et al, 
2003; Chang et al, 2004). Furthermore, telomere loss has also been implicated in 
acquired chronic degenerative diseases characterised by high tissue turnover, 
such as idiopathic pulmonary fibrosis and liver cirrhosis (Rudolph et al, 2000; 
Wiemann et  al, 2002; Garcia et  al, 2007). This has been confirmed in the 
telomerase-deficient mouse model where telomere dysfunction in Terc-/- 
animals subjected to liver damage resulted in impaired liver regeneration and 
accelerated development of liver cirrhosis, conditions that were reversed by 
restoring telomerase activity and telomere function following adenoviral 
delivery of Terc (Rudolph et al, 2000).
 Telomere dysfunction is at least partly signalled by p53 which seems to 
exert its anti-proliferative and pro-ageing effects mainly via its transcriptional 
target p21WAF1. Whilst p53 deletion in late generation telomerase-deficient mice 
attenuated the cellular and organ defects arising from telomere dysfunction, it 
also contributed to accelerated tumourigenesis following the establishment of 
genetic crisis (Chin et  al, 1999). p21waf1 deletion in the same experimental 
model, on the other hand, not only improved stem cell function in both 
haematopoietic and epithelial compartments it also increased lifespan without 
contributing to chromosomal instability or cancer formation (Choudhury et al, 
2007). Over-expression of telomerase can extend the replicative lifespan of 
several cell strains in culture (Bodnar et al, 1998). This, together with the 
evidence presented from the telomerase-deficient mouse model as well as 
progeroid and chronic degenerative disorders in humans suggests that 
dysfunctional telomeres contribute to ageing by limiting stem-cell renewal in 
proliferative compartments. Testing the role of telomerase in organismal ageing 
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was therefore the next issue to address but presented a challenge given the 
well documented cancer-promoting effect of telomerase in the Tert-transgenic 
mouse (González-Suárez et  al, 2001). Although constitutive expression of 
telomerase improved wound healing and epidermal stem cell function it also 
resulted in a decreased lifespan because animals died early from cancer and 
this was shown to be associated with loss of p53 function (González-Suárez et 
al, 2002). Thus the only way to independently address the role of telomerase 
expression in organismal ageing was to separate it from its effect on cancer.
 For this purpose, Blasco and colleagues devised a novel mouse model 
constitutively expressing TERT in a cancer-resistant genetic background (Tomás-
Loba et  al, 2008). These tumour-resistant Tert-transgenic mice, also known as 
Sp53/Sp16/SpArf/TgTert, result from intercrosses between TgTert  mice (or K5-Tert 
mice) selectively over-expressing the Tert  gene in epithelial stem cell 
compartments due to its expression via the keratin 5 promoter (González-Suárez 
et al, 2001; 2002) and Sp53 (or ‘Super-p53’) and Sp16/SpArf (or ‘Super Ink4a/
Arf’) animals carrying extra alleles of the tumour suppressor genes p53 and a 
transgenic copy of the entire Ink4a/Arf locus (García-Cao et  al, 2002; Matheu 
et al, 2004). Expression of telomerase in a cancer-resistant background 
significantly delayed ageing, improved fitness in several epithelia as well as the 
brain and muscle (organs that do not express TgTert) and increased longevity in 
these animals. This anti-ageing activity was achieved by slowing telomere 
attrition and by preserving the proliferative potential of stem cells via the 
combined synergistic action of telomerase and the tumour suppressor genes 
being over-expressed. It could be argued that these anti-ageing effects could 
be due to non-canonical functions of telomerase which do not require 
telomerase elongation activity. However, this has been addressed by Blasco's 
group when they previously showed that, in contrast with TgTert  mice, animals 
over-expressing telomerase but carrying a germline deletion of its catalytic 
component, that is TgTert  mice in a Terc-/- background, failed to show 
increased tumourigenesis and increased wound healing (Cayuela et al, 2005). 
This indicates that the Terc component of telomerase seems to be required for 
its function as far as these effects are concerned. It is however still possible that 
other functions of telomerase, independent of telomerase activity, can also 
have a beneficial effect on ageing. Given that telomeres are considerably long 
in mice, regardless the expression of TgTert, and that expression of the tumour-
suppressor genes seems to also contribute to a slower rate of proliferation, 
which has been previously associated with decrease incurrence of DNA 
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damage and better clearance of damaged cells by senescence and/or 
apoptosis (Matheu et al, 2007), it seems likely that telomerase exerts its action 
by generally preserving telomere health rather than telomere size. Potential 
causes of telomere dysfunction that might have had their action counteracted 
by telomerase are damage generated by oxidative stress and DNA damage in 
the form of DSBs at the telomere. 
 DePinho and colleagues went further to show that telomerase 
reactivation in aged telomerase-deficient mice was actually capable of 
reversing the multi-system degeneration associated with telomere dysfunction 
(Jaskelioff et  al, 2011). They have modified late generation Terc-/- mice by 
introducing a knock-in allele encoding a 4-hydroxytamoxifen (4-OHT)-inducible 
telomerase reverse transcriptase-oestrogen receptor (TERT-ER) under 
transcriptional control of the endogenous TERT promoter. Telomerase 
reactivation in G4TERT-ER mice (in the presence of 4-OHT) lead to tissue 
rejuvenation in organs as diverse as the liver, spleen, testes, brain and even 
resulted in increased fecundity. As reactivation of telomerase was performed 
over a short period it did not promote carcinogenesis and thus raises the 
potential of its use as a telomere rejuvenation strategy at the organismal level.
 Since then, the use of telomerase activator TA-65 as a diet supplement in 
mice has been reported to have beneficial anti-ageing effects (Bernardes de 
Jesus et  al, 2011). It resulted in increased telomerase activity with effective 
rescue of telomere shortening and an increase in health-span indicators such 
as glucose tolerance, osteoporosis and skin fitness in female adult/old mice, 
without significantly increasing tumourigenesis. The same research group went 
on to try telomerase gene therapy using an adeno-associated virus (AAV) of 
wide tropism administered by injection on their tail-vein (Bernardes de Jesus et 
al, 2012). AAV vectors are very appealing tools for gene therapy and extensive 
studies in humans attest to their safety and efficacy; they are non-integrative, 
show poor immunogenicity and a good safety profile as well as the ability to 
transduce a wide range of tissues, with distinct proliferative capacities. AAV9 
mediated expression of mouse TERT in adult and old mice also increased 
health-span and fitness, had an impact on biomarkers of ageing and, more 
importantly, also increased median lifespan of these animals (Bernardes de 
Jesus et  al, 2012). This suggests that the ageing process can be modulated by 
telomerase at the organismal level and reenforces the role of telomere 
dysfunction in ageing. 
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 Overall, studies like these (Bernardes de Jesus et  al, 2011; 2012) using 
ectopic treatments to modulate ageing or studies in genetically modified mice 
where clearance of senescent cells has a compelling effect on ageing 
phenotypes (Baker et  al, 2011) suggest that interventions in ageing are possible 
at the organismal level and attest for the contribution of senescent cells to 
ageing in vivo.
The mitochondria connection 
 Although the decline in stem cell function associated with telomere 
attrition can account for the reduced regeneration ability in highly proliferative 
tissues it does not readily explain the telomere-related functional decline in 
post-mitotic tissues or onset of metabolic disorders.
 Although telomere dysfunction in mice resulted primarily in decrease of 
function in the epithelial and haematopoietic systems (Rudolph et al, 1999), 
reactivation of TERT in this model (late generation Terc-/- animals) reversed the 
generalised ageing-related decline even in organs like the liver, spleen, testes 
(with an increase in fecundity) and the brain (Jaskelioff et  al, 2011). 
Additionally, constitutive expression of telomerase in cancer-resistant mice also 
improved brain and muscle function (Tomás-Loba et  al, 2008) and the use of 
telomerase activators (Bernardes de Jesus et al, 2011) or telomerase as gene 
therapy (Bernardes de Jesus et  al, 2012) improved metabolic factors such as 
glucose tolerance and osteoporosis. Finally, although bone marrow failure and 
epithelial disorders are the defining features of dyskeratosis congenita, one of 
the human telomere-maintenance disorders, patients also display pulmonary 
and liver disease as well as mental retardation, deafness and osteoporosis 
(Kirwan & Dokal, 2009). This evidence indicates that telomere dysfunction 
affects mitotic, post-mitotic and metabolic ageing.
 It is well established that it is the shortest telomere, rather than average 
telomere length, that triggers telomere dysfunction-induced senescence in 
cultured cells (Hemann et al, 2001). Telomerase targets the shortest telomere 
keeping cells in cycle both in vitro (Bodnar et  al, 1998) and in vivo (Tomás-Loba 
et al, 2008). However, murine telomeres are characteristically long and not in 
danger of becoming critically short due to constitutive telomerase activity 
(Kipling & Cooke, 1990; Kipling, 1997) which is also the case for the cancer-
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resistant transgenic Tert  model (Tomás-Loba et al, 2008). Also, although 
senescent human fibroblasts have critically short telomeres, with almost total 
absence of telomeric repeats in some cases, telomere length is still highly 
variable (Baird et al, 2003). Whereas telomere shortening in primarily 
precipitated by increased rate of cell division, other factors contribute to 
accelerated telomere shortening or telomere dysfunction. Besides, telomeres 
become dysfunctional through loss of their protected status rather than by a 
complete loss of telomeric DNA (Karlseder et al, 2002). Exposure to chronic mild 
levels of oxidative stress, which is known to promote telomere shortening, was 
suggested as a possible explanation for the heterogeneity of replicative 
lifespan of cells in culture (Martin-Ruiz et al, 2004).
 Mitochondrial dysfunction, characterised by increased production of 
ROS, a breakdown of membrane potential and activation of mitochondrial 
biogenesis, has been shown contribute to telomere dysfunction (Passos et  al, 
2007a). Replicatively senescent human fibroblasts, characterised by short 
telomeres, showed an increase in superoxide levels accompanied by an 
elevation of mitochondrial mass and mtDNA copy number as well as other 
features of mitochondrial dysfunction. Reduction of the mitochondrial 
membrane potential (MMP) or mitochondrial uncoupling, which results in 
decreased production of mitochondrial superoxide, was found to delay 
replicative senescence by slowing down oxidative stress-dependent telomere 
shortening. Thus, mitochondrial dysfunction and superoxide production seem to 
contribute to telomere loss and TIF formation with induction of TDIS. This is 
thought to occur via p21WAF1-p38MAPK-TGF-"  signalling (Passos et  al, 2010). 
Similarly, oncogene-induced senescence was found to contribute to 
mitochondrial dysfunction and increased ROS production via MAPK signalling 
(Moiseeva et  al, 2006) and to contribute to TDIS by accelerating telomeric 
attrition and by affecting telomere structure (Suram et  al, 2012). Telomeres, 
given their G-rich chemistry, are particularly susceptible to oxidative damage 
and preferred targets for reaction with ROS which can render them 
permanently dysfunctional (Petersen et al, 1998; Hewitt et al, 2012). 
 Conversely, telomere dysfunction has also been shown to contribute to 
mitochondrial impairment (Sahin et al, 2011). Mouse models of telomere 
dysfunction, exhibiting decline in proliferative and quiescent organs resembling 
premature ageing, showed repression of mitochondrial regulators PGC-1# and 
PGC-1"  as well as their downstream targets, compromised mitochondrial 
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biogenesis and function with increase in ROS production, reduction in 
gluconeogenesis and cardiomiopathy. This was found in both G2 Terc-/- and G4 
Tert-/- models (showing comparable telomere dysfunction) indicating that these 
phenotypes result from lack of telomerase catalytic activity (canonical) and, 
therefore, from telomeric compromise. More importantly, forced expression of 
telomerase or PGC-1#, or germline deletion of p53 in these animals restored the 
PGC expression network, mitochondrial respiration as well as cardiac and 
hepatic function. p53 was found to directly repress PGC-1# and PGC-1" 
therefore establishing a telomere-p53-mitochondria regulatory axis. Since p53 
deficiency in mice with dysfunctional telomeres only partially restores PGC 
levels and mitochondrial function (Sahin et  al, 2011) this suggests that other 
pathways might also contribute to mitochondrial and metabolic compromise. 
Other candidates are p63, sirtuins, the Bmi-p16INK4a pathway and p21WAF1-
dependent signalling (Sahin, 2012). 
 From these observations an integrated view of ageing (Fig. 1.8) emerged 
which links the telomere and the mitochondria (Sahin & DePinho, 2012). The 
central molecule in the telomere-mitochondria axis is p53. Both generalised 
damage to the DNA in the form of DSBs or specialised damage such as 
telomere dysfunction signal p53 activation. This indirectly contributes to 
mitochondrial dysfunction via suppression of mitochondrial regulators PGC-1# 
and PGC-1"  (Sahin et al, 2011). Impaired mitochondria function causes 
increased ROS production and the resulting oxidative stress generates further 
damage to the DNA (in the form of persistent foci), particularly to the 
telomeres, eliciting a persistent DDR through p21WAF1 signalling which will again 
contribute to mitochondrial compromise (Passos et  al, 2007a; 2010; Hewitt et al, 
2012; Fumagalli et  al, 2012). The vicious cycle that gets established in the cell 
where genotoxic damage contributes to oxidative damage, and vice-versa, 
might explain how damage to the telomeres with consequent telomere 
dysfunction contributes to age-related functional decline in organs without 
regenerative capacity (Sahin & DePinho, 2012).
 In summary, the telomere-p53-mitochondrion model accounts for 
ageing driven by DNA damage and for the various ageing syndromes and 
phenotypes described above such as mice with extra copies of p53 (‘Super’ 
p53), models of telomere dysfunction (Terc-null and Tert-null mice) and models 
of telomere dysfunction (PGC-1#-null, PGC-1"-null and Bmi-1-null mice) thereby 
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providing a unified explanation for ageing driven by DNA damage and 
metabolic pathways (Sahin & DePinho, 2012). 
Figure 1.8. The integrated view of ageing linking telomeres and mitochondria. This 
models suggests reciprocal interaction between telomere dysfunction, p53 
activation and mitochondrial dysfunction. Legend: CR = caloric restriction (in (Sahin 
& DePinho, 2010)).
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 Based on this model, one can predict that interventions where telomere 
function is restored could also improve or restore mitochondrial activity. It would 
be interesting to assess whether an improvement in mitochondrial biogenesis 
and function is observed in animal models where telomere function has been 
restored, through expression of telomerase, with attenuation of ageing 
phenotypes, such as Sp53/Sp16/SpArf/TgTert  mice (Tomás-Loba et al, 2008), 
mice treated with telomerase activator TA-65 (Bernardes de Jesus et al, 2011) 
and mice subjected to telomerase gene therapy through a viral vector 
(Bernardes de Jesus et  al, 2012). So far, some interventions known to improve 
mitochondrial biogenesis and function, such as over-expression of PGC-1# in 
mice (Wenz et  al, 2009) or physical activity and the use of resveratrol, a sirtuin 
activator, in humans (Little et  al, 2011; Timmers et al, 2011) have been shown to 
reduce age-related decline. Additionally, the development of these or other 
therapeutic strategies to rejuvenate aged tissue or prevent the onset of ageing 
disorders, through intervention in components of the p53 pathway for example, 
could be considered.
 The ROS theory of ageing has been challenged on the grounds that in 
both birds and rodents long-lived species do not exhibit lower levels of oxidative 
damage in their tissues when compared with short lived species. Parrots that 
live for 40 years do not have lower levels or oxidative damage or better levels of 
oxidative defence enzymes than quails that live for 5 years (Montgomery et al, 
2012). Similarly, naked mole rats (NMRs) that live for 30 years do not have lower 
levels of oxidative damage than other rodents that live for only 2-3 years (Pérez 
et al, 2009; Lewis et  al, 2013). However, this can be reconciled if one considers 
recent evidence showing that telomerase can resolve otherwise irreparable 
DNA DSBs at the telomere (Suram et al, 2012), which are likely caused by ROS 
during normal ageing. Parrots have higher levels of telomerase than shorter-
lived bird species (Venkatesan & Price, 1998; Haussmann et al, 2004; 2007) and 
NMRs have positively selected for genes involved in telomere maintenance 
(Kim et al, 2011). This hypothesis would also explain why ectopic telomerase 
expression in mouse epithelium can increase both lifespan and healthspan on a 
cancer-resistant background and reduce telomere damage, despite the fact 
that mouse telomeres are generally very long (Tomás-Loba et al, 2008). Thus, 
the apparent anomalies within the animal kingdom do not necessarily disprove 
the oxidative damage theory of ageing for which there is abundant evidence 
in experimental models such as Drosophila melanogaster, Saccharomyces 
cerevisiae and Caenorhabditis elegans (Kenyon, 2010; Sohal & Orr, 2012). 
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However, it will be interesting to test the role of irreparable telomeric DSBs by 
examining their accumulation during the ageing of NMRs and long-lived birds 
as compared to their shorter lived relatives.
DNA DSBs and the telomere
 Telomeric DNA evades detection by the DNA repair machinery by being 
protected by the telomeric proteins that form the Shelterin complex. These 
proteins cap the telomere and shape it into the protective loop that conceals 
the 3’ overhang preventing it from being recognised as a DNA break and 
processed for repair, as happens on other sites of DNA damage (de Lange, 
2005). TRF2 is the shelterin component known to be able to induce the 
formation of t-loops (Griffith et al, 1999) and is thought to be assisted by various 
recombinational and repair proteins that could promote the strand invasion of 
the 3’-overhang (de Lange, 2004). The MRE11 complex (containing MRE11, 
RAD50 and NBS1 proteins), involved in homologous recombination (HR) and 
RECQ helicases (WRN/BLM), involved in unwinding of the double helix, are likely 
candidates as they are known to associate with TRF2 (de Lange, 2004).  
 Structurally, t-loops resemble intermediates in DNA repair pathways, such 
as the strand-invasion intermediate in homologous recombination (see Chapter 
4), and transitional structures in replication-restart events. The t-loop is 
evolutionarily conserved and is thought to have evolved from an ancient 
pathway for repair of DNA ends upon collapse of replication forks in 
prokaryotes called recombination-dependent recombination or RDR (Fig. 1.9). 
The early steps of RDR resemble t-loop formation and proteins that associate 
with modern telomeres, such as POT1, RAD51, components of the RAD52 family 
and the MRE complex, are evolutionarily related to proteins that play a role in 
RDR (reviewed in (de Lange, 2004)).
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 Figure 1.9. T-loop formation resembles RDR. a. Recombination-dependent replication 
(RDR) of phage T4, and b. T-loop formation in eukaryotes, where we can see the 
similarities between a subset of telomeric proteins and some of the RDR factors (in 
(de Lange, 2004)).
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 Although DNA repair proteins (DNA-PKcs, Ku70/80, ERCC1/XPF, RecQ 
helicases) associated with the telomere contribute to the formation and 
stabilisation of the protective telomeric loop they also help process 
chromosome ends when they get exposed, in an attempt to repair the terminal 
DNA, which may lead to chromosomal instability (de Lange, 2005). Terminal 
DNA can get exposed following telomere attrition as a consequence of cell 
division (Bodnar et  al, 1998) or following telomere dysfunction via loss of TRF2 
and its protected status (van Steensel et al, 1998). Telomere dysfunction through 
inhibition of TRF2 ultimately results in chromosome end-to-end fusions through 
non-homologous end-joining (NHEJ) between the C-strand of one telomere to 
the G-strand of another; this involves degradation of the 3‘overhang and 
subsequent telomere end-joining by DNA ligase IV/XRCC4 (van Steensel et al, 
1998; Smogorzewska et al, 2002). Normal cells attempt to prevent chromosomal 
instability arising from telomere fusions by signalling cell cycle arrest.
 Telomere attrition in normal human cells results in cellular senescence 
and can be averted by telomerase (Bodnar et  al, 1998) whilst telomere 
dysfunction via loss of TRF2 can elicit senescence, in human fibroblasts and 
some cell lines, or apoptosis, in human T lymphocytes and certain p53-deficient 
cancer cells (van Steensel et al, 1998; Karlseder et al, 1999). In either case, 
senescence is induced by alterations in the capped state of the telomere and 
not by complete loss of telomeric DNA as it was shown that over-expression of 
TRF2 reduced the senescence setpoint by protecting critically short telomeres 
from fusion (Karlseder et  al, 2002). Exposed telomeric DNA leads to cell cycle 
arrest via activation of ATM-p53 signalling also known as the DNA damage 
response (DDR). 
 Telomere uncapping through inhibition of TRF2 or telomere shortening 
following replicative exhaustion causes telomere dysfunction-induced 
senescence (TDIS) in normal human fibroblasts (d'Adda di Fagagna et al, 2003; 
Takai et  al, 2003). Dysfunctional telomeres associate with several DNA damage 
factors such as 53BP1, H2AX, Rad17, MDC1, NBS1, ATM and MRE11 to form 
telomere dysfunction-induced foci (TIFs), suggesting that they resemble DNA 
lesions (Takai et al, 2003). In addition, these cells display activated forms of 
Rad17, ATM, CHK1, CHK2, p53, p21WAF1 and H2AX (ɣ-H2AX). The latter is known 
to recruit checkpoint and DNA repair proteins to sites of DNA damage 
containing DSBs and ATM to be a signal transducer for DSBs, suggesting that 
exposed chromosome ends are perceived and processed as a DNA DSB (Takai 
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et al, 2003; d'Adda di Fagagna et al, 2003). ATM activation results in up-
regulation of p53 and its transcriptional target p21WAF1 followed by G1 arrest 
(Herbig et al, 2004). More importantly, inactivation of the checkpoint kinases 
(CHK) or of ATM restored cell cycle progression which indicates that firstly, 
stable arrest requires continuous signalling and secondly, that the signal emitted 
by dysfunctional telomeres seems similar to the signal generated by IR-induced 
DSBs and is transduced by the classical DNA damage pathway of senescence 
(d'Adda di Fagagna et  al, 2003; Herbig et  al, 2004). Despite the similarities, 
telomere dysfunction is a particularly potent cell cycle inhibitor since the 
presence of a single TIF is capable of causing long-term arrest (Herbig et  al, 
2004). This suggests that the damage signal arising from dysfunctional telomeres 
is distinct from the signal emerging from DSBs occurring in other areas of the 
genome and possibly more complex.
 DNA double-strand breaks (DSBs) accumulate in human senescent cells 
and ageing mice suggesting that the accumulation DNA lesions containing 
unrepairable DSBs may contribute to mammalian ageing (Sedelnikova et  al, 
2004; Wang et al, 2009). However, only 20% of the DNA damage foci (ɣ-H2AX) 
colocalise with telomeres in normal human fibroblasts undergoing senescence 
(Sedelnikova et  al, 2004). Permanent DNA lesions differ from transient lesions, 
where efficient repair occurs, and have recently been characterised as DNA-
SCARS or ‘DNA segments with chromatin alterations reinforcing 
senescence’ (Rodier et al, 2011). Persistent DNA damage foci in these structures 
fail to associate with certain repair proteins but accumulate activated forms of 
DDR mediators, particularly H2AX, which sustain both the senescence-
associated growth arrest and cytokine secretion. Recent findings, however, 
show that persistent DDR foci accumulate preferentially at the telomeres in 
senescent cells and ageing tissues alike (Fumagalli et al, 2012; Hewitt et al, 
2012). This seems to be because while DNA damage in non-telomeric regions of 
the genome is generally repairable, damage at the telomeres is unrepairable 
(Fig. 1.10). Telomeres are particularly susceptible to genotoxic stress (Hewitt et 
al, 2012; Suram et  al, 2012) and telomeric DNA resists repair due to its 
association with telomeric factor TRF2 (Fumagalli et  al, 2012). Mammalian TRF2 
has been shown to prevent chromosome fusions in vivo (van Steensel et al, 
1998) and, conversely, TRF2 inhibition results in fusions generated by DNA ligase 
IV-dependent non-homologous end joining, or NHEJ (Smogorzewska & de 
Lange, 2002). In order to test that telomeres resist DSB repair, Fumagalli et  al 
(Fumagalli et  al, 2012) first used the HO endonuclease inducible system in S. 
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cerevisiae cells to generate DSBs adjacent to areas containing or lacking 
telomeric repeats. They found that whilst HO-induced DSBs in non-telomeric 
regions were repaired by NHEJ, DSBs located next to telomeric repeats were 
not repaired, similarly to what happens in a DNA ligase 4-deleted control strain. 
Further analysis by ChIP and qPCR showed that the recruitment of DNA ligase IV 
(the enzyme responsible for the final ligation step in NHEJ) was inhibited in areas 
with DSBs flanking telomeric repeats as opposed to other DSB sites. 
Subsequently, the specific involvement of TRF2 was demonstrated by using a 
system which mimics a telomere containing the telomeric protein TRF2 but 
lacking telomeric DNA. Authors expressed the LacI-TRF2 fusion protein in cells 
from a mouse fibroblast line carrying a single integrated I-SceI cleavage site 
which is flanked by lactose operator (LacO) repeats on one side and 
tetracycline operator (TetO) repeats on the other. In addition, the expression of 
the tetracycline repressor fused to yellow fluorescent protein (YFP-Tet) allowed 
for the visualisation of this locus in the nucleus. I-SceI-induced DNA breaks 
resulted in a DDR, as measured by co-localisation of YFP-Tet with ɣ-H2AX. 
Consequently, after a 24h period following I-SceI inactivation to allow for repair, 
the percentage of DDR-positive cells expressing LacI alone was significantly 
lower then in cells expressing the LacI-TRF2 fusion protein. In the latter the DDR 
foci persisted due to lack of repair. This suggests that when TRF2 is ectopically 
expressed next to a DNA break it inhibits its repair and this seems to be because 
it inhibits recruitment of repair factors such as DNA ligase IV to the site of 
damage (Fumagalli et al, 2012). Thus it seems that the main factor that turns 
telomeres into protective structures, by preventing chromosome fusions 
resulting from exposed DNA, is also what turns them into unrepairable areas of 
the genome. All this evidence attests for the contribution of telomere 
dysfunction to organismal ageing.
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Figure 1.10. Distinction between DNA damage responses at telomeric and non-
telomeric sites. a. DNA damage at non-telomeric DNA causes DDR-mediated 
transient growth arrest since most of the damage is repaired, and b. DNA damage 
at telomeres causes chronic DDR signalling which results in permanent growth arrest 
and activation of the SASP, since it is irreparable due to inhibition of repair by TRF2 (in 
(van Tuyn & Adams, 2012)).
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1.5. Background of the project
 In cultured human fibroblasts, telomere dysfunction generated by 
expression of the dominant-negative mutant of TRF2 (TRF2!B!M) is associated 
with a DNA damage response (DDR) and DNA damage foci that locate to the 
telomeres (TIFs) (d'Adda di Fagagna et al, 2003; Takai et al, 2003; Herbig et  al, 
2004). In the skin of ageing primates, 80% of the fibroblasts show markers of 
senescence but only 15% show telomere-induced foci (Jeyapalan et  al, 2007) 
which could indicate that either the remaining 65% are using a telomere-
independent mechanism of senescence or that TIFs are just insensitive 
indicators of telomere-driven senescence in vivo.
 The effect of telomere uncapping in epidermal keratinocytes is distinct 
from that observed in fibroblasts. In keratinocytes, dysfunctional telomeres, also 
generated by depletion of the telomere-binding factor TRF2 via retroviral 
expression of TRF2!B!M, caused a senescent-like cell cycle arrest; however, this 
was accompanied only by a transient two fold increase in 53BP1 foci and p53 
phosphorylation at Serine 15 with no detectable induction of p21WAF1, p53’s 
transcriptional target (Minty et  al, 2008). The surprisingly subtle DDR observed 
suggests that the weak DNA damage signal generated by activation of p53 
may be sufficient to elicit senescence in keratinocytes, but it can also indicate 
that damaged telomeres in epidermal cells use an alternative signalling 
pathway towards senescence. Therefore, other markers were sought. 
Microarray analysis five days after expression of TRF2!B!M revealed several 
genes up-regulated by two fold or more. Expression levels for four of these 
genes (HIST2H2BE, ICEBERG, S100A7 and HOPX) increased with telomere 
uncapping and decreased with restoration of telomere length via ectopic 
expression of TERT. This was observed in normal human epidermal keratinocytes 
expressing TRF2!B!M (NHEK-TRF2!B!M) and late passage D17 cells, which suggests 
regulation by telomerase (Muntoni et  al, 2003; Minty et al, 2008). The D17 cell 
line (Muntoni et  al, 2003) is an atypical oral dysplasia lacking functional p16INK4a 
and p14ARF but retaining wild-type p53. Although possessing an extended 
lifespan, D17 cells still undergo senescence following considerable telomere 
erosion close to the end of their replicative lifespan. The data presented by 
Minty et  al suggest that HIST2H2BE, ICEBERG, S100A7 and HOPX might be 
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specific markers for telomere-induced senescence in normal human epidermal 
keratinocytes. This hypothesis was supported by the down-regulation of the 
above markers following the ectopic expression of telomerase in D17 in parallel 
with telomere elongation and immortalisation (Minty et al, 2008).
 Ideally, biomarkers should be secretable and detectable in body fluids, 
but lack of specificity for telomere dysfunction is a problem with all the secreted 
biomarkers identified so far (Jiang et al, 2008). The identification of biomarkers 
that are sensitive indicators of telomere function (be that length or capping 
status) can be clinically useful as they can be used as indicators of disease 
progression and, by being mechanism-specific, can be targeted for future anti-
ageing strategies (Sahin & DePinho, 2010). The purpose of this study is to assess 
the specificity of the putative markers of telomere-induced senescence 
HIST2H2BE, ICEBERG, S100A7 and HOPX and their potential use as biomarkers for 
TDIS.
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1.6. Aims of the project
Initial aims
• Assess if the small induction of DNA damage is enough to cause senescence 
or to induce the candidate genes.
• Assess if the candidate genes are non-specific markers of any type of growth 
arrest. 
• Assess whether the markers are specific to telomere dysfunction or are non-
specific markers of all forms of senescence.
Overall aims of the project
• To assess the specificity of previously identified markers of keratinocyte 
telomere dysfunction.
• To test their role in telomere-induced keratinocyte senescence.
• To assess their utility in marking telomere dysfunction in vivo.
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Chapter 2. Materials and Methods.
2.1. Materials
Standard laboratory and cell culture materials (VWR International)
Standard laboratory solutions and chemicals (Sigma-Aldrich)
2.1.1. Biological Materials
Cell strains/lines
Name Description ID
BICR-6 Squamous cell carcinoma (hypopharynx) Cell line
D17 Oral pre-malignant keratinocytes Cell strain*
NHEK-131 Normal human epidermal keratinocyte strain 
131
Cell strain
NHOF-1 Normal human oral fibroblast strain 1 Cell strain
Phoenix A Phoenix amphotropic packaging cell line Cell line
Phoenix E Phoenix ecotropic packaging cell line Cell line
Retropack ™ PT67 PT67 amphotropic packaging cell line Cell line
SCC-25 Squamous cell carcinoma Cell line
SVHFK SV-40 transformed human foreskin keratinocytes Cell line
Swiss 3T3 Random bred mouse Swiss 3T3 fibroblasts Cell line
Table 1. List of cell lines and cell strains. * = cell strain in extended lifespan
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Cell culture medium, supplements and other reagents
Name ID Company
Adenine hydrochloride A3159 Sigma
Cholera toxin 9012-63-9 MP Biomedicals
DMEM 4.5 g/L glucose BE12-604F Lonza
Donor Adult Bovine Serum (BS) SH30075.03 Hyclone
EDTA Disodium Salt E5134 Sigma
Epidermal growth factor (EGF) E9644 Sigma
Ham’s F12 BE12-615F Lonza
HEPES 1M in 0.85% NaCl BE17-737E Lonza
Hyclone Fetalclone II Serum (FCII) HYC-001-323F Fisher Scientific
Hydrocortisone hemisuccinate H2270 Sigma
Insulin I9278 Sigma
KGM BulletKit CC-3111 Lonza
L-Glutamine 200 mM 17-605E Lonza
PBS tablets BR0014G Oxoid
Penicillin/Streptomycin 17-602E Lonza
Transferrin T1283 Sigma
Trypsin TL Worthington LS003667 Lorne
Table 2. List of cell culture medium, supplements and other reagents used for cell 
culture.
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Selection agents for gene expression
Name Conc (ug/mL) Description ID Company
Ampicillin 100 Prokaryotic 
selection agent
A0166 Sigma
Blasticidin S HCl 8 to 10 (NHEK & 
D17)
Eukaryotic selection 
agent
R210-01 Invitrogen
Geneticin (G418) 200 (D17) Eukaryotic selection 
agent
11811-023 Invitrogen
Kanamycin 
sulfate
25 Prokaryotic 
selection agent
11815-024 Invitrogen
Puromycin 
dihydrochloride
1 (NHEK)
2 (PhE & NHEK)
2.5 (PT67)
Eukaryotic selection 
agent
P8833 Sigma
Table 3. List of antibiotics used for drug selection of eukaryotic and prokaryotic cells.
Competent cells
Name ID Company
XL1-Blue Competent cells 200249 Stratagene
DH5# Competent cells From stab culture 
(12540)
Addgene 
Stbl2 ™  Competent cells 10268-019 Invitrogen
Table 4. List of competent E. coli cells used for transformation.
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Retroviral vectors
Plasmid Vector 
backbone
Gene/
Insert
Selection 
cassette
ID Provider/PI
pLPC-NMYC pLPC puro no insert 
(EV)
Puromycin 12540 Addgene/
Titia de 
Lange*
pLPC-NMYC 
TRF2 deltaB 
deltaM
pLPC puro hTRF2 Puromycin 16069 Addgene/
Titia de 
Lange*
pBabe GFP pBabe 
puro
no insert 
(EV)
Puromycin - Cleo 
Bishop**
pBabe p14ARF pBabe 
puro
p14ARF Puromycin - Gordon 
Peters***
pBabe p16INK4a pBabe 
puro
p16INK4a Puromycin - Gordon 
Peters***
pBabe p53 pBabe 
puro
p53 Puromycin - Gordon 
Peters***
pGFP-B-RS pRS no insert 
(EV)
Blasticidin TR30018 Origene
pGFP-B-RS S 
shRNA anti-
HOPX
pRS non-
effective 
scrambled
Blasticidin TR30019 Origene
pGFP-B-RS A 
shRNA anti-
HOPX
pRS shRNA A Blasticidin TR319501 Origene
pGFP-B-RS B 
shRNA anti-
HOPX
pRS shRNA B Blasticidin TR319501 Origene
pGFP-B-RS C 
shRNA anti-
HOPX
pRS shRNA C Blasticidin TR319501 Origene
pGFP-B-RS D 
shRNA anti-
HOPX
pRS shRNA D Blasticidin TR319501 Origene
Table 5. List of retroviral vectors used for retroviral transduction. * The Rockefeller University, 
NY, USA. **BICMS, London, UK. ***Cancer Research UK, London, UK.
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Antibodies
Primary antibody 
anti-human
Host species Clonality KDa Dilution ID/
Company
GAPDH Rabbit Polyclonal 37 1:5000 (WB) ab9485/
Abcam
HOPX (FL-73) Rabbit Monoclonal 20 1:200 (WB)
1:100 (IF)
sc-30216/
Santa Cruz
p16INK4a (C20) Rabbit Monoclonal 16 1:200 (WB)
1:1000 (IF)
sc-468/
Santa Cruz
p21WAF1 (C70) Mouse Monoclonal 21 1:250 (WB) 610233/BD 
Transducti
on Labs
p53 (DO-1) Mouse Monoclonal 53 1:250 (WB) sc-126/
Santa Cruz
TRF2 (clone 4A794) Mouse Monoclonal 66 1:500 (WB) 05-521/
Millipore
#-Tubulin Rabbit Polyclonal 72 1:1000 (WB) ab4074/
Abcam
"-Actin Rabbit Polyclonal 40 1:1000 (WB) ab75186/
Abcam
Table 6. List of primary antibodies.
Secondary Ab HRP-conjugated Host 
species
Dilution ID/Company
Anti-mouse IgG Goat 1:2500 32430/Thermo 
Scientific
Anti-rabbit IgG Goat 1:2500 32460/Thermo 
Scientific
Anti-goat IgG Sheep 1:10000 A-9452/Sigma-
Aldrich
Table 7. List of secondary antibodies used for Western blotting.
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Secondary Ab Description Host 
species
ID Company
Anti-rabbit IgG Alexa Fluor 488 Goat A-11008 Invitrogen
Anti-mouse IgG Alexa Fluor 568 Goat A-11031 Invitrogen
Table 8. List of secondary antibodies used for Immunocytochemistry.
Other biological materials
• Goat Serum (Dako)
• LB broth (Sigma)
• Milk Powder, <1% fat (Marvel)
59
2.1.2. Chemical Materials
Chemicals and reagents
Name ID Company
2-Mercaptoethanol M3148 Sigma
DAPI D3571 Invitrogen
DMSO D1435 Sigma
Ethanol Absolute 24013 Sigma
Formaldehyde 38% (v/v) F8775 Sigma
FuGENE6® 11 815 091 001 Roche
Glycerol G5516 Sigma
Glycine 50046 Sigma
M-PER® Mammalian Protein Extraction 
Reagent
78501 Thermo Scientific
Methanol 20847.320 VWR
NaCl 27800.360 VWR
Nonidet® P 40 Substitute 74385 Fluka
NuPAGE 20® NP0002 Invitrogen
PFA P6148 Sigma
Polybrene® H9268 Sigma
Restore™ PLUS WB Stripping buffer 46430 Thermo Scientific
Rhodamine B R-6626 Sigma
SDS sample buffer (4x) NP0007 Invitrogen
Trizma®  base 93350 Sigma
Tween® 20 P1379 Sigma
Table 9. List of chemicals and reagents.
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Commercial kits and molecular biology graded reagents
Name ID Company
Amersham™ ECL Plus WB Detection 
System
RPN2132 GE Healthcare
cOmplete® Mini EDTA-free Tablets 04 693 159 001 Roche
DC™ Protein assay 500-0116 Bio-Rad 
DyNAmo™ cDNA synthesis kit F470L New England Biolabs
HyperLadder ™ V BIO-33031 Bioline
LightCycler® 480 SYBR Green I Master 04 707 516 001 Roche
Nuclease-free H2O 129114 Ambion
NuPAGE 10% Bis-Tris gels NP0301BOX Invitrogen
NuPAGE 4-12% Bis-Tris gels NP0335BOX Invitrogen
Plasmid DNA purification maxi kit 12162 Qiagen
Precision Plus Protein™ Standards, Dual 
Color
161-0374 Bio-Rad
QIAquick PCR purification kit 28104 Qiagen
QIAshredder 79654 Qiagen
RNase-free DNase Set 79254 Qiagen
RNeasy Mini kit 74104 Qiagen
tRNA solution R4251 Sigma
Table 10. List of commercial kits and molecular biology graded reagents.
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Primer sequences 
Name bp Forward Reverse
CCNA2 108 CCATACCTCAAGTATTTGCCATC TCCAGTCTTTCGTATTAATGATTCAG
CCND1 166 CGTGGCCTCTAAGATGAAGG GTGTTCAATGAAATCGTGCG
HIST2H2BE 134 GGTAGATCCACCCTTATGCTT TTAAGAGGGGAACACCATGAG
HOPX 84 ACTTCAACAAGGTCGACAAGC GGGTCTCCTCCTCGGAAA
ICEBERG 175 CTTGCTGGATTGCCTATTAGAG TTGAGGGTCTTCTTCACAGAG
IVL 83 TGCCTGAGCAAGAATGTGAG TTCCTCATGCTGTTCCCAGT
p14ARF 66 CTACTGAGGAGCCAGCGTCTA CTGCCCATCATCATGACCT
p16INK4a 58 CCAACGCACCGAATAGTTACG GCGCTGCCCATCATCATG
p21WAF1 127 TCACTGTCTTGTACCCTTGTGC GGCGTTTGGAGTGGTAGAAA
p53 85 AGGCCTTGGAACTCAAGGAT CCCTTTTTGGACTTCAGGTG
POLR2A 73 GCAAATTCACCAAGAGAGACG CACGTCGACAGGAACATCAG
S100A7 128 AAAGCAAAGATGAGCAACAC AAGTTCTCCTTCATCATCGTC
TRF2 105 CCAGATGAAGACAGTACAACCAA CCAGTTTCCTTCCCCATATTT
TRF2DN 94 GTTGATTTCTGAAGAAGATTTGTT GTGGAAGTAGAACTTGAGCAC
YAP1 83 CCCAGATGAACGTCACAGC GATTCTCTGGTTCATGGCTGA
Table 11. List of primer sequences used for qPCR. bp = product length in base pairs.
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2.1.3. Other Materials/Equipment
Other Materials Company
Amersham ECL Hyperfilm ™ GE Healthcare Life Sciences
Immobilon®-FL 0.45 !m PVDF membrane Millipore
Immobilon®-PSQ 0.2 !m PVDF membrane Millipore
Immu-Mount Thermo Scientific
Lab-Tek™ II 8-Chamber Slides Thermo Scientific
Nalgene® Mr Frosty Thermo Scientific
Nunc ™ cryovials Thermo Scientific
Parafilm® M barrier film Sigma
Table 12. List of other materials.
Equipment Company
460R bench-top centrifuge Hettich Rotanta
5415D bench-top centrifuge Eppendorf
ABI 3730 sequencer* Applied Biosystems
G-Box transilluminator Syngene
GSR D1 Cs-137 low dose-rate gamma irradiator** GSM
J2-MC centrifuge Beckman-Coulter
Lightcycler® 480 qPCR system Roche
Megafuge 2.0R centrifuge Heraeus
Microcentrifuge Labnet International
NanoDrop ND1000 spectrophotometer Thermo Scientific
Novex® Mini-Cell WB tanks Invitrogen
PowerEase 500 Invitrogen
PowerPac 200 Bio-Rad
Synergy HT spectrophotometer BioTek
Veriti ™ 96-well thermal cycler Applied Biosystems
Table 13. List  of equipment. * Service provided by  The Genome Centre,  QMUL; ** service 
provided by QMUL.
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2.2. Methods
2.2.1. Cell culture
 Routine cell culture was performed in Class II type A laminar flow hoods 
using aseptic technique. Cells were maintained in standard humidified cell 
culture incubators, at 37ºC and 10% / 90% air CO2 atmosphere or 5% / 95% air 
CO2 atmosphere. Cell pellets were obtained by centrifugation in a Megafuge 
2.0R centrifuge (Heraeus). All solutions used in cell culture were isotonic, 
prepared with calcium- and magnesium-free phosphate buffered saline (PBS). 
Cells were cryopreserved in 2 mL NuncTM cryovials (Thermo Scientific) placed in 
Nalgene® Mr Frosty (Thermo Scientific) containers that allow a 1ºC/min cooling 
rate down to -80ºC overnight and then transferred to vapour phase liquid 
nitrogen storage (-196ºC). When required, cells were irradiated using the GSR 
D1 device (GSM), a Cs-137 low dose-rate research gamma irradiator (service 
provided by Queen Mary University of London). A list of all cell strains/lines, cell 
culture medium composition and other reagents used in cell culture can be 
found in the Materials section under Biological Materials.
Normal Human Epidermal Keratinocytes
 NHEK-131 (GIBCO) at 6.8 MPD originate from expansion of primary 
human keratinocytes, produced from a pool of a minimum of 3 neonatal 
foreskins. Cells were sourced from the cell bank within the laboratory, thawed 
rapidly in water at 37ºC and co-cultured with lethally irradiated 3T3 ‘feeder’ 
cells at the correct density in FAD- medium (3 parts DMEM 4.5 g/L glucose, 1 
part Ham’s F12, 10% (v/v) Hyclone Fetalclone II serum, 20 mM HEPES buffer, 100 
U/mL Penicillin, 100 U/mL Streptomycin and 2 mM L-Glutamine, supplemented 
with 1.8 x 10-4 M Adenine, 5 !g/mL Insulin, 5 !g/mL Transferrin, 0.4 !g/mL 
Hydrocortisone and 8.4 ng/mL Cholera Toxin). Medium was replenished every 
third or fourth day with FAD+ complete medium (FAD- supplemented with 10 ng/
mL EGF). Cells were routinely cultured at 37ºC in a 10% CO2 atmosphere.
 Cells were subcultured, at 50-80% confluence, by first removing ‘feeders’ 
with 0.02% EDTA and PBS, pipetted vigorously against the dish, followed by 
disaggregation of the NHEK colonies into single cells, by incubation with 0.1% 
trypsin / 0.01% EDTA for 10 to 20 minutes at 37ºC. Cell pellets were obtained by 
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centrifugation of single cell suspensions at 800 rpm for 5 min. Cells were 
cryopreserved in 90% (v/v) Hyclone Fetalclone II serum, 10% (v/v) DMSO at 8-12 
MPD. 
 The number of population doublings (PDs) was calculated based on the 
formula:
 PD = 3.32 x (log10 # cells harvested - log10 # cells seeded)
 NHEK colonies were revealed in the culture dish (visible with the naked 
eye) with rhodamine B staining. Cells were first fixed on the cell culture dishes 
with a solution of 10% (v/v) formalin (3.8% (v/v) formaldehyde) in PBS for 30 min 
at room temperature, inside a fume hood. After washing with PBS, cells were 
stained with a 1% (m/v) Rhodamine B aqueous solution for 30 min at room 
temperature. Plates were thoroughly rinsed with tap water, left to air dry and 
cloning or plating efficiency was calculated:
 Cloning efficiency (%) = # colonies obtained / # cells seeded x 100
 For irradiation, cells were transported to and from the nearby irradiation 
facilities in the cell culture dishes, sealed with Parafilm® M barrier film, in a 
polystyrene box at room temperature. Samples were irradiated at 1.493 Gy/min 
for 1 min 20 sec for a total dose of 2 Gy, at 1.493 Gy/min for 13 min 23 sec for a 
total dose of 20 Gy, and at 0.747 Gy/min for 13 min 23 sec for a total dose of 10 
Gy. Controls were handled in the same way but received no irradiation.
3T3 and derived cell lines
 3T3 cells originally derive from random-bred Swiss mouse embryo 
cultures. PT67 RetroPackTM cells are a NIH 3T3-derived cell line. 3T3 and derived 
cell lines were obtained from the cell bank, thawed rapidly in water at 37ºC 
and routinely cultured in 10C medium (90% (v/v) DMEM 4.5 g/L glucose, 10% (v/
v) Hyclone donor adult Bovine Serum, 20 mM HEPES, 100 U/mL Penicillin, 100 U/
mL Streptomycin and 2 mM L-Glutamine) at 37ºC in a 5% CO2 atmosphere. At 
80% confluence, cells were subcultured by rinsing with PBS followed by 
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incubation with 0.1% trypsin for 5 min at 37ºC. Cells were cryopreserved in 90% 
(v/v) donor adult bovine serum, 10% (v/v) DMSO. 
 To use as ‘feeders’, 3T3 or PT67 cells were grown to 100% confluence, 
trypsinised and re-suspended. Cells were transported on ice as a cell 
suspension, in BD FalconTM conical tubes, and irradiated at 1.493 Gy/min for 40 
min 11 sec for a total dose of 60 Gy. Irradiated 3T3 cells were frozen at 2.5 x 106 
cells/mL and a vial recovered from liquid nitrogen storage each time NHEKs 
were subcultured. PT67 cells were used freshly irradiated for co-culture with 
NHEKs during infection. 
Phoenix cells (293-derived cell lines)
 Phoenix A and E cells were obtained from the cell bank and routinely 
cultured in Growth Medium (90% (v/v) DMEM 4.5 g/L glucose, 10% (v/v) heat 
inactivated Hyclone Fetalclone II serum, 100 U/mL Penicillin, 100 U/mL 
Streptomycin and 2 mM L-Glutamine) at 37ºC in a 5% CO2 atmosphere.
 Cells were thawed rapidly at 37°C by holding the vial and gently shaking it 
in the water bath. As cells started to thaw 1 mL of growth medium (GM) was 
added immediately and the cell suspension transferred to a 15 mL sterile 
conical screw cap tube. Additional 2 mL of GM were added to allow osmotic 
equilibration followed by an extra 10 mL. Cell pellets were obtained by 
centrifugation at 1000 rpm for 5 min.
 Cells were subcultured at 1:4 or 1:5 at 70-80% confluence every 2-3 days 
for at least a week before being plated for transfection, to maximise 
transfection efficiency. First they were gently rinsed with PBS (cells do not 
adhere strongly to the culture dish and therefore detach very easily) and then 
trypsinised with 0.05% trypsin / 0.01% EDTA for about 30 sec at room 
temperature. Cells easily detached and were readily pipetted into a single cell 
suspension by adding GM. Cells were cryopreserved in 90% (v/v) heat 
inactivated Hyclone Fetalclone II serum, 10% (v/v) DMSO.
Keratinocyte cell lines
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 Keratinocyte cell lines SCC-25, SVHFK and BICR-6 were obtained from the 
cell bank and routinely cultured in 10H medium (90% (v/v) DMEM 4.5 g/L 
glucose, 10% (v/v) Hyclone Fetalclone II serum, 20 mM HEPES buffer, 100 U/mL 
Penicillin, 100 U/mL Streptomycin and 2 mM L-Glutamine, supplemented with 
0.4 !g/mL Hydrocortisone) in the 'feeder' system or in KGM in the 'serum-free 
system', at 37ºC in a 10% CO2 atmosphere.
 Cells grown in the 'feeder system' were subcultured, at 50-80% 
confluence, by first removing the ‘feeders’ with 0.02% EDTA and PBS, pipetted 
vigorously against the dish, followed by disaggregation of the colonies into 
single cells, by incubation with 0.1% trypsin / 0.01% EDTA for 10 to 20 min at 37ºC. 
Cells grown in the 'serum-free system' were subcultured, at 50-80% confluence, 
by rinsing 1x with PBS followed by incubation with 0.1% trypsin / 0.01% EDTA for 
10 to 20 min at 37ºC. Cell pellets were obtained by centrifugation at 800 rpm for 
5 min. Cells were cryopreserved in 90% (v/v) Hyclone Fetalclone II serum, 10% 
(v/v) DMSO. 
2.2.2. Immunocytochemistry
 Keratinocytes were seeded in Lab-Tek™ II 8-Chamber Slides (Thermo 
Scientific). Cells were rinsed with PBS and fixed in 4% (v/v) para-formaldehyde 
(PFA) for 10 min at room temperature. Cells were rinsed with PBS and 
permeabilised with 0.5% (v/v) NP-40 buffer for 10 min at room temperature.
 Non-specific binding sites were blocked by incubating with 10% goat 
serum in 0.5% NP-40 buffer for 30 min. Incubation with primary antibody (Table 
6), diluted in 10% goat serum in 0.5% NP-40 buffer, was performed for 2h at room 
temperature. Cells were washed 3x for 5 min in 0.5% NP-40 buffer. Incubation 
with secondary antibody (Table 8), diluted in 10% goat serum in 0.5% NP-40 
buffer, was performed for 45 min at room temperature, away from light. Cells 
were washed 3x for 5 min in 0.5% NP-40 buffer. 
 Cells were then incubated with DAPI (1:1000 in PBS) for 5 min at room 
temperature, away from light and washed for 5 min in PBS. Coverslips were 
mounted with Immu-Mount  (Thermo Scientific) and stored in the dark at 4°C.
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2.2.3. Gene expression analysis
RNA isolation
 Extraction of total RNA was performed using the RNeasy Mini Kit 
(Qiagen) according to manufacturer's instructions. The kit is based on the use of 
a high-salt buffer system that selectively binds RNA longer than 200 nucleotides 
to a silica membrane on a mini spin column. As smaller RNA molecules (rRNA 
and tRNA) are excluded, the procedure provides an enrichment for mRNA. All 
centrifugation steps were performed in a 5415D bench-top centrifuge 
(Eppendorf). Samples were kept on ice.
 Growth medium was removed from adherent cells, these were 
trypsinised and pelleted by centrifugation. Cell pellets were re-suspended in 1 
mL of cold PBS (to remove any traces of growth medium), transferred to 1.5 mL 
eppendorf tubes and the number of cells determined. Cell suspensions were 
centrifuged for 10 min at 2,500 x g and cell pellets obtained by aspirating 
supernatants carefully. These were either frozen immediately at -80ºC, after 
removing the supernatant, or processed straight away. Cells were lysed by 
adding 350 !L RLT buffer (contains 10 !L "-ME per mL of RLT buffer) and 
vortexing to mix. RLT is a highly denaturing buffer containing guanidine-
thiocyanate, which eliminates RNases, and "-ME. Lysates were pipetted directly 
into QIAshredder (Qiagen) spin columns placed in 2 mL collection tubes and 
centrifuged for 2 min at full speed. One volume of 70% (v/v) ethanol was 
added to the homogenised lysates and mixed well by pipetting. The 
QIAshredder biopolymer-shredding system combined with 70% ethanol ensures 
ideal binding conditions to the spin column. Samples (up to 700 !L) were then 
transferred to RNeasy spin columns placed in 2 mL collection tubes, centrifuged 
for 15 sec at 10,000 x g and flow-through discarded. RNA binds to the silica-
membrane in the column and contaminants are removed in subsequent 
washes. DNase treatment was also performed with  the RNase-free DNase Set 
(Qiagen) to eliminate any genomic DNA contamination.
 Buffer RW1 (350 !L) was added to the RNeasy spin column followed by 
centrifugation at 10,000 x g for 15 sec to wash the spin column membrane and 
flow-through discarded. A volume of 10 !L of DNase I stock solution was added 
to 70 !L buffer RDD, mixed by gently inverting the tube and centrifuged briefly 
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in a micro centrifuge to collect residual liquid from the sides of the tube. The 
DNase I incubation mix (80 !L) was added directly to the RNeasy spin column 
membrane, and placed on the benchtop (20–30°C) for 15 min. Buffer RW1 (350 
!L) was added to the RNeasy spin column followed by centrifugation at 10,000 
x g for 15 sec to wash the spin column membrane and flow-through discarded. 
Buffer RPE (500 !L) was added to the RNeasy spin column, followed by 
centrifugation at 10,000 x g for 15 sec to wash the spin column membrane and 
flow-through discarded. This step was repeated but for 2 min now. The RNeasy 
spin column was placed in a new 2 mL collection tube and centrifuged at 
maximum speed for 1 min to eliminate any residual buffer in the sample. Finally, 
the column was placed in a 1.5 mL collection eppendorf tube, 20 !L to 40 !L of 
RNase-free water (Qiagen) added to it directly and column centrifuged for 1 
min at 10,000 x g to elute RNA. Its concentration and purity was measured using 
a NanoDrop ND1000 spectrophotometer (Thermo Scientif ic). RNA 
concentrations of 200 ng/!L or higher and A260/280 in the 2.00-2.10 range were 
obtained and indicate good quality RNA. 
cDNA synthesis
 Purified RNA was reverse transcribed using with Finnzymes DyNAmoTM 
cDNA synthesis kit (New England BioLabs), which is intended for cDNA synthesis 
for two-step qRT-PCR for amplicons around 100 bp in length. The reverse 
transcriptase used (M-MuLV RNase H+) has RNase H activity, thus degrading the 
RNA template following reverse-transcription. This confers the advantage of 
facilitating the annealing of primers to the cDNA, when later amplified by 
qPCR. 
 cDNA synthesis was performed on a VeritiTM 96-well thermal cycler 
(Applied Biosystems), using 0.7-1.0 !g purified RNA, 1x RT buffer, 15 ng/!L 
random hexamer primer set, 10% (v/v) RNase-free H2O, and 10% (v/v) M-MuLV 
RNase H+ to a final reaction volume of 20 !L, and with the following protocol: 
25ºC, 10 min for primer extension, 37ºC, 30 min for cDNA synthesis, 85ºC, 5 min 
for reaction termination and 4ºC hold for cooling the sample. cDNA templates 
were finally stored at -20ºC and diluted in DNase-free water (Qiagen) prior to 
use.
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Primer design
 Primers for HOPX, HOP homeobox (NCBI GeneID: 84525), for p21WAF1 or 
CDKN1A cyclin-dependent kinase inhibitor 1A (NCBI GeneID: 1026), for p14ARF 
or CDKN2A cyclin-dependent kinase inhibitor 2A beta (NCBI GeneID: 1029) and 
for TRF2 or TERF2 telomeric repeat-binding factor 2 (NCBI GeneID: 7014) were 
designed using the Roche Applied Science primer design tool. Primers for the 
dominant negative mutant of TRF2, TRF2DN or TRF2!B!M were designed 
manually; initial base was G or C and each sequence between 19 and 25 
nucleotides long for a Tm between 60°C and 70°C. 
Tm (°C) = G/C x 4 + A/T x 2 
 
 Primers for HIST2H2BE histone cluster 2 (NCBI GeneID: 8349), ICEBERG  or 
CARD18 caspase recruitment domain family member 18 (NCBI GeneID: 59082) 
and S100A7 or S100 calcium-binding protein A7 (NCBI GeneID: 6278) were 
previously published (Minty et  al, 2008). Primers were obtained from Sigma-
Aldrich.
 Primers for IVL or Involucrin (NCBI GeneID: 3713), for p53 or TP53 tumour 
protein p53 (NCBI GeneID: 7157), for CCNA2 or Cyclin A2 (NCBI GeneID: 890), 
for POLR2A or polymerase (RNA) II (DNA directed) polypeptide A (NCBI GeneID:
5430) and for YAP1 or Yes-associated protein 1 (NCBI GeneID: 10413) were 
kindly donated by Dr Muy-Teck Teh (Institute of Dentistry, QMUL, London, UK). 
Primers for p16INK4a or CDKN2A cyclin-dependent kinase inhibitor 2A alpha (NCBI 
GeneID: 1029) were kindly donated by Dr Cleo Bishop (BICMS, London UK) and 
primers for CCND1 or Cyclin D1 (NCBI GeneID: 595) were kindly donated by Dr 
Ann-Marie Bergin (Institute of Dentistry, QMUL, London, UK).
 All primer sequences (Table 11) were run through the online NCBI Primer-
BLAST tool to confirm specificity, binding sites and product length. 
Quantitative Polymerase Chain Reaction (qPCR)
 Real-time quantitative PCR was performed in the LightCycler 480® qPCR 
system (Roche Applied Science), using SYBR® Green chemistry. The following 
protocol was used in the LC480 for all reactions:
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Denaturation (Hot Start)
95ºC for 5 min
Amplification (45 cycles)
95ºC for 10 sec (melting)
65ºC for 6 sec (annealing)
72ºC for 6 sec (extension)
76ºC for 1 sec (acquisition)
Melting Analysis
95ºC for 30 sec (melting)
65ºC for 30 sec (cooling/annealing)
65ºC to 99ºC (gradual heating with continuous acquisition)
40ºC for 5 sec (cooling/termination)
 
 PCR products were amplified using 5 !L cDNA template, 1x SYBR® Green 
I Master Mix (Roche Applied Science), 0.7 !M F/R primers and SYBR® Green I 
H2O, PCR-grade (Roche Applied Science) to a final reaction volume of 50 !L, 
and purified using the QIAquickTM PCR Purification Kit (Qiagen). A volume of 250 
!L of Buffer PB was added to 50 !L PCR sample, mixed and added to a 
QIAquickTM spin column placed in a 2 mL collection tube. Column was 
centrifuged at 17,900 x g for 1 min to bind DNA and flow-through discarded. A 
volume of 700 !L of Buffer PE was added to the column, to wash DNA, 
centrifuged as before and flow-through discarded. The column was 
centrifuged for an additional minute to eliminate residual ethanol from buffer 
PE. Column was then placed in a 1.5 mL micro centrifuge tube and DNA eluted 
with 40 !L of molecular grade DNase-free water (Qiagen) by centrifuging for 1 
min. DNA concentration was measured using a NanoDrop ND1000 
spectrophotometer (Thermo Scientific) and the purified product diluted to a 
concentration of 1011 copies of the gene per 2 !L using the following equation:
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= volume required to dilute original DNA stock to obtain a final concentration of 
1011 copies of the gene per 2 !L 
 This stock was subsequently diluted, using 25 !g/mL tRNA (Sigma) as a 
DNA carrier, to prepare a PCR standard dilution series (109 to 102 copies of the 
gene per 2 !L). This was used to perform standard curves to achieve absolute 
quantification for each gene. All dilutions were stored at -20ºC.
 qPCR reactions were performed using 2 !L standard/cDNA template, 1x 
SYBR® Green I Master Mix (Roche Applied Science), 0.5 !M F/R primers and 
SYBR® Green I H2O, PCR-grade (Roche Applied Science) to a final reaction 
volume of 10 !L, in LightCycler® 480 96-well plates (Roche Applied Science), in 
duplicate or triplicate for each sample. Data analysis was performed using 
LightCycler® 480 relative quantification software (with built-in multiple reference 
genes normalisation algorithm).
Gel electrophoresis
 PCR products were run on a 2.5% (m/v) agarose gel containing 3 !L 
ethidium bromide, to confirm product size. A total of 4 !L of DNA was mixed 
with 1 !L DNA loading dye and loaded into the gel. Electrophoresis was 
conducted at 100 volts for 40 min and gel developed using a G-Box 
transilluminator (Syngene).   
2.2.4. Protein expression analysis
Protein isolation
 Growth medium was removed from adherent cells, these were 
trypsinised and pelleted by centrifugation. Cell pellets were re-suspended in 1 
mL of cold PBS (to remove any traces of growth medium), transferred to 1.5 mL 
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eppendorf tubes and the number of cells determined. Cell suspensions were 
centrifuged for 10 min at 2,500 x g and cell pellets obtained by aspirating 
supernatants carefully. These were either frozen immediately at -80ºC, after 
removing the supernatant, or processed straight away. 
 Cells were lysed by adding M-PER® Mammalian Protein Extraction 
Reagent (Thermo Scientific), containing EDTA-free Protease Inhibitor (Roche 
Applied Science), at a ratio of 100 !L M-PER® Reagent per 1 Million cells, and 
the mixture pipetted up and down to re-suspend the pellet. Mixture was gently 
shaken for 10 min at room temperature and cell debris removed by 
centrifugation at 14,000 x g for 15 min in an 5415D bench-top centrifuge 
(Eppendorf). Finally, the supernatant was transferred to a new tube and protein 
lysate either kept on ice for further analysis or stored at -80ºC.
 Protein concentration in the samples was determined the colorimetric 
Bio-Rad DC Protein Assay (Bio-Rad). Working reagent A' was prepared by 
adding 20 !L of reagent S per 1 mL of reagent A. A total of 3 - 5 dilutions of BSA 
protein standard containing from 0.2 mg/mL to 2 mg/mL protein were prepared 
in M-PER® Reagent to generate a standard curve each time the assay was 
performed. A volume of 5 $l of standards and samples was pipetted into a 
microtiter plate and 25 !L of reagent A' added into each well. This was followed 
by the addition of 200 !L reagent B. Plates were gently agitated to mix the 
reagents and, after 15 min, absorbances were read at 650 nm in a Synergy HT 
spectrophotometer (BioTek). Samples with amounts of total cellular protein of 20 
!g to 40 !g per 20 !L of sample, containing 20% (v/v) SDS sample buffer 
(Sigma), were boiled on a hot plate at 100ºC for 5 min. Samples ready for 
Western blot analysis were stored at -20ºC.
Western blotting
 Protein in the samples (20 !L) and Precision Plus ProteinTM (Bio-Rad ) dual 
colour standards (10 !L) were separated by SDS polyacrylamide gel 
electrophoresis, under denaturing and reducing conditions, on 10% SDS or 
4-12% SDS NuPAGE Bis-Tris pre-cast resolving gels (Invitrogen) at 130 volts on 1x 
NuPAGE running buffer (Invitrogen). Wet transfer to 0.2 !M or 0.45 !M 
ImmobilonTM PVDF membranes (Millipore), pre-soaked in methanol for 1 min, 
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was performed on transfer buffer (25 mM Tris, 190 mM glycine and 20% 
methanol) at 30 volts for 90 min at 4ºC. 
 PVDF membranes were blocked in 5% low fat milk in Tris-buffered saline 
and Tween 20 (TBS-T or wash buffer: 1 M Tris, pH 8.0; 5 M NaCl; 0.05% Tween 20) 
at room temperature for 1h with shaking. Incubation with primary antibodies 
(Table 6), prepared in 5% low fat milk in TBS-T, was performed for 2h at room 
temperature or overnight at 4ºC, with agitation, followed by three 5 min washes 
with TBS-T. Incubation with hrp-conjugated secondary antibodies (Table 7), 
prepared in 5% low fat milk in TBS-T, was performed for 1h at room temperature 
with agitation, followed by three 5 min washes with TBS-T. Antigen-antibody 
complexes were detected by incubating the PVDF membranes with 1 mL 
Amersham ECL Plus chemiluminescent detection reagent (GE Healthcare Life 
Sciences) at room temperature for 5 min, followed by detection on Amersham 
ECL Hyperfilm (GE Healthcare Life Sciences) developed in a dark room on a 
standard film developer machine. 
 Densitometry analysis was performed on scanned films using the Java-
based image processing software ImageJ (NIH). First, the background is 
subtracted from the image by applying a suitable rolling ball radius (RBR) and 
each lane on the blot, containing the band of interest, is then independently 
selected. Lanes are plotted and the background threshold set. The bands 
appear as peaks and the area of each peak is then measured. Finally, the 
relative intensities of the bands of interest are normalised against the values 
obtained for the corresponding loading control (GAPDH).
2.2.5. Retroviral transduction
 A list of all the retroviral vectors, competent bacterial cells and 
packaging cell lines used can be found in the Materials section under 
Biological Materials.
Transformation
 Super-competent cells (Table 4) were thawed on ice and 100 !L 
aliquoted into pre-chilled 14 mL BD Falcon polypropylene round-bottom tubes. 
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Transformations were performed both with and without plasmid DNA using 
aseptic microbiological technique. A total of 100 ng of plasmid DNA (Table 5) 
was added to the cells followed by incubation on ice for 30 min. Tubes were 
then placed in a 42°C water bath for exactly 2 min followed by incubation on 
ice for 10 min. Four times the volume of preheated LB broth (Sigma) was then 
added and mixture incubated at 37°C for 1h with shaking at 250 rpm. A 100 !L 
aliquot of the transformation mixture was plated, using a sterile spreader, on LB 
agar plates containing the appropriate antibiotic (Table 3) and plates 
incubated at 37°C overnight.
  
Plasmid DNA purification
 Vectors were prepared using the Plasmid DNA purification maxi kit 
(Qiagen), according to manufacturer's instructions. The method is based on a 
modified alkaline lysis procedure and selective binding of plasmid DNA to an 
anion-exchange resin. All centrifugation steps were performed in a J2-MC 
centrifuge (Beckman-Coulter). 
 A single colony was picked from a freshly streaked selective plate and 
used to inoculate a starter culture of 5 ml LB broth (Sigma) containing the 
appropriate selective antibiotic (Table 3). The mixture was incubated for 6h at 
37°C with shaking at 250 rpm. Glycerol stocks were prepared by adding 700 !L 
of each vector to the same volume of 60% (v/v) glycerol (Sigma) and stored at 
-80°C. The starter culture (400 !L) was diluted 1/1000 into selective LB medium in 
a flask with a volume of at least 4 times the volume of the culture and 
incubated overnight at 37°C with shaking at 250 rpm. Bacterial cells were 
harvested by centrifugation at 6000 x g for 15 min at 4°C. The bacterial pellet 
was lysed in alkaline conditions by re-suspending in 10 mL Buffer P1 followed by 
mixing with 10 mL Buffer P2 until lysate appeared viscous. Mixture was then 
incubated at room temperature for exactly 5 min. Genomic DNA, proteins and 
cell debris were precipitated by mixing immediately with 10 mL of chilled Buffer 
P3 and incubating on ice for 20 min. They were then removed by centrifugation 
and in subsequent medium-salt washes. The mixture was centrifuged at 16,000 
rpm for 30 min at 4°C and supernatant containing plasmid DNA removed 
promptly. Centrifugation was repeated at 16,000 rpm for 15 min at 4°C, 
supernatant containing plasmid DNA again removed promptly and applied to 
an empty QIAGEN-tip 500 column, pre-equilibrated with 10 mL Buffer QBT. 
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 The supernatant enters the column by gravity flow allowing plasmid DNA 
to bind the anion-exchange resin in the column, under appropriate low salt and 
pH conditions. Contaminants such as genomic DNA, proteins and cell debris 
were removed in two subsequent medium-salt washes with 30 mL Buffer QC. 
Plasmid DNA was then eluted in 15 mL Buffer QF (a high-salt buffer), 
precipitated and desalted with 10.5 mL room-temperature isopropanol 
followed by centrifugation at 14,000 rpm for 30 min at 4°C. The DNA pellet was 
washed with 5 mL of room temperature 70% (v/v) ethanol (Sigma) and 
centrifuged at 14,000 rpm for 10 min. The pellet was air-dried for 5–10 min to 
remove all traces of ethanol and DNA redissolved in 300 !L TE buffer, pH 8.0. 
Plasmid DNA concentration and purity were measured using a NanoDrop 
ND1000 spectrophotometer (Thermo Scientific). A260/280 higher than 1.8 was 
obtained for all vectors, denoting good quality purified plasmid DNA. Vectors 
were further diluted in Tris-EDTA (TE) buffer to a working concentration of 500 !g/
mL and stored at -20°C.
Sequencing
 Retroviral vectors were validated by nucleotide sequencing analysis on 
the ABI 3730 using BigDye® 3.1 chemistry (Applied Biosystems). Plasmids were 
used at 100 ng/!L and primers at 10 pmol/!L. Primers for the multiple cloning 
site (MCS) of pBabe vectors were kindly donated by Dr Cleo Bishop (BICMS, 
London, UK) and their sequences are presented below: 
pBabe fwd: 5’ CTTTATCCAGCCCTCAC 3’ (for the psi packaging signal) 
pBabe rev: 5’ ACCCTAACTGACACACATTCC 3’ (for the SV40 enhancer)
 Sequencing data was analysed using 4Peaks software (mekentosj.com) 
and the identity of the inserts confirmed with the online NCBI’s BLASTn 
database.
Transfection and Infection
 Retroviral transduction was used for gene delivery to the target cells. 
Both indirect and direct strategies were used for infection. The indirect strategy 
involved production of ecotropic virus which was used to generate infectious 
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amphotropic cell lines; these were then co-cultured with the target cells to 
deliver the transgenes. The direct strategy involved production of amphotropic 
virus used to directly infect the target cells via spinfection. Spinfection was 
performed in a  460R benchtop heated centrifuge (Hettich Rotanta).
Indirect strategy of infection
Transfection (production of ecotropic virus)
 Phoenix E cells were seeded at 2 x 105 cells per well (6-well plate) in 
duplicate, 24h before transfection. Cells were then transfected with 5 !g of 
plasmid DNA and FuGENE® 6 (1:2.5 ratio). FuGENE® 6 was added drop wise to 
serum-free medium (DMEM 4.5 g/L glucose, 12.5 mM HEPES buffer), mixed 
gently and left for 5 min at room temperature. DNA (5 !g) was added, mixed 
gently and left for 20 min at room temperature. The medium was then aspirated 
from cells, replaced with the transfection mixture and left to incubate at room 
temperature for 10 min. Finally, 1 mL of GM was added to the cells and plates 
returned to the 37°C incubator for 5h. Another 2 mL of GM was then added 
and cells returned to the incubator for 48h.
 At this stage, duplicates were pooled into 10 mm dishes with selective 
medium (GM containing 2 !g/mL puromycin). At confluence, spent medium 
was removed, replaced with 1/2 volume of fresh GM and cells incubated at 
32°C. Virus was obtained by harvesting the conditioned medium at 48-72h, 
filtering through a 0.45 !m filter and freezing the viral supernatants immediately 
at -80°C, in 1mL aliquots. 
Infection I (generation of infectious amphotropic cell lines)
 PT67 cells were seeded at 2 x 105 cells per well (6-well plate) in duplicate, 
24h before infection. Cells were incubated at 37°C for 15 min with polybrene in 
10C medium at 5 !g/mL. Supernatants were thawed at room temperature, 
polybrene (Sigma) added to a final concentration of 5 !g/mL and the mixture 
added to the cells. The plates were centrifuged at 350 rpm for 1h at 32°C. Cells 
were then washed with PBS and returned to the 37°C incubator in fresh medium 
for 48h. At this stage duplicates were pooled into 10 mm dishes with selective 
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medium (10C medium containing 2.5 !g/mL puromycin). Medium was 
refreshed every third day until drug-resistant populations of PT67s were 
obtained. Stocks of these stable cell lines were stored in liquid nitrogen (vapour 
phase).
Infection II (delivery of transgenes to the target cells)
 Infectious PT67 cells were recovered from the cell bank, grown in 
selective medium (10C containing 2.5 !g/mL puromycin) to confluence and 
irradiated at 60Gy. One million NHEK-131 were seeded, at equal density, with 
lethally irradiated 3T3 cells and infectious PT67 cells in 100 mm dishes with FAD- 
medium for 48h, at which time selective medium (FAD+ containing 1.0 !g/mL 
puromycin) was introduced. All ‘feeders’ were replaced with 1 x 106 lethally 
irradiated 3T3 neo/puroR cells, in selective medium, 48h later. NHEKs were kept 
on drug selection for the following 72h, at which point selective medium was 
replaced with FAD+, and cells left to grow overnight and harvested the 
following day. 
Direct strategy of infection
Transfection (production of amphotropic virus)
 Phoenix A cells were seeded at 1 x 106 cells per 60 mm dish or 2.5 x 106 
per 100 mm dish, 24h before transfection. On the day of transfection cells were 
inspected and dishes selected based on ideal cell density, distribution and 
absence of clumping. 
 Cells were transfected at a 1 !g DNA to 2.5 !L FuGENE®6 ratio (1/2.5 
ratio) in serum-free medium. First, 10 !L/25 !L (60 mm dish/100 mm dish) of 
FuGENE® 6 (Roche Applied Science) was added to 550 !L/150 !L S/F medium in 
a drop wise manner, mixed gently and left at room temperature for 5 min. Then, 
4 !g/10 !g of plasmid DNA was added, mixed gently and the mix left at room 
temperature from 25 to 45 min. Cells were removed from the incubator and the 
DNA-Fugene mix added to the medium in a drop wise manner. The dish was 
gently swirled to ensure good distribution before returning cells to the incubator 
for 24h. 
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 At this point transfection efficiency was assessed by noting fluorescence, 
transfection medium replaced by half the volume of GM and cells placed in an 
incubator overnight at 32°C for virus production. Virus was obtained by 
harvesting the conditioned medium at 48h, 54h, 72h and 78h after transfection. 
Viral supernatants were collected with a 10 mL syringe, filtered through a 0.45 
!m filter and aliquoted into cryovials (1 mL or 2 mL aliquots). These were either 
used immediately for infection or snap frozen in dry ice and immediately 
transferred to storage at -80°C. Medium was replenished after each harvest 
and cells returned to the 32°C incubator until the next time point.
Infection (delivery of transgenes to target cells)
 Keratinocytes were seeded at 5 x 104 cells per well with lethally irradiated 
3T3s at 1.6 x 105 cells per well, 72h before infection. On the day of infection, 
'feeders' were first removed and cells incubated at 37°C for 15 min with FAD 
medium containing 5 !g/mL polybrene (Sigma-Aldrich). Supernatants were 
thawed quickly in a 37°C water bath (or used directly after collection), diluted 
in equal volume of FAD medium and polybrene added to a final concentration 
of 5 !g/mL. The mixture was added to the cells, plates were returned to the 
32°C incubator until 10% / 90% air CO2 atmosphere was reached and 
immediately sealed w/ Parafilm® M barrier film. Spinfection was performed in 
two rounds, at 300 rpm for 1h at 32°C. Cells were washed with PBS and returned 
to the 37°C incubator in fresh medium until the next infection, 6h later. Cells 
were washed once again and fresh 'feeders' added in FAD medium. Plates 
were returned to the 37°C incubator for 24h and FAD replaced with selective 
medium, containing the appropriate antibiotic. Cells remained in drug 
selection for 72h at which point medium was replaced with FAD overnight until 
sample collection. 
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Chapter 3. Introduction to and establishment of 
the experimental model.
3.1. Introduction
3.1.1. Background
 Fibroblasts have been successfully grown in culture for the first half of the 
twentieth century and by the 1960s the first human diploid cell strain had been 
developed (WI-38, (Hayflick & Moorhead, 1961)), followed by others in the next 
decade (MRC-5, (Jacobs et  al, 1970) and IMR-90, (Nichols et al, 1977)). Growing 
keratinocytes however, remained a challenge. Early studies (discussed in 
(Rheinwald & Green, 1975a)) showed that, after disaggregation from skin, 
epidermal cell growth and maintenance depended on dermal fibroblasts or 
their products and that keratinocytes would grow in monolayers, but to a very 
limited extent. The problem was that, while absolutely essential for epithelial 
colony initialisation, the presence of fibroblasts would also constitute a 
hindrance as they would overgrow the keratinocytes and take over the culture, 
rendering sub-cultivation impossible. 
3.1.2. Serial sub-cultivation of keratinocytes
 Successful serial growth of human keratinocytes in culture was first 
possible due to the 3T3 cell line. In 1963, Todaro and Green (Todaro & Green, 
1963) were working with mouse embryo fibroblasts with the intention of 
obtaining an immortalised cell line that might be a suitable target for viral 
transformation. After testing several combinations of inoculation densities and 
transfer intervals, a unique cell line called 3T3 (3 x 105 cells innoculum at a 3 
days transfer interval) emerged. 3T3 cells demonstrated a distinctive property, 
contact inhibition or density-dependent inhibition of growth, which enabled 
them to arrest growth at confluence and, therefore, to be easily spotted upon 
successful transformation, as this characteristic would be lost. Later, after 
isolating epithelial cells from a mouse teratoma (germ line tumour able to 
differentiate into several somatic tissues), the authors observed that without a 
background of teratomal fibroblasts epithelial cells grew very slowly, yet when 
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supplemented with lethally irradiated 3T3 cells they showed exuberant growth 
in culture (Rheinwald & Green, 1975b). Shortly after, the same procedure was 
successfully applied to normal human diploid keratinocytes isolated from 
newborn foreskin and the first human epithelial cell strains were developed 
(Rheinwald & Green, 1975a).
 3T3 cells play a complex role as feeders in supporting the growth of 
keratinocytes. In general, lethally irradiated 3T3s act as a substitute for 
mesenchymal fibroblasts while also suppressing proliferation of the 
contaminating fibroblasts. In fact, irradiated 3T3 proved to be even more 
effective than irradiated human diploid fibroblasts in their supportive function in 
vitro (Rheinwald & Green, 1975a). However, keratinocyte cell strains and 
keratinocyte cell lines differ in their dependence upon the 3T3 cells and/or their 
products, and evolution of mesenchymal independence seems to be acquired 
upon immortalisation (Green, 1980). The presence of 3T3s is an absolute 
requirement in both for keratinisation, in cell strains for colony initiation and, in 
cell lines for colony initiation/growth only at low density. The latter are able to 
grow if inoculated at high density in complete absence of 3T3s and, for 
keratinocyte strains, 3T3-conditioned dishes can replace 3T3s in supporting initial 
colony growth, but are not as effective as the actual 'feeders'. Once colonies 
are formed, both keratinocyte lines and strains are able to maintain growth in 
the presence of 3T3-conditioned medium alone but, especially for cell strains, 
'feeders' are still a requirement upon sub-cultivation (Rheinwald, 1980). The 
complex function of 3T3s as 'feeders' seems to be carried out by a combination 
of secreted soluble products (growth factors), insoluble factors (matrix) 
deposited on the growth surface and the presence of the cells themselves 
(support), in close proximity to the keratinocytes (Rheinwald, 1980). 3T3s also 
remove the keratinocyte cell cycle inhibitor transforming growth factor "  or 
TGF-" (Rollins et al, 1989). 
 The 3T3 system relies not only on the use of lethally irradiated 3T3 cells but 
also in appropriate growth supplements and ideal growth conditions. The first 
supplement introduced in the cell culture medium was hydrocortisone (HC) 
(Rheinwald & Green, 1975a). It constitutes an absolute requirement for colony 
initiation from single cells in the 3T3 system and it allows colonies to acquire an 
organised epithelial-like morphology. The first culture conditions (based on DME, 
20% FCS and HC, in a 37°C 8% CO2 atmosphere) allowed cells to reach 50 
generations, if obtained from newborn skin (Rheinwald & Green, 1975a). Later, 
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the introduction of epidermal growth factor (EGF) (Rheinwald & Green, 1977) 
and cholera toxin (CT) (Green, 1978) enabled extension of culture lifetime to up 
to 150 generations. EGF (Rheinwald & Green, 1977) also contributes to an 
increase in colony-forming efficiency (if added once small colonies have 
formed and not whilst as single cells or it will have the opposite effect). Colonies 
become larger and less stratified, as EGF contributes to keeping a higher 
proportion of cells in a dividing state, preventing them from committing to 
terminal differentiation, or at least delaying them. Its effect, however, will only 
manifest itself on cells that are still in cycle. Cholera toxin (Green, 1978) acts by 
increasing the intracellular levels of cAMP, promoting the rate of cell 
proliferation, thereby increasing the proportion of small cells (dividing fraction) 
in culture. Further improvements in culture conditions included the addition of 
Ham's F12 (enabled a reduction in FCS from 20% to 5% or 10%), insulin and 
adenine (Allen-Hoffmann & Rheinwald, 1984). These resulted in a further 
increase in colony-forming efficiency to a standard that justified the use of 
these growth conditions until today.
 In parallel to the development of the 3T3 system there were alternative 
methods being investigated with the objective of dispensing the use of 
'feeders'. The first basal nutrient media that allowed serial cultivation of 
keratinocytes in the absence of a 'feeder' layer or conditioned medium was 
developed by Peehl and Ham in the 1980s (Peehl & Ham, 1980a). Initially it was 
based on medium 199 supplemented with 20% FBS, Bovine Pituitary Extract (BPE 
at 0.15 mg/mL) and HC (10 !g/mL). The authors found that the increase from 
0.4 to 10 !g/mL of HC was the determinant factor that allowed for 'feeders' to 
be absent (Peehl & Ham, 1980a). With the objective of obtaining a more 
defined system, they later dispensed the use of whole serum by substituting it 
with small amounts of dialysed FBS protein (1 mg/mL) (Peehl & Ham, 1980b). 
Also, the superior Ham's F12 replaced basal medium 199 and the introduction of 
adenine at higher levels (1.8 x 10-4) and calcium at low concentration (3 x 10-5) 
selectively promoted the growth of keratinocytes to the detriment of fibroblasts 
(Peehl & Ham, 1980b). The final optimised 'serum-free' system which is in use 
today is designed to support clonal growth of keratinocytes and allows cells to 
undergo up to 50 generations in culture, if derived from newborn skin (Wille et 
al, 1984). It is based on KBM basal medium (with Ham's F12 and low calcium, 0.1 
mM) supplemented with BPE (0.03 mg/mL) EGF (0.1 ng/mL), Insulin (5 g/mL) and 
HC (0.5 !g/mL) for KGM (keratinocyte growth medium) complete medium.   
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 The development of a 'feeder-free' system for sub-cultivation and clonal 
growth of keratinocytes was prompted by the need to eliminate confounding 
effects of another cell type when studying keratinocyte growth and 
differentiation (Peehl & Ham, 1980a). A study by Wille et  al (Wille et  al, 1984) 
showed that both are regulated by several factors in an integrated manner; 
insulin, EGF and BPE are more directly related to growth, whilst other growth 
factors, calcium and serum relate to differentiation. In general, upon growth 
arrest cells become enlarged and flattened, as they do in the 'feeder' system. 
However, in the presence of low calcium (0.1 mM), which is the environment in 
a 'serum-free' system, cells do not stratify or differentiate. This can only be 
induced by raising the calcium concentration above 0.4 mM (Owens et al, 
2000). The combination of growth promoting factors such as insulin, EGF and 
BPE, combined with low calcium keeps cells as a monolayer, in growth phase, 
away from terminal differentiation. This contrasts with the morphology of the 
colonies in the 'feeder' system which will be described below.  
 The early failures in successfully growing keratinocytes in vitro were not 
due to any intrinsic limitation of the keratinocyte as a cell type, but rather to the 
complex relationship between epidermal cells and fibroblasts (Rheinwald & 
Green, 1975a; Green et al, 1979). Until now no synthetic substitute has been 
found to completely replace the role of the 3T3 cells as 'feeders'. Despite the 
development of new systems (serum-free/feeder-free), technically less 
demanding and user friendly, the 3T3 system is still the cell culture method of 
choice for growing normal human keratinocytes in use today and the closest to 
the physiological setting.
3.1.3. Colony morphology and clonality of keratinocytes
  The development of the 3T3 system also enabled the isolation of clones 
of epithelial cells and their characterisation in culture. This is described in a 
series of studies by Green and colleagues in the 1980s.
 Once a single cell is attached to the culture dish and starts dividing a 
colony is formed. Keratinocytes expand laterally due to cell division as a single 
layer in direct contact with the surface. In addition, colonies also expand 
upwards forming layers in consequence of migration of cells from the base that 
have engaged the program of terminal differentiation. Upon stratification, the 
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bottom single layer of small compacted cells can easily be perceived as the 
multiplying front of the colony. All cells in this layer are engaged in cell division, 
even the ones at the base of the thick multilayered centre, as it was shown by 
thymidine incorporation assays (Dover & Potten, 1983). The cells of the upper 
layers are larger and appear flattened, giving the centre of the colony a 
characteristic appearance, and eventually shed as squames (Rheinwald, 
1980). This resembles the morphology/behaviour of normal human skin.  
 Colonies in culture are, therefore, a heterogeneous mixture of dividing 
and terminally differentiated cells. Upon sub-cultivation it is possible to isolate 
single cells and study their ability to form clones and characterise the latter 
(Barrandon & Green, 1985; 1987). Not surprisingly, it was clear that clonogenic 
potential was inversely proportional to cell size (Barrandon & Green, 1985). 
Keratinocytes that are 11 !m or less in diameter will divide and give rise to 
clones, whilst cells of 12 !m or greater in diameter will irreversibly get larger and 
terminally differentiate. Interestingly though, highly proliferating clones, 
originating from the smaller keratinocytes (<11 !m), are capable of giving rise to 
colonies regardless their diameter. The exception are clones larger than 20 !m 
which will not divide and have irreversibly committed to terminal differentiation. 
This shows that whilst the smallest cells are the most clonogenic, it is possible for 
bigger cells (up to 20 !m) to retain multiplying potential and give rise to cycling 
progeny of a smaller size.
 Further analysis of clones arising from a single cell enabled estimation of 
their growth potential, based on what colony types they give rise to, and 
resulted in their characterisation as holoclones, meroclones or paraclones 
(Barrandon & Green, 1987). Holoclones have the greatest replicative potential 
and give rise to a high proportion of proliferative colonies with less than 5% of 
colonies being abortive. Holoclones were originally thought to originate from 
stem cells. Paraclones, on the other hand, display the shortest replicative 
lifespan originating colonies that can undergo a maximum of 15 generations by 
which time they will abort and terminally differentiate. Meroclones are a 
transitional stage between holoclones and paraclones, and contain a mixture 
of cells of different replicative potential. The biggest colonies obtained from 
meroclones are distinctive from proliferative colonies (originated by holoclones) 
as they display a characteristic wrinkled perimeter in contrast with the regular 
round edges from the latter.
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 As fibroblasts (Hayflick, 1965), normal human epidermal keratinocytes 
display a limited replicative lifespan in culture (Rheinwald & Green, 1975a). Also 
similarly, the culture lifetime of keratinocytes declines with age of donor 
(Rheinwald & Green, 1975a). Moreover, there is a shift in the relative frequency 
of holoclones and paraclones in populations of keratinocytes with age 
(Barrandon & Green, 1987). Holoclones are the predominant clonal type in 
populations deriving from newborn skin while paraclones are the most 
abundant in samples from older donors. Contrarily to what had been initially 
suggested, replicative senescence, not terminal differentiation or apoptosis, is 
the process responsible for the eventual exhaustion of replicative potential of 
keratinocytes with ageing (Norsgaard et al, 1996).
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3.2. Establishment of experimental model
3.2.1. Choice of in vitro model
 Normal human epidermal keratinocytes (NHEKs) were chosen as the in 
vitro model for the first part of this study. Since the aim is to work in the context 
of normal human epidermal ageing the choice of normal cells, with a limited 
replicative lifespan and thus able to undergo senescence, as opposed to a cell 
line, which has lost this ability, is suited. Plus, the epidermis is the classical 
epithelial model, thoroughly characterised and easy to obtain. With the choice 
of in vitro model, the intention is to minimise the introduction of variables due to 
in vivo and in vitro ageing.
 The fact that cells derive from newborn foreskin should minimise variables 
due to in vivo ageing. Cells are from obviously very young donors, and thus 
should display optimum colony-forming efficiency and lifespan in culture. In 
addition, they are expected to possess intact pathways of senescence, with 
functional, though not activated, p53, p14ARF and p16INK4a. The latter is further 
guaranteed by the fact that they originate from foreskin, which means cells 
have not been subjected to UV damage, the main environmental causal 
agent of skin ageing (Fisher et al, 2002).
 In order to minimise variables to in vitro ageing, cells are used at very 
early passage (between 8 and 20 MPD which corresponds to about 16 and 30% 
of the total lifespan, respectively) and cultured in the 3T3 'feeder' system, which 
delays the induction of p16INK4a (the main effector of senescence in 
keratinocytes grown on dish) and the appearance of prematurely senescent 
keratinocytes (Darbro et al, 2005). Keratinocytes cultured with 'feeders' show an 
increased replicative lifespan relatively to cells growing in specialised serum-
free medium ('feeder' free system) (Ramirez et  al, 2001; Rheinwald et al, 2002). 
The 'feeder' system provides optimum conditions for keratinocytes growth, 
primarily due to the growth factors and mesenchymal/epithelial support 
provided by the 'feeder' layer, and additionally for the presence of adequate 
supplements essential for colony-forming ability, normal colony morphology/
stratification and achievement of maximum lifespan (discussed in detail 
above). Nevertheless, as opposed to previous reports (Ramirez et al, 2001), 
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despite optimum culture conditions provided by the 3T3 system, keratinocytes 
can still undergo premature senescence via p16INK4a activation following 
continued expansion in culture and thus do not senesce exclusively via a 
telomere-dependent mechanism (Dickson et  al, 2000; Rheinwald et  al, 2002). 
The intention is that, by using optimum culture conditions and cells at early 
passage that have endured a short period of time in culture and therefore 
have undergone minimised manipulation, a possible bias due to the activation 
of a telomere-independent pathway of senescence and other undefined 
effects of ageing are eliminated. Another source of possible experimental bias 
comes from the use of 3T3s. Keratinocyte cell extracts will contain a residual 
amount of 'feeders', even though most would be removed by EDTA and 
washing, so this was accounted for by introducing a 3T3 control in all 
experiments.   
3.2.2. NHEK culture in the 'feeder' system
 The successful culture of normal human epidermal keratinocytes (NHEKs) 
in the 3T3 'feeder' system was established. Colony morphology and cloning 
efficiency were assessed and the growth conditions optimised. They are 
described below.
 NHEKs and lethally irradiated 3T3s were inoculated into the culture dish 
as a mixture. The 3T3 cells attach first to the surface and quickly form a 
monolayer on which the small round keratinocytes rest. These are hardly 
discernible from the 'feeders' in the first couple of days but about four days 
following inoculation small colonies start being visible. At this point cells have 
finally made contact with the surface of the culture dish and, as the colonies 
expand, keratinocytes push and displace the 'feeder' cells into a compacted 
'cuff' which delineates the periphery of each colony (Fig. 3.1.). 
 Keratinocyte colonies show a typical polygonal epithelial morphology, 
centrifugal growth and stratification, resembling normal epidermis. 
Keratinocytes divide from the centre to the periphery, forming a thin layer of 
small compacted cells that is always visible as a single layer at the edge of the 
colony. These cells are in close contact with the dish surface and, therefore, are 
thought to resemble the germinative cells in normal epidermis, harbouring the 
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potential for cell division. The centre of the colonies appears very thick and 
composed of stratified layers of flat squamous cells (Fig. 3.1.). 
 It is also possible to to identify two main types of keratinocyte colonies in 
culture, abortive and proliferative, reflecting the distinct growth potential of the 
clone-forming cell they derived from (Barrandon & Green, 1987). Proliferative 
colonies are bigger, composed of very small cells, and most likely derive from 
holoclones, whilst abortive colonies are smaller, containing big, flattened, 
squamous-like cells that aborted growth and terminally differentiated, therefore 
probably originating from a paraclone (Fig. 3.1.).
Figure 3.1. Morphology of NHEK colonies in the 'feeder' system. Arrows show  the ‘cuff’ of 
compacted ‘feeders’ pushed away by the growing keratinocyte colonies. A shows 3 
adjacent proliferative colonies and B an abortive colony. In C and D cells were stained 
with 1% rhodamine B, a dye that binds keratin therefore selectively staining 
keratinocytes. The staining highlights the pattern of centrifugal growth and stratification 
as well as the difference in colony size and cell morphology between proliferative (C) 
and abortive (D) keratinocyte colonies. NHEKs in A were seeded at  5 x  104 per 60 mm 
dish and cultured for 7 days; in B, C and D were seeded at 50 cells per 60 mm dish and 
cultured for 14 days. These phase contrast images were obtained at 100x 
magnification. 
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 NHEKs showed the best growth and cloning efficiency if kept in a 10% 
CO2/90% air atmosphere as opposed to the conventional 5% CO2/95% air used 
routinely in cell culture incubators. For seeding densities as low as 500 and 50 
cells per 60 mm culture dish (clonal densities) an optimum 10% cloning 
efficiency was obtained with 10% CO2/90% air contrasting strongly with the 4% 
obtained when cells were maintained in a 5% CO2/95% atmosphere (Fig. 3.2.).
Figure 3.2. Clonogenicity of NHEK cultured in the 'feeder' system. Normal human 
epidermal keratinocytes show optimum growth in a 10% CO2/90% air atmosphere. More 
colonies were obtained with 10% CO2/90% air compared to 5% CO2/95% air for the 
same seeding density (SD), reflecting an optimum 10% plating efficiency for 10% 
CO2/90% air as opposed to 4% obtained with 5% CO2/95% air. NHEK were plated at 
clonal densities of 50 and 500 cells per 60 mm culture dish and cultured for 14 days, at 
which point keratinocytes colonies were revealed by staining with 1% rhodamine B.
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3.2.3. Primer design
 If the cellular part of the work requires the use of a suitable, well 
established cell culture model, so does the molecular part need to rely on a 
good basis. The main objective of this study is to perform a transcriptional 
analysis of four genes that are candidate markers for telomere-induced 
senescence in keratinocytes. For the results to be reliable it is necessary to 
understand the requisites for and limitations of gene expression analysis using 
qPCR. A set of guidelines has been established to ensure homogeneity and 
accuracy in qPCR experimental design and data analysis and presentation 
(Bustin et  al, 2009). Poor choice of primers for qPCR has been put forward as 
one of the three main causes of technical error that influence assay 
performance. Others include inadequate sample storage, preparation and 
nucleic acid quality, as well as inappropriate data and statistical analysis. I will 
describe here the rationale behind the primer design strategy used for 
candidate markers HIST2H2BE, ICEBERG, S100A7 and HOPX, for reference genes 
YAP1 and POL2RA, as well as for TRF2, TRF2!B!M, p14ARF, p16INK4a, p53, p21WAF1, 
Involucrin and Cyclins A2 and D1. For further technical details please refer to 
the Materials and Methods section (Chapter 2).
 To ensure the best qPCR assay performance, good primer design should 
result in high PCR efficiency (ideally 100%, where every cycle generates double 
the amount of DNA), specific PCR products with no primer-dimers or other non-
specific secondary structures, and no co-amplification of genomic DNA or 
pseudogenes. Design accounts for characteristics of the primers alone, their 
spatial interaction with themselves, each other and the template, as well as for 
location of the annealing sites and amplicon length. Primer size should be 18-30 
bp (ideally 19-25 bp), with a GC content of 30-80% (ideally 40-60%) to generate 
a Tm (melting temperature) of 60-70°C (ideal 64°C) and Ta (annealing 
temperature) of 58-62°C (ideal 60°C). !Tm between forward and reverse primers 
should be lower than 4°C. Good quality primer design software accounts for 
nucleotide content and position to prevent occurrence of mismatches with the 
target DNA, and also checks for complementarity within primers to avoid 
hairpins. When possible (for multiple exon genes), it is ideal to design intron-
spanning primers to avoid co-amplification of genomic DNA (for single exon 
genes the alternative is to perform DNase treatment on the RNA). Finally, 
smaller amplicons generate higher PCR reaction efficiencies, the ideal size 
being 60-120 nucleotides. 
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 The following workflow was used for primer design or analysis. When 
sequences were already known and obtained from a source, they were first 
analysed using the NCBI Primer-BLAST tool which predicts the identity of the 
mRNA amplified, the annealing sites of the primers and product size. When 
primers were not already available they were designed using the online Roche 
Universal probe tool. Products were amplified using qPCR and analysed for 
generation of a single peak, for consistence in Tm and for quality/consistence of 
standard curves. If qPCR generated a specific, good quality product, primers 
were accepted. If not, or when primer sequences were not available, they 
were redesigned or designed from scratch. 
HIST2H2BE, ICEBERG, S100A7 and HOPX
 These four genes have been put forward as potential specific markers for 
telomere-induced senescence in normal human keratinocytes and primers for 
them have been previously described (Minty et al, 2008). The objective of this 
work is to assess their specificity for senescence induced by telomere 
dysfunction as opposed to senescence induced by other cellular pathways. 
Previously used primer sequences (Minty et al, 2008) were first introduced in the 
online NCBI Primer-BLAST tool to find out product lengths, annealing sites and 
specificity for the target. The results obtained are presented below (Figure 3.3). 
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Figure 3.3. Primer-BLAST analysis for sequences previously used (Minty, 2008) to amplify 
HIST2H2BE, ICEBERG (or CARD18), HOPX and S100A7. Products from partial alignments 
are not shown.
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 Based on Primer-BLAST analysis, all primer sets are specific for the genes 
in question and should theoretically generate a single product. Primers for 
HIST2H2BE and ICEBERG amplify a single variant (both genes produce solely one 
transcript variant). Primers for HOPX amplify transcript variants 1 and 5. Primers 
for S100A7 amplify S100A7 and S100A7A.
 More information on the genes to assess primer design strategy was 
obtained from the online NCBI Gene tool and gene maps are represented in 
Fig. 3.15. HIST2H2BE is processed as a single transcript containing a single exon 
so for this gene it is not possible to obtain primers that span an intron. ICEBERG 
also generates a single transcript containing 2 exons and an intron. S100A7 and 
S100A7A are two different genes, each generating a single transcript variant 
containing 3 exons and 2 introns, however sharing 95% homology (Fig. 3.4). 
Therefore, with the aforementioned primer set, amplification of S100A7 is 
accompanied by co-amplification of S100A7A.
Figure 3.4. BLAST analysis for homology between S100A7 and S100A7A transcripts. 
S100A7 mRNA is 439 bp, S100A7A mRNA is 4279 bp. Query = S100A7; Subject = S100A7A.
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 Finally, 5 transcript variants have been described for HOPX. Based on the 
gene map and primer annealing sites, and contrarily to the primer-BLAST 
prediction, two distinct products should be expected (Fig. 3.5). The forward 
primer anneals with a common area of exon 1 in variants 3, 1 and 5 while the 
reverse primer anneals with exon 2 of variant 3 and exon 3 of variants 1 and 5. 
Therefore, this set of primers should generate 2 products, one for variants 1 and 
5 with the same size (205 bp) and a smaller product for variant 3. 
Figure 3.5. Gene map for HOPX and primer annealing sites for sequences previously 
used (Minty, 2008) to amplify HOPX. Transcript variants 3, 1, 5, 4 and 2 for HOPX are 
represented, from top to bottom.
 All primer sets were tested by qPCR and the sets for HIST2H2BE, ICEBERG 
and S100A7 originated a single product (single melt curve) with the expected 
sizes (Fig. 3.17). However, due to the design strategy, directed solely at exons, 
some genomic DNA contamination was present (around 0.2% genomic DNA 
present in the final product). Despite limitations in product size (all products 
larger than 120 nucleotides) and design (not directed at exons spanning an 
intron) it was decided that the good quality of the products, the good 
efficiency of the qPCR reaction and the fact that using the same sequences 
would enable discussion of results in context with work previously published 
(Minty 2008), these primers were accepted and used for gene expression 
analysis of HIST2H2BE, ICEBERG and S100A7 (Fig. 3.15). 
 Contrarily to the primer-BLAST analysis (Fig. 3.3) but as predicted by 
looking at annealing sites in the gene map (Fig. 3.5), the primer set used for 
HOPX gave rise to 2 products, one of the predicted length and a smaller, less 
abundant product. The need for the generation of a single specific product, in 
addition to the disadvantageously long product size (well larger than 120 
95
nucleotides) generated by this primer set prompted me to design a new set of 
primers for this gene.
 In previous work (Minty et al, 2008) the primers used amplified variants 3, 
1 and 5. For the new design the decision was not to favour any transcript 
variants and to design a set that would amplify a common product to reflect all 
5 transcripts. This was not possible with an intron-spanning assay, so the design 
strategy was aimed at a common exon. The Roche Universal probe library 
generated the following set, that should result in a product of 84 nt. Primer-
BLAST analysis confirmed the generation of a single product, common to all 
variants, with the predicted size (Fig. 3.6 and 3.17). After testing by qPCR this 
was the set used for gene expression analysis of HOPX (fig. 3.15). 
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Figure 3.6. Primer-BLAST analysis for new primers designed to amplify all transcript 
variants of HOPX. Products from partial alignments are not shown.
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TRF2 and TRF2!B!M
 TRF2 or telomeric repeat binding factor 2 is crucial in the establishment of 
the telomeric complex in mammalian cells. The normal TRF2 gene is composed 
of 10 exons (Fig. 3.16) and encodes for the TRF2 protein which is composed of 
three main areas; the N-terminal basic domain, the dimerisation area and the 
C-terminal Myb domain. The latter is required for binding telomeric DNA. 
 A specific intron-spanning assay targeting the C-terminal Myb domain 
was used to design a set of primers which would amplify endogenous 
functional TRF2. Primers anneal to exons 9 and 10 (Fig. 3.16), area encoding for 
the Myb domain, and generate a 105 nt product (Fig. 3.7 and 3.17).
Figure 3.7. Primer-BLAST analysis for sequences designed to amplify TRF2. Products from 
partial alignments are not shown.
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 A dominant-negative mutant of TRF2 (TRF2!B!M) has been developed 
(van Steensel et al, 1998) which is characterised by lacking both the N-terminal 
basic and the C-terminal Myb domains. TRF2!B!M cDNA is conveyed in a pLPC 
plasmid backbone containing a Myc tag contiguous to the insert (Fig. 3.16). The 
latter contains only the coding regions required to originate the dimerisation 
domain of TRF2. 
 The design of a primer set to amplify exogenous TRF2!B!M was performed 
manually; the forward sequence directed at the Myc tag and the reverse 
sequence directed at the TRF2!B!M insert (Fig. 3.16). The resulting amplicon was 
94 nt in size, confirmed by gel electrophoresis (Fig. 3.17). Primer-BLAST analysis 
confirmed no endogenous sequences were amplified with this set of primers.
p14ARF and p16INK4a
 The gene CDKN2A or cyclin-dependent kinase inhibitor (CDKI) 2A 
encodes for two important tumour suppressors and main effectors of stress-
induced senescence, p14ARF and p16INK4a. Out of the 3 transcript variants 
described for this locus (fig. 3.16), variant 4 or " encodes for p14ARF, whilst 
variant 1 or # encodes for p16INK4a. Variant 3 originates a product which is 
expressed only in the pancreas. Each variant contains 2 introns and 3 exons, 
with the 2nd and 3rd exons being common between all and the first exon 
being specific to each of the variants - 1" for p14ARF and 1# for p16INK4a.
 A specific assay for variant 4 (p14ARF) was used to design a set of primers 
which would amplify p14ARF. Primers anneal to exon 1"  and exon 2, and span 
an intron (Fig. 3.16). qPCR analysis confirmed the generation of a single product 
of the correct size (Fig. 3.17), predicted by Primer-BLAST analysis (Fig. 3.8).
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Figure 3.8. Primer-BLAST analysis for sequences designed to amplify p14ARF. Products 
from partial alignments are not shown.
 A primer set for variant 1 (p16INK4a) was available and kindly donated by 
Dr Cleo Bishop (Blizard Institute, QMUL, London, UK). Based on primer-BLAST 
analysis (Fig. 3.9), design was aimed at exon 1# and exon 2; this indicates 
generation of 2 products, an amplicon 332 nt long corresponding to variant 3 
and the desired product of 58 nt corresponding to p16INK4a (Fig. 3.16). Since the 
first is too long and variant 3 is not expressed in keratinocytes, the generation of 
a single specific product of the correct size, corresponding to variant 1, was 
confirmed by qPCR (Fig. 3.17). 
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Figure 3.9. Primer-BLAST analysis for sequences designed to amplify p16INK4a. Products 
from partial alignments are not shown.
p53
 p53 is an important tumour suppressor and central molecule in apoptosis 
and senescence. A total of 7 transcript variants have been described for p53 
(Fig. 3.16). 
 A primer set for p53 was available and kindly donated by Dr Muy-Teck 
Teh (Institute of Dentistry, QMUL, London, UK). Design was aimed at common 
exons 7 and 8 (Fig. 3.16), based on primer-BLAST analysis (Fig. 3.10), and 
generated a 85 nt single product reflecting amplification of all variants. 
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Figure 3.10. Primer-BLAST analysis for sequences designed to amplify all transcript 
variants of p53. Products from partial alignments are not shown.
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p21WAF1
 p21WAF1 or CDKN1A, cyclin-dependent kinase inhibitor (CDKI) 1A, is the 
main downstream target of p53. The p21WAF1 gene encodes for 2 transcript 
variants, each containing 3 exons and 2 introns (Fig. 3.15). 
 A common assay was used to design a single set of primers to amplify 
both variants. Primers anneal to exons 2 and 3, and span an intron (Fig. 3.15). 
Amplicon size (127 nt) was just slightly above the recommended maximum of 
120 nt and qPCR analysis revealed a single product of good quality. A slight 
shift in Tm (of about 2°C) was observed between standards and samples, and a 
minimum amount of primer-dimers was present. Despite these limitations this set 
of primers was of better quality than other sets previously tested and that we 
had available. Designing primers for p21WAF1 is a challenge as it shares many 
common areas with other genes, which makes it a difficult gene to obtain a set 
for with maximum specificity and no unwanted secondary structures or partial 
annealing happening. Primer-BLAST analysis (Fig 3.11) showed specificity for the 
product but also over 30 other possible products from partial alignments. 
Amplicon size was confirmed (Fig. 3.17). 
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Figure 3.11. Primer-BLAST analysis for sequences designed to amplify all 
transcript variants of p21WAF1. Products from partial alignments are not shown.
Cyclins A2 and D1
 Cyclins are active regulators of the cell cycle. Both cyclin A2 and D1 
generate a single transcript variant, with 8 exons/7 introns and 5 exons/4 introns, 
respectively (Fig. 3.15. )Primer sets for both cyclins were available and kindly 
donated by Dr Muy-Teck Teh (Cyclin A2) and Dr Ann-Marie Bergin (Institute of 
Dentistry, QMUL, London, UK) (Cyclin D1). Primer-BLAST analysis (Fig. 3.12) of the 
sequences predicted the amplification of a single specific product and qPCR 
analysis confirmed and attested for the good quality of the amplicon 
generated and correct amplicon size (Fig. 3.17). It is possible to assess from the 
BLAST analysis that an intron-spanning assay was chosen for the design. The 
annealing sites are represented on Fig. 3.15; primers anneal to exons 6 & 7 for 
CCNA2, and to exons 2 & 3 for CCND1.   
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Figure 3.12. Primer-BLAST analysis for sequences designed to amplify CCND1 and 
CCNA2. Products from partial alignments are not shown.
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Involucrin
 Involucrin is a marker for terminal differentiation in keratinocytes. The 
involucrin gene originates a single transcript with only 2 exons and 1 intron (Fig. 
3.15). A primer set for involucrin was kindly donated by Dr Muy-Teck Teh. Both 
primer-BLAST (Fig. 3.13) and qPCR analysis revealed the expected product (Fig. 
3.17). Annealing sites are represented in Fig. 3.15 and clearly show that the 
design was directed at a single exon (exon 2). This is likely to be due to the 
really small size (only 27 bp) of the first exon, which would make it impracticable 
to aim for a intron-spanning assay.
Figure 3.13. Primer-BLAST analysis for sequences designed to amplify IVL. Products from 
partial alignments are not shown.
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YAP1 and POLR2A 
 The choice of appropriate reference genes for relative gene expression 
analysis by qPCR is essential for accurate quantification and reliability of the 
results (Bustin, 2009). Primer sets for YAP1 (AP1 Yes-associated protein 1) and 
POLR2A (POLR2A polymerase) were kindly donated by Dr Muy-Teck Teh. YAP1 
and POLR2A are 2 of 4 reference genes selected for their highest suitability as 
reference genes for keratinocytes (Gemenetzidis et  al, 2009). Gene maps with 
annealing sites (Fig. 3.16) and primer-BLAST analysis are presented below (Fig. 
3.14). Amplicon size was also confirmed (Fig. 3.17).
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Figure 3.14. Primer-BLAST analysis for sequences designed to amplify POLR2A and YAP1. 
Products from partial alignments are not shown.
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Figure 3.15. Gene maps for HOPX, HIST2H2BE, ICEBERG, S100A7, CCNA2, CCND1, IVL 
and CDKN1A showing primer annealing sites and product length. Maps represent the 
transcript  variants described in the NCBI database for each gene (boxes = exons; lines 
= introns; ! = fwd primer; " = rev primer).
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Figure 3.16. Gene maps for CDKN2A, p53, TRF2, TRF2!B!M, YAP1 and POLR2A showing 
primer annealing sites and product length. Maps represent  the transcript variants 
described in the NCBI database for each gene (boxes = exons; lines = introns; ! = fwd 
primer; " = rev primer) except for TRF2!B!M (exogenous gene) where the retroviral 
vector, containing the transgene, is represented. TRF2DN = TRF2!B!M (dominant negative 
mutant of human TRF2 with deletions in the basic and myb domains).
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Figure 3.17. Confirmation of PCR product size by gel electrophoresis. qPCR products 
were run on a 2.5% agarose gel and separated by electrophoresis. All cDNA was 
reverse transcribed from 1 !g RNA except for DN (+) control where 10 ng of plasmid 
DNA was used instead. Legend: DN = TRF2!B!M; -RT = no reverse transcriptase control; 
HIST = HIST2H2BE; ICE = ICEBERG; SA7 = S100A7; HOP = HOPX.
cDNA 
product
Gene name Transcript 
variant
mRNA 
accession #
CCNA2 Cyclin A2 [Homo sapiens] - NM_001237.3
CCND1 Cyclin D1 [Homo sapiens] - NM_053056.2
HIST2H2BE Histone cluster 2, H2be [Homo sapiens] - NM_003528.2
HOPX HOP homeobox [Homo sapiens] 5 variants -
ICEBERG CARD18 caspase recruitment domain family, 
member 18[Homo sapiens]
- NM_021571.2
IVL Involucrin [Homo sapiens] - NM_005547.2
p14ARF CDKN2A cyclin-dependent kinase inhibitor 2A 
[Homo sapiens]
Variant 4 or " NM_058195.2
p16INK4a CDKN2A cyclin-dependent kinase inhibitor 2A 
[Homo sapiens]
Variant 1 or # NM_000077.3
p21WAF1 CDKN1A cyclin-dependent kinase inhibitor 1A 
[Homo sapiens]
2 variants -
p53 Tumour protein p53 [Homo sapiens] 7 variants -
POLR2A Polymerase (RNA) II (DNA directed) 
polypeptide A [Homo sapiens]
- NM_000937.3
S100A7 S100 calcium binding protein A7 [Homo 
sapiens]
- NM_002963.3
TRF2 Telomeric repeat binding factor 2 [Homo 
sapiens]
- NM_005652.2
YAP1 Yes-associated protein 1 [Homo sapiens] 2 variants NM_006106.3
Table 14. Summary of gene information for products amplified by the sets of primers 
used.
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3.3. Discussion
 Keratinocytes differ from fibroblasts in their need for mesenchymal 
support for successful growth in culture. Under appropriate growth conditions 
sub-cultivation of normal human epidermal keratinocytes is possible for the full 
range of their lifespan of about 50 - 60 MPD. The establishment of appropriate 
cell culture conditions for growth is extremely important for this cell type as 
keratinocytes are particularly sensitive to cell culture stress and will readily 
activate p16INK4a and engage premature senescence due to inadequate 
support (Ramirez et  al, 2001). I  have obtained an optimum 10% plating 
efficiency during sub-cultivation, higher than the reported average of 1 to 5% 
but within the values obtained for cultures initiated from newborn foreskin 
(Rheinwald & Green, 1975a). This was possible due to the use of keratinocytes 
derived from this source, at early passage, combined with the good practice of 
subculturing cells whilst in exponential growth, the use of a ‘feeder’ layer and 
optimised growth conditions.
 Epidermal cells constitute a good in vitro model for the study of 
replicative senescence as the epidermis is characterised by a high cell turnover 
and is, therefore, a truly proliferative tissue in vivo. The use of keratinocytes 
derived from newborn foreskin was aimed at minimising experimental bias due 
to in vivo ageing by ensuring pathways of senescence are intact and not 
activated by UV damage, for instance. Variables due to in vitro ageing were 
minimised by using cells at very low passage under the lowest possible level of 
culture stress.
  Finally, since this is a gene expression study for the isolation of potentially 
specific markers for a mechanism of senescence, a great deal of importance 
was given to primer design. Poor choice of primers for qPCR has been reported 
as one of the main factors influencing assay performance and, ultimately, data 
analysis and interpretation (Bustin et  al, 2009). The rationale behind the 
strategies used for design, workflow and analysis of primer sets were presented. 
In general, I aimed at the best possible strategy for design and, when this was 
not feasible, limitations were presented and accounted for to ensure 
experimental accuracy.
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Chapter 4. Analysis of markers specificity to DNA 
damage-induced senescence. 
4.1. Introduction
4.1.1. DNA damage and repair
 Damage to the DNA is a frequent event. It usually affects just one of the 
strands of the molecule and can result from the action of both endogenous 
and exogenous agents (reviewed in (Hoeijmakers, 2001)). The most common 
type of lesions in the DNA are non-bulky alterations to bases, base substitutions 
or even deletions, as a consequence of spontaneous reactions or reaction with 
products of normal cell metabolism (Fig. 4.1). Damage can result from 
methylation due to alkylating agents, oxidation due to ROS (superoxide anions, 
hydroxyl radicals and hydrogen peroxide), deamination due to loss of the 
amino group converting cytosine to uracyl and depurination, or loss of purines, 
due to spontaneous hydrolysis of the N-glycosidic bond resulting in abasic sites. 
In addition, Ionising radiation (in the form of X-rays or ɣ-rays) can originate 
breaks in one of the DNA strands, single-strand breaks (ss-breaks or SSBs).
 Other agents can cause bulky alterations to the bases which result in 
both a helical distortion of the DNA duplex and a modification of the DNA 
chemistry (Fig. 4.1). The most significant of these lesions are pyrimidine dimers 
(cyclobutane pyrimidine dimers and 6-4 photoproducts) which result from the 
establishment of covalent bonds between two adjacent pyrimidine bases 
caused by the UV component of sunlight. Others include bulky chemical 
adducts and DNA intra-strand cross-links due to reaction with ROS and 
polycyclic aromatic hydrocarbons.
 In addition, despite its high replication fidelity and inherent proofreading 
ability, DNA polymerase errors can result in insertion of wrong bases during DNA 
replication resulting in base mismatches, insertions and deletions (Fig. 4.1). Many 
of these alterations block transcription and also interfere with DNA replication. 
Therefore, in order to maintain genomic stability and prevent the occurrence of 
mutations, several mechanisms have evolved to repair DNA damage. 
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 In general, resolution of lesions that affect only one strand of the DNA 
molecule relies on the intact complementary DNA strand, which can be used 
as a template for repair. It involves three main steps: excision, re-synthesis and 
ligation. Briefly, the damaged area is first recognised and excised by nucleases 
leaving a 'nick' in the faulty DNA strand, a single-strand break (ss-break or SSB). 
A repair DNA polymerase is then recruited to the area to restore the original 
sequence, using the complementary strand as a template for synthesis. Finally, 
the nick left in the sugar-phosphate backbone of the repaired strand is sealed 
by a DNA ligase. Whilst the re-synthesis and ligation steps use similar enzymes 
(DNA polymerases and ligases, respectively), the excision step requires 
specialised nucleases, depending on the modification that occurred in the 
DNA molecule. From here emerge specialised repair pathways: BER, NER and 
MMR.
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 Figure 4.1. Causes of DNA damage, consequences and repair. a. Some of the most 
common DNA damaging agents, the lesions provoked by them and the mechanisms 
used for repair; b. The acute and permanent effects of DNA damage in the cell. 
Abbreviations: (6-4)PP =  6-4 photoproduct; CPD = cyclobutane pyrimidine dimer; cis-Pt 
= cisplatin; MMc = mitomycin C (in (Hoeijmakers, 2001)).
Base-excision repair (BER) pathway 
 The BER pathway (Lindahl & Wood, 1999; Mol et al, 1999) corrects lesions 
arising from the normal cellular metabolism. It is involved in repairing non-bulky 
modifications to bases in the DNA, resulting from methylation, oxidation, 
deamination, spontaneous hydrolysis or SSBs. BER operates through two sub-
pathways (Fig. 4.2), the “short-patch” (main pathway) and the “long-
patch” (backup pathway).
 “Short-patch” BER implies the replacement of the damaged base with a 
single new nucleotide. It is initiated by the action of a DNA glycosylase which 
flips the base out of the helix and cleaves the N-glycosidic bond between the 
damaged base and the sugar phosphate backbone of the DNA. This cleavage 
generates an abasic site in the DNA, which can also arise by the spontaneous 
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hydrolysis of the N-glycosidic bond. In either case, the abasic site is 
subsequently processed by APE1 (endonuclease AP1) which cleaves the 
phosphodiester backbone immediately 5' to the abasic site, resulting in a 3' 
hydroxyl group and a transient 5' abasic deoxyribose phosphate (dRP). 
Removal of the dRP is accomplished by the action of DNA polymerase beta 
(DNA pol"), which adds one nucleotide to the 3' end of the nick and removes 
the dRP moiety via its lyase activity. The strand nick is finally sealed by the 
XRCC1-ligase 3 complex, thus restoring the integrity of the DNA.
 “Long-patch” BER is employed to repair SSBs or modified bases which 
are resistant to the lyase activity of DNA pol". Although it requires many of the 
same factors involved in the “short-patch” repair, including a DNA glycosylase, 
APE1 and DNA pol", it alternatively results in the replacement of approximately 
2-10 bases, along with the damaged base, and it is a PCNA-dependent 
pathway. Single-strand breaks will activate PARP (poly (ADP-ribose) 
polymerase) and PNK (polynucleotide kinase) which will then bind the SSB, via 
interaction with the scaffold protein XRCC1, in order to protect and trim the 
ends for repair synthesis. This involves PCNA (proliferating cell nuclear antigen) 
and DNA pol%/& and results in the displacement of the damaged site as part of 
a DNA “flap” containing 2-10 nucleotides. The oligonucleotide ‘overhang’ is 
then excised by endonuclease FEN-1 the sequence sealed by DNA ligase 1.
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Figure 4.2. Base excision repair (BER) pathways. I. cleavage of damaged base by a 
DNA glycosylase; II. strand incision at the abasic site by APE1 endonuclease; III. XRCC!-
mediated protection and trimming of SSB ends by PARP and PNK; IV. XRCC1-mediated 
1-nucleotide gap-filling reaction by DNA pol"; V. removal of the 5’-baseless sugar 
residue by DNA pol"  lyase activity; VI. sealing by the XRCC1-ligase 3 complex; VII. 
PCNA-mediated repair synthesis (2-10 nucleotides) by DNA pol%/&; VIII. removal of 
displaced DNA “flap” by FEN1 endonuclease; IX. sealing by DNA ligase 1(in 
(Hoeijmakers, 2001)).
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Nucleotide-excision repair (NER) pathway
 The NER pathway (de Laat et  al, 1999) is involved in repairing bulky 
modifications to bases in the DNA, which result in helical distortion and 
chemical modifications of the DNA duplex. These result, for example, from 
covalent bonds between bases and hydrocarbons (bulky adducts) or 
pyrimidine dimers from exposure to UV light, which require removal of the entire 
nucleotide. The NER process includes damage recognition (by specialised 
nucleases), local opening of the DNA duplex around the lesion (by DNA 
helicases), dual incision of the damaged DNA strand, gap repair synthesis and 
strand ligation. NER also operates through two sub-pathways (Fig. 4.3), the 
global genome NER (GG-NER), which corrects damage in transcriptionally silent 
areas of the genome, and the transcription-coupled NER (TC-NER), which 
repairs lesions on the actively transcribed strand of the DNA. They are 
fundamentally identical, except in their mechanism of damage recognition. 
 In GG-NER, the XPC/HHR23B protein complex is responsible for the initial 
detection of damaged DNA, which is essentially based on recognition of 
disrupted base pairing rather than of actual lesions. Conversely, damage 
recognition during TC-NER does not require XPC, but rather is thought to occur 
when the transcription machinery is stalled at the site of injury. The stalled RNA 
polymerase complex must then be displaced in order to allow the NER proteins 
access to the damaged DNA. This displacement is aided by the action of the 
CSA and CSB proteins, as well as other TC-NER-specific factors. The subsequent 
steps of GG- and TC-NER proceed in an essentially identical manner. XPA and 
the hetero-trimeric replication protein A (RPA) then bind at the site of injury and 
further assist damage recognition. Next, the XPB and XPD helicases, 
components of the multi-subunit transcription factor TFIIH, unwind the DNA 
duplex in the immediate vicinity of the lesion. The endonucleases XPG and 
ERCC1/XPF then cleave one strand of the DNA at positions 3' and 5' to the 
damage, respectively, generating an approximately 30 base oligonucleotide 
containing the lesion. This oligonucleotide is displaced, making way for gap 
repair synthesis (performed by DNA pol%/&, as well as several replication 
accessory factors). Finally, the nick in the repaired strand is sealed by a DNA 
ligase, thus completing the NER process.
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Mismatch repair (MMR) pathway
 The DNA mismatch repair (MMR) pathway plays an essential role in the 
correction of replication errors such as base-base mismatches and insertion/
deletion loops (IDLs) that result from DNA polymerase mis-incorporation of 
nucleotides and template slippage, respectively (Hoeijmakers, 2001). Mis-pairs 
generated by the spontaneous deamination of 5-methylcytosine and hetero-
duplexes formed following genetic recombination are also corrected via MMR. 
The overall process of MMR is similar to the other excision repair pathways (see 
long-patch BER, and NER), in that the DNA lesion (mismatch or IDL) is 
recognised, a patch containing the lesion is excised, and the strand is 
corrected by DNA repair synthesis and re-ligation.
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Figure 4.3. Nucleotide excision repair (NER) pathways. I. recognition of helix-distorting 
lesions by the XPC/HHR23B complex  or displacement of stalled RNA pol II by CSA and 
CSB; II. opening of the DNA duplex around the lesion by XPB and XPD helicases, part of 
the multi-subunit transcription factor TFIIH; III. stabilisation of the open intermediate by 
RPA binding to the undamaged strand; IV. incision of the 3’ by XPG and of the 5’ by 
ERCC1/XPF endonucleases with generation of a 24-30 oligonucleotide; V. gap-filling by 
the regular DNA replication machinery (in (Hoeijmakers, 2001)).
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 Standard DNA repair pathways (BER, NER and MMR) operate only to 
repair damage restricted to one of the strands of the double helix. However, 
there are situations where both strands are broken simultaneously originating 
DNA lesions called double-strand breaks (ds-breaks or DSBs) that are 
particularly genotoxic (reviewed in van Gent 2001; Hoeijmakers, 2001), since 
they pose problems for transcription, replication, and chromosome segregation 
(Fig.4.1). Damage of this type is caused by a variety of sources including 
exogenous agents, such as ionising radiation and certain genotoxic chemicals, 
such as strong oxidising agents and anti-tumour drugs. Also, endogenously 
generated reactive oxygen species, mechanical stress on the chromosomes 
and other endogenous processes can result in DSBs. Replication in an area of 
the DNA already containing a SSB will be converted into a DSB in one of the 
sister chromatids and DSBs are also naturally occurring intermediate structures 
during recombination in meiosis and in specific DNA rearrangement events in 
the immune system such as V(D)J recombination for assembly of Ig or T-cell 
receptor genes and Ig heavy chain class switching (Fig. 4.1 and 4.4). Since DSBs 
differ from most other types of DNA lesions in that they affect both strands of 
the DNA duplex and, therefore, prevent use of the complementary strand as a 
template for repair, two specialised pathways have evolved to deal with these 
defects - homologous recombination (HR) and non-homologous end joining 
(NHEJ) (Fig. 4.4). 
 The cellular decision as to which pathway to use for DSB repair seems to 
mainly depend on the stage within the cell cycle at the time of damage 
acquisition. NHEJ and HR differ in the requirement for an homologous template, 
in the accuracy of repair and in the phase of the cell cycle each is functional 
on. 
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Figure 4.4. Non-homologous end joining (NHEJ) and Homologous recombination (HR). 
Pathways for DSB repair. I. processing of 3’-ssDNA overhangs by the MRE11/RAD50/NSB1 
complex; II. nucleoprotein filament assembly by RAD5-related proteins; III. DNA strand 
exchange and synthesis; IV. ligation and resolving of recombination intermediate; V. 
recognition of free DNA ends by Ku70/Ku80; VI. recruitment of DNA-PKcs, XRCC4, DNA 
ligase 4 and processing factors; VII. ; processing and ligation (in Hoeijmakers, 2001).
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Non-homologous end-joining (NHEJ) pathway
 NHEJ (van Gent et  al, 2001; Hoeijmakers, 2001; Dobbs et  al, 2010) can 
operate in any phase of the cell cycle, it is the pathway predominantly used by 
mammalian cells and usually results in the correction of the break in an error-
prone manner with inherent loss or gain of nucleotides. This pathway is also 
required and regularly used to process DSB intermediates generated through V
(D)J recombination. Essential to NHEJ is the activity of the Ku70/Ku80 hetero-
dimeric protein. The Ku hetero-dimer initiates NHEJ by binding to the free DNA 
ends and recruiting other NHEJ factors such as DNA-PKcs (DNA-dependent 
protein kinase), XRCC4 and DNA Ligase IV to the site of injury. DNA-PKcs 
becomes activated upon DNA binding, and phosphorylates a number of 
substrates including p53, Ku and the DNA Ligase IV cofactor XRCC4. Processing 
factors such as the exo-endonuclease MRN complex (MRE11/Rad50/NBS1), as 
well as endonucleases FEN-1 and Artemis also get activated and are recruited 
to the site of injury. They process the DNA ends prior to ligation by Ligase IV in a 
complex that also includes XRCC4 and Ku (Fig. 4.4. NHEJ).
 
Homologous recombination (HR) pathway
 Unlike NHEJ, HR-directed repair (Haber, 2000; van Gent et  al, 2001; 
Hoeijmakers, 2001) corrects DSB defects in an error-free manner, with no loss of 
nucleotides, using a mechanism that retrieves genetic information from a 
homologous, undamaged DNA molecule. However, the majority of HR-based 
repair can only take place when a DSB occurs shortly after DNA has been 
replicated (in late S and G2) when an undamaged sister chromatid is available 
for use as a repair template. HR is, therefore, an alternative DSB repair pathway 
to NHEJ and it is similar to the homologous recombination that occurs during 
meiosis, except here there is no exchange of genetic material. HR is mediated 
by the RAD52 group of proteins, including RAD50, RAD51, RAD52, RAD54, and 
MRE1. Initial response to the DSB involves activation of ATM and one of its 
downstream targets, NBS1. The exposed DNA ends are first recognised by 
RAD52 protein and then processed into 3'-end single-stranded DNA (3’-ssDNA) 
overhangs via the nucleolytic activity of the MRE11/RAD50/NBS1 complex. The 
newly generated ssDNA ends are bound by RAD51 to form a nucleoprotein 
filament. RAD51, in conjunction with RPA, RAD52, RAD54, BRCA1, BRCA2, and 
several additional RAD51-related proteins, serve as accessory factors in filament 
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assembly and subsequent activities. The RAD51 nucleoprotein filament then 
searches the undamaged DNA on the sister chromatid for a homologous repair 
template. Once the homologous DNA has been identified, the damaged DNA 
strand invades the undamaged DNA duplex in a process referred to as DNA 
strand exchange. A DNA polymerase then extends the 3' end of the invading 
strand and subsequent ligation by DNA ligase I yields a hetero-duplexed DNA 
structure. When this recombination intermediate is resolved, the precise error-
free correction of the DSB is complete (Fig. 4.4. HR).
Consequences of DNA damage
 All DNA damage repair mechanisms described previously are in place to 
ensure genomic stability. However, when damage is too extensive and/or repair 
is not successful this can have varied consequences to the cell. Accumulation 
of DNA damage can result in mutations that ultimately induce permanent 
changes towards cancer (Fig. 4.1). Two main types of genetic instability, 
mutational and chromosomal, have been observed in tumour cells (reviewed in 
(van Gent et al, 2001; Hoeijmakers, 2001). 
 Mutational instability (MIN) is associated with ss-breaks resulting from 
point mutations or small deletions and usually arise from defects in the BER 
pathway. The condition xeroderma pigmentosum, characterised by an an 
extreme sensitivity of skin to UV-light and a high propensity to skin cancer, is an 
example of impairment of the NER pathway in which thymine dimers (formed 
following exposure to UV light) are not repaired. 
 Chromosomal instability (CIN) relates to extensive rearrangement of 
chromosomes, mainly as a result of unrepaired DSBs which are particularly 
genotoxic. Loss of entire chromosomes or chromosome fragments can result in 
inactivation of tumour-suppressor genes whilst gain or amplification of 
chromosomal regions can lead to activation of proto-oncogenes, both 
contributing to genomic instability and tumourigenesis. Chromosomal 
rearrangements such as translocations, where chromosome arms are 
exchanged, can also occur. This causes deregulation of gene expression or 
even fusion between genes that may then acquire oncogenic potential. 
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 Several human syndromes arise from mutations in key genes in the 
specialised DNA ds-break repair pathways HR and NHEJ and highlight their 
importance in the maintenance of genomic integrity. Ataxia telangiectasia (AT) 
is a classic human syndrome characterised by high incidence of chromosomal 
translocations and predisposition to lymphomas. Patients with AT are extremely 
sensitive to ionising radiation as they are not able to repair DSBs due to a 
mutation in the key gene ATM (Ataxia telangiectasia mutated). Nijmegen 
breakage syndrome (NBS) shows a similar cellular phenotype to AT, 
characterised by radio-sensitivity but now by a mutation in the NBS1 gene. The 
latter is a target for phosphorylation by ATM and, consequently, regulates the 
activity of the MRE11-RAD50-NBS1 complex. Mutations in BRCA1 and BRCA2, 
genes that are also phosphorylated by ATM, result in susceptibility to breast 
cancer. Two other conditions, Werner's and Bloom syndromes, are caused by 
mutations in WRN and BLM genes, respectively, both encoding for DNA-
unwinding enzymes from the RecQ helicase family. Interaction of WRN with the 
Ku hetero-dimer results in increased WRN exonuclease activity whilst a 
defective BLM gene originates more sister chromatid exchanges in HR. 
Cell cycle checkpoints and cell cycle arrest                                                               
 As DSBs have a high potential for genotoxicity several cell cycle 
checkpoints are in place to prevent cells from carrying these lesions to their 
progeny. In eukaryotes, the G1/S and G2/M checkpoints control progression to 
DNA replication and to mitosis, respectively (Fig. 4.1). Damage to the DNA is 
acknowledged and signalled so that cell cycle arrests transiently to allow 
enough time for repair before progression into replication or division. If repair is 
successful cell cycle is resumed, but if damage is too extensive and/or repair is 
just not possible the signalling from cell-cycle checkpoints persists to enforce 
permanent shutdown of the cell.
 Cellular fate upon activation of cell cycle checkpoints is dependent on 
the severity of the DNA damaging agent and on the cell type. In general, 
normal cells, as opposed to transformed cells, will tend towards senescence as 
they have intact signalling pathways (Ben-Porath & Weinberg, 2005). Ionising 
radiation at relatively low doses activates DNA damage signalling resulting in 
transient cell cycle arrest from which fibroblasts recover. High doses of IR, 
however, cause persistent signalling and ultimately trigger permanent cell cycle 
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arrest (Rodier et  al, 2009). Generally, senescence is induced by lower levels of 
damage than those required to ensue apoptosis (Ben-Porath & Weinberg, 
2005). p53 and ATM/ATR are central proteins in the signal transduction cascade 
to DNA damage, especially in the response to DSBs, towards apoptosis or 
cellular senescence (Campisi & d'Adda di Fagagna, 2007). Molecularly, factors 
such as differences in post-translational modifications, in binding proteins and in 
transcriptional targets of p53 upon different stimuli, have been implicated in 
how cells might commit to each of these two possible fates (Ben-Porath & 
Weinberg, 2005).
4.1.2. DNA damage-induced senescence (p53 pathway)
 Damage to the DNA, especially in the form of DSBs, trigger a cascade of 
events called the DNA damage response (DDR) where p53 is the main effector 
molecule that ultimately halts cell cycle progression (reviewed in (Campisi & 
d'Adda di Fagagna, 2007)). Damage to the double helix is first recognised by 
DNA damage sensors which activate the transducers of signal ATM (Ataxia 
telangiectasia mutated) and ATR (Ataxia telangiectasia and Rad-3 related), 
enzymes with protein kinase activity. Sensors include the MRN complex (MRE11/
RAD50/NBS1), which interacts with ATM, and RPA and RFC-like complexes 
(containing RAD17) that recruit the RAD9/HUS1/RAD1 complex (911 complex), 
which in turn interacts with ATR. Histone H2AX also localises to sites of damage, 
is activated via phosphorylation by ATM/ATR or by DNA-PKcs and triggers 
chromatin modifications that will consequently recruit other proteins. Some will 
be involved in repair efforts (DNA-end stabilising heterodimers Ku70/80, DNA 
ligase IV, MRE11 exonuclease, DNA helicase BLM) and others in boosting ATM/
ATR signalling and further transducing the signal. Adaptor proteins such as 
53BP1/MDC1 and BRCA1/Claspin mediate the signal from upstream kinases 
ATM/ATR to downstream kinases CHK2/CHK1, respectively, which ultimately 
activate their main phosphorylation target, effector protein p53 (Fig. 4.5). 
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Figure 4.5. The DNA damage response (DDR). 53BP1, p53-binding protein-1; ATM, Ataxia 
telangiectasia mutated protein; ATR, ATM and Rad-3 related protein; BRCA1, breast 
cancer type-1 susceptibility protein; CHK1 and CHK2, checkpoint-1 and checkpoint-2 
proteins; HUS1, hydroxyurea-sensitive-1 protein; MDC1, mediator of DNA damage 
checkpoint protein-1; MRE11, meiotic recombination-11 protein; NBS1, Nijmegen 
breakage syndrome-1 protein; SMC1, structural maintenance of chromosomes 
protein-1 (in (Campisi & d'Adda di Fagagna, 2007)).
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  Upon replicative senescence or following exposure to DNA damaging 
agents (IR, UV and bleomycin), p53 activation occurs essentially via ATM/ATR-
related increase/decrease in phosphorylation at different sites, with p53-
phosphoSer15 being the post-translational modification of p53 common to all. 
Replicative senescent cells, for example, acquire additional distinctive 
phosphorylation patterns such as an increase at Thr18/Ser376 and decrease at 
Ser 392 (Webley et al, 2000). A comparison between the pattern of changes on 
phospho-specific p53 epitopes observed in normal human fibroblasts (NHFs) 
after senescence and following irradiation (UV and IR) is presented in Figure 4.6. 
Figure 4.6. Modifications in p53 upon activation by different stimuli. Venn diagram 
representing the effects of senescence, UV radiation, and IR on phosphospecific p53 
epitopes in human diploid fibroblasts. Increase in DO-1 binding relates to a decrease in 
p53-phosphoSer20 and increase in PAb421 binding relates to a decrease in p53-
phosphoSer376 (in (Webley et al, 2000)).
 p53 engages the senescence program, as a consequence of direct 
damage to the DNA, via its main transcriptional target p21WAF1 (CDKN1A), a 
cyclin-dependent kinase inhibitor (CdkI) which acts a a central regulator of the 
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G1 checkpoint (reviewed in (Ben-Porath & Weinberg, 2005)). p21WAF1 inhibits cell 
cycle progression directly, either by interfering with CDK2/Cyclin A, CDK4/Cyclin 
D and CDK6/Cyclin D complexes, required to proceed from G1 (Zhang et al, 
1994) or by interfering with DNA replication in S phase by interaction with PCNA, 
the subunit of DNA pol% (Li et  al, 1994). p21WAF1 can also halt cell cycle 
progression indirectly, by activating pRb via inhibition of CDK2/Cyclin E and 
CDK1/Cyclin B complexes; pRb, in turn, arrests the cell cycle by binding E2F 
transcription factor (reviewed in (Campisi, 2005)). 
 In normal human fibroblasts exposed to DNA strand breaking chemicals, 
such as bleomycin or actinomycin D, cellular proliferation is permanently halted 
via DDR with immediate activation of p53 and p21WAF1 after damage (Robles & 
Adami, 1998). p21WAF1 signalling is sustained for several days by which point 
both p53 and p21WAF1 levels return to baseline and p16INK4a levels increase. This 
suggests that p53/p21WAF1 initiate the senescence signal while p16INK4a seems to 
be responsible for maintaining it (Itahana et al, 2001; Ben-Porath & Weinberg, 
2005). Ionising radiation induces similar activation of the DDR with transient 
growth arrest after low doses and permanent cell cycle arrest after high doses, 
but levels of p16INK4a were not assessed (Rodier et al, 2009). In replicatively 
senescent fibroblasts, however, p21WAF1 and p16INK4a seem to be independently 
up-regulated. Single cell analysis showed that the signal from dysfunctional 
telomeres is transmitted preferentially through ATM/Chk2 accompanied by a 
characteristic G1 arrest. Stable arrest, however, requires continuous signalling 
and this pathway did not affect expression of p16INK4a, the delayed induction of 
which occurs in a telomere- and DNA damage- independent, and apparently 
stochastic, manner (Herbig et al, 2004). 
 DNA ds-breaks, as visualised by markers of the DDR, accumulate in 
mouse tissues with age (Wang et al, 2009). However, more recently it has 
become apparent that the unrepaired persistent DSBs (Sedelnikova et  al, 2004), 
as visualised by the 53BP1/ɣ-H2AX dual staining and an increase in ɣ-foci size, 
are the lesions responsible for inducing the expression of a variety of secreted 
proteins indicative of SASP (Rodier et al, 2009). Other markers (Rodier et al, 
2011) have now defined these unrepairable DSBs as DNA SCARS and it is 
thought these lesions are a major trigger for senescence in vivo (Fumagalli et  al, 
2012). Terminal DNA is not exposed and thus is not recognised and processed 
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by the cell as a DSB because it is protected by telomeres. These specialised 
capping structures also ensure that DSB repair pathways HR and NHEJ are not 
inappropriately activated at chromosome ends, preventing deletion of 
telomeric DNA, formation of dicentric chromosomes and other serious cell 
anomalies (reviewed in de (de Lange, 2005)). However, telomeres are also very 
poor at repairing DSBs, especially in response to oxidative damage (Kruk et  al, 
1995; Petersen et  al, 1998) and recent data suggests that DDR markers may 
locate to the telomere because they are a preferential site for unrepaired DSBs 
(Fumagalli et  al, 2012; Hewitt et al, 2012). In other words, the location of DSBs at 
telomeres may be a coincidental consequence of poor DNA repair unless they 
are eliminated by telomerase.
 Although it has been shown in human fibroblasts that dysfunctional 
telomeres are recognised by the DNA damage machinery and trigger a DDR 
that ultimately results in senescence (d'Adda di Fagagna et  al, 2003; Takai et  al, 
2003; Herbig et  al, 2004), telomere dysfunction in human keratinocytes, either 
via experimental telomere uncapping or via telomere erosion following 
replicative exhaustion, caused a senescent-like growth arrest accompanied by 
a very weak DDR (Minty et al, 2008). Subsequent microarray analysis revealed 
several genes induced by telomere dysfunction, and four (HIST2H2BE, ICEBERG, 
S100A7 and HOPX) apparently regulated by telomerase (Minty et  al, 2008). 
These show potential as markers for telomere dysfunction-induced senescence 
(TDIS).
 One possible reason for the differences observed between fibroblasts 
and keratinocytes could be that the latter are unusually sensitive to telomere 
uncapping and ensuing DDR. This could mean that some of the candidate 
biomarkers would also be induced following induction of DNA damage (using 
ionising radiation, for example) and, consequently, might not be as specific to 
telomere damage as first realised. Indeed this is a problem with all the secreted 
biomarkers identified so far (Jiang et al, 2008). To investigate HIST2H2BE, 
ICEBERG, S100A7 and HOPX’s specificity as markers for keratinocyte TDIS I 
started by testing their response to both acute and permanent DNA damage.
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4.2. Induction of acute DNA damage
 Telomere uncapping via expression of TRF2!B!M generated a surprisingly 
weak DDR in human keratinocytes that, nevertheless, resulted in senescence 
and elevation of the four candidate markers (Minty et al, 2008). This low level of 
activation of the p53 pathway was demonstrated by a small increase in p53 
phosphorylation at Serine 15 (p53-pS15) and p21WAF1 protein levels, 
accompanied by a low incidence of 53BP1 DNA damage foci. Furthermore, 
when keratinocytes lacking p16INK4a undergo replicative senescence following 
telomere erosion, the induction of p53-pS15 and p21WAF1 protein is similarly weak 
(Muntoni et  al, 2003), showing that the results can be repeated in a natural 
model of telomere dysfunction-induced senescence. One possible explanation 
for this is that keratinocytes might be unusually sensitive to the DDR and exit the 
cell cycle before DNA damage foci can accumulate. Thus, in order to test 
whether the low level of p53 activation was the factor responsible for inducing 
the candidate biomarkers normal human epidermal keratinocytes (NHEK) were 
synchronously irradiated with a relatively low dose of ionising radiation. This 
should cause a similar number of random DSBs in the DNA (approximately 50 
DSBs, (Löbrich et  al, 1994)) to the number of uncapped telomeres that might be 
initiated by expression of TRF2!B!M and recognised by the cell as DNA damage. 
 Keratinocytes were subjected to a relatively low dose (2 Gray) of IR, 
capable of inducing repairable DNA DSBs, and allowed a short period (6 hours) 
of recovery for repair. Engagement of the DDR was demonstrated by up-
regulation of p21WAF1, the downstream target of p53 and cell cycle inhibitor. 
Keratinocytes subjected to 2 Gy of IR show a 1.4-fold increase in p21WAF1 
transcript levels when compared to a non-irradiated control, after a 6hr 
recovery. Protein levels of p21WAF1 show a similar increase whilst total p53 is only 
mildly elevated (Fig. 4.7). Similar up-regulation of p21WAF1 and total p53 has 
been observed in NHEK with 1 Gy (ɣ-rays) after a 6hr recovery (Minty et al, 2008) 
and in the human diploid fibroblast strain HCA2 with 0.5 Gray (X-rays) following 
a 2hr recovery period (Rodier et  al, 2009). p21WAF1 has been reported to return 
to control levels on irradiated cells from 10h to 24h (Rodier et al, 2009) as by this 
point DSBs are thought to have been resolved, therefore eliminating the need 
for further DDR signalling (transient arrest). 
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Figure 4.7. Engagement of the DDR following induction of acute DNA damage. p21WAF1 
transcript  (graph) and protein (blot) levels in keratinocytes 6 hours following exposure to 
a relatively low  dose (2 Gray) of IR. mRNA levels (fold) were normalised against the non-
irradiated control (0 Gray). Results are represented as mean ± s.d. (n=2). Legend: ( + ) = 
positive control (SVHFK cell line) - last lane loaded with double the amount of total 
protein.
 Despite induction of p53, via activation of its transcriptional target 
p21WAF1, previously elevated to a similar level and accompanied by 
phosphorylation of p53 at Serine 15 (p53-pS15) in similar experimental conditions 
(Minty et al, 2008), none of the candidate markers showed a significant 
elevation of their transcript levels 6 hours following exposure to a 2 Gray dose of 
IR when compared to a non-irradiated control (Fig. 4.8). 
Figure 4.8. Candidate markers response upon induction of acute DNA damage. Gene 
expression levels of HOPX, HIST2H2BE, ICEBERG and S100A7 in keratinocytes 6 hours 
following exposure to a relatively low  dose (2 Gray) of IR. Values were normalised 
against the non-irradiated control (0 Gray). Results are represented as mean ± s.d. 
(n=3).
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 As expected, given this relatively low dose of IR, the activation of the p53 
pathway was transient and did not induce permanent growth arrest via 
senescence; this is supported by analysis of Cyclins A2 and D1 mRNA which 
remained at control levels (Fig. 4.9). A 2 Gray dose of ɣ-rays also produced no 
effect on keratinocyte differentiation following a 6 hr recovery period, as shown 
by unaltered transcript levels of involucrin (Fig. 4.9).
Figure 4.9. Effect of induction of acute DNA damage on cell proliferation and 
differentiation. Chart shows gene expression levels of Cyclins (A2 and D1) and Involucrin 
(IVL) in keratinocytes, 6 hours following exposure to a relatively low dose (2 Gray) of IR. 
mRNA levels (fold) were normalised against the respective non-irradiated control (0 
Gray). Results are represented as mean ± s.d. (n=3).
 
 The results indicate that the low level of p53 activation (weak DDR) does 
not seem to have been the factor responsible for the previously observed 
induction of the candidate markers. 
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4.3. Induction of permanent DNA damage
 Exposing keratinocytes to a dose of IR that mimics the level of damage 
to the DNA caused by telomere uncapping generated a similarly low DDR yet 
did not result in elevation of any of the candidate markers. However, expression 
of TRF2!B!M induces a senescent-like growth arrest in keratinocytes, despite the 
low DDR (Minty et al, 2008), whilst exposure to such a low dose as 2 Gray of IR 
does not. I therefore wondered whether a higher level of DNA damage caused 
by senescence-inducing doses of IR could induce the candidate markers. This is 
particularly important in view of the recent data implicating unrepairable DSBs 
in senescence (Rodier et  al, 2009) and ageing (Sedelnikova et  al, 2004) and 
that unrepairable DSBs are preferentially located at the telomeres (Fumagalli et 
al, 2012; Hewitt et al, 2012).
 To test this, keratinocytes were exposed to high doses (10 and 20 Gray) 
of IR, capable of generating unrepairable DNA DSBs, and given a 5 day 
recovery period to resolve any repairable DSBs. Engagement of the DDR was 
again demonstrated by up regulation of p53‘s transcriptional target, p21WAF1. 
Keratinocytes subjected to 10 Gy and 20 Gy show an over 2-fold increase in 
p21WAF1 mRNA levels, when compared to a non-irradiated control, which was 
accompanied by a similar increase of its protein levels. Total p53, however, was 
only mildly elevated (Fig. 4.10). It should be noted that p21WAF1 levels are 
constitutively higher in keratinocytes than in fibroblasts because of the well 
established role of p21WAF1 in epidermal differentiation (Macleod et al, 1995).
 Similar induction of p53 had been previously demonstrated, for 
comparable doses of IR, with p53-pS15 in addition to elevation of p21WAF1 and 
total p53 (Minty et al, 2008; Rodier et  al, 2009), and persistent 53BP1 foci (Rodier 
et al, 2009). In normal human fibroblasts, p21WAF1 signalling was sustained, as 
doses of this magnitude generate persistent DNA damage foci (PDDF) 
indicating permanent damage to the DNA through unresolved DSBs (Rodier et 
al, 2009).
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Figure 4.10. Engagement of the DDR following induction of permanent DNA damage. 
p21WAF1 transcript (graph) and total p53 and p21WAF1 protein (blot) levels in 
keratinocytes, 5 days following exposure to senescence-inducing doses (10 and 20 
Gray) of IR. mRNA levels (fold) were normalised against the non-irradiated control (0 
Gray). Results are represented as mean ± s.d. (n=2). Legend: ( + ) = positive control 
(SVHFK cell line); ( - ) = negative control (BICR-6 cell line).
 Accordingly, I observed that the amount of DNA damage generated 
and the constitutive DDR signalling that followed seemed to have resulted in 
growth arrest and senescence. Following exposure to senescence-inducing 
doses of IR (10 and 20 Gray), the average number of cells obtained 5 days 
following irradiation was similar to the value obtained for the day 0 control, 
which suggests a halt in cell division. In contrast, non-irradiated keratinocytes (0 
Gray) underwent normal proliferation yielding about 3x the average number of 
cells by day 5 (Fig. 4.11 Cell yields). In addition, a significant decrease in Cyclin 
A2 (CCNA2) accompanied by increase in Cyclin D1 (CCND1) transcript levels 
was observed in irradiated keratinocytes when compared to non-irradiated 
controls, 5 days following irradiation (Fig. 4.11 Cyclins). Since it is is well 
established that CCNA2 levels decline in senescent fibroblasts and CCND1 
levels increase (Duli' et al, 1993) and expression array data suggests that this is 
also true for keratinocytes (Hunter et  al, 2006), the growth arrest observed is 
consistent with senescence.
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 In addition, since two of the candidate markers (S100A7 and HOPX) 
have been implicated in terminal differentiation of human keratinocytes 
(Watson et  al, 1998; Yang et al, 2010) I monitored the expression levels of 
involucrin (IVL), a marker of later stages of epithelial differentiation (Rice & 
Green, 1979). This was particularly relevant for keratinocytes exposed to 
senescence-inducing doses of IR (10 and 20 Gray) and/or that remained for 
several days in culture. Five days following irradiation, involucrin transcript levels 
in irradiated keratinocytes were not significantly different from the levels found 
in non-irradiated cells (Fig. 4.11 Involucrin). This suggests that senescence-
inducing doses of IR do not induce terminal differentiation in normal human 
epidermal keratinocytes. I then decided to assess levels of keratinocyte 
differentiation markers over the 5-day period between irradiation and recovery. 
I found, by looking at changes in the non-irradiated controls, that although 
average transcript levels of IVL remained unaltered, p21WAF1 transcript was 
elevated by over 2-fold in keratinocytes which had undergone 5 days in culture 
(Fig. 4.11 non-irradiated controls). p21WAF1 expression is known to contribute to 
differentiation-associated growth arrest in keratinocytes (Missero et  al, 1996) by 
promoting commitment to the initial stages of differentiation. However, p21WAF1 
protein becomes down-regulated, both in vitro and in vivo, at later stages. In 
fact, p21WAF1 sustained expression is thought to act as a negative regulator and 
suppress terminal differentiation (Di Cunto et al, 1998). This suggests that over 5 
days keratinocytes were undergoing the initial stages of differentiation.
136
Figure 4.11. Effect of induction of permanent DNA damage on cell proliferation and 
differentiation. Top chart shows gene expression levels of Cyclins (A2 and D1)and 
Involucrin in keratinocytes, 5 days following exposure to senescence-inducing doses (10 
and 20 Gray) of IR; mRNA levels (fold) were normalised against the respective non-
irradiated control (0 Gray). Bottom left chart  shows cell yields obtained per treatment 
(0, 10 or 20 Gray) between day 0 and day 5 whilst bottom right chart shows transcript 
levels of Involucrin (IVL) and p21WAF1, in the non-irradiated controls (0 Gray) between 
day 0 and day 5; values were normalised against the respective day 0 control. Results 
are represented as mean ± s.d. (n=3); *p<0.05. Statistical significance was calculated by 
one-way ANOVA followed by Tukey’s post hoc test. 
 
137
 Despite activation of the p53 pathway of senescence 5 days following 
exposure to 10 or 20 Gray of IR, candidate markers HOPX, ICEBERG and S100A7 
did not show a significant elevation of their transcript levels, when compared to 
a non-irradiated control (Fig. 4.12). HIST2H2BE, however, demonstrated a dose-
dependent elevation of its mRNA levels with ɣ-radiation. I observed an average 
increase of 1.6-fold and 1.9-fold, 5 days following exposure to doses of 10 and 
20 Gray of IR, respectively (Fig. 4.12). Therefore, results show that only one of the 
markers, HIST2H2BE, was up-regulated by senescing-inducing doses of IR.
Figure 4.12. Candidate markers response upon induction of permanent DNA damage. 
Gene expression levels of HOPX, HIST2H2BE, ICEBERG and S100A7 in keratinocytes 5 days 
following exposure to senescence-inducing doses (10 and 20 Gray) of IR. Values were 
normalised against  the non-irradiated control (0 Gray). Results are represented as mean 
± s.d. (n=3); *p<0.05. Statistical significance was calculated by one-way ANOVA 
followed by Tukey’s post hoc test.
 Although HIST2H2BE was the only gene up-regulated by ɣ-radiation, we 
observed that, interestingly, all candidate markers were induced by time in 
culture alone, probably due to cells undergoing the early stages of terminal 
differentiation as indicated by the increase in p21WAF1 (el-Deiry et  al, 1995); see 
also Fig 4.11). HOPX, HIST2H2BE and ICEBERG transcript levels increased by 
about 2-fold, and S100A7 by around 8-fold between day 0 and day 5, in the 
non-irradiated controls (Fig. 4.13). A similar level of induction was found for 
HOPX, ICEBERG and S100A7 also across the irradiated groups; for HIST2H2BE, this 
baseline induction was accompanied by an IR-dependent elevation (Fig.4.13). 
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It is possible that p21WAF1 might be regulating the expression of all candidate 
markers in a differentiation-dependent manner and also HIST2H2BE in a 
senescence-dependent manner (via the p53 pathway). 
Figure 4.13. Effect of differentiation in the candidate markers gene expression levels. 
Charts show  transcript levels of of HOPX, HIST2H2BE, ICEBERG and S100A7, per treatment 
(0, 10 or 20 Gray) between day 0 and day 5. Values were normalised against the 
respective day 0 control. Results are represented as mean ± s.d. (n=3). 
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4.4. Discussion
 Keratinocytes seem to differ from fibroblasts in their response to 
dysfunctional telomeres. Telomere uncapping as a consequence of expression 
of the well characterised dominant negative mutant version of the telomeric 
protein TRF2, TRF2!B!M, results in a senescent-like growth arrest accompanied by 
an unexpectedly weak DNA damage response (DDR). Keratinocytes expressing 
TRF2!B!M show a characteristic transcriptional profile with up-regulation of genes 
involved in chromatin remodelling (HIST2H2BE, histone from the H2B family), 
inflammation (ICEBERG) and terminal differentiation (HOPX and S100A7). I 
hypothesised that either keratinocytes are extremely sensitive to the DDR or 
telomere uncapping is mainly being signalled through an alternative pathway 
to the classical DNA damage p53-dependent senescence pathway. 
 I tested the first argument by inducing a similar number of repairable 
DSBs to those predicted by telomere uncapping, with a relatively low dose of 
IR, and found that none of the candidate markers were induced by acute DNA 
damage (Section 4.2). This lead me to conclude that the the original elevation 
of HIST2H2BE, HOPX, ICEBERG and S100A7 expression levels by TRF2!B!M (Minty et 
al, 2008) was not a result of the low level of DDR observed following telomere 
uncapping.  
 In order to investigate the second argument, I started by assessing the 
influence of the activation of the DNA damage pathway of senescence in the 
candidate markers expression levels. I generated unrepairable DSBs using 
senescence-inducing doses of IR (Section 4.3) and found that histone HIST2H2BE 
was the only marker up-regulated as a consequence of permanent DNA 
damage. This is consistent with recent reports showing that chromatin 
components, such as H2A and H2B histones, are actively involved in the 
response to DNA damage. Monoubiquitylation of histone H2B has been 
identified as an additional post-translational protein modification to ATM-
dependent phosphorylation of various cellular targets, part of the DDR (Shiloh 
et al, 2011). H2B histones are ubiquitylated in response to DSBs and promote 
recruitment of repair proteins (Shiloh et al, 2011), such as Rad18 and BRCA1, to 
the DNA lesions in a RNF168-dependent manner (Panier et  al, 2012). In addition, 
impaired histone H2B monoubiquitylation was also recently described as a 
novel property of cancer cells in vivo, reported in breast, colon and lung 
tumours (Urasaki et  al, 2012). This indicates that HIST2H2BE is an active player in 
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the DDR response to generalised DNA damage and, therefore, is not a specific 
marker for telomere-dysfunction induced senescence. Results also suggest that 
the original elevation of HOPX, ICEBERG and S100A7 expression levels by 
TRF2!B!M (Minty et al, 2008) cannot be attributed to the activation of p53 via the 
DNA damage pathway. Therefore, although it was previously shown that the 
candidate markers are regulated by telomere dysfunction and telomerase 
(Muntoni et al, 2003; Minty et al, 2008), they do not appear to be up-regulated 
by p53. 
 Recently, several sequential molecular events that distinguish transient 
from persistent DDR signalling have been identified, following generation of 
DSBs by IR (Rodier et  al, 2011). Relatively low doses of ionising radiation result in 
many small DNA damage foci, the majority of which is resolved within 6 h and 
the remaining by 24 h. These transient foci contain various repair or adaptor 
proteins such as MDC1, 53BP1, NSB1 and MRE11, the modified histone ɣH2AX 
and activated ATM/ATR, indicative of DDR signalling. This shows that active 
repair is taking place by NHEJ as well as by HR, because cells damaged in S 
phase show evidence of ssDNA-binding proteins such as Rad51 and RPA70 in 
addition to DNA synthesis. On the other hand, cells exposed to senescence-
inducing doses of IR initially also accumulate many small DNA damage foci 
and attempt repair over a period of 24 h, where some of the small foci become 
resolved. However, in these cells some of the foci increase in size (contain more 
53BP1) and fail to resolve, with cell cycle arrest occurring within 24 h. In these 
persistent foci there is no evidence of repair; instead there is a characteristic 
association between 53BP1 and PML NBs (pro-myelocytic leukaemia protein 
nuclear bodies) as well as accumulation of activated forms of p53, CHK2 and 
ɣH2AX. Therefore, authors suggest that these permanent lesions, they 
designated as DNA-SCARS or ‘DNA segments with chromatin alterations 
reinforcing senescence’, do not contain sites of DNA damage but rather 
harbour stable modifications in chromatin, resulting from excessive damage or 
failure to repair it, responsible for maintaining the growth arrest. 
 DNA-SCARS are thought to constitute a reservoir of DDR signalling, 
including activated p53 and other DDR proteins, essential to the SASP (Rodier et 
al, 2009) as opposed to p53. Ubiquitylated H2B histones are some of the 
activated chromatin proteins involved in the ATM/CHK2 DDR pathway and in 
the recruitment of proteins involved in HR repair (Shiloh et  al, 2011; Panier et al, 
2012). This might explain the dose-dependent elevation of the candidate 
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marker HIST2H2BE in response to senescence-inducing doses of IR. DNA-SCARS 
include TIFs (Takai et  al, 2003) and foci resulting from both oxidative and 
oncogenic damage and, although the SASP component is an integral part of 
these lesions, the growth arrest component can be uncoupled from them in 
cells with non-functional p53 and pRb senescence pathways (Rodier et  al, 
2011). This means that it is unlikely the other candidate markers might be 
induced by inflammatory cytokines, such as IL-6, as they are part of the SASP, 
but other inflammatory pathways upstream of p53 and pRb should not be ruled 
out. Especially since ICEBERG is known to be induced by pro-inflammatory 
stimuli, despite its role as negative regulator of IL-1"  generation by inhibition of 
caspase-1 (Humke et al, 2000). Similarly S100A7, which is also known as psoriasin 
for having been firstly isolated from psoriatic skin, has  also therefore been linked 
with inflammatory pathways (Watson et al, 1998). In addition, the candidate 
markers can still be up-regulated by p53, pRb or components of these 
senescence pathways since neither functional p53 or pRb are required for the 
formation of DNA-SCARS (Rodier et al, 2011). 
 One interesting find from these experiments was the fact that all 
candidate markers were elevated just with time in culture. I related this to a 
natural elevation in p21WAF1 expression levels in the already higher basal levels 
characteristic of keratinocytes due to the role of p21WAF1 in terminal 
differentiation (Missero et  al, 1996). I hypothesise that senescence driven by 
telomere dysfunction might have also triggered terminal differentiation in 
keratinocytes, which could have contributed to the original elevation of the 
candidate markers (Minty et al, 2008). 
 This hypothesis is supported by the following arguments. Senescent 
keratinocytes are still capable of undergoing differentiation in culture 
(Norsgaard et  al, 1996). Although its expression is p53-dependent in response to 
DNA damage, p21WAF1 is also regulated independently of p53 in normal 
development of several murine tissues and during cell differentiation; in the 
latter it is also subjected to post-transcriptional regulation (Macleod et  al, 1995). 
I have observed that some of the candidate markers (HOPX, ICEBERG and 
S100A7) are not regulated by p21WAF1 in a p53-dependent manner in response 
to DNA damage but seem to be regulated in parallel with p21WAF1, 
independently of p53, during differentiation (HIST2H2BE included). In addition, 
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two subsequent studies to Minty et al’s (Minty et al, 2008) have identified 
terminal differentiation as a phenotype associated with ageing in both 
melanocytes (Inomata et  al, 2009) and keratinocytes (Velarde et al, 2012) in 
response to both DSBs and telomere dysfunction.
 p21WAF1 is responsible for the initial growth arrest preceding terminal 
differentiation and, although it promotes the commitment of keratinocyte 
populations to differentiation it also reduces the expression of late 
differentiation markers, such as loricrin and involucrin, in keratinocytes of the 
uppermost layers (Missero et  al, 1996). This is consistent with what I have 
observed for involucrin transcript which remained at control levels alongside 
elevation of p21WAF1. Increased expression of p21WAF1 has been shown to result 
in MAPK activation at the transcriptional level in a keratinocyte-specific and 
cell cycle-independent manner. IGF-1 was the factor upstream of the MAPK 
signalling cascade identified as responsible for the suppressive effect on 
terminal differentiation (Devgan et al, 2006). Since the candidate markers seem 
to be influenced by p21WAF1 independently of p53  it is, therefore, possible that 
candidate markers HOPX, ICEBERG and S100A7 might be regulated by any of 
the MAPK pathways. In fact, it has been recently shown in normal human 
fibroblasts that the SASP is regulated by p38MAPK via NF-K"  signalling, 
independently of the DDR and, thus, of p53 (Freund et al, 2011). Consistently, a 
role for the NF-K"  pathway in cellular senescence has also recently been 
reported in fibroblasts (Rovillain et al, 2011).
 The next priority was to investigate whether the candidate markers might 
be induced by over-expression of any of the effectors (p14ARF, p16INK4a and p53) 
of the know pathways of senescence (Chapters 5 and 6). Based on my findings 
so far, out of the three potential specific markers (HOPX, ICEBERG and S100A7) 
for TDIS, the homeobox gene HOPX seemed the most interesting candidate. 
HOPX expression levels were not induced by DNA damage and instead appear 
to be consistently slightly inhibited by it (Sections 4.2 and 4.3). Also, HOPX has 
recently been described as a tumour-suppressor gene (Chen et  al, 2007; De 
Toni et  al, 2008; Yamashita et al, 2008; Yamaguchi et  al, 2009) and this is a 
common feature of genes involved in cellular senescence. I have, therefore, 
also proceeded to investigate the functional role of HOPX in keratinocyte TDIS 
(Chapter 7).
143
Chapter 5. Establishment of an optimal low stress 
system for retroviral transduction of normal 
human epidermal keratinocytes to induce 
senescence by defined genes.
5.1. Introduction
5.1.1. Background
 Retroviruses were first discovered in the beginning of the twentieth 
century, however their full potential as gene delivery vectors only started to be 
acknowledged in the late 1960s and 1970s, following the discovery of their 
causal role in cancer and AIDS (Varmus, 1988). These viruses are mobile genetic 
elements belonging to the family of retrotransposons. They are distinctive from 
all other viruses for containing an RNA genome that replicates via a DNA 
intermediate, the provirus, as represented in Fig. 5.1 (Varmus, 1988; C Heiser, 
2004a).  
 The retroviral genome contains three genes, gag, pol and env which 
encode for all the proteins contained in the virion (Fig. 5.2). The gag gene 
encodes for the structural proteins of the core - matrix, capsid, nucleocapsid 
and contains the packaging sequence (. The pol gene encodes for the viral 
enzymes also contained in the core - protease, reverse transcriptase and 
integrase. The viral envelope originates from the hosts membrane (lipid bilayer) 
with additional surface and transmembrane proteins, products of the env 
gene. The receptors and entry co-factors determine the tropism of the retrovirus 
(Varmus, 1988; C Heiser, 2004a).
 The provirus is flanked by two long terminal repeats or LTRs (Fig. 5.2), 
involved in gene expression, that are composed by the following; region U3, 
containing the promoter and enhancer; region R, the starting point of 
transcription in the 5' end and the polyadenylation site in the 3' end; and region 
U5. In addition, 5'U3 contains a TATA box responsible for recruiting the basal 
transcription machinery to the promoter and a large number of transcription 
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factors binding sites. All these features make the retroviral LTR a powerful 
promoter in driving gene expression (Varmus, 1988; C Heiser, 2004a).
Figure 5.1. The retroviral life cycle. Steps involve 1. Binding to membrane receptors, 2. 
Fusion to cell membrane, 3. Un-coating and reverse transcription of RNA genome (2 
identical single strands), 4. Nuclear entry of DNA intermediate, 5. Integration of provirus, 
6. Transcription and 7. Translation into viral proteins, 8. Assembly of viral constituents, 9. 
Budding through the cell membrane and 10. Maturation of the viral particles (in (C 
Heiser, 2004a)).
 Retroviruses are obligatory intracellular parasites, they thus need to be 
able to integrate and use the cell's replication, transcription and translation 
machinery to propagate and be infectious. Simple retroviruses (e.g. MLV) 
require the host cell to be actively dividing for integration to occur, while 
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complex retroviruses (e.g. HIV), also called lentiviruses, have developed 
strategies to overcome this limitation and are able to infect non-dividing cells. 
Adenoviruses, on the other hand, have a DNA genome and do not integrate in 
the host's genome or replicate during cell division (C Heiser, 2004a).
Figure 5.2. The proviral sequence. LTR = Long Terminal Repeat; ( =  psi or packaging 
signal. 
 Retroviruses are very efficient tools for gene delivery, especially 
compared to transfection of naked DNA, with some vectors being able to 
stably transduce close to 100% of target cells with minimal or no physiological 
effects on the target cells (Mulligan, 1993). In addition to high transduction 
efficiency and low toxicity, other advantages of retroviral vectors over non-viral 
methods and adenoviruses are their genetic stability, due to integration of the 
provirus in the host's genome, the high expression levels of the transgene, due 
to their powerful promoter, and the flexibility of their genome which allows 
varied design strategies (Varmus, 1988). The fact that retroviruses use viral 
receptors to target the host cell endows them with a great advantage over 
non-viral methods, cell type specificity. They fuse with the cell membrane, 
transpose this first barrier and are then effectively uncoated and transported 
into the cell nucleus. The absolute necessity for the presence of a cellular viral 
receptor for cell targeting and their specificity to a narrow range of cellular 
receptors can be a disadvantage (Mulligan, 1993). However, this has been 
overcome by pseudotyping envelopes from other viruses into a parent 
retrovirus, therefore broadening the viral tropism (C Heiser, 2004a). Retroviral 
vectors can only infect cells that are actively dividing (Miller et al, 1990). This is 
an important limitation when compared to adenoviruses and lentiviruses since, 
as opposed to the latter, they absolutely depend on cellular replication for 
integration and, consequently, for effective transduction to occur. However, this 
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also means that they are safer options for the handler (Mulligan, 1993; C Heiser, 
2004a). 
 The main modification in retroviruses that first allowed them to be used 
safely as vectors for gene delivery was to make them replication-incompetent. 
Therefore, they integrate the host cell genome but are not infectious because 
they are missing or have deletions in coding regions required for packaging 
and virion replication. As a consequence they can now accommodate 
transgenes and various other sequences of interest which opened up a world 
of retroviral vector design options in parallel to the development of packaging 
cell lines.
5.1.2. Retroviral vectors and packaging cell lines
 The design of a retroviral vector consists in cloning the retroviral 
sequence into the multiple cloning site of a plasmid backbone using restriction 
enzymes. A classical vector must contain the LTRs, the packaging sequence (, 
the polypurine tract (PPT), control elements and the gene of interest, between 
the two LTRs, under the control of the LTR promoter. Other genes, encoding for 
selection markers, fluorescent markers or other molecular tags, and even 
Internal Ribosome Entry Sites (IRES), as well as additional promoters can also be 
inserted providing a wealth of possible design strategies to suit the objective of 
the work (C Heiser, 2004a). For example, CMV promoters are more powerful in 
driving gene expression than MLV promoters. Each promoter will allow for 
generation of separate transcripts encoding for transgene and selection 
marker, for instance, each with distinct expression levels. IRES vectors however, 
allow for both transgene and selection marker or fluorescent tag to be 
generated as a single transcript. This greatly reduces the probability of loss of 
expression of each insert independently and allows for generation of clones 
where the level of expression of the tag/marker should directly reflect the 
expression level of the transgene. This makes IRES vectors superior to 
conventional ones. Whilst the retroviral vector provides the gene(s) of interest 
and essential cis  elements for packaging, reverse transcription and integration, 
the packaging cell line provides the helper genome (gag, pol and env), that 
encodes for the viral proteins, in trans (Fig. 5.3) (Nolan lab website).
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 The concept of packaging cell lines was born from the observation that 
cells carrying a virus with a defective ( would produce replication-incompetent 
viruses (C Heiser, 2004a) and revolutionised the use of retroviral vectors for gene 
transfer (Mulligan, 1993).
Figure 5.3. Contribution of the retroviral vector and the packaging cell line for viral 
production. The retroviral vector provides the gene(s) of interest and essential cis 
elements for packaging, reverse transcription and integration. The packaging cell line 
provides the helper genome (gag, pol and env), which encodes for the viral proteins, in 
trans (LTR = Long Terminal Repeat; ( = psi or packaging signal).
 
 The first packaging cell line (-2 was based on NIH-3T3 cells and MLV with 
a deletion in ( and, obviously, limited tropism for murine cells (Mann et al, 
1983). Several other ecotropic lines followed with tropism for avian and some 
mammalian cells and the first amphotropic cell line (-AM was developed in the 
1980s. All first generation packaging cell lines were very efficient in producing 
retroviruses with high-titer (107 U/mL), but their major limitation was the 
generation of replication-competent helper viruses as a consequence of 
recombination events (Miller et al, 1990; C Heiser, 2004a). 
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 The next improvements focused on introducing multiple deletions in the 
helper genome and on reducing homology between the latter and the vector 
construct (Miller et al, 1990; C Heiser, 2004a). Therefore, second generation 
packaging cell lines (e.g. PA317) carry deletions in the splice donor site and in 
the 3'LTR in addition to deletions in (, already present in the previous cell lines 
(Miller, 2002). This strategy did not affect the titer and greatly reduced the 
probability of generating replication-competent retroviruses as two 
recombinant events would be required for this to occur. 
 An additional refinement was introduced to guarantee helper-free 
vectors (Miller et  al, 1990; Miller & Chen, 1996; C Heiser, 2004a). Third generation 
packaging cell lines ((-CRE, (-CRIP, GP+E-86, GP+envAM12, RetroPack PT67) 
carry a split helper genome which means that the gag-pol regions are 
separated from the env region . Three recombination events would be required 
for helper-viruses to be generated, which makes this extremely unlikely to occur. 
The viral genes can also be controlled using heterologous control elements 
(other than the LTR and poly-A) which greatly decreases the homology 
between helper and vector sequences. PT67 cells (Miller & Chen, 1996) are 
based on 10A1 MLV genome and have the particularity of producing vectors 
that use multiple receptors for cell entry. They contain the alternative receptor 
Glvr-1, in addition to the amphotropic receptor Ram-1, thus presenting an 
important advantage over the best amphotropic packaging cell lines in 
infecting human cells. 
 The latest generation packaging cell lines (BOSC23 and Phoenix) include 
several other refinements. Phoenix (Swift et al, 2001), as their predecessor 
BOSC23, were generated by introducing constructs expressing retroviral 
functions into 293T cells (Pear et  al, 1993). The latter derive from the HEK 293 
immortal cell line, developed in 1977 after transformation of human embryonic 
kidney cells in vitro with adenovirus type 5 DNA (Graham et  al, 1977). These cells 
have been used extensively since, for their ability to be easily transfected, and 
originated the 293T cell line after insertion of the SV40 T-antigen mutant gene 
(DuBridge et  al, 1987). Both BOSC23 and Phoenix systems are bipartite and 
capable of carrying episomes for rapid generation of high titer stocks of helper-
free retroviruses (Pear et al, 1993) although Phoenix lines do not demonstrate 
loss of titer over time, as did BOSC23, and are more stable due to a bipartite 
helper genome built with a good choice of promoters driving the expression of 
gag-pol (RSV) and env (CMV) (Nolan lab website). By using the gag-pol and 
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env regions separately and from two different viruses, homology between them 
was eliminated therefore preventing the generation of replication competent 
retroviruses. This was previously possible in a bipartite genome originating from 
the same virus if three homologous recombinational events occurred (Miller et 
al, 1990). By using non-Moloney promoters there is also less probability of 
recombination with the introduced retroviral construct carrying the transgene. 
In addition, it is possible to monitor gag-pol production via the expression of a 
surface marker (IRES-CD8) and to select Phoenix cells expressing gag-pol and 
env via two co-selectable markers (Nolan lab website).
5.1.3. Gene delivery
 The retroviral vector needs to be delivered to the packaging cell line for 
retroviral production. Gene delivery can be achieved by chemical and 
physical methods and is referred to as transfection. The lipid-based system 
FuGENE® 6 for transfection of mammalian cells constitutes an example of the 
many new lipid formulations/recipes that delivered improvements in 
transfection efficiency, compared to early chemical methods for DNA delivery 
like calcium phosphate and DEAE-dextran (Luo & Saltzman, 2000). The latter are 
based on the formation of complexes between the respective chemical and 
the DNA which are then in direct contact with the cells and subsequently 
internalized by endocytosis. DEAE-dextran and calcium phosphate methods 
are equally simple but more cytotoxic; calcium phosphate renders only a 50% 
transfection efficiency and, due to variation in the sizes of the calcium 
phosphate-DNA complexes, originates poor reproducibility between 
experiments; DEAE-dextran results in a much higher transfection efficiency, has 
good reproducibility but requires low or no serum in the growth medium and 
during transfection (Luo & Saltzman, 2000; C Heiser, 2004b).  
 The main limitations of the lipid-based methods are the still poor 
understanding of the lipid-DNA complexes and the variations in the formulation 
as a consequence of the fabrication process (Luo & Saltzman, 2000). Generally, 
a successful DNA delivery system should promote the contact with the cell 
membrane, mediate the uptake of the DNA by the cell via endocytosis, protect 
the DNA from degradation by endosomic/lysosomic enzymes and cytoplasmic 
nucleases, and finally should allow the dissociation of the DNA from the 
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condensed complexes for effective entry into the nucleus (Luo & Saltzman, 
2000; C Heiser, 2004b). Once in the nucleus, the transfection efficiency is now 
solely dependent on the composition of the gene expression system (Luo & 
Saltzman, 2000). A plasmid construct is an episome and therefore does not 
integrate in the cell's genome and replicates independently, resulting only in 
transient gene expression. Despite being a transient system, it should still render 
a good expression level as these plasmids carry the SV40 bi-directional origin of 
replication (ORI) and therefore have a higher rate of episomal replication in 
cells expressing the SV40 large T antigen (Pear et al, 1993), which is the case of 
Phoenix, for example, as they are derived from the 293T cell line.
5.2. Establishment of experimental model
5.2.1. Overview of and choice of retroviral delivery systems
 HOPX, HIST2H2BE, ICEBERG and S100A7 showed potential specific 
markers of telomere-driven senescence as they were up-regulated following 
telomere uncapping ensued from expression of TRF2!B!M; this, however, seemed 
to occur independently of a DDR (Minty et al, 2008). In fact, HOPX, ICEBERG 
and S100A7 were not even elevated by the strong DDR generated by 
senescence-inducing doses of IR which results in activation of p53 and its 
transcriptional target p21WAF1 (Chapter 4). However, the response to IR might 
differ from direct over-expression of p53 since it triggers distinct molecular 
events towards activation of the p53 pathway. I am, therefore, interested in 
further investigating how the candidate markers are regulated by each of the 
main effectors of senescence independently, especially when these are over-
expressed in normal keratinocytes. 
 To test this, I aim to manipulate newborn foreskin keratinocytes to 
ectopically express p53 (Sugrue et  al, 1997), p16INK4a (McConnell et al, 1998) 
and p14ARF (Dimri et  al, 2000) as well as the dominant negative mutant form of 
the telomere-binding protein TRF2 (TRF2!B!M) to artificially uncap telomeres (van 
Steensel et al, 1998). The intention is to obtain pure populations of keratinocytes 
that are selectively undergoing senescence either via the p53/pRb common 
pathway, the telomere-independent pathways (p14ARF/p53 and p16INK4a/pRb) 
or via the telomere-p53-dependent pathway and observe the candidate 
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markers response in each independent system of senescence. In addition, I 
aimed to introduce the transgenes into keratinocytes without causing undue 
cellular stress as this would be likely to induce p16INK4a and cause an 
unacceptable background of spontaneous senescence (Ramirez et al, 2001). 
Since the main objective is to obtain early downstream markers of telomere 
dysfunction in keratinocytes, the best suited system of delivery of the transgenes 
would be one in which it is possible to achieve high expression levels in a short 
period with maximum efficiency.
 As opposed to normal cells, cell lines such as HEK 293 and its variant 293T 
are particularly easy to transfect (Graham et  al, 1977; Pear et al, 1993) and 
were the base for the development of several packaging cell lines aimed at 
generating retroviral particles in high titre for successful transduction of normal 
cells (Swift et al, 2001). In the case of normal keratinocytes, it is very difficult to 
achieve stable transfection with plasmid constructs, however close to 100% 
success has been reported with retroviral vectors (Garlick et  al, 1991; Mathor et 
al, 1996; Levy et al, 1998). These have been thoroughly used for their safety in 
handling, high transduction efficiency and low toxicity to the target cells. 
Retroviral gene delivery systems have previously been employed with success 
to over-express p16INK4a in the TIG-3 strain of human diploid fibroblasts 
(McConnell et  al, 1998) and p14ARF in WI-38 (Dimri et al, 2000), both using 
pBabe-puro vectors. Similarly, they have also been used to ectopically express 
TRF2!B!M in IMR-90 and WI-38 using pBabe-puro and pLPC-puro vectors 
(Smogorzewska & de Lange, 2002), and in NHEK using pLPC vectors sub-cloned 
into the IRES vector pMIG (Minty et al, 2008). 
 The main challenge with past attempts to transduce normal human 
keratinocytes has been achieving long-term expression of the transgenes. This 
might have been due to early arrest of LTR-driven gene expression, which might 
call for keratinocyte-specific enhancers and further improvements in vector 
design, or to a general difficulty in targeting holoclones, with consequent loss of 
the transgene with cell division (discussed in (Levy et al, 1998)). 
 Early strategies to transduce keratinocytes involved three steps: 
transfection of the retroviral vector into an ecotropic packaging cell line for 
transient production of retroviral particles; infection of an amphotropic cell line 
that will stably produce virus; and infection of keratinocytes by co-culture with 
the virus-producing amphotropic cells. Garlick et  al used a 3rd generation eco 
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packaging cell line ((-CRE), and 1st ((-AM), 2nd (PA-317) and 3rd ((-CRIP) 
amphotropic packaging cell lines. Keratinocytes were co-cultured with 
infectious producer lines as feeders under G418 selection (Garlick et  al, 1991). 
Later, Mathor et  al turned to 3rd generation both eco (GP+E-86) and 
amphotropic (GP+envAM12) packaging lines and keratinocytes were now co-
cultured with a 1:2 mixture of lethally irradiated 'feeders' and infectious 
producer cells, still under G418 selection. They achieved an improvement in the 
number of generations the transgenes were expressed for and high 
transduction efficiencies (Mathor et al, 1996). 
 Subsequently, further improvements were introduced in the delivery 
strategy, as opposed to refinement of the existing retroviral vectors, in order to 
obtain better results (Levy et al, 1998). Levy et  al used pBabe-puro vectors 
where the transgene was placed under the control of the LTR promoter, as it 
previously rendered high expression levels, whilst the SV40 promoter directed 
puromycin expression. Puromycin was chosen as the selectable marker as it 
rapidly killed non-transduced controls with no harmful effects on transduced 
keratinocytes, as opposed to G418 which revealed greater cell-toxicity and 
reduced efficiency in killing uninfected cells. In addition, latest generation 
transfection reagents as well as 3rd generation eco (GP+E-86) and 
amphotropic (GP+envAM12) packaging cell lines were preferred to earlier 
methods. The amphotropic line was infected more successfully with 48-72h viral 
supernatants and then these infectious cells were used as 'feeders' in co-culture 
to infect keratinocytes. This optimised protocol is the most efficient method 
reported until now for transduction of normal keratinocytes (Fig. 5.4.).
 In previous work from our lab (Minty et al, 2008) this last strategy was 
adapted to selection by FACS for expression of TRF2!B!M in keratinocytes. pLPC 
vectors were sub-cloned into the IRES vector pMIG with GFP as a marker. This 
made it possible to accurately select populations of keratinocytes expressing 
high and low levels of the transgene as this directly reflected high and low GFP 
signal. Although the use of a superior retroviral vector as well as latest 
generation packaging cell lines (Phoenix E and Retropack PT67) resulted in high 
levels of gene expression in a short time frame it also came with limitations 
(Minty, 2007). FACS sorting introduces a greater deal of physical stress to the 
cells and keratinocytes are known for being particularly sensitive to 
physiological/external stressors. Cells can respond by undergoing apoptosis 
(Frisch & Francis, 1994) or by expressing p16INK4a prematurely and undergoing 
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senescence (Ramirez et al, 2001), which will result in cell loss or introduction of 
experimental bias. Additionally, the preparation of the cells for sorting and the 
procedure itself resulted in greater cell losses and introduction of 
contamination, consequently with the same outcome. As this indirect strategy is 
also technically demanding and time consuming, a more direct strategy for 
infection of keratinocytes using amphotropic supernatants was tested, yet 
resulted in poor infection rates (as low as 3%) (Minty, 2007). In accordance with 
this, Levy et al had already observed that producer lines generated by 
retroviral infection originate higher viral titres than lines obtained by transfection 
(Levy et al, 1998).
Figure 5.4. Schematic representation of the protocol used for obtaining amphotropic 
cell lines producing virus in high titre. This indirect strategy involves transfection of the 
retroviral vector into an ecotropic packaging cell line (GP+E). Virus produced from 
these cells was used to infect another producer line (AM12), now to generate 
amphotropic viral particles. The amphotropic producer cells with highest titre were then 
used as 'feeders' in co-culture to infect normal keratinocytes (in (Levy et al, 1998)).
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 Based on the alternatives, I  have decided to use the original pBabe-puro 
(Stott et al, 1998; McConnell et al, 1998; Dimri et al, 2000) and pLPC-puro 
(Smogorzewska & de Lange, 2002) retroviral vectors, transduce the 
keratinocytes via the indirect strategy of infection (Levy et al, 1998; Minty et  al, 
2008) and isolate transduced populations of NHEK using drug selection (Levy et 
al, 1998). This should be the most straightforward approach to obtain efficient 
transduction of NHEK, cultured in the 'feeder' system, in a short period and with 
the least deleterious effects on the cells. 
5.2.2. Indirect strategy for infection of keratinocytes (via 
ecotropic virus)
 In pBabe-puro vectors, the transgenes p53, p14ARF, p16INK4a and the GFP 
tag are under the control of the 5'LTR while the SV40 promoter drives the 
expression of puromycin. In pLPC-puro N-myc constructs, the 5'LTR controls 
puromycin expression and both TRF2!B!M and the Myc tag are under the control 
of the CMV promoter. Maps of the plasmid backbones used are presented 
below (Fig. 5.5).
Figure 5.5. Maps of empty vectors pBabe-puro and pLPC N-myc puro. Both vectors 
contain the required retroviral LTRs, a truncated gag gene carrying the packaging 
signal (, a gene for puromycin resistance, an additional promoter (SV40 internal early 
promoter for pBabe and CMV promoter for pLPC) and multiple cloning sites (MCS) 
where transgenes can be inserted. 
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 Vectors were transfected into Phoenix Eco cells using a lipid-based 
transfection reagent (FuGENE®6) reported to have a good transfection 
efficiency. Because the plasmid constructs are introduced as episomes, and 
therefore do not integrate in the genome and replicate independently, this 
results in transient gene expression with high levels within 48-96 hours following 
DNA transfection. Transient transfection allows for rapid generation of 
supernatants containing high titre infectious viral particles, which were 
collected within this time frame. The cationic polymer polybrene was added to 
the viral supernatants for its ability to heighten infection efficiency by increasing 
the virus adsorption rates (Davis et  al, 2002). The virions produced by Phoenix 
Eco have an ecotropic envelope and can, therefore, infect murine cells like the 
amphotropic Retropack PT67s. Infection, followed by drug selection, resulted in 
the generation of stable PT67 lines continuously producing infectious viral 
particles carrying an amphotropic envelope. The outline for the experimental 
design is represented in Fig. 5.4, except for the use of later generation producer 
lines. Finally, infection of NHEK was performed by co-cultivation with lethally 
irradiated infectious PT67 which, by being in close contact with the recipient 
cells, promote efficient transmission of the virus particles.
 Early attempts to optimise the transduction protocol were unsuccessful 
and presented many challenges. Initially I was only able to obtain a pBabe-
puro empty vector control, which by lack of a fluorescent tag made 
transduction efficiency difficult to monitor. It meant that success or failure could 
only be assessed post-infection of the amphotropic producer line followed by a 
week long process of drug selection and would be solely based on the rate of 
cell survival. I later acquired the desired pBabe-puro GFP empty vector control 
which permitted a visual assessment of transfection/infection efficiencies at any 
stage of the process. As Levy et al (Levy et  al, 1998) have previously observed, it 
was clear that the transfection of the first producer line was the determinant 
step of the whole procedure. Optimisation of Phoenix E seeding density and 
good cell culture practice were essential to guarantee ideal cell distribution, 
without formation of clumps, and cells in active proliferation. Successful 
transfection also assured that drug selection time on transfected cells was 
minimised generating good quality viral supernatants within 72h. Subsequent 
optimisation of PT67 seeding density for infection allowed for generation of 
amphotropic producer lines stably expressing the transgenes. Originally , 
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infectious PT67 lines, obtained in this manner, were treated as regular 'feeder' 
cells, that is to say they were lethally irradiated, stored in liquid N and revived 
just before culture. The first attempt to infect keratinocytes was performed by 
co-culture of NHEK with 1 Million irradiated PT67-GFP or PT67-p16, obtained 
directly from the cell bank. It became clear that PT67s are not as robust as 3T3s 
and do not recover well from frozen. As a consequence, the 'feeder' layer was 
too sparse resulting in small and abortive keratinocyte colonies in all 
experimental groups. Cells were then stained for p16INK4a and, as expected, all 
experimental groups stained positive, indicating cells started expressing p16INK4a 
due to culture stress (Fig. 5.6). Two questions arose from this that needed 
addressing; first, I wondered whether keratinocytes were in stress just because 
the PT67 layer was sparse or if PT67 are generally unsuitable as 'feeders' and 
NHEK absolutely require irradiated 3T3s in culture for growth; and second, if the 
infection procedure was actually successful and NHEK co-cultured with PT67-
p16 were expressing endogenous and/or exogenous p16INK4a.
157
Figure 5.6. Expression levels of p16INK4a in transduced NHEK. NHEK transduced with 
empty vector control (NHEK-EV) and p16INK4a (NHEK-p16) were immunostained with an 
antibody against p16INK4a (red). DNA was counterstained with DAPI (blue). Merged 
images are shown in the right panels. SVHFK cell line was used as a positive control and 
SCC-25 as a negative control. Photos were taken at 600x magnification.
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 At this stage it was important to consider the limitations of transducing 
normal keratinocytes with p14ARF, p16INK4a, p53 and TRF2!B!M for this study. The 
nature of the transgenes, the aim for early time points and the need to prevent 
keratinocytes from entering premature senescence in culture via p16INK4a 
determine experimental design. All transgenes are being introduced to induce 
senescence in keratinocytes and are, therefore, expected to inhibit 
proliferation. This means that upon co-culture with infectious PT67s as ‘feeders’ 
followed by a 48h period required for gene expression, transgenes will be 
expressed causing cells to arrest. Based on this alone, ideally NHEK should be 
seeded at high density for infection as they are allowed merely 2 days to grow 
following infection, to make sure sufficient cells can be obtained. However, in 
order to achieve high infection rates, lower densities (clonal, ideally) at time of 
infection are preferred as this maximises contact with infectious producer cells 
and would also mean less cell death following drug selection later on. There will, 
therefore, have to be a compromise between these two factors to ensure high 
enough infection rates that will also render sufficient cell yields. Plus, as I am 
aiming for early time points, drug selection cannot be carried out for too long 
which highlights again the importance of high infection efficiency. By ensuring 
a reduced number of non-transduced cells drug selection would cause less cell 
death and, consequently, would render the desired higher yields of transduced 
cells.
 Two experimental approaches were devised to answer the questions 
arisen from the afore mentioned optimisation attempts (Fig. 5.7). In the first (Fig. 
5.7 method 1) the idea was to replicate the original protocol that had been 
successful (Levy et  al, 1998) in order to confirm if infection had indeed 
occurred. Therefore, NHEK were seeded at clonal density with 1 Million freshly 
irradiated infectious PT67; this also to test whether poor recovery had been the 
cause for previous failure. In the second (Fig. 5.7 method 2), 3T3 'feeders' were 
introduced to account for the possibility that PT67, even at the correct density, 
might not be sufficient to provide feeder support to the keratinocytes. If this was 
the cause of failure in infection then the first system will originate again abortive 
colonies, despite NHEK density. Therefore, in the second method I introduced 
106 instead of 105 NHEK as this would reproduce the seeding densities I needed 
to work with to obtain adequate cell yields following the induction of 
senescence.  
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Figure 5.7. Assessment of two methods used for retroviral transduction of normal human 
epidermal keratinocytes. Phase contrast images of NHEK colonies ectopically 
expressing GFP-flagged empty vector control (left and centre columns) and p16INK4a 
(right  column) at two time points (day 2 and day 5).  Early passage NHEKs (around 10 
MPD) were co-cultured at clonal density with infectious PT67 packaging cells (method 
1) and at high density with infectious PT67 packaging cells with ‘feeders‘ (method 2), 
and drug selected with puromycin 48h later for a total culture time of 5 days. Photos 
were taken at 100x magnification after removing ‘feeders‘.
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 In both experimental methods (Fig. 5.7 diagrams of experimental 
design), infection corresponded to co-culture of NHEK with infectious freshly 
irradiated PT67s (day -2) followed by a 48h period to allow gene expression. At 
this point (day 0) drug selection was introduced (1 !g/mL puromycin) and 
'feeders' were removed and replaced with irradiated 3T3 puromycin resistant 
48h later (day 2). Cells remained under drug selection until day 5, by which time 
there was 100% cell death in the mock control, 'feeders' were removed and 
NHEK processed for RNA collection. 
 With the use of an empty vector expressing GFP it was possible to visually 
assess transduction efficiency by observing fluorescence (Fig. 5.7 B, E and H, K). 
Also, obtaining puromycin-resistant proliferative colonies in the EV control (Fig. 
5.7 D and J) as opposed to abortive puromycin-resistant colonies in the p16INK4a 
group suggests infection was successful. Seeding keratinocytes at clonal density 
(method 1) originated fewer and smaller colonies with infection rates reaching 
100% as early as 2 days after introduction of puromycin (Fig. 5.7 A and B) and at 
the end of the experiment, when colonies were bigger, on day 5 (Fig. 5.7 D and 
E). Coherently, when NHEK were seeded at high density (method 2) resulting 
colonies are bigger and more numerous. Consequently infection rates are not 
as high (about 50%) 2 days after introducing drug selection (Fig. 5.7 G and H). 
However, by day 5 close to 100% transduced cells were obtained, as observed 
by fluorescence in the GFP empty vector control (Fig. 5.7 J and K). Seeding 
NHEK at higher densities has the disadvantage of generating pseudo colonies, 
that is colonies arising from individual clones that merge due to proximity during 
growth. This may allow for non-transduced cells (not expressing GFP) in the 
centre of the pseudo colony to remain sheltered by the outer cells and escape 
drug selection (Fig. 5.7 J and K). Despite a slight decrease in transduction rate 
this is preferable, since high density at seeding ensures a higher yield of 
transduced cells in the p16INK4a experimental group (Fig. 5.7 I and L) when 
compared to the group seeded at clonal density (Fig. 5.7 C and F). Following 
the drug selection period, colonies expressing p16INK4a were generally smaller 
and abortive; cells looked enlarged with a classical senescent appearance 
(Fig. 5.7 F and L), whilst colonies expressing GFP empty vector only were 
generally bigger and proliferative, containing small cells with a high nuclear/
cytoplasm ratio (Fig. 5.7 D and J).
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 Results also showed that, provided they were expanded beforehand 
and used freshly irradiated, infectious PT67s alone were suitable as 'feeders' and 
could successfully support the growth of keratinocyte colonies (Fig. 5.7 D and 
E). These appeared as healthy as colonies where irradiated 3T3s were 
introduced in addition to infectious PT67, in co-culture with NHEK (Fig. 5.7 J and 
K). Nevertheless, the latter modification was extended to the generation of all 
other systems of senescence in keratinocytes via expression of p14ARF, p53 and 
TRF2!B!M. This was to assure that despite possible experimental variation arising 
from PT67 cell density during infection, resulting transduced NHEK colonies 
would not prematurely express p16INK4a and become abortive due to lack of 
proper 'feeder' support. Additionally, p16INK4a expression levels were assessed by 
qPCR to ensure they remained at control levels in all experimental groups 
except in NHEK ectopically expressing it.
 The optimised protocol was extended to all other constructs (Fig. 5.8). 
Five days following expression of transgenes cell yields for p53 and p16INK4a were 
lower (by approximately half) than for the empty vector control, which suggests 
cell division arrest. Additionally, the morphological appearance of the colonies 
was consistent with senescence for both transgenes (Fig. 5.8 p53 and p16INK4a). 
Although similar numbers of keratinocytes expressing EV and p14ARF were 
obtained, the larger colonies expressing the latter have a mosaic-like pattern 
with some cells appearing to be senescent whilst others seem proliferative (Fig. 
5.8 p14ARF top). This suggests p14ARF might not be as potent an inducer of 
senescence in keratinocytes as p16INK4a and is consistent with the fact that 
p14ARF has been shown not to accumulate when human keratinocyte senesce 
(Munro et al, 1999). In the case of TRF2!B!M this strategy for infection seems to 
not have worked, as colonies expressing the transgene proliferated more than 
colonies expressing the corresponding EV (not shown). 
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Figure 5.8. NHEK transduced with all transgenes via an indirect strategy of infection. 
Phase contrast images of NHEK colonies ectopically  expressing GFP-flagged empty 
vector control (left column), p14ARF, p53 and p16INK4a at day 5. Early passage NHEKs 
(around 10 MPD) were co-cultured at high density with infectious PT67 packaging cells 
and ‘feeders‘, and drug selected with puromycin 48h later for a total culture time of 5 
days (diagram of experimental design). The graph represents the number of cells 
obtained on day 5 for each experimental group. Photos were taken at 100x 
magnification after removing ‘feeders‘.
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 Expression of all transgenes was confirmed by qPCR analysis (Fig. 5.9 
transgenes). A decrease in CCNA2 transcript levels was also observed in 
keratinocytes over-expressing p14ARF, p16INK4a and p53, which is consistent with 
senescence, but not for TRF2!B!M where CCNA2 was actually elevated 
relatively to the empty vector control, indicating cells were actively proliferating 
(Fig. 5.9 CCNA2). CCND1 transcript was only elevated in keratinocytes over-
expressing p16INK4a (Fig. 5.9 CCND1) which, in conjunction with decrease in 
CCNA2, reiterates induction of senescence. Levels of CCND1 in cells expressing 
the other transgenes remained at control levels. These results indicate that 
p16INK4a was the most effective inducer of senescence in normal keratinocytes, 
followed by p53 and p14ARF, based on the level of reduction in CCNA2 
accompanied by elevation of CCND1 obtained following their expression. 
Results also show that this infection strategy was unsuccessful for TRF2!B!M, with 
the transgene being expressed at a level (4-fold) that seemed insufficient to 
trigger senescence in NHEK.
 Early studies (van Steensel et  al, 1998) using an inducible system to 
express TRF2!B!M in a human fibrosarcoma cell line have reported 'leaky 
expression' of TRF2!B!M, based on immunofluorescence analysis. A fraction of 
the induced cells, which did not show morphological alterations consistent with 
senescence and no expression of SA-"  Gal, coincidently expressed very low 
levels of TRF2!B!M. This difference was apparently subtle enough not to be 
noticed by Western blot analysis. Later, in normal human keratinocytes, it was 
observed that although expression levels of TRF2!B!M are high initially they 
decrease over time with some colonies being able to reverse the phenotype by 
down-regulating TRF2!B!M expression and resuming proliferation (Minty et  al, 
2008). It is worth mentioning that in the last study cells were not subjected to 
selective pressure. I have conducted a time point study and observed a 
gradual decrease in protein levels of TRF2!B!M in keratinocytes maintained 
under selective pressure, with maximum levels 5 days following expression of the 
transgene and minimum at day 13, when the experiment was terminated (Fig. 
5.10).
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Figure 5.9. Gene expression levels of transgenes and Cyclins in NHEK transduced via an 
indirect strategy of infection. Graphs represent transcript levels of transgenes p14ARF, 
p16INK4a, p53 and TRF2!B!M as well as cyclins A2 (CCNA2) and D1 (CCND1) in 
keratinocytes ectopically expressing empty vector control (EV), p14ARF, p16INK4a, p53 
and TRF2!B!M. Values are normalised against the respective empty vector control (n=1).
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Figure 5.10. Time point analysis of TRF2!B!M expression levels in NHEK following retroviral 
transduction. Phase contrast images of NHEK colonies (top panel) expressing GFP-
flagged empty vector control plus empty vector control (EV) and TRF2!B!M (DN). EV and 
DN share the same vector backbone. GFP-flagged EV was included to assess 
transduction efficiency. Early passage NHEKs (around 10 MPD) were co-cultured with 
infectious PT67 packaging cells and ‘feeders‘, and drug selected with puromycin 48h 
later for a total culture time of 13 days (diagram of experimental design). Photos were 
taken at 100x magnification after removing ‘feeders‘. Protein lysates were collected at 
day 2, 5, 9 and 13 for western blot analysis (bottom panel).  
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 These levels of expression, however, were not sufficient to elicit a 
phenotype. This suggests that expression levels of TRF2!B!M need to surpass a 
certain threshold to be capable of inducing senescence and that ideal time for 
analysis is 5 days following transduction, when expression is at its peak and 
before cells start down-regulating it. I  reasoned that the process of transfection 
of TRF2!B!M into Phoenix cells was the root of the problem, generating lower titre 
viral supernatants. Original protocols include drug selection on the transfected 
Phoenix cells in order to maximise viral titre. If this can possibly be 
advantageous in the case of constructs carrying transgenes that are somehow 
beneficial to the target cells, this is not the case with TRF2!B!M. I have indeed 
observed that both p53 and TRF2!B!M have a harmful effect on the producer 
Phoenix cells following prolonged periods of drug selection. The combination of 
the transgenes and the selective pressure acts as a hindrance. I therefore 
thought that by optimising transfection and using the Phoenix system as the 
transient system it is and by collecting concentrated viral supernatants as early 
as 48h up to 76h post-transfection with no drug selection on the producer cells, 
viral titre might actually be improved, especially in the case of the TRF2!B!M 
construct. In addition, by eliminating the second producer line and generating 
amphotropic virus from Phoenix  A which could infect NHEK directly, I might 
prevent a 'dilution' effect in the expression of TRF2!B!M. Direct strategies for 
infection of normal epidermal keratinocytes have been reported to have poor 
success rates ((Minty, 2007) and discussed in (Levy et al, 1998)). Nevertheless, as 
in the case of Levy et al's (Levy et  al, 1998) attempt to achieve long-term 
expression of the integrin gene in keratinocytes, I thought it was just a question 
of optimising the steps towards obtaining the maximum expression of 
deleterious genes in a short time frame. 
5.2.3. Direct strategy for infection of keratinocytes (via 
amphotropic virus)
 Since the aim was to obtain good quality amphotropic virus to infect 
NHEK directly, Phoenix A cells were transfected based on Roche's Fugene6 
original manufacturer protocol for maximum efficiency. Also, volume of growth 
medium was reduced prior to overnight incubation at 32ºC so that 
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concentrated viral supernatants could be obtained 48-78 hours post-
transfection, thereby eliminating the drug selection step on the transfected 
Phoenix cells. Due to technical limitations (heated centrifuge only holds 6-well 
plates) experimental design for the subsequent infection had to change to be 
adapted to 6-well plates; NHEK seeding density was optimised for infection in 
wells (5 x  104 NHEK + 1.6 x 105 irr3T3 per well) as well as the concentration of 
puromycin (kill curve revealed 2.0 !g/mL was ideal). In order to obtain enough 
cells for analysis, each construct was expressed in a total of 12 wells (2 plates 
per construct) per experiment, which should yield around 0.5 Million transduced 
senescent NHEK at the end of the experiment.
 The main advantage of co-culture with infectious 'feeders' in the 
previous indirect strategy is the close contact between these and the NHEK 
which maximises exposure of the latter to the viral particles for a period of 48h. 
In this new direct strategy, infection is performed by centrifugation at 350 rpm 
for 1 hour at 32ºC so, although both centrifugation and temperature maximise 
viral uptake, contact time with the virus is a lot shorter. Therefore, I thought that 
by subjecting keratinocytes to more than one round of spinfection with freshly 
collected supernatants I might be able to increase infection efficiency. 
Supernatants have the highest viral titre 48h to 72h after transfection and can 
be collected every 6 hours. I thus compared infection rates between one or 
several rounds of infection (up to 3 rounds) using EV-GFP supernatants 
collected at 48h, 54h and 72h (Fig. 5.11). One round of infection resulted in up 
to 50% of cells expressing GFP, per colony; colonies showing close to 100% 
fluorescence were rare. With two or three rounds of infection however, infection 
rates were higher with more than half of the cells per colony expressing GFP; 
several colonies showed close to 100% fluorescence and colonies with no GFP 
signal were the exception. 
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Figure 5.11. Assessment of NHEK transduction efficiency following one or more rounds of 
infection. Phase contrast images of NHEK colonies ectopically expressing GFP-flagged 
empty vector following 1 (GFP + Mock + Mock), 2 (GFP + GFP + Mock) or 3 (GFP + GFP + 
GFP) rounds of infection. Control mock infections were performed  using the same 
procedure but without viral supernatants. Early passage NHEKs (around 10 MPD) were 
infected with retroviral supernatants using spinfection and cultured for a total of 8 days, 
without drug selection. Photos were taken 8 days after the first infection, at 100x 
magnification, after removing ‘feeders‘.
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 Since there was no apparent difference between using two or three 
rounds of infection, I opted for adapting the infection protocol to two 
successive infections with a 6 hour interval between them. Using 2 rounds also 
has the advantage of not depriving the keratinocytes of 'feeders' for a period 
longer than 8 hours, whilst 3 rounds are likely to cause stress to the target cells 
by being without 'feeders' for period of 24h. Prior to spinfection NHEK cultures 
were prepared by removing 'feeders' to promote contact of the virus with the 
keratinocytes. Additionally, plates were gassed, at 32ºC, until a 10% CO2 
atmosphere was obtained and immediately sealed to ensure these conditions 
were maintained during spinfection to prevent culture stress. Following 
infection, NHEK were allowed a gene expression time of 24h after which drug 
selection was introduced (2 !g/mL puromycin) and cell extracts collected 5 
days later. This method was extended to all constructs and proved to be very 
successful for all, especially TRF2!B!M (Fig. 5.12 diagram of experimental design). 
 In general, five days following expression of the transgenes, the number 
of cells obtained expressing p14ARF, p16INK4a, p53 or TRF2!B!M was about half of 
the number obtained for the respective empty vector control (Fig. 5.12 graph). 
This observation, combined with the senescent appearance of the NHEK 
colonies suggests proliferation arrest (Fig. 5.12 photos).  
 Quantitative PCR analysis confirmed over-expression of all transgenes in 
all NHEK populations (Fig. 5.13). It is well established that CCNA2 levels decline 
in senescent fibroblasts and CCND1 levels increase (Duli' et al, 1993) and 
expression array data suggests that this is true for keratinocytes also (Hunter et 
al, 2006). Analysis also revealed a decrease in CCNA2 transcript levels, 
sometimes accompanied by increase in CCND1, when compared to the 
respective empty vector control, which is consistent with senescence (Fig. 5.14).
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Figure 5.12. NHEK transduced with all transgenes via a direct strategy of infection. Phase 
contrast images of NHEK colonies ectopically expressing GFP-flagged empty vector 
control, p14ARF, p53 and p16INK4a (columns); empty vector control and TRF2!B!M (rows), 
at day 5. Early  passage NHEKs (around 10 MPD) were infected with retroviral 
supernatants using spinfection, and drug selected with puromycin 24h later for a total 
culture time of 5 days (diagram of experimental design). Graphs represent the number 
of cells obtained on day 5 for each experimental group (n = 2; bars show st  dev). 
Photos were taken at 100x magnification after removing ‘feeders‘.
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 Figure 5.13. Gene expression levels of transgenes in NHEK transduced via a direct 
strategy of infection. Graphs represent transcript levels of transgenes p14ARF, p16INK4a, 
p53 and TRF2!B!M in populations of keratinocytes ectopically expressing empty vector 
control (EV), p14ARF, p16INK4a, p53 and TRF2!B!M. Values are normalised against the 
respective empty vector control.
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Figure 5.14. Gene expression levels of cyclins in NHEK transduced via a direct strategy 
of infection. Graphs represent transcript levels of cyclins A2 (CCNA2) and D1 (CCND1) 
in populations of keratinocytes ectopically expressing empty vector control (EV), p14ARF, 
p16INK4a, p53 and TRF2!B!M. Values are normalised against the respective empty vector 
control.
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  In the conditions tested, an overview of the two strategies for 
transduction of keratinocytes showed that a direct strategy for infection was 
generally more effective than an indirect one (Tables 15 and 16).
LOW MEDIUM HIGH
TRF2!B!M A1
(12-fold)
A5
(15-fold)
A2
(18-fold)
p14ARF A1
(89-fold)
EA
(142-fold)
A5
(220-fold)
p16INK4a A1
(18-fold)
A5
(60-fold)
EA
(116-fold)
p53 A1
(10-fold)
EA
(7-fold)
A5
(29-fold)
Table 15. Summary of levels of expression (LOW, MEDIUM  or HIGH) of p14ARF, p16INK4a, 
p53 and TRF2!B!M in NHEK populations expressing the transgenes, obtained via a direct 
strategy (A1, A2 and A5) and via an indirect strategy of infection (EA). Legend: A = 
amphotropic; EA = ecotropic/amphotropic.
 
LOW MEDIUM HIGH
TRF2!B!M -/40%
(12-fold)
50%/-
(15-fold)
40%/40%
(18-fold)
p14ARF 40%/-
(89-fold)
30%/-
(142-fold)
40%/-
(220-fold)
p16INK4a 40%/-
(18-fold)
60%/-
(60-fold)
30%/30%
(116-fold)
p53 20%/20%
(10-fold)
50%/-
(7-fold)
30%/20%
(29-fold)
"CCNA2/CCND1# "CCNA2/CCND1# "CCNA2/CCND1#
Table 16. Summary of induction levels of cyclins CCNA2 and CCND1 in NHEK 
populations expressing LOW, MEDIUM  or HIGH levels of p14ARF, p16INK4a, p53 and 
TRF2!B!M.
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 This was the case especially for TRF2!B!M as effective expression levels of 
the construct, high enough to engage senescence, were only obtained with 
the direct infection strategy. Out of the 3 NHEK populations obtained, A1 
resulted in the lowest expression level of TRF2!B!M (12-fold), still higher than the 
previous 4-fold in NHEKs infected with an indirect strategy. A1 keratinocytes 
down-regulated CCNA2 by 10% and up-regulated CCND1 by 40%, whilst in EA 
keratinocytes CCNA2 was up-regulated and CCND1 remained at control levels 
which indicates proliferation rather than arrest. In NHEK populations A2 and A5 
higher levels of expression, 15-fold and 18-fold respectively, were obtained 
resulting in a 40-50% down-regulation of CCNA2, accompanied by 40% 
increase in CCND1 for A5. 
 For all the other transgenes two additional NHEK populations were 
obtained, using the direct infection strategy. A5 resulted in the highest 
expression levels for p14ARF and p53, while A1 resulted in the lowest. Despite this, 
in all cases a reduction in CCNA2 was observed, accompanied by elevation of 
CCND1 in the case of p53 when expressed at the highest levels. As for p14ARF it 
was interesting to notice that a consistent 30-40% down-regulation of CCNA2 
occurred despite the level of expression of this transgene in keratinocytes; it is 
worth noticing that these vary from 89-fold to 220-fold. 
 As for p16INK4a, this transgene constitutes the exception with the highest 
expression levels achieved with the indirect infection strategy which rendered a 
116-fold elevation of its transcript, followed by 30% decrease in CCNA2 and 
increase in CCND1. However, in A1 and A2 keratinocytes p16INK4a was still 
induced by 18-fold and 59-fold accompanied by a convincing 40-50% 
decrease in CCNA2 transcript, which is consistent with senescence. 
 In conclusion, I found that generally the highest the expression level 
obtained for the transgene the most profound was the influence on the cyclins, 
with more effective induction of senescence. As I found there was intra- and 
inter-experimental variation in expression, as a consequence of experimental 
variation or infection strategy used, populations of transduced keratinocytes 
were not pooled. Instead they were analysed individually based on LOW, 
MEDIUM, or HIGH expression levels of each effector of senescence.
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5.3. Discussion
 I have been trying to investigate the specificity of candidate markers 
HOPX, HIST2H2BE, ICEBERG and S100A7 to telomere-dysfunction induced 
senescence (TDIS). Although they are all induced telomere dysfunction and 
seem to be regulated by telomerase (Muntoni et  al, 2003; Minty et  al, 2008), 
HOPX, ICEBERG and S100A7 are not elevated as a result of p53 activation and 
ensuing DDR following exposure to senescence-inducing doses of IR (Chapter 
4). I cannot however exclude possible induction of the markers by other forms 
of activation of p53, or by other main effectors of senescence, such as p14ARF 
and p16INK4a. The latter is particularly important as premature senescence by 
induction of p16INK4a, also known as ‘stress or aberrant signalling-induced 
senescence’ (STASIS), is the main competitor mechanism to replicative 
senescence via telomere shortening or TDIS in cultured keratinocytes 
(Rheinwald et  al, 2002). Therefore, to further investigate the effect of activation 
of the main pathways of senescence in the candidate markers, I aimed to use 
retroviral transduction for establishing stable populations of keratinocytes 
ectopically over-expressing p53 (Sugrue et al, 1997), p16INK4a (McConnell et  al, 
1998), p14ARF (Dimri et  al, 2000) or the dominant negative mutant form of the 
telomere-binding protein TRF2 (TRF2!B!M) to artificially uncap telomeres (van 
Steensel et al, 1998). 
 Given the challenge that normal keratinocytes present as target cells for 
gene delivery I based my experimental approach on a successful indirect 
strategy for infection, which has previously been reported for these cells (Levy 
et al, 1998). Briefly, it is based first on the production of ecotropic retroviral 
particles which are used to infect an amphotropic packaging cell line thereby 
stably expressing the transgene of interest. The latter is then used as a ‘feeder’ 
layer to infect normal keratinocytes which become stably transduced following 
selective pressure. Our group has previously adopted this approach to 
fluorescence-activated cell sorting (FACS) as a means of selection of 
transduced cells by cloning the original retroviral vector (expressing TRF2!B!M in 
this case) into an IRES vector expressing a GFP tag (Minty, 2007; Minty et  al, 
2008). Despite the good expression levels, which resulted in a senescent-like 
phenotype from expression of the transgene, the process of cell sorting was a 
cause of undue stress to the cells and presented other limitations. I have, 
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therefore, opted for using the original retroviral vectors, pBabe-puro for 
expression of p53, p16INK4a and p14ARF or pLPC-NMYC-puro for expression of 
TRF2!B!M, given their reported efficiency and low toxicity of the drug selection 
agent in normal human epidermal keratinocytes (Levy et al, 1998).
 Nevertheless, I found that the transduction efficiency using the previous 
strategy was greatly influenced by the transgene being expressed. Despite 
being effective for the empty vector construct expressing solely the GFP tag 
and for p16INK4a, the strategy rendered low levels of expression for p14ARF, p53 
and particularly for TRF2!B!M. I found that p14ARF, p53 and TRF2!B!M all affected 
the performance of the first packaging line (Phoenix), especially if this was also 
subjected to drug selection. Also, that the use of a second producer line had a 
sort of ‘diluting’ effect in the expression of TRF2!B!M which was probably made 
worse by the longer time required for drug selection when compared with 
sorting by FACS. Whichever the explanation(s), by the time keratinocytes were 
transduced, the levels of expression obtained for TRF2!B!M were not high 
enough to induce a senescent-like arrest, using this strategy. Since this is an 
exogenous dominant negative mutant which depletes telomeres of its 
endogenous functional TRF2, it is not surprising that it would be selected against 
by the cells and in fact TRF2!B!M’s expression has been characterised as 
‘leaky‘ (van Steensel et al, 1998). I found that in order to elicit senescence a 
certain threshold level of expression needed to be surpassed and this is 
consistent with the findings of others (J. Jacobs - personal communication). The 
emergence of revertant keratinocyte colonies following down-regulation of 
TRF2!B!M expression levels has also previously been reported (Minty et al, 2008).   
 Given the previous observations I went back to basics and decided to 
challenge the pre-conception that normal human keratinocytes are difficult 
cells to transduce directly. Since the nature of the transgenes, especially 
TRF2!B!M, required a straightforward approach with as few intermediate steps 
as possible I have decided to use the highly efficient and latest generation 
Phoenix system to produce amphotropic viral particles without drug selection 
for optimum titre 2 to 3 days following transfection. These were then used to 
directly infect keratinocytes in two consecutive rounds of infection, performed 
on the same day (6 hours apart) with an optimised low speed centrifugation 
method, in order to promote viral uptake thereby hopefully increasing infection 
rates and maximising expression levels of the constructs. Selective pressure was 
also introduced earlier in order to prevent unwanted variants to take over the 
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culture, especially cells which might have lost the transgene whilst still retaining 
the puromycin cassette, and to obtain levels of expression of the constructs 
high enough to generate a phenotype in five days time. This was a limitation I 
needed to account for, considering my general experimental approach when 
compared with the superior expression system consisting of an IRES vector 
combined with FACS sorting, previously used by our lab (Minty et al, 2008). I 
found that this direct strategy of infection was the only successful method 
capable of generating a senescent-like phenotype following the expression of 
TRF2!B!M, as demonstrated by decrease in Cyclin A2 transcript and colony-
forming efficiency analysis. Overall, this approach generated the highest 
expression levels of the constructs (with the exception of p16INK4a), despite some 
inter-experimental variation, which in turn was associated with a stronger 
phenotype (exception for p14ARF). 
 From a technical point of view, these manipulations were extremely 
challenging and given the limitations of working with both normal keratinocytes 
and transgenes which halt proliferation and induce deleterious effects on the 
cells one would have to agree with others (Levy et al, 1998) in thinking that an 
inducible system applied to keratinocytes is much warranted and long 
overdue. Despite the challenges, the optimisation of both infection strategies 
towards obtaining a low stress system for retroviral transduction of NHEK allowed 
me to obtain populations of keratinocytes expressing defined levels (divided 
into low, medium or high) of the inducers of senescence p14ARF, p16INK4a, p53 
and TRF2!B!M. These senescent populations will serve as models in the 
assessment of the effect that activation of the various cellular pathways of 
senescence might have on the candidate markers for keratinocyte TDIS 
(Chapter 6). 
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Chapter 6. Analysis of markers specificity to 
other forms of senescence.
6.1. Introduction
6.1.1. Pathways of senescence
 p53 and pRb are the main effectors of senescence and are activated 
through independent, although also interacting, molecular pathways (Fig. 6.1). 
These are selectively or mutually induced by various stimuli and the 
engagement of each pathway can be both cell type-specific and species-
specific. Intrinsic and extrinsic stimuli act simultaneously in a population of 
normal growing cells thereby resulting in a mosaic effect where the 
senescence program is being engaged by distinct pathways in different cells 
(Ben-Porath & Weinberg, 2005; Campisi & d'Adda di Fagagna, 2007). 
Figure 6.1. Molecular pathways of senescence. p53 and pRb are the central effectors 
of senescence (adapted from (Ben-Porath & Weinberg, 2005)).
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The p53/p21WAF1 pathway
 p53 mediates the response to DNA damage, telomere dysfunction and 
oxidative stress (Fig. 6.2). As discussed previously (Chapter 4) p53 is the central 
protein in the classical DNA damage pathway of senescence activated by 
stimuli that generate a DDR (Ben-Porath & Weinberg, 2005). In consequence of 
exposure to DNA damaging agents such as ionising radiation (Di Leonardo et 
al, 1994), DNA strand breaking chemicals (Robles & Adami, 1998) or 
endogenous insults such as dysfunctional telomeres (d'Adda di Fagagna et  al, 
2003; Takai et  al, 2003; Herbig et al, 2004) and ROS (Moiseeva et al, 2006), 
normal human fibroblasts activate ATM/ATR and CHK2/CHK1. These are the 
upstream regulators of p53 that transmit the DNA damage signal and mediate 
the post-translational activation of p53 through phosphorylation, mainly at the 
Serine 15 site (p53-pS15). p53 then triggers several downstream transcriptional 
targets of which p21WAF1 is the most pivotal, acting as the principal mediator of 
p53-dependent senescence (Di Leonardo et al, 1994; Brown et al, 1997). 
 p21WAF1 is, along with p16INK4a, a cyclin-dependent kinase inhibitor (CDKI). 
However, as opposed to p16INK4a, it interacts with a range of CDK/Cyclin 
complexes, therefore acting as an important regulator of the cell cycle. For 
instance, by inhibiting CDK2 activity and thus disrupting CDK2/Cyclin E 
complexes, it suppresses phosphorylation of pRb and, therefore, its inactivation. 
In its hypo-phosphorylated form, pRb is active and enforces senescence by 
inhibiting the transcription of E2F1 target genes, required for cell-cycle 
progression (Ben-Porath & Weinberg, 2005; Campisi & d'Adda di Fagagna, 
2007). The p53-p21WAF1-pRb pathway can be triggered by oxidative stress 
(Itahana et  al, 2003) and in consequence of chronic stimulation of the anti-
proliferative cytokines such as Interferon ", which acts by increasing intracellular 
ROS (Moiseeva et  al, 2006). Although p53 can activate senescence by 
triggering the parallel RB pathway through p21WAF1 (Fig. 6.2), p53/p21WAF1 alone 
can induce senescence independently from the RB family primarily by 
interfering with CDK2/Cyclin A complexes (Smogorzewska & de Lange, 2002). 
However, cells that senesce exclusively via p53/p21WAF1 can resume growth 
following inactivation of the p53 pathway but eventually arrest with 
characteristics of crisis (Beauséjour et al, 2003).
180
Figure 6.2. Endogenous stimuli that engage p53. In human cells, telomere uncapping 
and general DNA damage activate primarily p53, via the ATM/ATR kinases, and 
secondarily p16INK4a. Oxidative stress can result in damage to DNA and accelerate 
telomere shortening, triggering p53, but can also activate p16INK4a via p38-MAPK. In the 
mouse, these stimuli preferentially activate p53 via ARF (in (Ben-Porath & Weinberg, 
2005)).
 The nature of p53 activation/stabilisation depends on the triggering 
stimuli. Replicative senescence and DNA damaging agents, such as IR, UV and 
bleomycin, activate the p53 pathway via post-translational modifications in p53 
(Webley et  al, 2000; Minty et al, 2008). Although phosphorylation at Serine 15 
also contributes to stabilisation of p53 by disruption of MDM-2 binding (Shieh et 
al, 1997), not a significant increase in total p53 was observed in NHFs following 
senescence or exposure to any of these DNA damaging agents (Webley et  al, 
2000) or in NHEKs subjected to IR (Minty et  al, 2008). Over-expression of wild-
type p53 (in p53-deficient cells) however, engages the pathway essentially via 
stabilisation of the molecule with ensuing increase in p21WAF1 and MDM-2 
expression levels (Sugrue et al, 1997). MDM-2 (also known as HDM-2 to 
distinguish from the murine homologue mdm-2) is an E3 ubiquitin ligase whose 
function is to functionally inactivate p53 by promoting its proteolytic 
degradation in the nucleolus. Upon senescence, p53 activation/stabilisation 
induces MDM-2 which, in turn, negatively regulates p53 expression (Dimri et  al, 
2000; Ben-Porath & Weinberg, 2005). 
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 Whilst in human cells general damage to the DNA is detected and 
signalled through upstream kinases ATM/ATR, other physiological stressors are 
signalled to p53 by its other upstream regulator ARF.
The p14/p53 pathway
 ARF (p14ARF in humans and p19arf in mice) regulates the stress-dependent 
pathway that activates p53 (Fig. 6.3) and plays a central role in response to 
physiological stressors in mouse cells. It is up-regulated in rodent fibroblasts 
(Kamijo et  al, 1997) and in human fibroblasts (Dimri et  al, 2000) upon 
senescence. In contrast, p14ARF does not seem to be involved in keratinocyte 
senescence (Munro et  al, 1999). p14ARF is also activated by ectopic expression 
of oncoproteins such as activated MYC, RAS and RAF, and by supra-
physiological mitogenic signals such as E2F1 and E1A (Serrano et al, 1997; Dimri 
et al, 2000; Itahana et al, 2001). Phosphorylation of p53 following DNA damage 
caused by IR does not involve ARF but apparently ARF also contributes to p53 
stabilisation in these situations (Ben-Porath & Weinberg, 2005).
 ARF stabilises p53 and directs its accumulation by sequestering the E3 
ubiquitin ligase MDM-2 in the nucleolus (Fig. 6.1), therefore preventing p53 from 
being targeted for proteolytic degradation (Sherr, 1998; Stott et al, 1998; Dimri 
et al, 2000). Over-expression of p14ARF in normal human fibroblasts results in 
elevation of p53 total protein to levels higher than those found in replicatively 
senescent cells; this is followed by an increase in p21WAF1 protein levels (Dimri et 
al, 2000). Expression of oncogenic RAS in normal human cells also results in 
stabilisation of p53 and premature senescence (Serrano et al, 1997). 
 Several molecules act as regulators of p14ARF (Fig. 6.1). Transcription 
factor E2F1, which regulates cell cycle progression by either trans-activating 
target genes needed for DNA synthesis or by binding the active form of pRb, 
Cyclin A and MDM-2, is also an activator of p14ARF (Dimri et al, 2000). E2F3 and 
Twist, on the other hand, act as repressors of the p14ARF protein (Ben-Porath & 
Weinberg, 2005). The INK4a locus, which encodes for both p14ARF and p16INK4a, is 
controlled by upstream regulators such as Bmi-1, a member of the Polycomb 
family (Itahana et  al, 2003) and CBX7 (Gil et al, 2004) which repress both 
products and are down-regulated at senescence. 
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Figure 6.3. Endogenous and exogenous stimuli that activate products of the INK4a 
locus, p14ARF and p16INK4a. In mice, ARF regulates the stress-dependent pathway which 
activates p53, however in humans this role is taken primarily by p16INK4a with activation 
of pRb (in (Ben-Porath & Weinberg, 2005)).
The p16INK4a/pRb pathway
 The p16INK4a/pRb pathway acts in parallel to the p53 pathway and seems 
to have a redundant role as it responds to all the stresses that activate p53 but 
to a lesser extent. For instance, following DNA damage (Di Leonardo et al, 
1994) and telomere damage (d'Adda di Fagagna et al, 2003; Herbig et al, 
2004) senescence is mediated by p53 and usually accompanied by expression 
of p21WAF1. However, both DNA damage and dysfunctional telomeres can also 
induce p16INK4a (Fig. 6.2), although with delayed kinetics (Robles & Adami, 1998; 
Stein et  al, 1999; Smogorzewska et al, 2002; Jacobs & de Lange, 2004). The 
p16INK4a/pRb pathway seems to act as a second barrier to proliferation of cells 
with severe DNA damage that are at risk of undergoing malignant 
transformation and is, therefore, redundant to the p53 pathway (Bartkova et al, 
2005; Gorgoulis et al, 2005). It is, however, the pathway of choice in response to 
stresses such as activated oncogenic or mitotic proteins, nutrient/growth factor 
deficiency, and improper cell-cell and cell-matrix contacts (Ben-Porath & 
Weinberg, 2005) (Fig. 6.3). 
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 p16INK4a is, along with p21WAF1, a CDKI and specifically inhibits the activity 
of cyclin-dependent kinases 4 and 6 (CDK4/CDK6), therefore inactivating 
complexes with Cyclin D. As a consequence, it suppresses the phosphorylation 
and inactivation of pRb allowing the latter to repress E2F transcriptional targets 
and halt cell cycle progression (Narita et al, 2003). Over-expression of p16INK4a in 
early passage human diploid fibroblasts induces premature senescence which 
is accompanied by accumulation of pRb in its hypo-phosphorylated form 
(McConnell et al, 1998). p16INK4a is selectively up-regulated in aged human skin 
(Ressler et  al, 2006) and has a particularly important role in human keratinocyte 
senescence (Munro et  al, 1999; Rheinwald et  al, 2002). However, it is unclear 
whether p16INK4a operates independently of the p14ARF/p53 pathway, as 
disruption of p16INK4a function alone does not result in a significant extension of 
NHEK replicative lifespan (Rheinwald et al, 2002; Haga et  al, 2007). However, 
BMI-1, which inactivates p14ARF and p15INK4b in addition to p16INK4a (Jacobs et  al, 
1999) is much more effective in extending keratinocyte replicative lifespan than 
knock-down of p16INK4a alone (Maurelli et al, 2006; Haga et al, 2007).
 p16INK4a is activated in situations of stress and is responsible for premature 
stress-induced senescence, also known as ‘stress or aberrant signalling-induced 
senescence’ or STASIS. In human epithelial cells (especially mammary epithelial 
and keratinocytes) p16INK4a spontaneously starts being expressed just with time 
in culture under standard conditions. This phenomenon, also known as cell 
culture stress or 'culture shock', can be delayed by using 'feeder' layers for 
culture growth, but cells will still undergo p16INK4a-dependent and telomere-
dependent senescence later on (Ramirez et al, 2001; Rheinwald et al, 2002). 
However, the precise signals that activate p16INK4a, independently of DSBs are 
unclear.
 Oncogenes such as activated RAS and oxidative stress also induce 
p16INK4a-dependent senescence. In human cells, RAS activates p53 and p16INK4a 
in parallel, but p16INK4a has a more prominent role in oncogene-induced 
senescence (Serrano et  al, 1997; Brookes et al, 2002), at least in the absence of 
DSBs. Oncogenic RAS can activate p16INK4a by phosphorylating and activating 
Ets transcription factors; p38-MAPK proteins mediate activation of both p53 and 
p16INK4a in RAS-induced senescence (Iwasa et al, 2003). Oxidative stress 
activates p16INK4a also through p38-MAPK in some cells (Forsyth et al, 2003), but 
in certain cell strains the p53/p21WAF1 pathway is activated instead (Itahana et 
al, 2003). Oncogene-induced senescence in cancer precursor lesions such as 
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dysplastic nevi show a mosaic pattern of p16INK4a expression, however 
associated with indicators of a DDR (Suram et al, 2012). 
 Additionally, expression of p16INK4a has been shown to directly correlate 
with several markers of keratinocyte migration and to inversely correlate with 
genes involved in terminal differentiation (Darbro et  al, 2005). Senescent 
keratinocytes in vitro expressing p16INK4a often co-express the ɣ2 chain of 
laminin 5 and exhibit an increase in directional mobility (Natarajan et  al, 2006). 
This has been associated with the early stages of invasion in SCCs and with the 
wound healing process in normal epithelia via generation of non-dividing 
motile cells (Natarajan et  al, 2003). The inhibitor of epithelial cell proliferation 
TGF-" is one of the molecules known to be expressed in wounded epithelium 
and its chronic signalling is known to induce senescence by promoting p16INK4a/
pRb heterochromatin formation (Zhang & Cohen, 2004). Chromatin state is a 
regulator of p16INK4a; treatment with histone deacetylase inhibitors (HDACIs) 
acts as a positive regulator (Munro et  al, 2004) whilst chromatin remodelling 
gene Bmi-1 acts as a negative regulator (Itahana et al, 2003). Bmi-1 is down-
regulated at senescence and its over-expression results in extension of the 
replicative lifespan of human fibroblasts via suppression of the p16INK4a/pRb 
senescence pathway (Itahana et al, 2003).
 p16INK4a/pRb can establish self-maintaining senescence-associated 
heterochromatin which is thought to contribute to the irreversibility of the cell 
cycle arrest upon senescence (Funayama & Ishikawa, 2007). As opposed to 
what happens with the p53 pathway, cells that have engaged the p16INK4a/
pRb pathway for several days cannot resume growth despite ensuing 
inactivation of p16INK4a, pRb or p53 (Itahana et  al, 2003). Loss of p16INK4a/pRb in 
human mammary epithelial cells alternatively engages the p14ARF pathway 
partly because E2F also stimulates p14ARF expression (Zhang et al, 2006). Up-
regulation of p16INK4a during senescence inhibits Cyclin D/CDK4/CDK6-
mediated phosphorylation of pRb. In its active, hypo-phosphorylated form, pRb 
recruits heterochromatin-forming proteins to E2F target promoters resulting in 
distinct chromatin structures called senescence-associated heterochromatin 
foci (SAHF). This condensed chromatin state prevents E2F from accessing its 
promoters thereby silencing target genes, such as cyclin A (CCNA2), required 
for cell cycle progression (Narita et al, 2003). 
185
6.1.2. Telomere dysfunction-induced senescence
 Telomere shortening, as a consequence of cell division, is the molecular 
event thought to lie behind the phenomenon of replicative senescence. Due 
to the end-replication problem, cells lose around 100bp, out of the 15Kb reserve 
length of telomeric DNA, per population doubling (Harley et al, 1990; Bodnar et 
al, 1998). Replicative senescence is triggered by the shortest dysfunctional 
telomere as opposed to the average telomere length of a population of cells 
(Hemann et al, 2001). Telomere length analysis in fibroblasts (STELA) confirmed 
gradual telomere shortening consistent with losses through end-replication and 
close to total loss of telomeric repeats at senescence (Baird et al, 2003).
 TRF2 is an essential telomeric protein responsible for inducing the 
protective t-loop conformation characteristic of the telomeric complex (de 
Lange, 2002). Over-expression of TRF2 accelerates telomere shortening yet 
delays the onset of senescence by allowing cells to proliferate beyond the 
normal senescence set-point of 6 to 7Kb (Karlseder et  al, 2002). It is possible that 
a critically short telomere may no longer be able to bind enough TRF2 to 
acquire a protective capped state and thus will emit a dysfunctional signal that 
triggers senescence (Karlseder et  al, 2002). Therefore, what makes a telomere 
dysfunctional is not the complete loss of telomeric DNA but rather its capped 
status (Blackburn, 2000).  
 Telomere-dependent senescence can be studied by growing normal 
cells in culture until they are 'old', i.e., have reached their replicative limit or by 
inducing prematurely dysfunctional telomeres in 'young' cells, i.e., that have 
undergone only a few divisions. TRF2 is, along with TRF1, a telomeric DNA-
binding protein (Fig. 6.4). The normal TRF2 allele encodes for a sequence 
composed of an N-terminal basic domain, in contrast with the acidic motif 
found in TRF1; a dimerisation area that allows binding of other TRF2 molecules to 
form functional homo-dimers as well as binding of accessory proteins (Rap1, 
TIN2 and TPP1); and, finally, a characteristic C-terminal Myb domain, similar to 
the one found in TRF1, strictly required for binding telomeric DNA (reviewed in 
(de Lange, 2005).
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Figure 6.4. Telomere-binding proteins TRF1 and TRF2. Schematic representation of TRF1 
and TRF2 domain structures with binding sites to accessory proteins (Rap1, TIN2, TPP1 
and POT1) and to telomeric DNA (top). Assembly of the human telomeric complex 
showing interactions between telomeric proteins, TRF1 and TRF2, and accessory 
proteins as well as with telomeric DNA (bottom) (in de Lange, 2005).
 Two TRF2 mutants have been developed to disrupt TRF2 protective 
function at the telomere (van Steensel et al, 1998). The TRF2!B mutant lacks the 
basic domain whereas TRF2!B!M (TRF2DN or TRF2 dominant negative) lacks both 
the basic and Myb domains (Fig. 6.5). The latter acts as a strong dominant 
negative mutant for its ability to dimerise with endogenous TRF2 whilst carrying 
an absent telomeric DNA-binding domain. 
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Figure 6.5. Human TRF2 deletion mutants. Schematic representation of full-length human 
TRF2 and mutants lacking the basic domain, TRF2!B or both the basic and the Myb 
domains, TRF2!B!M (in van Steensel, 1998).
 TRF2!B!M sequesters endogenous full-length TRF2 into defective dimers 
that are incapable of binding the telomere, therefore depleting it from TRF2 
complexes and, ultimately, exposing the telomeric DNA. This results in growth 
arrest accompanied by phenotypical characteristics of senescence (van 
Steensel et al, 1998). The main advantage of using this system as opposed to 
replicative exhaustion is that senescence can be induced prematurely in 
normal cells that have undergone only a few divisions thereby minimising the 
chance of accumulation of any other cellular changes (Smogorzewska & de 
Lange, 2002). There is, however, debate on whether acute induction of 
telomere dysfunction truly mimics senescence occurring naturally via 
replicative exhaustion or merely elicits a phenotype evocative of crisis in normal 
cells (Herbig et al, 2004). Although chromosome end-fusions were reported for 
IMR-90 cells (Smogorzewska & de Lange, 2002), TRF2!B!M-expressing NHEK did 
not show any evidence of anaphase bridges and were, therefore, senescent 
and not in crisis (Minty et al, 2008).
 The cellular consequences of telomere dysfunction vary between 
species and, within the same species, differ between cell types. In mouse cells, 
experimental uncapping of telomeres primarily engages the p53 pathway of 
senescence whilst in human cells it engages both p53 and p16INK4a/pRb 
(Smogorzewska & de Lange, 2002). Within the latter, expression of TRF2!B!M 
induces apoptosis in certain mammalian cell types, such as T-lymphocytes and 
p53-competent cancer cell lines (Karlseder et  al, 1999), and senescence in 
both fibroblasts (Smogorzewska & de Lange, 2002) and keratinocytes (Minty et 
al, 2008). 
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 Dysfunctional telomeres trigger a classical DNA damage response in 
human diploid fibroblasts (Takai et al, 2003; d'Adda di Fagagna et al, 2003; 
Herbig et  al, 2004). The first observation was that following expression of 
TRF2!B!M, many of the 53BP1 foci generated colocalised with the telomere. 
These were referred to as telomere-dysfunction induced foci or TIFs (Takai et al, 
2003) and also contained several other DNA damage response factors. The 
fact that indicators of a DDR such as 53BP1, Mre11 and the phosphorylated 
forms of ATM, H2AX and Rad17 were present at dysfunctional telomeres 
suggested that these might be perceived by the cell as sites of DNA damage 
(Takai et al, 2003). In addition to activated H2AX (ɣ-H2AX), which also 
colocalised with DNA damage checkpoint protein Mdc1 and DSB repair factor 
NBS1, there was evidence for activation of upstream protein kinases ATM and 
ATR, their downstream transducer kinases CHK1 and CHK2, and target proteins 
Rad17, Mdc1, p53 plus its transcriptional target p21WAF1. This indicates the 
generation of a DDR followed by engagement of the p53/p21WAF1 pathway of 
senescence similarly to the well characterised response elicited by DSBs 
following exposure to IR (d'Adda di Fagagna et  al, 2003). Single-cell analysis 
further confirmed that the signal from uncapped telomeres is transmitted 
primarily via ATM and CHK2, with ATR taking this role and processing the signal 
mainly via CHK1 in cells depleted of ATM. In addition, the signal activates p53 
and p21WAF1 causing G1 arrest without influencing p16INK4a expression (Herbig et 
al, 2004). Importantly, this can happen without the total loss of TRF2 from most 
fibroblasts telomeres, suggesting that the physiological uncapping of telomeres 
does not require total TRF2 depletion, or that DSBs can occur at the telomere in 
the absence of telomere shortening or uncapping, as it has recently been 
demonstrated (Hewitt et al, 2012; Fumagalli et al, 2012). 
 In normal epidermal keratinocytes, telomere uncapping results in a 
senescent-like arrest although accompanied by a surprisingly low DDR (Minty et 
al, 2008). This is characterised by a number of 53BP1 foci which is much lower 
than the number obtained following exposure to as low a dose of IR as 2 Gray 
and accompanied by a coherently mild phosphorylation of p53 at Serine 15. In 
addition, total p53 and p21WAF1 protein levels remained at control levels. 
Although this contrasts with what was previously reported for normal human 
fibroblasts (Herbig et  al, 2004), it is very similar to what has been reported for the 
keratinocyte dysplasia line D17 upon telomere erosion following serial passage 
to senescence (Muntoni et  al, 2003). D17 cells are mortal but have a mutation 
in the INK4a locus which makes them both p14ARF and p16INK4a-deficient while 
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retaining functional wild-type p53. As a consequence they are unable to 
senesce via these pathways but do so via the p53 pathway alone. Induction of 
p16INK4a has been reported in fibroblasts as a late event succeeding the initial 
DDR as a result of telomere dysfunction (Jacobs & de Lange, 2004) but in both 
replicative senescent fibroblasts (Herbig et  al, 2004) and TRF2!B!M-expressing 
keratinocytes (Minty et al, 2008) p16INK4a becomes up-regulated in a stochastic, 
telomere- and DNA damage-independent manner with increasing replicative 
age.
6.2. Over-expression of the main effectors of 
senescence
 Genes HOPX, ICEBERG and S100A7 show potential as markers for 
telomere dysfunction-induced senescence since they were up-regulated in 
keratinocytes with dysfunctional telomeres (via forced expression of TRF2!B!M or 
via natural telomere uncapping) and their expression returned to control levels 
following ectopic expression of telomerase (Muntoni et al, 2003; Minty et al, 
2008). Moreover, these candidate markers were not affected by induction of 
general DNA damage in the form of repairable or unrepairable DSBs (Chapter 
4). HOPX, ICEBERG and S100A7 were not elevated in response to induction of 
p53 following exposure to ionising radiation so it is possible that, in keratinocytes, 
dysfunctional telomeres might be signalled differently from DSBs and not 
through the classical DNA damage pathway of senescence as happens in 
fibroblasts (Takai et al, 2003; d'Adda di Fagagna et  al, 2003; Herbig et al, 2004). 
Although these data and previous work (Minty et  al, 2008) indicate that these 
genes do not appear to be regulated by p53, I wondered whether direct over-
expression of p53 or of the other two main effectors of senescence, p14ARF and 
p16INK4a, would induce the candidate markers.
 To test this, retroviral gene transfer was used to generate models of 
keratinocyte senescence. Cell cycle inhibitors p14ARF, p16INK4a, p53 and the 
dominant negative version of TRF2, TRF2!B!M were independently over-
expressed in NHEKs via retroviral transduction. Keratinocytes were either 
infected indirectly, by co-culture with infectious packaging cell lines producing 
retroviral particles capable of infecting human cells or, alternatively, by being 
exposed directly to amphotropic viral supernatants (Chapter 5). Retroviral 
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vectors were allowed a 24h (direct strategy) or 48h (indirect strategy) 
expression time before NHEKs were placed under drug selection. Populations of 
keratinocytes selectively senescing via each of the main pathways of 
senescence (p14ARF/p53 pathway, p53 pathway and p16INK4a/pRb pathway) 
and via telomere dysfunction were obtained and analysed 5 days after 
infection. The response of the candidate markers (via gene expression analysis) 
in each of the classical models of senescence was compared to the model of 
telomere dysfunction-induced senescence.
 Delivery of the transgenes to the keratinocytes was at the first instance 
visually confirmed by the high percentage of fluorescence (close to 100%) 
obtained in the GFP-expressing empty vector control and by the distinct 
phenotypical appearance of the cells/colonies expressing p14ARF, p16INK4a, p53 
and TRF2!B!M when compared to the empty vector control (Chapter 5). Levels 
of expression of the transgenes were assessed by qPCR. These varied between 
experiments and also depended on the strategy used for delivery. For instance, 
I have found that TRF2!B!M was only expressed at levels high enough to induce 
senescence via a direct strategy of infection. Similarly, this strategy generally 
resulted in higher expression levels for p14ARF and p53. For p16INK4a, however, 
delivery via an indirect strategy of infection proved to be more successful 
(Chapter 5). As a result, distinct populations of keratinocytes selectively over-
expressing the transgenes at LOW, MEDIUM or HIGH levels were obtained. The 
transcriptional profiles of each NHEK population are presented in Figures 6.6 to 
6.9. 
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Figure 6.6. Transcriptional profile of populations of normal human epidermal 
keratinocytes expressing TRF2!B!M at different levels. Keratinocyte populations 
expressing TRF2!B!M at LOW (12-fold), MEDIUM  (15-fold) and HIGH (18-fold) were 
analysed by qPCR for induction of transcript levels of candidate markers (HOPX, 
HIST2H2BE, ICEBERG and S100A7), cyclins (CCNA2 and CCND1) and effectors of 
senescence (p14ARF, p16INK4, p53 and TRF2!B!M). TRF2 mRNA levels were also assessed to 
confirm they remain unaltered by expression of its dominant negative mutant TRF2!B!M 
(TRF2DN). Results are expressed in fold mRNA levels normalised against the respective 
empty vector (EV) control. Legend: EV = NHEK expressing empty vector control; DN = 
NHEK expressing TRF2!B!M.
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Figure 6.7. Transcriptional profile of populations of normal human epidermal 
keratinocytes expressing p14ARF at different levels. Keratinocyte populations expressing 
p14ARF at LOW (89-fold), MEDIUM  (142-fold) and HIGH (220-fold) were analysed by qPCR 
for induction of transcript levels of candidate markers (HOPX, HIST2H2BE, ICEBERG and 
S100A7), cyclins (CCNA2 and CCND1) and effectors of senescence (p14ARF, p16INK4, p53 
and TRF2!B!M). TRF2 mRNA was also assessed to confirm it remains at control levels. 
Results are expressed in fold mRNA levels normalised against the respective empty 
vector (EV) control. Legend: EV = NHEK expressing empty vector control; p14 = NHEK 
expressing p14ARF.
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Figure 6.8. Transcriptional profile of populations of normal human epidermal 
keratinocytes expressing p16INK4a at different levels. Keratinocyte populations 
expressing p16INK4 at LOW (18-fold), MEDIUM  (60-fold) and HIGH (116-fold) were 
analysed by qPCR for induction of transcript levels of candidate markers (HOPX, 
HIST2H2BE, ICEBERG and S100A7), cyclins (CCNA2 and CCND1) and effectors of 
senescence (p14ARF, p16INK4, p53 and TRF2!B!M). TRF2 mRNA was also assessed to 
confirm it remains at control levels. Results are expressed in fold mRNA levels normalised 
against the respective empty vector (EV) control. Legend: EV = NHEK expressing empty 
vector control; p16 = NHEK expressing p16INK4.
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Figure 6.9. Transcriptional profile of populations of normal human epidermal 
keratinocytes expressing p53 at different levels. Keratinocyte populations expressing 
p53 at LOW (10-fold), MEDIUM  (7-fold) and HIGH (29-fold) were analysed by qPCR for 
induction of transcript  levels of candidate markers (HOPX, HIST2H2BE, ICEBERG and 
S100A7), cyclins (CCNA2 and CCND1) and effectors of senescence (p14ARF, p16INK4, p53 
and TRF2!B!M). TRF2 mRNA was also assessed to confirm it remains at control levels. 
Results are expressed in fold mRNA levels normalised against the respective empty 
vector (EV) control. Legend: EV = NHEK expressing empty vector control; p53 = NHEK 
expressing p53.
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 Successful delivery of the retroviral vectors and over-expression of the 
main effectors of senescence p14ARF, p16INK4a and p53 as well as expression of 
the dominant negative mutant TRF2!B!M resulted in a large reduction in CFE 
(colony-forming efficiency). Cloning efficiency was reduced by 50% with p14ARF 
and by at least 75% with p16INK4a, p53 and TRF2!B!M, when compared to the 
respective empty vector control (Figure 6.10). Also, in addition to the distinct 
phenotypical appearance of the cells/colonies upon senescence (Chapter 5) 
a significant decrease in transcript levels of Cyclin A2 (CCNA2) accompanied 
by elevation of Cyclin D1 (CCND1) was observed in keratinocytes expressing at 
least MEDIUM or HIGH levels of the transgenes, which is consistent with 
senescence (Figures 6.6 to 6.9). Taken together this shows that the transduced 
cells went on to exit the cell cycle rather than terminal differentiate or die. 
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Figure 6.10. Analysis of cloning efficiency of NHEK transduced with p14ARF, p16INK4a, p53 
and TRF2!B!M. NHEK were transduced via a direct strategy of infection and, 48h later, 
trypsinised and seeded at clonal density (7 x  103 cells per 6-well plate). Cells were 
cultured for 2 weeks under drug selection and finally fixed and stained with rhodamine 
B to reveal keratinocyte colonies. Cloning efficiency, displayed as percentage and 
normalised against the respective EV control, was calculated by dividing the total 
number of colonies obtained per well by the total number of cells seeded per plate 
(7,000). Photos show  wells representative of the results obtained for each construct. GFP 
= empty vector control for p14ARF, p16INK4, p53; EV = empty vector control for TRF2!B!M 
(DN).
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 In general, the level of expression of the transgene correlated directly 
with the level of reduction in CCNA2/elevation in CCND1, so there seems to be 
a threshold level of expression above which senescence seems to be engaged. 
This was most evident with TRF2!B!M and has previously been reported in 
fibroblasts (van Steensel et al, 1998). Levels of expression of TRF2!B!M of 4-fold 
did not result in cell cycle arrest as cells proliferated as well as the empty vector 
control (experiments described in Chapter 5). An 11-fold expression level, 
however, resulted in a mild decrease (10%) in CCNA2 yet 40% elevation of 
CCND1 whereas 15-fold and 18-fold levels resulted in a convincing 50% 
reduction in CCNA2 and 40% decrease in CCNA2/40% increase in Cyclin D1, 
respectively (Figure 6.6). Over-expression of p16INK4a by 18-fold resulted in a 40% 
decrease in CCNA2, 59-fold augmented it to 60% and, finally, 116-fold caused 
a 30% reduction in CCNA2 accompanied by the same elevation in CCND1 
(Figure 6.8). Elevation of p53 by 7-fold resulted in a 50% decrease in CCNA2 and 
a similar expression level of 10-fold resulted in poorer reduction of CCNA2 (just 
20%) followed by a mild increase in CCND1 (also 20%). Over-expression of p53 
by 28-fold, however, reduced CCNA2 by 30% and CCND1 maintained a mild 
elevation (Figure 6.9). The exception to the direct correlation between 
expression of the transgene and effective cell cycle arrest was p14ARF. 
Regardless being over-expressed at a LOW (89-fold), MEDIUM (142-fold) or HIGH 
(220-fold) level it resulted always in 30-40% reduction of CCNA2 alone (Figure 
6.7). I have considered, therefore, that MEDIUM and HIGH levels of expression of 
the transgenes were capable of inducing senescence in NHEK (exception for 
p53 where 7-fold reduced CCNA2 to a higher level than did 10-fold).
 Each candidate marker responded differently to over-expression of 
each of the known effectors of senescence (Figures 6.6 to 6.9). As 
demonstrated before (Minty et  al, 2008), all candidate markers were elevated 
upon telomere dysfunction-induced senescence in keratinocytes via expression 
of TRF2!B!M (Fig. 6.6). Interestingly, whilst high doses of IR with consequent 
activation of p53 only induced HIST2H2BE (Chapter 4), direct over-expression of 
p53, depending on the level, did induce some of the other markers (Fig. 6.9). A 
7-fold induction of p53 induced both HOPX and HIST2H2BE by 40%. A 4x higher 
expression level (28-fold), however, induced HIST2H2BE and S100A7 by 1.5-fold, 
198
and HOPX and ICEBERG by over 2-fold and 3-fold, respectively. p14ARF induced 
only HOPX and HIST2H2BE, by around 50% (Fig. 6.7) whilst p16INK4a did not cause 
significant elevation of any of the markers (Fig. 6.8). The average transcript 
levels of the candidate markers HOPX, HIST2H2BE, ICEBERG and S100A7 
between populations of keratinocytes expressing the transgenes at MEDIUM 
and HIGH levels are summarised in Figure 6.11.
Figure 6.11. Transcript levels of HOPX, HIST2H2BE, ICEBERG and S100A7 in keratinocytes 
transduced with p14ARF, p16INK4a, p53 and TRF2!B!M. Gene expression levels of the 
candidate markers (HOPX, HIST2H2BE, ICEBERG and S100A7) were normalised against 
the respective empty vector control (EV) and averaged (n=2) between populations of 
NHEK expressing MEDIUM  and HIGH levels of the transgenes (p14ARF, p16INK4, p53 and 
TRF2!B!M). Bars represent standard deviation and arrows induction of the markers.
 HOPX was induced, in average, at a higher level by p14ARF (1.6-fold) and 
p53 (1.8-fold) than by TRF2!B!M (1.4-fold). HIST2H2BE was also induced by p14ARF 
(1.5-fold) and p53 (1.4-fold), however at a lower level than by TRF2!B!M (1.9-
fold). ICEBERG was significantly induced by p53 (2.4-fold) whilst S100A7 was not. 
Both ICEBERG and S100A7 were also not induced by p14ARF or p16INK4a yet were 
elevated by 1.5-fold and 2.4-fold, respectively, following expression of TRF2!B!M. 
Nevertheless, expression of the dominant negative mutant of TRF2 resulted in 
generally lower (by about 1-fold) levels of expression of the candidate markers 
than what had been previously reported using a different technique for 
retroviral transduction (Minty et al, 2008). Minty et al obtained an elevation of 
2.5-fold for HOPX versus 1.4-fold, 2.4-fold for HIST2H2BE versus 1.9-fold, 2.8-fold for 
ICEBERG versus 1.5-fold and 3.5-fold for S100A7 versus 2.4-fold, therefore 
demonstrating that relative levels between markers are similar. HOPX, HIST2H2BE 
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and ICEBERG are elevated to a similar level (about 1.5-fold) following 
expression of TRF2!B!M, whilst S100A7 is always about half to 1-fold higher (Fig. 
6.11).
 Results from the retroviral transduction experiments suggest that S100A7 is 
the most promising candidate as a specific marker of telomere dysfunction-
induced senescence as it was not induced by over-expression of the main 
effectors of senescence yet was selectively elevated following telomere 
uncapping via expression of TRF2!B!M. 
6.3. Discussion
 I have been investigating the hypothesis that telomere dysfunction in 
keratinocytes might be signalled through an alternative pathway to the 
classical p53-dependent senescence pathway activated in response to 
generalised DNA damage. As a consequence of expression of the dominant 
negative mutant version of the telomere protection factor 2, TRF2!B!M in 
newborn human epidermal keratinocytes (Minty et al, 2008) a weak DDR 
ensued and the senescent-like arrest that followed was accompanied by a 
characteristic transcriptional profile with up-regulation of genes involved in 
chromatin remodelling (HIST2H2BE, histone from the H2B family), inflammation 
(ICEBERG) and terminal differentiation (HOPX and S100A7). These genes show 
potential as markers for keratinocyte TDIS. 
 So far I have shown that the weak DDR was not the factor responsible for 
the induction of any of these genes and that a strong DDR, activated in 
response to extensive DNA damage following exposure to senescence-
inducing doses of IR, was only responsible for inducing the histone HIST2H2BE 
(Chapter 4). Despite being regulated by telomere dysfunction and telomerase 
(Muntoni et al, 2003; Minty et  al, 2008), this suggests that HOPX, ICEBERG and 
S100A7, are apparently not regulated by p53, at least, not via the DNA 
damage pathway of senescence. However, since the nature of p53 activation 
depends on the triggering stimuli it is still possible that p53 or the other main 
effectors of senescence might be at play.
 In order to assess the influence of the activation of each of the main 
pathways of senescence (p14ARF/p53 or p53/p21WAF1 or p16INK4a/pRb) in the 
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expression of the candidate markers I have used retroviral transduction to over-
express p14ARF, p16INK4a and p53 in keratinocytes, as well as expression of 
TRF2!B!M as a model for telomere dysfunction (Chapter 5). 
 Activation of p53 has been reported to occur as a consequence of 
telomere uncapping (Takai et al, 2003; d'Adda di Fagagna et  al, 2003; Herbig 
et al, 2004) or following exposure to IR (Di Leonardo et  al, 1994) through 
phosphorylation of the molecule at the Serine 15 site and, at least in 
keratinocytes, IR does not cause considerable elevation of p53 transcript or 
stabilisation of the protein, within five days (Minty et  al, 2008). Whilst HIST2H2BE 
was the only candidate marker elevated in response to senescence-inducing 
doses of IR, HOPX and ICEBERG were also induced by direct over-expression of 
p53 using retroviral vectors. This may be because with this manipulation p53 
activation occurs due to stabilisation of the molecule rather than due to post-
transcriptional modifications. 
 Over-expression of p14ARF also resulted in up-regulation of HIST2H2BE and 
HOPX probably because p14ARF also contributes to stabilisation of p53. ARF acts 
by sequestering the E3 ubiquitin ligase MDM-2 in the nucleolus thereby 
preventing p53 from being targeted for proteolytic degradation (Sherr, 1998; 
Stott et  al, 1998; Dimri et  al, 2000). This can easily be confirmed by looking at 
protein levels of total p53 in keratinocytes transduced with p14ARF. It is however 
unlikely that activation of p14ARF might have been the factor responsible for the 
original induction of the markers (Minty et al, 2008); first, because p14ARF is 
known not to play a role in keratinocyte senescence (Munro et al, 1999) and 
second, since the other two candidates, ICEBERG and S100A7, did not seem to 
be affected by over-expression of p14ARF. Since all the aforementioned 
manipulations resulting in activation of p53 (Di Leonardo et al, 1994; Sugrue et 
al, 1997; Dimri et al, 2000) also result in activation of p21WAF1, p53’s 
transcriptional target, this data suggests that HIST2H2BE, HOPX and ICEBERG are 
regulated by p21WAF1 in a p53-dependent manner. As S100A7 was the only 
candidate marker whose expression levels seemed unaffected by direct over-
expression of either p14ARF or p53, or by p53 activation following irradiation 
(Chapter 4), S100A7 does not seem to be regulated by p53. Nevertheless, 
S100A7 seems to be regulated by p21WAF1, however in a p53-independent 
manner, more likely related to the process of terminal differentiation in 
keratinocytes (Chapter 4). 
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 Finally, over-expression of p16INK4a did not cause elevation in transcript 
levels of any of the candidate markers. The frequency of expression of p16INK4a 
increases in keratinocytes during serial passage in culture (Rheinwald et  al, 
2002) and in human skin with age (Ressler et  al, 2006). The p16INK4a-dependent 
pathway of senescence is therefore the main competitor mechanism to 
telomere dysfunction-dependent senescence in keratinocytes (Ramirez et  al, 
2001; Rheinwald et al, 2002). These data suggest they operate independently 
and p16INK4a was not a contributing factor in the up-regulation of the candidate 
markers. Also, since all genes seem to be affected by terminal differentiation 
and since p16INK4a causes growth arrest without an effect on differentiation (Di 
Cunto et al, 1998) this is consistent with our findings.
 Some secreted proteins are induced by CDKI ectopic expression 
(McConnell et al, 1998) but many are not (Coppe et al, 2011) and instead 
require activation of the NF-KB pathway (Freund et al, 2011), which is often 
activated in fibroblast senescence (Rovillain et al, 2011; Vaughan & Jat, 2011). I 
have not tested the role of NF-KB directly or any candidate upstream regulators 
of p16INK4a other than IR. However, NF-KB is activated by DSBs (Freund et al, 
2011) and IR causes DSBs but does not induce the expression of HOPX, ICEBERG 
or S100A7 (Chapter 4). Therefore, it seems unlikely that NF-KB activation or its 
upstream transcriptional regulator p38 would induce any of these candidate 
biomarkers of telomere dysfunction.
 Genes HOPX, HIST2H2BE, ICEBERG and S100A7 were put forward as 
potential markers for TDIS in normal human epidermal keratinocytes since their 
expression levels were elevated following telomere dysfunction and returned to 
normal upon ectopic expression of telomerase (Minty et al, 2008). I  have 
investigated the specificity of the four candidate markers to DNA damage-
induced senescence (Chapter 4) and to other forms of senescence (Chapter 
6) in relation to telomere dysfunction-induced senescence (TDIS). Overall, results 
suggest that S100A7 is the most promising candidate as a specific marker of 
TDIS as it was the only gene selectively elevated following telomere uncapping 
via expression of TRF2!B!M and not by senescence-inducing doses of IR or by 
over-expression of p14ARF, p16INK4a or p53.
 S100A7 (or psoriasin) is a member of the S100 family, first isolated from 
psoriatic skin (Madsen et  al, 1991). Its up-regulation has been associated with 
abnormal terminal differentiation, pathogenesis of inflammatory skin disease 
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and progression of breast, bladder and skin cancer (Celis et al, 1996; 
Moubayed et al, 2007). In addition, S100A7 has also been shown to be severely 
down-regulated in immortal keratinocytes (immortal dysplasias and 
carcinomas) that have p53 and p16INK4a dysfunction and which express 
telomerase (Parkinson, unpublished data), and in the D17 keratinocyte 
dysplasia, which has functional p53 but lacks the products of the INK4a locus, 
p14ARF and p16INK4a, and has not activated telomerase (Muntoni et  al, 2003; 
Minty et al, 2008). The growth arrest associated with senescence following 
expression of its main effectors p53 and p16INK4a has been shown to be 
uncoupled from the SASP (Coppe et al, 2011). In fact, p53 activation (Coppé et 
al, 2008) and ectopic expression of p21WAF1 or p16INK4a (Coppe et  al, 2011) were 
found to restrain the SASP in epithelial cells. Neither p53 activation (Chapter 4), 
p53 or p16INK4a over-expression (Chapter 6) restrained S100A7 expression like 
they do the rest of the senescence secretome which suggests that S100A7 
regulation seems to occur independently from the inflammatory cascade. 
Although PAI, a component of the senescent secretome, has been shown to 
be transcriptionally up-regulated by p16INK4a (McConnell et  al, 1998) this does 
not seem to be the case for S100A7 in keratinocytes. This is in agreement with 
previous findings on how p16INK4a does not induce the main components of the 
SASP (Coppe et  al, 2011). Finally, the fact that p16INK4a expression has been 
directly associated with genes involved in keratinocyte migration during 
senescence, wounding and micro-invasive dysplasia as opposed to genes 
associated with terminal differentiation (Natarajan et  al, 2003; Darbro et  al, 
2005; Natarajan et  al, 2006) might also explain why S100A7 was not up-
regulated by over-expression of p16INK4a.
 The ideal biomarker should be cell type- and mechanism-specific as well 
as a secreted molecule for ease of detection. The secreted biomarkers 
identified so far for telomere dysfunction are also induced by generalised DNA 
damage (Jiang et al, 2008) and thus not mechanism-specific. This might be 
because when telomeres become critically short they are reinterpreted as DSBs 
and processed as such (Takai et  al, 2003; d'Adda di Fagagna et  al, 2003). 
Keratinocytes, however, seem to respond differently to telomere dysfunction 
and selectively up-regulate S100A7 following TDIS. Therefore, this gene shows 
great potential as a biomarker for TDIS since it is also keratinocyte-specific and 
a secreted molecule which shows no elevation in the serum of patients with 
psoriasis (Anderson et al, 2009). 
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Chapter 7. Analysis of the functional role of 
homeobox gene HOPX in TDIS.
7.1. Introduction
 Following the work in Chapter 4 a decision was made to proceed with the 
functional analysis of a lead candidate downstream effector of keratinocyte 
telomere dysfunction-induced senescence (TDIS). The homeobox gene HOPX 
was chosen as the lead candidate marker based on the results obtained at the 
time and also because there was evidence for its role as a tumour suppressor 
gene.
 Upon telomere uncapping, and associated low DDR, HOPX was up-
regulated in normal human epidermal keratinocytes (Minty et  al, 2008). I further 
showed that, although HOPX is induced by telomere dysfunction it does not 
seem to be influenced by either a weak or a strong DDR, following induction of 
DNA damage in keratinocytes (Chapter 4). Consistent with this is the fact that 
HOPX has also been shown to be severely down-regulated in immortal 
keratinocytes expressing telomerase and lacking functional p53 and p16INK4a (E. 
K. Parkinson, unpublished microarray data). These findings suggest HOPX might 
be regulated by telomerase but not by p53. However, HOPX also showed some 
down-regulation in a cell line (D17 dysplasia, (McGregor et al, 2002)) that lacks 
p16INK4a and p14ARF but possesses functional p53 and normal levels of 
telomerase (Muntoni et al, 2003; Minty et al, 2008). Importantly, elevation of 
HOPX transcript following telomere uncapping in D17 was reversed by ectopic 
expression of telomerase (Muntoni et al, 2003; Minty et al, 2008). So, the fact 
that HOPX does not seem to be regulated by p53, at least not via the DDR, 
suggests that dysfunctional telomeres in keratinocytes might be signalled 
through an alternative pathway to the classic DNA damage pathway, used to 
signal telomere damage in fibroblasts (Takai et al, 2003; d'Adda di Fagagna et 
al, 2003; Herbig et al, 2004). HOPX is even more interesting as it has recently 
been described as a tumour-suppressor gene (Chen et  al, 2007; De Toni et  al, 
2008; Yamashita et al, 2008; Yamaguchi et al, 2009), a characteristic shared by 
several genes involved in cellular senescence. I intend to proceed with 
functional analysis of HOPX by attempting its stable knockdown using retroviral-
delivered short hairpin RNAs (shRNAs) to generate short interfering RNA (siRNA). 
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By ablating its function I aim to assess whether HOPX is actively involved in the 
TDIS pathway in keratinocytes. 
 HOPX belongs to the group of HOX genes, well known for their role in 
embryogenesis and development, which are characterised by containing a 60 
aminoacid domain required for DNA binding. HOPX is, however, an unusual 
homeobox gene as it encodes for a homeodomain protein that does not bind 
DNA, acting instead by binding the serum response factor (SRF) as a means to 
regulate transcriptional activity and it was first associated with modulation of 
cardiac development (Chen et al, 2002; Kook & Epstein, 2003; Kook et  al, 2006). 
Post-natal expression of HOPX occurs normally in several terminally 
differentiated organs such as the heart and the brain, as well as in skeletal 
muscle and epithelia. Studies show its involvement in the late stages of terminal 
differentiation in both the lens (Vasiliev  et al, 2007) and the skin (Yang et  al, 
2010), and in the induction of skeletal muscle differentiation (Kee et  al, 2007). In 
mice, up-regulation of HOPX is associated with an increase in differentiation 
and results in the development of severe cardiac hypertrophy and fibrosis 
(Kook et  al, 2003). HOPX is also up-regulated in senescence, namely in normal 
epidermal keratinocytes undergoing TDIS (Minty et al, 2008). Conversely, HOPX 
down-regulation generally is associated with proliferation and has been 
reported in lung cancer (Chen et al, 2003; 2007), head and neck squamous cell 
carcinoma (Lemaire et al, 2004), choriocarcinoma (Asanoma et  al, 2004), 
uterine endometrial cancer (Yamaguchi et al, 2009) and gastric cancer (Ooki 
et al, 2010). In contrast, HOPX seems to be over-expressed in thyroid carcinoma 
(Pauws et  al, 2004). Recent studies show that transcriptional silencing of HOPX 
during malignant transformation is a result of hyper-methylation of its promoter 
(Yamaguchi et al, 2009; Ooki et al, 2010). HOPX knockdown in HPV-immortalised 
keratinocytes treated with anti-viral drugs (I. Paterson,  University of Bristol, 
personal communication) and in immortalised human endometrial cells 
(Yamaguchi et al, 2009) results in accelerated proliferation, whilst the forced 
expression of HOPX in keratinocyte lines has the opposite effect, i.e., slowing 
down proliferation (I. Paterson,  University of Bristol, personal communication). 
Based on this body of evidence HOPX has been recently classified as a tumour-
suppressor gene.
RNA interference (RNAi)
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 The process of gene silencing was first observed in plants (Napoli et al, 
1990) but only understood and characterised several years later as RNA 
interference (RNAi). This coincided with the discovery that dsRNA (double-
stranded RNA), containing a pair of both sense and anti-sense strands of the 
target mRNA, was the inducer of effective gene silencing in both C. elegans 
(Fire et al, 1998) and mammalian cells (Elbashir et  al, 2001). RNAi is thought to 
have evolved as a protective cellular mechanism against dsRNA viruses and 
other mobile genetic elements such as transposons, especially in nematodes, 
insects and plants. However, in addition to its role in mRNA degradation, RNAi 
has a more complex role as it is also involved in regulation of transcription, 
translation, chromatin structure and genomic integrity (Medema, 2004; Kim & 
Rossi, 2007). RNA silencing pathways are conserved in eukaryotes, from yeast to 
plants and mammals, and have been since characterised (reviewed in
(Medema, 2004; Kim & Rossi, 2007)). 
 The siRNA pathway mediates port-transcriptional gene silencing via 
effector short interfering RNA molecules (siRNAs). These are small double-
stranded complementary RNA molecules with dinucleotide 3' overhangs 
resulting from processing of exogenous larger dsRNA by the RNase III enzyme 
Dicer. siRNAs mediate mRNA cleavage by activating the RNA-induced silencing 
complex (RISC). The sense strand of the double-stranded siRNA is first cleaved 
by the endonuclease component Argonaute 2 (AGO2) freeing the anti-sense 
strand which guides RISC to the fully complementary target mRNA. Following 
cleavage this is finally degraded by exonucleases. siRNAs can also mediate 
transcriptional gene silencing through chromatin modifications such as histone 
methylation (Fig. 7.1 left). 
 The miRNA pathway is involved in gene regulation during development 
and differentiation and acts through effector micro RNAs (miRNAs). These are 
small RNAs (around 22nt in length) which, as opposed to siRNAs, derive from a 
single transcript folded into a ds-hairpin containing loops. The endogenous long 
primary transcript (Pri-miRNA) is transcribed by RNA polII in the nucleus and 
processed by the Drosha/DGCR8 microprocessor complex into stem-loop 
precursors (pre-miRNA) around 70 nt long. These are exported to the cytoplasm 
by dsRNA-binding protein Exportin 5 (XPO-5) where they are processed into 
miRNAs by the Dicer/TRBP/PACT complex. Instead of being cleaved by AGO2, 
due to imperfect sequence complementarity, the miRNA sense or passenger 
strand is unwound and discarded through RISC's helicase activity. The 
206
remaining mature miRNA anti-sense strand then binds 3' untranslated regions 
(3'UTRS) in the target mRNA through RISC activation which directs translational 
repression and mRNA degradation in cytoplasmic P-bodies (Fig. 7.1 right). The 
choice between achieving gene silencing through block of transcription, 
translation or via direct transcript degradation is thought to depend not on the 
nature of the RNAi effectors (whether they are siRNAs or miRNAs) but on the 
degree of complementarity between the interference molecules and the 
target mRNA.  
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Figure 7.1. RNA interference (RNAi) pathways in mammalian cells. siRNA pathway (left) 
and miRNA pathway (right). Legend: TRBP = TAR RNA-binding protein (TRBP); PACT = 
protein activator of protein kinase PKR (PACT); AGO2 = Argonaute 2; RISC =  RNA-
induced silencing complex  (RISC); DGCR8 = DiGeorge syndrome critical region gene 8; 
DCP1 and DCP2 = de-capping enzymes 1 and 2; H3K9, histone 3 lysine 9; H3K27, histone 
3 lysine 27; m7G, 7-methylguanylate; ORF, open reading frame (in (Kim & Rossi, 2007)).
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  Several RNAi effector molecules have been developed for use as gene 
silencing tools (Medema, 2004; Kim & Rossi, 2007). Early on it became clear that 
large dsRNA could not be used to generate siRNA in mammalian cells since 
sequences larger than 30 base pairs would trigger an interferon inflammatory 
response which ultimately resulted in non-specific gene silencing through 
generalised block in protein synthesis (Williams, 1997). However, it was soon 
discovered that short interfering dsRNA sequences (siRNAs) could be 
successfully used instead (Elbashir et al, 2001). Synthetic siRNAs are introduced 
directly via transfection either unmodified or containing chemical modifications 
to improve stability (Fig. 7.2 a). Although this results in a transient knock-down of 
the target gene, lasting just up to 6 days, the strategy is very effective since 
high copy numbers of siRNAs are obtained in the cell. Effector siRNAs can also 
be generated indirectly in cells transduced with vectors expressing short hairpin 
RNAs (shRNAs) since these are processed into functional siRNAs by Dicer 
through the endogenous RNAi pathway (Fig. 7.2 b). In this case stable knock-
down of the target gene is achieved due to continuous expression of the 
shRNA and, therefore, siRNA production in the target cell. Despite having the 
advantage of being used to transduce primary or non-dividing cells, especially 
with the use of retroviral, adenoviral or lentiviral systems, shRNAs are less 
effective than siRNAs in mediating gene silencing as they generate fewer siRNA 
molecules. Drug selection on the various vector-based systems will have a 
similar effect. Therefore, in order to achieve effective gene silencing through a 
vector-based system, the choice of a target sequence efficiently recognised 
by the few copies of siRNAs generated is an essential consideration in hairpin 
design.
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Figure 7.2. Overview of various RNAi effector molecules used as gene silencing tools. 
Synthetic siRNAs (a) and expressed shRNAs (b) (in Kim, 2007).
 In order to proceed with HOPX functional analysis and further investigate 
its role in keratinocyte TDIS I  opted for a retroviral vector-based system for 
expression of shRNAs designed to silence HOPX transcript. The aim was to 
induce stable knock-down of HOPX in two keratinocyte models of TDIS. The first 
is based on artificial telomere uncapping, through expression of the dominant-
negative mutant version of telomere-binding factor TRF2 (TRF2!B!M), in newborn 
early passage normal human epidermal keratinocytes. The second, a model of 
natural telomere uncapping, consists of an oral keratinocyte dysplasia line 
(D17) characterised by deletion of the INK4a locus, wild type functional p53 
and a finite, although extended, lifespan. If HOPX is essential to keratinocyte 
TDIS its ablation should block or mute telomere-dysfunction induced 
senescence thereby extending replicative lifespan. If this strategy succeeds, a 
new pathway from dysfunctional telomeres to senescence would be identified. 
Ultimately, the objective would be to demonstrate this in vivo.
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7.2. Establishment of experimental model 
 The choice of a retroviral-based shRNA system for silencing HOPX 
expression in normal keratinocytes was appropriate given the objectives of this 
work and despite shRNAs' overall lower efficiency when compared to siRNAs'. 
As a general rule, cell strains are difficult to transfect directly with plasmid DNA 
and keratinocytes are a particularly challenging cell type. One of the most 
successful systems for the expression of transgenes in normal human epidermal 
keratinocytes involves transduction with retroviral vectors (Levy et al, 1998). In 
addition, since the predicted phenotype following HOPX KD in keratinocyte 
TDIS models is the bypass of senescence checkpoints and, thus, extension of 
replicative lifespan, effective KD needs to be maintained for several days or 
weeks. Stable knock-down using shRNA is therefore preferable to transient KD 
via siRNA. 
 Based on the preceding considerations I obtained a set of commercially 
designed shRNAs against human HOPX (Origene) conveyed in pGFP-B-RS 
vectors, which are based on a pRS plasmid backbone (Fig. 7.3). pGFP-B-RS 
constructs contain a GFP cassette under the control of a CMV promoter. As the 
GFP sequence does not get integrated with the retroviral vector, fluorescence is 
used solely to monitor transfection efficiency (transfection control). Also, since I 
intended to super-infect keratinocytes with TRF2!B!M and this construct is 
associated with a puromycin selection marker (pLPC N-MYC vector - see 
Chapter 5), I opted for a retroviral construct containing an alternative selection 
marker, blasticidin (BSD). In addition to being a driver of selective pressure for 
gene expression (in this case shRNA expression), resistance to blasticidin should 
also provide information on the transduction rate of the target cells. Within the 
retroviral vector, the blasticidin resistance cassette (BSDr) is under the control of 
an SV40 promoter, whereas the human U6 promoter directs shRNA expression. 
The shRNA cassette consists of a 29bp target specific sequence, a 7bp loop 
and another 29bp reverse complementary sequence followed by a termination 
sequence (TTTTTT) located immediately downstream to stop transcription by 
RNA pol III. 
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Figure 7.3. Map of shRNA cloning vector pGFP-B-RS. The GFP cassette is under the 
control of a CMV promoter. In the retroviral construct, an SV40 promoter drives 
expression of the blasticidin-resistance cassette (BSDr), whilst the human U6 promoter 
directs shRNA expression. The shRNA cassette consists of a 29bp target specific 
sequence, a 7bp loop and another 29bp reverse complementary sequence followed 
by a termination sequence (TTTTTT) located immediately downstream to stop 
transcription by RNA pol III.
 The various commercially obtained hairpins (shRNA sequences A, B, C 
and D) were assessed and the best two selected for the least off-target effects 
and highest knock-down efficiency. Origene's hairpin design predicted that at 
least one of the four constructs should produce more than 70% knock-down 
(72h post-transfection), provided a minimum transfection efficiency of 80% is 
achieved. This was a rather optimistic prediction since most vector-based 
systems render only around 50% maximum KD efficiency, as opposed to 80% or 
higher obtained with siRNAs. Although the design of these shRNA constructs 
was directed against a maximum number of transcriptional variants at this gene 
locus (based on Origene’s datasheet), the fact that multiple alternatively 
spliced transcript variants (at least 5 so far) were identified for HOPX could 
influence target specificity and reduce KD efficiency. Nevertheless, an efficient 
level of KD for human HOPX was previously reported using these constructs in 
immortal oral keratinocytes (Ian Paterson, University of Bristol, personal 
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communication). In addition to the specific anti-HOPX shRNAs, a hairpin 
containing a scrambled shRNA sequence non-specific to HOPX was also 
provided, to control for KD background (scrambled control). An empty vector 
control was included as an additional negative control for KD and as a 
reference for normal gene expression level and phenotype.
 To assess the quality of the hairpins, shRNA constructs were first 
transduced into normal human epidermal keratinocytes (NHEK) via a direct 
strategy of infection through generation of amphotropic retroviral particles (see 
Chapter 5). Briefly, pGFP-B-RS plasmid constructs containing shRNA sequences 
A, B, C or D, the shRNA scrambled sequence (scrambled control, S) or vector 
only (empty vector control, EV) were transfected into the amphotropic Phoenix 
packaging cell line (Phoenix A cells). Infectious retroviral particles were 
collected 48h following transfection and used to directly infect keratinocytes 
cultured in the 'feeder' system via spinfection (see Chapter 2). Drug selection 
(8!g/mL blasticidin, based on kill curve) was introduced 24h after infection and 
level of KD assessed 12 days later. 
 The transfection efficiency was higher than 80% for all constructs as 
observed by levels of fluorescence. This, consequently, resulted in good 
infection rates given the low number of keratinocytes that succumbed to drug 
selection and a good number of successfully transduced healthy colonies. 
Blasticidin proved to be a very efficient selection agent, causing 100% cell 
death in the mock control within just 3 days and exhibiting very low toxicity on 
the transduced cells given the lack of any visible deleterious effects, when 
compared to non-transduced cells (mock control). The level of knock-down, 
inferred from reduction in HOPX protein levels in the cells transduced with the 
shRNAs, was assessed by western blot followed by densitometry analysis against 
the background generated by the scrambled control. By normalising against 
the scrambled control I ensured it is solely the target specific KD that is being 
calculated. shRNA sequences A and B resulted in the highest level of HOPX KD, 
50% and 32% respectively, whilst C and D generated less than 20% and less than 
10% KD, respectively (Fig. 7.4 HOPX KD in NHEK). Hairpins A and B were, 
therefore, the most effective and selected (out of the possible 4) to induce 
HOPX KD in both models of TDIS. 
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Figure 7.4. Assessment of the level of HOPX knockdown induced by shRNA systems. 
HOPX KD in NHEK (left) and in D17 oral keratinocyte dysplasia (right). Densitometry 
analysis was performed in NHEK using Image J software and results normalised against 
GAPDH. Level of KD obtained by the hairpins was calculated in relation to the 
scrambled control and plotted as a percentage. A, B, C and D correspond to 4 
different shRNA hairpin sequences. EV and S are the empty vector control and 
scrambled control, respectively. M  (mock control) corresponds to mock infection. + = 
human HOPX positive control sc-170056 (293T lysate).
 Next, shRNA sequences A and B were used to attempt HOPX knock-
down in the keratinocyte oral dysplasia D17 (Fig. 7.4 HOPX KD in D17), using the 
same procedure described for NHEK. Whilst western blot analysis in NHEK 
revealed a single (and what seems to be) specific band for HOPX at 10 KDa, in 
D17 generated several apparently unspecific bands. I have obtained products 
corresponding to 20, 22 and 25 KDa which were also present in the positive 
control used (293T lysate recommended by Santa Cruz Biotechnology). Of note 
was also the fact that that the HOPX signal in NHEK was a lot stronger than in 
D17 as can be seen by the higher level of background in D17 blots due to 
double the exposure time for these films. HOPX has been shown to be down-
regulated in D17 (Hunter et  al, 2006). It is, therefore, possible that the bands 
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obtained for D17 were unspecific and the product of specific size was not 
detected due to low levels of expression of HOPX protein in these cells. 
However, Santa Cruz Biotechnology (Fig 7.4), did report band sizes of 
approximately 20, 22 and 25 KDa in human cells. The data sheet suggests that 
the most specific band generated with this antibody against HOPX corresponds 
to 20KDa. Whichever the case, the signal of bands at 20 and 25 KDa did seem 
to have been affected by the expression of the hairpins, with sequence A 
generating a greater signal reduction, followed by sequence B (as I previously 
observed and measured in NHEK). Consequently, I have not been able to 
accurately assess and measure the level of HOPX KD in D17 following expression 
of hairpins A and B. 
 The overall distinct migration pattern observed in D17 (NHEK do not 
generate any additional bands of higher molecular weight) hints that different 
HOPX isoforms might be selectively expressed in keratinocytes originating from 
oral and epidermal tissues. A total of 5 transcript variants encoding for 3 distinct 
protein isoforms (NCBI Gene database ID: 84525), as a result of alternative 
splicing patterns and expression controlled by 2 distinct promoters (Yamashita 
et al, 2008), have been described so far for the human HOPX gene (Fig. 7.5). 
According to the NCBI database, variants 2, 3 and 4 encode for protein isoform 
b, variant 1 for isoform a and variant 5 for isoform c.
Figure 7.5. Gene expression products described for the human HOPX locus. Isoform a = 
91aa (10.4 KDa); isoform b = 73aa (8.3 KDa); isoform c = 112aa (12.5 KDa). Legend: 
coding region; untranslated region. 
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 My western blot data suggests that protein isoform a, product of 
expression of splice variant 1, is the predominant HOPX isoform in epidermal 
keratinocytes and two recent studies have reported similar results (Yang et al, 
2010; Obarzanek-Fojt et  al, 2011). I also predict that an isoform of higher 
molecular weight might be the main one expressed in oral keratinocytes and 
others (K. Hunter, University of Sheffield, personal communication) have found 
that in fact protein isoform c, product of transcript variant 5, is the main HOPX 
isoform found in keratinocytes of oral origin. Therefore, since epidermal 
keratinocytes seem to predominantly express HOPX protein isoform a and oral 
keratinocytes isoform c, an shRNA design strategy directed specifically at 
transcript variant 1, in case of NHEK, and at transcript variant 5, in case of D17, 
could possibly result in higher KD efficiency. Finally, given the difficulty in 
detecting protein levels of HOPX in D17, knock-down could alternatively be 
assessed by looking at reduction of transcript (by qPCR analysis) rather than of 
protein levels, following expression of shRNAs.  
 Next I investigated the distribution of HOPX at the cellular level, 
anticipating the possibility of extending this analysis to human tissue. I have, 
therefore, optimised the staining conditions in cultured keratinocytes for a 
commercial antibody against HOPX which has been reported in the literature 
(Ooki et al, 2010). Predominant nuclear staining was selectively obtained in 
normal keratinocytes (NHEK) in contrast with a squamous cell carcinoma (SCC) 
line expressing telomerase (SCC-25), used as negative control. I have also 
observed some cytoplasmic staining mainly in cells at the centre of the colony 
in NHEK, as opposed to low background cytoplasmic levels displayed in SCC-25 
(Fig. 7.6). Recent studies in normal human epidermal keratinocytes confirm a 
nuclear localisation for HOPX (Yang et al, 2010) but also migration of the protein 
to the cytoplasm during terminal differentiation (Obarzanek-Fojt et al, 2011). This 
is coherent with the fact that NHEK colonies grow from the centre to the 
periphery and stratify at the centre of the colony as a result of the normal 
program of differentiation, active in cells cultured in the 3T3 ‘feeder’ system. 
Therefore, HOPX is mainly present in the nucleus but can also be found in the 
cytoplasm of normal epidermal keratinocytes occupying stratification areas.
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Figure 7.6. Optimisation of immunocytochemistry conditions for detection of HOPX 
protein at the cellular level. Staining shows predominant nuclear localisation for HOPX in 
NHEK, but also some protein present in the cytoplasm of a subset of cells (mainly at the 
centre of the colony). In contrast, the SCC-25 cell line used as a negative control shows 
low  levels of cytoplasmic staining for HOPX. Legend: NHEK = normal human epidermal 
keratinocytes; SCC-25 = squamous cell carcinoma cell line 25.
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7.3. Functional analysis of HOPX
 I intended to conduct a functional analysis of HOPX in keratinocyte TDIS 
in three stages. The first would involve the use of shRNA constructs against HOPX 
followed by superinfection with the well characterised dominant negative 
mutant of TRF2 (TRF2!B!M) in order to induce senescence via telomere 
dysfunction. If HOPX is a key intervenient in the signalling pathway from 
dysfunctional telomeres to senescence, HOPX knock-down should block or 
mute premature telomere-driven senescence, in newborn keratinocytes used 
at early passage, by allowing cells to resume proliferation. Re-entry of the 
keratinocytes into the cell cycle can be assayed by Ki67 staining. The second 
stage would be to extend this to a natural epithelial model of telomere 
dysfunction, the oral dysplasia D17 which is characterised by having deletions 
in the INK4a locus therefore resulting in inactive p14ARF and p16INK4a proteins, 
despite retaining functional p53 (McGregor et al, 2002). This means that these 
oral keratinocytes show an extended lifespan (maximum reported of 45 MPDs) 
but are still capable of undergoing senescence through replicative exhaustion. 
Therefore, the D17 dysplasia is mortal but does not undergo premature STASIS 
via p16INK4a, senescing only as a consequence of telomere erosion at the end 
of its replicative lifespan or via other p53-activating stimuli. Further extension of 
D17's replicative lifespan as a consequence of HOPX knock-down would solidify 
its role in keratinocyte TDIS. Finally, the third stage would be to demonstrate an 
age-related increase of HOPX expression in older human skin, when compared 
to young skin, especially in pools of senescent cells characterised by 
dysfunctional telomeres.    
 Due to technical difficulties in expressing TRF2!B!M in keratinocytes using 
an indirect strategy for retroviral transduction (described in Chapter 5), I 
decided to proceed straight to the D17 dysplasia. Late passage (> 40 MPDs) 
D17 oral keratinocytes were transduced with amphotropic retroviral particles 
carrying shRNA sequences A or B against HOPX, the shRNA scrambled 
sequence (scrambled control, S) or vector only (empty vector control, EV) and 
subjected to drug selection (10 !g/mL blasticidin) 24h after infection. A mock 
infection, using the exact same procedure but with supernatants from non-
transfected Phoenix A cells, was conducted in parallel as a control (mock 
control, M). I have also applied the same experimental procedure to D17 cells 
expressing the catalytic subunit of telomerase, TERT. Since TERT expression 
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restores telomere length and these cells have no p16INK4a checkpoint, TERT is 
sufficient to immortalise D17 keratinocytes (Muntoni et  al, 2003). Therefore, I 
expected HOPX knock-down to have no effect on the predicted proliferation 
pattern for D17-TERT cells.     
 Assuming a KD efficiency of 50% for hairpin A and 32% for hairpin B in 
D17s, as I previously demonstrated in NHEK (Section 7.2), in case of a potential 
role of HOPX in keratinocyte TDIS, I expected a stronger phenotype in D17 
expressing shRNA A than shRNA B. Confirmation of reduction of both mRNA, by 
qPCR analysis, and protein levels, by western blotting and densitometry 
analysis, was not conducted for this experiment due to time constraints and 
technical difficulties in detecting HOPX protein in D17s (Section 7.2). Preliminary 
results (Fig. 7.7), resulting from a single experiment, show firstly some variation in 
maximum replicative lifespan between D17 and D17-neo cells (EV control for 
the TERT construct) with the first undergoing a maximum of 43 MPDs and the 
latter 46 MPDs. This difference is unlikely due to possible induction of premature 
senescence from exposure to the drug selection agent as cells in the mock 
control for both populations, which were not exposed to blasticidin, show a 
matching replicative limit. The D17-neo population underwent a maximum 
number of PDs that matches the maximum reported for this oral dysplasia, of 
around 45 MPDs (McGregor et al, 2002). The exception in the D17 population 
were cells expressing hairpin B, which underwent 3 additional population 
doublings when compared to D17s expressing all other shRNA constructs and 
mock control (46 MPDs versus 43 MPDs). However, the fact that hairpin A did 
not cause the same effect in D17s and that the extension of lifespan matches 
the limit obtained in neoEV-expressing D17 cells, regardless which shRNA 
construct they were expressing, suggests that the lifespan extension in D17s 
might not be related to expression of the hairpin. Basically, the increase was 
modest and did not surpass the maximum reported for this cell line and might 
just reflect variation within the cell population. As expected, D17-neoTERT 
keratinocytes went over the maximum replicative lifespan by more than 20 
population doublings suggesting immortalisation via ectopic expression of 
telomerase. These cells, containing repaired telomeres, were not affected by 
expression of either of the hairpins against HOPX. Therefore, so far, the data 
suggest that HOPX might not have a functional role in keratinocyte TDIS.
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Figure 7.7. Effect of HOPX knockdown in the replicative lifespan of oral keratinocyte 
dysplasia D17. Hairpin containing shRNA sequence B caused extension of the 
replicative lifespan in D17 by 3 MPD but did not affect TERT-expressing D17 
keratinocytes. D17 and D17-TERT expressing keratinocytes, at 40 MPDs, were transduced 
with retroviral vectors expressing shRNA constructs (A and B) against HOPX, vector only 
(EV) or scrambled (S) control and drug selected with blasticidin. A mock (M) infection 
control, not subjected to drug selection, was also included. Legend: CMPD = 
cumulative mean population doublings; Time = time in culture; Infection = indicates 
introduction of the shRNA constructs by retroviral transduction.
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  However, it was not possible to state conclusively that ablation of HOPX 
function did not have an effect at the cellular level. First, there is the question of 
whether the shRNA sequences used caused the same level of KD in D17 as they 
did in NHEK and second, whether this level of KD is sufficient to elicit a 
phenotype. Unless I had access to a positive control for HOPX KD where 
enough of the transcript is targeted to deplete the cellular levels of protein 
enough to ablate function and generate a cellular phenotype, it would be 
difficult to distinguish between a truly negative result and a technical limitation. 
As it is apparent that different transcript variants are expressed predominantly in 
either epidermal or oral keratinocytes, a more targeted hairpin design to the 
relevant mRNA sequence might improve KD efficiency. An alternative might 
also be to try and use siRNAs in very nearly senescent D17s followed by 
assessment of re-entry in the cell cycle by staining for Ki67, and of senescence, 
by staining for SA-" galactosidase. Cells originating from a dysplasia line should 
be more receptive to transfection than normal keratinocytes and siRNAs are 
more efficient KD tools, but the fact that this is is a transient system will make if 
difficult to retain a phenotype for more than a week. The difficulty in detecting 
the low levels of HOPX protein levels present in oral dysplasias would still remain 
a challenge. This can be circumvented by using qPCR analysis to assess the 
decrease in transcript instead. The use of this method to assess KD is not as 
accurate though since reduction in mRNA levels does not always reflect an 
equivalent reduction in protein levels. Therefore, to conclusively determine the 
role of HOPX in keratinocyte TDIS additional experiments and possibly a 
different experimental approach may be required. 
 To assess the role of HOPX in TDIS in vivo consent has been requested at 
the beginning of the project for the use of samples of human skin obtained 
from bat-ear corrections and other facial and ear procedures such as 
mastoidectomy, meatoplasty and tympanoplasty. These were to be collected 
from Hospitals under the jurisdiction of the Greater Glasgow Health Board and 
snap frozen in liquid nitrogen, prior to storage and use. The intention would be 
to assess HOPX by indirect immunofluorescence (ICC) using the antibody we 
have acquired and for which an ICC procedure was optimised (Fig. 7.5). In 
some experiments some sections were to be double stained for HOPX and 
53BP1 to assess the relative sensitivity of the two methods. The actual age of 
each sample would be assessed using SAHF and Mcm antibodies as above. 
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Since authorisation was not granted for the use of human skin obtained from 
biopsies, I  have established a collaboration with Dr Utz Herbig's lab (New Jersey, 
NY, USA) to investigate the abnormal expression of HOPX in human tissue 
containing epidermal cells harbouring dysfunctional telomeres. 
 Dr Herbig had samples of epidermis flanking melanotic naevi, where 
most cells are undergoing TDIS, and lab member Neetu Razdan examined the 
expression of HOPX in these samples at my request (Fig. 7.8). Although 
melanocytes (Fig. 7.8 red) in the dysplastic naevi have dysfunctional telomeres 
(Suram et  al, 2012), as assessed by the colocalisation of DNA damage foci with 
the telomeres (Takai et al, 2003), they do not express HOPX, as they show 
staining only at background levels. In these samples, we found that HOPX 
expression was mainly confined to the keratinocytes in the upper layers of the 
epidermis (Fig. 7.8 green in top and bottom rows), observation that is consistent 
with previous reports of HOPX distribution in the skin (Yang et  al, 2010). However, 
HOPX-positive keratinocytes were also present in unusual locations of the 
epidermis (Fig. 7.7 green middle row) flanking nevi. This stochastic distribution in 
other layers of the epidermis raises the possibility that HOPX might be 
specifically expressed in keratinocytes undergoing TDIS. Therefore, it would be 
interesting to test whether the cells expressing HOPX in the lower layers of the 
epidermis also contain telomere dysfunction-induced DNA damage foci (TIF). 
This analysis is ongoing.
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Figure 7.8. Expression of HOPX protein in dysplastic melanotic naevi. Staining revealed 
HOPX expression (mainly nuclear) predominant in cells of the upper layers of the 
epidermis (left panels top and bottom) but also in other locations (left centre). 
Melanocytes are revealed in red and do not express HOPX (centre panels). Legend: 
HOPX; MelanA; DAPI. Work conducted by Neetu Razdan under the supervision of Dr Utz 
Herbig (Herbig’s lab, UMDNJ, New Jersey, USA). 
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7.4. Discussion
 Genes HOPX, HIST2H2BE, ICEBERG and S100A7 showed potential as 
specific markers for telomere dysfunction-induced senescence (TDIS) in 
keratinocytes (Minty et al, 2008) since their expression levels were elevated 
following telomere uncapping, and associated weak DDR, but returned to 
control levels following ectopic expression of telomerase. The main objective of 
the present work was to further assess their specificity to TDIS as opposed to 
DNA damage-induced senescence and other forms of senescence, and then 
select the lead candidate for further investigation.
 Following the initial assessment of the candidates response to DNA 
damage-induced senescence I found that HOPX, ICEBERG and S100A7 were 
not induced either by a weak or a strong DDR ensued by low or high levels of 
DNA damage, respectively (Chapter 4). Whilst ICEBERG and S100A7 transcript 
remained at control levels, however accompanied by some inter-experimental 
variation, the amount of HOPX transcript was inversely proportional to the 
intensity of DNA damage being generated. Therefore, HOPX levels showed a 
consistent reduction trend with DNA-damage induced senescence contrasting 
with the previously observed elevation trend with telomere dysfunction-induced 
senescence. Based on these initial results HOPX seemed like the most interesting 
candidate to follow. However, both HOPX and S100A7 were particularly 
interesting genes from the beginning as their expression levels are also severely 
down-regulated in immortal keratinocytes (immortal dysplasias and 
carcinomas) that have p53 and p16INK4a dysfunction as well as activated 
telomerase (E. K. Parkinson, unpublished microarray data). HOPX took 
precedence when several recent reports emerged confirming its role as a 
tumour-suppressor gene. 
  I  started by assessing the potential functional role of HOPX in TDIS. I 
hypothesised that if HOPX plays an essential role in the pathway signalling 
dysfunctional telomeres towards growth arrest by senescence, the ablation of 
HOPX function should delay, prevent or reverse the establishment of the 
senescence program. The intention was first, to attempt stable KD of HOPX in 
newborn low passage NHEK expressing TRF2!B!M, an artificial model of telomere 
dysfunction, and see if the senescent phenotype could be reversed in these 
cells. Then I would proceed to a natural model of telomere dysfunction, oral 
keratinocytes from the dysplasia line D17 which have dysfunctional p14ARF and 
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p16INK4a (due to deletion in the INK4a locus) but retain functional p53 and 
normal expression levels of telomerase. These cells are mortal and senescence 
naturally via telomere shortening at the end of their slightly extended 
replicative limit; I  would investigate whether HOPX KD could further extend the 
replicative lifespan of these cells.
 Stable KD of HOPX was established in NHEK by expression of shRNAs via 
retroviral transduction. However, the best hairpin rendered just a maximum of 
50% reduction in HOPX protein levels in NHEK. Concomitantly, due to technical 
difficulties in expression of TRF2!B!M in NHEK using a previously reported 
successful transduction strategy in keratinocytes (Levy et al, 1998) I had to first 
optimise this technique to the required experimental conditions for this 
construct (Chapter 5). Therefore, I  decided to proceed directly to the 
keratinocyte D17 dysplasia. This came with its own set of technical challenges. 
Western blotting analysis revealed several bands for HOPX protein none of 
which matching the predicted size of the protein isoforms and, since HOPX is 
down-regulated in oral dysplasias, I suspected the bands obtained were 
unspecific and the antibody used could not detect the low levels of HOPX 
protein in D17 cells. Nevertheless, I have transduced D17s with the two best 
hairpins against HOPX, previously optimised in NHEK. Results indicated that 
HOPX KD may extend D17 replicative lifespan very slightly and did not affect 
the growth of D17 ectopically expressing telomerase which have, therefore, 
repaired their telomeres. The observed increase was, however, not noteworthy 
or consistent (between 2 populations of D17). This could be because HOPX has 
no active role in a signalling pathway signalling dysfunctional telomeres in 
keratinocytes towards senescence. Alternatively, it might be because the 
amount of KD obtained, with the experimental strategy used, was not high 
enough to ablate HOPX function to a level capable of generating a cellular 
phenotype. Therefore, these results are inconclusive in what concerns the 
functional role of HOPX in keratinocyte TDIS.
 HOPX homeobox is a relatively recently identified gene. The literature 
and gene databases are not always in agreement in terms of information 
regarding its transcript variants and protein isoforms. New data is now emerging 
faster due to the recent interest in HOPX for its tumour suppressor activity  and 
this has also prompted the development of new, and hopefully more specific 
and efficient, experimental tools such as antibodies, siRNAs and shRNAs. For 
instance, since it has become apparent that epidermal and oral keratinocytes 
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predominantly express different HOPX transcript variants which result in distinct 
protein isoforms, RNAi efficiency could be greatly improved by targeting the 
relevant mRNA sequence. Therefore, an improvement in experimental design 
by acquiring more specific tools should allow us to generate conclusive results 
in future.
 The final aim was to assess the lead candidate as a potential in vivo 
marker for TDIS in keratinocytes. Although HOPX is not a secreted protein, its 
potential specificity to TDIS would be very appreciated as it could be used to 
identify telomere-driven senescent cells in vivo. The original intention was to 
compare HOPX expression in skin from young and old persons. However, I was 
unable to acquire the skin samples for analysis and instead established a 
collaboration with Herbig’s lab for the analysis of HOPX expression in 
melanocytic naevi. In these benign skin lesions most cells display hallmarks of 
TDIS (Suram et al, 2012) such as DDR foci that colocalise with dysfunctional 
telomeres (TIF) and high levels of heterochromatic proteins (macroH2A). 
Although the dysfunctional telomeres in melanocytes are not critically short and 
retain TRF2 they are fragile due to the accumulation of telomeric DNA" lesions 
and stochastic telomere attrition, resulting from replication stress associated 
with oncogene-induced senescence (OIS). We have found that HOPX was not 
expressed in melanocytes of naevi but only in keratinocytes of the upper layers 
of the epidermis and stochastically in keratinocytes of the supra-basal layers. Dr 
Herbig (personal communication) has also observed that the presence of 
keratinocytes with dysfunctional telomeres in these naevi is sporadic and 
apparently unrelated to ageing. This could mean that telomere dysfunction is 
not the major driving force behind keratinocyte stem cell ageing, but equally 
could be related to the fact that senescent keratinocytes may have a short 
tenure in the epithelium as a result of terminal differentiation (Chapter 4) or as a 
result of clearance by the innate immune system (Xue et al, 2007). 
 These results are inconclusive regarding a functional role of HOPX in 
keratinocyte TDIS or its use as a specific marker for TDIS in vivo. Nevertheless, 
whilst HOPX might not be actively involved in the pathway that signals 
dysfunctional telomeres in keratinocytes, its up-regulation seems to be specific 
to telomere dysfunction-induced senescence (TDIS) as opposed to DNA 
damage-induced senescence (Chapter 4) or STASIS, stress or aberrant 
signalling-induced senescence (Chapter 5). HOPX has been associated with 
terminal differentiation in cardiac (Kook & Epstein, 2003) and skeletal muscle 
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(Kee et al, 2007), in the lens (Vasiliev  et  al, 2007) and in the skin (Yang et al, 2010; 
Obarzanek-Fojt et  al, 2011). In epidermal keratinocytes I also observed this 
association (Chapter 4) and HOPX is also known to induce other terminal 
differentiation markers in the epidermis (Obarzanek-Fojt et  al, 2011). Therefore, if 
TDIS ultimately engages the terminal differentiation program in keratinocytes 
this will place the stem cell pool under increased replicative stress and stem 
cells are known to be prone to poor clonal growth with increasing age perhaps 
as a result of premature transit cell differentiation or senescence. Impaired stem 
cell function contributes indirectly to epidermal stem cell ageing. 
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Chapter 8. General Discussion and Future 
Perspectives.
Cellular senescence and in vivo ageing 
 A connection between the process of replicative senescence in cultured 
cells and organismal ageing was first proposed by Hayflick and Moorhead in 
the 1960s (Hayflick & Moorhead, 1961) and the nature of this relationship has 
been a matter of extensive investigation over the following decades. The 
prevalence of senescent cells has been shown to directly correlate with 
chronological age in animal models  (Jeyapalan et  al, 2007; Janzen et  al, 2006) 
and in humans (Dimri et al, 1995; Ressler et  al, 2006). Telomere dysfunction is 
relevant to epithelial ageing as its causal role has been demonstrated in mice 
(Lee et al, 1998; Rudolph et  al, 1999) and also because telomeres are shorter in 
the epidermis of older humans (Lindsey et  al, 1991; Nakamura et  al, 2002; 
Sugimoto et  al, 2006). In fact, human telomeres shorten with age in several 
human tissues where, by definition, the stem cells are responsible for the 
telomere length of the tissue (reviewed in (Sharpless & DePinho, 2007)). 
However, whether overall telomere length correlates with chronological age 
has been a controversial matter. Whilst some report a low rate of telomere loss 
with ageing in the epidermis apparently due to telomerase activation (Krunic et 
al, 2009), several groups report consistent tissue-specific loss of telomeric DNA 
with age in human skin, both in the epidermis and dermis, and oral epithelium 
(Lindsey et  al, 1991; Nakamura et al, 2002; Sugimoto et al, 2006). Of note is that 
the methodology used by these groups to measure telomere length varies from 
southern blotting to in situ hibridisation, but techniques such as STELA, which 
can detect the shortest telomeres in a cell population, has not yet been 
applied to human epidermis. However, mean telomere length is a poor 
indicator of the telomere status of a tissue since the shortest telomere is 
capable of triggering senescence (Hemann et al, 2001). Furthermore, telomeres 
may not need to be critically short to contribute to ageing as Tomás-Loba et al 
have shown that TERT targeted to the epidermis improved lifespan and health 
span of cancer-resistant mice and that this was associated with increased 
telomere function (Tomás-Loba et  al, 2008). The mechanism by which 
dysfunctional telomeres cause senescence is not completely clear. 
Identification of more specific markers for TDIS can aid the treatment of 
epithelial ageing as they can be potential targets for therapeutic intervention. 
228
 Ideally, in vivo markers should be cell- and mechanism-specific as well as 
non-invasive to facilitate early detection and allow for prompt therapeutic 
intervention. Reliable bio markers for telomere dysfunction are lacking and the 
ones identified so far are not specific as they are also up regulated by DSBs in 
non-telomeric DNA and infection (Jiang et  al, 2008). Telomere-associated DSBs 
can be detected as DNA damage foci, also known as telomere dysfunction-
induced foci or TIFs (Takai et  al, 2003) but such complexes may be transient and 
insensitive indicators of telomere dysfunction (Jeyapalan et al, 2007). Firstly, 
because the complete loss of a telomere may not score as a TIF, merely a DSB 
and also, because as TIFs do not accumulate with age in human epidermis (U. 
Herbig, personal communication), they are unlikely to be reliable indicators of 
telomere dysfunction in this cell type. Secondly, previous work from our group 
has shown that experimental telomere uncapping following the ectopic 
expression of TRF2!B!M or following replicative senescence does not result in a 
dramatic increase in DNA damage foci (Minty et  al, 2008) or a strong DDR 
(Muntoni et al, 2003; Minty et al, 2008).
 In addition, the cell cycle inhibitor p16INK4a is a robust biomarker of 
ageing in human skin (Ressler et al, 2006) and, using a novel approach to 
delete p16INK4a-positive cells in the BubR1 progeroid mouse model, Baker et al 
(Baker et al, 2011) showed that several age-related phenotypes such as muscle 
weakness, fat loss and cataracts were delayed when p16INK4a-positive cells 
were deleted and all but cataracts were reversed when p16INK4a-positive cells 
were deleted in aged animals. However, when human keratinocytes were 
induced to senesce following the expression of TRF2!B!M no acute induction of 
p16INK4a was observed, suggesting that the initial events following telomere 
uncapping do not induce p16INK4a.
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Keratinocyte stem cell ageing
 Although it is agreed that human skin thins and shows diminished 
function with chronological age it has been suggested that this is not the result 
of keratinocyte stem cell ageing but only due to mesenchymal ageing (Stern & 
Bickenbach, 2007; Giangreco et al, 2008). Epithelial stem cells do not get 
depleted with increasing age in vivo (Martin et  al, 1998b; Giangreco et al, 
2008). However, their function does appear to become impaired, as evidenced 
by a reduced clone size following damage by ionising radiation in murine 
intestine (Martin et  al, 1998a; 1998b), and this may contribute to tissue 
deterioration. Thus, epithelial stem cells under-perform in response to injury and 
at least some of this is likely to be due to accumulation of DNA damage 
(Velarde et al, 2012) and to the intrinsic properties of the aged human 
keratinocytes themselves (Barrandon & Green, 1987) and not only to the 
senescence of the mesenchyme (Giangreco et al, 2008). In the 
haematopoietic system, the action of the senescence effector p16INK4a 
regulates stem cell ageing through the stem cells themselves and also through 
the mesenchyme (Janzen et  al, 2006; Sharpless & DePinho, 2007). In 
experiments using the p16INK4a knockout mouse it has been shown that stem 
cells retain their function better when p16INK4a is absent (Sharpless et al, 2001) 
and although no epidermal stem cell ageing phenotype has been reported in 
p16INK4a-deficient mice this could be explained by the report that p15INK4b 
compensates for p16INK4a in the epidermis of these animals (Krimpenfort et al, 
2007). It has been hypothesised that silent changes in the stem cells manifest 
themselves only when asymmetric divisions generate transit amplifying 
(progenitor) cells, whereupon p16INK4a directs premature senescence and 
reduced tissue function ((Sharpless & DePinho, 2007) and Fig. 8.1). 
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Figure 8.1. INK4a expression and stem cell ageing. Impaired stem cell function is 
manifested in the stem cells reduced ability to originate functional progenitors. With 
ageing, and upon asymmetric division, p16INK4a expression directs premature 
senescence thereby removing cells from the progenitor pool and consequently 
affecting the regenerative capacity of the tissue. Premature senescence can also 
be driven by DNA damage or telomere dysfunction which can lead to terminal 
differentiation and immune clearance with a similar outcome for the renewing 
capability of the tissue (adapted from (Sharpless & DePinho, 2007)).
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 p16INK4a- (Ressler et al, 2006; Waaijer et al, 2012) SA-"Gal (Dimri et al, 
1995) positive keratinocytes do accumulate with age in human skin but they 
are generally singletons and limited to the basal layer (Fig. 8.2) rather than in 
groups or columns. This suggests that p16INK4a expression does not lead to 
terminal differentiation of the keratinocytes expressing it and, furthermore, that 
they have a short tenure in the epidermis. This could be explained on the 
grounds that senescent cells are known to be targeted by both the innate (Xue 
et al, 2007; Ventura et al, 2007) and adaptive (Kang et al, 2011) immune system 
and thus may turn over rapidly.
Figure 8.2. p16INK4a expression in human epidermis. p16INK4a-positive cells (arrows) 
accumulate as singletons in the epidermis of older persons (bottom panel) when 
compared to younger persons (top panel) and are confined to the basal layer (in 
(Waaijer et al, 2012)).
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 An increase in p16INK4a expression with serial passage in culture 
correlated with keratinocyte clonal exhaustion and p16INK4a inactivation was 
shown to be required, in addition to hTERT expression, in order to achieve 
immortalisation (Rheinwald et  al, 2002). Although p16INK4a knock-down alone is 
not sufficient to extend replicative lifespan in most cases (Rheinwald et  al, 2002) 
this may be due to technical insufficiency and poor knockdown (Maurelli et al, 
2006). For instance, we have found (Parkinson, unpublished results) that the use 
of the transcriptional repressor of the INK4a locus Bmi-1 as opposed to shRNAs 
against p16INK4a has proved more efficient in sustaining p16INK4a inactivation, 
supporting the findings of others (Maurelli et  al, 2006; Haga et al, 2007). Since 
Bmi-1 knocks down both products of the INK4a locus, p14ARF and p16INK4a, and 
nearly all immortal keratinocytes in neoplasia have deletions of INK4A both in 
vitro (Munro et  al, 1999) and in vivo (Reed et al, 1996) this suggests that the co-
deletion of p14ARF and p16INK4a may be a requirement for immortalisation. 
 Admittedly, it is possible that p16INK4a and not telomere dysfunction might 
be the major contributor to stem cell ageing in the epidermis. As shown by 
immunocytochemistry analysis, p16INK4a expression directly correlates with donor 
age in human skin in vivo and, conversely, Bmi-1 was significantly down-
regulated with increasing age (Ressler et al, 2006). Inactivation of p16INK4a in 
vitro, using an anti-sense strategy, in cells retaining high proliferative potential 
and not in transient amplifying keratinocytes blocks clonal evolution, averts 
senescence and retains keratinocytes in the stem cell compartment (Maurelli et 
al, 2006). Also in both physiological and premature ageing Bmi-1 down-
regulation and expression of p16INK4a were shown to strongly correlate, with 
Bmi-1 over-expression resulting in reduced p16INK4a activity and increase in 
clonogenicity (Cordisco et al, 2009). These data suggests that in epidermal cells 
inactivation of p16INK4a accompanied by expression of Bmi-1 are necessary to 
maintain stemness and that the opposite results in clonal exhaustion and 
senescence during ageing. Finally, the expression of p16INK4a in the epidermis 
(but not the dermis) is a strong indicator of physiological age (Waaijer et  al, 
2012). However, I could find no evidence that experimental uncapping of 
telomeres in human keratinocytes was capable of inducing the p16INK4a 
transcript (Chapter 6), which generally correlates with p16INK4a protein levels 
(Hara et al, 1996).
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Telomere dysfunction-induced senescence and DSBs
 Recently, a strong association between the accumulation of permanent 
damage to the DNA and the processes of senescence and ageing has been 
established (Sedelnikova et  al, 2004; Fumagalli et al, 2012; Hewitt et  al, 2012) 
suggesting that unrepairable DSBs have a causal role in mammalian ageing.
 In normal human cell strains, of both mesenchymal and epithelial origin, 
the incidence of ɣ-H2AX foci and of SA-" gal-positive cells increases towards 
the end of their replicative lifespan. Similarly, the same trend for cryptogenic ɣ-
foci is observed with increasing age in several murine tissues. They colocalise 
with several repair proteins and, therefore, mark persistent DNA lesions 
containing irreparable DSBs (Sedelnikova et  al, 2004). DNA DSBs also 
accumulate following radiotherapy in mice (Le et al, 2010) and in fibrosis in 
humans (Pitiyage et  al, 2011), where they are associated with senescence. 
Terminal DNA normally goes undetected by the cells' DNA repair machinery 
because it is organised in a protective nucleoprotein complex which prevents 
exposure of chromosomal ends (de Lange, 2005). However, telomeric DNA can 
become exposed and processed as a DSB following telomere shortening or 
telomere dysfunction (d'Adda di Fagagna et al, 2003; Takai et al, 2003). As a 
consequence of the end-replication problem telomeres become gradually 
shorter after each cell division and it has been observed that in replicatively 
senescent fibroblasts critically short telomeres associate with DNA damage foci 
and trigger a DDR which results in senescence (d'Adda di Fagagna et  al, 2003). 
Similar results were obtained in normal fibroblasts containing long telomeres but 
that have been rendered dysfunctional due to ectopic expression of the 
dominant negative mutant TRF2!B!M, which strips telomeres off the endogenous 
telomere protection factor TRF2, essential for the formation of the protective 
telomeric loop (Takai et al, 2003; d'Adda di Fagagna et al, 2003).
 These two areas were linked when it was shown that although DSBs do 
not particularly associate with the telomeres in replicatively senescent cells 
(Sedelnikova et al, 2004) or in ageing murine tissues (Wang et  al, 2009), 
unrepairable DSBs do (Fumagalli et al, 2012; Hewitt et al, 2012). As previously 
demonstrated (Rodier et  al, 2011), these two groups confirmed that the 
continuous DDR signalling which is responsible for sustaining the permanent cell 
cycle arrest associated with senescence, triggered in normal human fibroblasts 
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by IR-induced genotoxic stress, arises from persistent DNA damage foci which 
mark permanent DNA lesions. What was interesting was that these unrepairable 
DSBs, originating from genotoxic (Fumagalli et  al, 2012; Hewitt et  al, 2012) or 
oxidative (Hewitt et  al, 2012) stress, were preferentially located at the telomeres. 
Moreover, irreparable damage to the telomeres was shown to occur in both 
mitotic and post-mitotic tissues in vivo, such as mouse neurons following whole 
body irradiation, as well as in neurons and hepatocytes of baboons (Fumagalli 
et al, 2012) and murine hepatocytes and enterocytes (Hewitt et  al, 2012) with 
physiological ageing, and to correlate with senescence. A connection 
between telomere damage and ageing had only previously been reported in 
fibroblasts originating from the skin of baboons (Herbig et al, 2006). This occurs 
independently of telomere length and seems related instead to the fact that 
telomeres are specialised structures which resist DNA repair and are also 
particularly sensitive to damage (Fumagalli et al, 2012; Hewitt et al, 2012). 
 Both the structure of telomeric DNA and the telomere-associated protein 
TRF2 prevent DNA repair (Fumagalli et  al, 2012). In yeast, when telomeric 
repeats were experimentally engineered adjacently to a DSB, the recruitment 
of DNA ligase IV to that area was impaired, inhibiting repair. Similarly, in mouse 
cells carrying the LacI-TRF2 fusion protein placing TRF2 next to a DSB site also 
specifically inhibited repair and resulted in the accumulation of persistent ɣ-
H2AX foci. This is consistent with previous studies where it was shown that TRF2 
prevents the occurrence of chromosome end-to-end fusions in vivo (van 
Steensel et al, 1998). The mechanism by which this occurs was demonstrated in 
vitro to be inhibition of ligase IV-mediated NHEJ as cells where telomeres were 
depleted of TRF2, by over-expression of the mutant TRF2!B!M, displayed an 
increase in telomere fusions (Smogorzewska & de Lange, 2002). Later, it was 
further confirmed in vitro that telomere-associated proteins such as TRF2 and 
RAP1 directly inhibit both DNA-PK and ligase IV-mediated end-joining (Bae & 
Baumann, 2007). In sum, exposure of telomeric DNA resists repair and, therefore, 
triggers sustained DDR signalling by activation of the DNA damage checkpoint 
(Fumagalli et  al, 2012). It has been argued (Fumagalli et  al, 2012) that telomeres 
have evolved as specialised structures to protect the ends of linear 
chromosomes from end-to-end fusions by inhibiting NHEJ and that, as a 
consequence, became irreparable areas of the genome. 
 Telomeres are not only poor at repair but also preferred targets for 
certain types of DNA damage (Hewitt et al, 2012). They have been shown to be 
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particularly sensitive to oxidative stress (Petersen et  al, 1998; Hewitt et  al, 2012), 
radiation-induced (Hewitt et al, 2012) and drug-induced (Suram et al, 2012) 
genotoxic stress as well as oncogenic stress (Suram et al, 2012). This can be 
because telomeres repair UV lesions (Kruk et  al, 1995) and ss-breaks (Petersen et 
al, 1998) less efficiently and do not repair DSBs (Fumagalli et al, 2012; Hewitt et 
al, 2012). It can also be for the fact that guanine triplets, which are part of the 
TTAGGG telomeric repeat, are particularly susceptible to oxidative 
modifications (Oikawa et  al, 2001). Also, higher levels of ROS found in senescent 
fibroblasts seem to correlate with telomeric ɣ-H2AX foci (Passos et al, 2007a). 
More recently, it has also been shown that telomeres are hypersensitive to 
oncogene-induced and drug-induced replication stress (Suram et al, 2012). 
Since telomeric regions seem to be more sensitive to stress that other areas of 
the genome it has been argued that telomeres could have evolved as 
specialised sensors of DNA damage to enforce the senescence program (van 
Tuyn & Adams, 2012). 
 In all, this recent work (Fumagalli et  al, 2012; Hewitt et al, 2012; Suram et 
al, 2012) suggests that in normal fibroblasts, as far as genotoxic stress is 
concerned, only DNA damage at the telomeres causes senescence since it is 
irreparable and, therefore, capable of triggering persistent DDR signalling. 
Unrepairable, but not repairable DSBs, induce the chronic expression of a 
variety of secreted proteins, such as cytokines, growth factors and proteases, 
known as the SASP or 'senescence-associated secretory phenotype' (Coppé et 
al, 2008; Rodier et al, 2009). The permanent DNA lesions thought to be 
responsible for sustaining the damage-induced growth arrest and SASP have 
been characterised and termed DNA-SCARS or 'DNA segments with chromatin 
alterations reinforcing senescence (Rodier et al, 2011). The secretome is largely 
(Freund et al, 2011) but not exclusively (McConnell et al, 1998) dependent on 
NF-K"  signalling, which is associated with senescence (Rovillain et  al, 2011; 
Vaughan & Jat, 2011). For instance, senescence induced by ectopic expression 
of p21WAF1 and p16INK4a did result in activation of the plasminogen activator 
inhibitor (PAI-1) at the transcriptional level (McConnell et al, 1998). In fact, the 
SASP seems to be uncoupled from the senescence-associated cell cycle arrest 
(Rodier et  al, 2011). Although p53 is required to initially trigger growth arrest 
(Campisi & d'Adda di Fagagna, 2007), the classical effectors of senescence 
p53 and p16INK4a are neither required (Coppé et  al, 2008) or in most cases 
sufficient (Coppe et al, 2011) to elicit a functional SASP.
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TDIS in epidermal keratinocytes induces a weak DDR and induces markers of 
terminal differentiation
 Telomere dysfunction, induced by expression of TRF2!B!M, in normal 
human epidermal keratinocytes resulted in senescence and was 
accompanied by a weak DDR and a characteristic transcriptional profile (Minty 
et al, 2008). This included genes involved in chromatin remodelling (HIST2H2BE, 
a histone from the H2B family), inflammation (ICEBERG or CARD18, a caspase 
recruitment domain family member) and terminal differentiation (HOPX, an 
atypical homeobox gene and S100A7, a calcium binding protein of the S100 
family) that showed potential as specific markers for TDIS in keratinocytes. This is 
because they were up-regulated by artificial telomere uncapping and natural 
telomere erosion, and down-regulated by telomere recapping following 
ectopic expression of telomerase (Muntoni et al, 2003; Minty et  al, 2008). 
However, it was possible that the weak DDR was enough to trigger senescence 
and induce terminal differentiation in keratinocytes, as previously reported for 
melanocytes (Inomata et al, 2009) and HSCs (Wang et  al, 2012). To test this 
hypothesis and to test the specificity of the candidate markers for TDIS I have 
tested the influence that other inducers of senescence such as radiation-
induced DNA damage, p14ARF, p16INK4a and p53 might have on their expression 
levels. 
The effect of the senescence effectors on candidate markers expression levels 
 Normal human epidermal keratinocytes were exposed to doses of 
ionising radiation capable of generating acute or permanent damage to the 
DNA (Chapter 4) or transduced with retroviral constructs expressing p14ARF, 
p16INK4a, p53 or TRF2!B!M (Chapter 6). Whilst S100A7, HOPX or ICEBERG were not 
induced by repairable or unrepairable DSBs (Chapter 4) or by the effector of 
senescence p16INK4a (Chapter 5), ICEBERG and HOPX were induced by p53 and 
p14ARF when these were ectopically expressed at higher levels (Chapter 5). The 
levels of initial growth arrest, as assessed by reduction in CCNA2 expression 
levels (Chapter 5) and irreversible growth arrest, as assessed by cloning 
efficiency (Chapter 6) were nearly identical following expression of each of the 
main effectors of senescence. Thus, S100A7 seems to be the most specific early 
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marker for telomere dysfunction in keratinocytes since it was selectively 
induced by telomere uncapping via expression of TRF2!B!M (Minty et al, 2008) 
and Chapter 6) and not by DSBs (Chapter 4) or by over expression of p14ARF, 
p53 or p16INK4a (Chapter 6). This is important because p16INK4a-positive cells 
accumulate in the epidermis of elderly individuals (Ressler et  al, 2006) and their 
number in the skin has been shown to inversely correlate with younger 
biological age in the offspring of long-lived humans (Waaijer et  al, 2012). A 
recent paper reporting how glucocorticoids suppress the SASP and NF-K" 
signalling without affecting the senescence-associated growth arrest (Laberge 
et al, 2012) allied to the fact that keratinocyte growth medium contains 
hydrocortisone might explain the weak DDR following telomere uncapping in 
keratinocytes and why SASP components such as inflammatory cytokines were 
not detected in the microarray analysis of keratinocytes expressing TRF2!B!M 
despite the growth arrest (Minty et al, 2008). It is thus possible that most of the 
DDR is a consequence of the SASP and NF-K" signalling and also that the 
induction of S100A7, the most promising marker, may also be independent of 
the inflammatory cascade. This is in general agreement with recent data 
showing that the senescence effectors in general and p16INK4a in particular do 
not induce the SASP (Coppe et al, 2011; Rodier et al, 2011). This raises the 
question of what upstream pathways activating p16INK4a and p53, other than 
DSBs, regulate S100A7 (see future plans). 
TDIS and terminal differentiation
 Dysfunctional or critically short telomeres activate a DDR which triggers 
cell cycle arrest through senescence in fibroblasts (Takai et al, 2003; d'Adda di 
Fagagna et al, 2003; Herbig et al, 2004). However, our previous work showed 
that telomere dysfunction induced by TRF2!B!M in normal epidermal 
keratinocytes and by replicative senescence in the D17 keratinocyte dysplasia 
stopped cells from dividing but surprisingly did not induce high levels of DSBs or, 
in either case, a strong DDR (Muntoni et  al, 2003; Minty et  al, 2008). Instead, 
markers of terminal differentiation were induced and their expression was 
reversed by telomerase (Minty et  al, 2008). This is in line with a recently reported 
link between stem cell ageing and terminal differentiation in response to DNA 
damage and telomere dysfunction (Inomata et al, 2009; Wang et  al, 2012; 
Velarde et al, 2012).
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 In mice, irreparable DSBs, induced by IR, caused melanocyte stem cells 
(MSCs) to prematurely differentiate into mature melanocytes which ultimately 
resulted in hair greying, the most common ageing phenotype (Inomata et al, 
2009). Additionally, both IR and telomere dysfunction result in an induction of 
lymphoid differentiation in favour of myeloid differentiation of murine HSCs. 
Lymphoid competent HSCs seem to be more sensitive to incremental DNA 
damage which affects their differentiation potential and ultimately limits their 
repopulation capacity (Wang et  al, 2012). ATM deficiency protected MSCs from 
premature differentiation (Inomata et  al, 2009). Baft and p21WAF1 KD 
independently rescued the repopulation capacity of telomere dysfunctional or 
irradiated HSCs and their over expression impaired HSC function in response to 
both ageing and DNA damage, in murine and human cells (Wang et al, 2012). 
This had previously been reported for p21WAF1 in telomere dysfunctional HSCs 
(Choudhury et al, 2007). These studies point to the existence of a 'stemness 
checkpoint', ATM-dependent in MSCs (Inomata et  al, 2009) and Batf- and 
p21WAF1-dependent in HSCs (Wang et al, 2012), which sensitises stem cells to 
terminal differentiation upon accumulation of DNA damage thus removing 
them from the stem cell pool. Finally, ageing phenotypes of the skin such as 
reduced mitochondrial activity, senescence and reduced thickness of the 
epidermis have also been associated with DNA damage and induction of 
terminal differentiation (Velarde et  al, 2012). Using a mouse model of Sod2 
deficiency, which results in mitochondrial oxidative stress, it has been 
demonstrated that impaired mitochondrial function induces DNA damage and 
senescence but not apoptosis. The reduction in the number of cells and 
thickness of the epidermis has been associated with a decrease in proliferation 
due to senescence combined with an increase in terminal differentiation. It has 
early on been demonstrated in human keratinocytes that senescent cells are 
still capable of undergoing terminal differentiation (Norsgaard et al, 1996). 
 Although these studies (Inomata et  al, 2009; Wang et  al, 2012; Velarde et 
al, 2012) suggest that terminal differentiation is a likely outcome of senescence 
resulting from activation of DNA damage checkpoints, I  have found that the 
low levels of DSBs induced by telomere uncapping in epidermal keratinocytes 
(Minty et al, 2008) or irreparable DSBs caused by senescence-inducing doses of 
IR were not capable of inducing the candidate markers HOPX or S100A7, which 
are associated with terminal differentiation. Therefore, although telomere 
dysfunction in keratinocytes, induced by ectopic expression of TRF2!B!M, seems 
to ultimately commit cells to terminal differentiation this does not seem to be 
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due to DNA damage signals at the telomere but rather due to other properties 
of the dysfunctional telomere itself (Fig. 8.1). In this case keratinocytes will 
exfoliate and thus have a short tenure in the epidermis and it might explain why 
senescent cells expressing indicators of telomere dysfunction TIFs, do not 
accumulate in this compartment with age. This last hypothesis is not supported 
by the lack of supra-basal SA-" Gal staining in the suprabasal layers of aged 
epidermis (Dimri et  al, 1995). However, senescent cell loss by other mechanisms 
such as immune clearance (Fig. 8.1) could contribute to epidermal ageing 
indirectly, as the stem cells are placed under additional replicative stress, which 
in turn will result in further telomere shortening, damage and dysfunction and 
telomere shortening is seen in squamous epithelia with age (Lindsey et al, 1991; 
Nakamura et  al, 2002; Sugimoto et  al, 2006). This correlation was first 
demonstrated in hepatocytes subjected to chronic damage where constant 
attempts at regeneration and consequent high cell-turnover resulted in 
accelerated telomere shortening and senescence (Wiemann et al, 2002). At 
the cirrhosis stage hepatocytes show significantly reduced proliferation ability 
and mesenchymal cells take over forming the characteristic fibrotic scar tissue. 
 However, telomeres do not need to be strikingly shortened to contribute 
to ageing. Telomerase targeted to the epidermis reduces TIFs and extends both 
lifespan and healthspan of mice (Tomás-Loba et al, 2008) and telomerase-
activating drugs can do the same (Bernardes de Jesus et al, 2011; 2012). The 
TERT protein is known to possess non-canonical functions (Parkinson et al, 2008), 
however, Tomás-Loba et  al (Tomás-Loba et al, 2008) presented evidence that 
even long telomeres possessed DSBs that were removed by telomerase in line 
with the recent reported ability of telomerase to resolve otherwise unrepairable 
DSBs at the telomeres (Suram et  al, 2012). This is thus thought to occur through 
canonical telomerase functions. Although telomeres do shorten in mice with 
age (Sharpless & DePinho, 2007) it is unlikely that they ever get critically short to 
the point of exposing the DNA double strand, nevertheless they do show an 
increase in TIFs, which is reduced by the expression of telomerase (Tomás-Loba 
et al, 2008). This may be connected with the recent report that telomerase can 
resolve unrepaired DSBs at the telomere (Suram et  al, 2012) and so telomeres 
may not need to be short to direct ageing-related phenotypes. In humans 
epidermal TIFs do not increase with age (U. Herbig, personal communication) 
and the reason for this discrepancy is not clear. The heterogeneous nature of 
the human population coupled with an inadequate population size may offer 
one explanation but also the failure of epidermal keratinocytes to demonstrate 
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DSBs when telomeres are uncapped (Minty et  al, 2008) and the possible short 
tenure of senescent basal keratinocytes in humans (Dimri et  al, 1995) may also 
be relevant. 
  
S100A7 as a marker for TDIS 
 In order to determine the actual contribution of TDIS to epidermal 
ageing and to effectively distinguish it from p16INK4a-induced senescence it will 
become necessary to find reliable indicators of telomere functional status in the 
epidermis. S100A7 is a promising marker since it seems to be keratinocyte-
specific, mechanism-specific and because it is also a secreted protein. S100A7, 
also known as psoriasin, was first identified as a protein abundantly expressed in 
keratinocytes originating from psoriatic skin (Madsen et al, 1991). Besides skin 
inflammation, its up-regulation has since been reported at the early stages of 
various carcinomas such as SCC of the bladder (Celis et al, 1996), SCC, BCC 
and precancerous lesions of the skin (Moubayed et  al, 2007). It is recently 
emerging as a good non-invasive marker of squamous cell and large cell lung 
cancer (Zhang et al, 2008) since its expression in the lung seems independent 
from differentiation and inflammation and seems to decrease during 
progression to invasive carcinoma. As SCCs harbour cells with short and 
dysfunctional telomeres (Gordon et al, 2003) and this may be an early event 
because the breakdown of senescence occurs only in late dysplasia 
(McGregor et al, 2002; Natarajan et al, 2003) it is possible that this is another 
situation where S100A7 elevation is linked to keratinocyte TDIS. The work I have 
presented in this thesis supports our earlier findings (Minty et al, 2008) which 
suggest that S100A7 is TDIS-specific and elevated in the early stages of 
senescence (chapters 4 and 6). In addition, the fact that it is secreted in blood, 
urine and saliva and that although it is elevated in psoriatic skin (Madsen et al, 
1991) it is not in sera of patients with psoriasis (Anderson et  al, 2009) makes it a 
promising biomarker. I have also established that the main senescence 
effectors do not induce S100A7 and, indirectly, that NF-K"  is not likely to be 
required. However, since NF-K"  acts downstream of DSBs, the next aim will be to 
test other upstream activators of p16INK4a and p53 other than DSBs and to 
investigate S100A7 expression in the context of neoplasia and ageing. 
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General perspectives for the causal role of senescence in ageing
 There is now considerable evidence that senescence can cause tissue 
(Baker et  al, 2011) and organismal ageing (Tomás-Loba et al, 2008) and also 
that senescence may limit stem cell function (Janzen et  al, 2006; Krishnamurthy 
et al, 2006; Sharpless & DePinho, 2007). However, and as discussed in detail 
above, as stem cells numbers do not diminish with age it is still very unclear how 
ageing stem cells contribute to tissue dysfunction. One hypothesis is that 
defects in stem cells may remain silent until differentiation takes place 
whereupon poor regenerative capacity and wound repair may be attributable 
to transit cell dysfunction. 
 It is well established that expression of senescence markers such as SA-" 
gal and p16INK4a is associated with organismal ageing (Dimri et  al, 1995; Ressler 
et al, 2006). p16INK4a is a hallmark of senescence in human cells and a robust 
biomarker of ageing in human skin (Ressler et  al, 2006). Furthermore, p16INK4a 
expression in the epidermis (but not the dermis) has been shown to actually 
reflect the physiological age of the individual (Waaijer et al, 2012). Thus, the 
relevance of p16INK4a-dependent senescence to organismal ageing is now 
unquestionable. However, the contribution of p16 INK4a-independent 
senescence, namely p53- and telomere-related senescence, to ageing of 
proliferative compartments such as the epidermis is still a controversial matter. 
 Congenital defects in components of the telomerase complex (Vulliamy 
et al, 2001; Garcia et  al, 2007; Kirwan & Dokal, 2009) and chronic diseases in 
humans characterised by rapid telomere shortening (Wiemann et al, 2002), 
support a connection between telomere dysfunction and ageing. In contrast, 
although murine ageing has many similarities with human ageing it originally 
appeared to occur independently of telomere length. Mouse telomeres are on 
average longer than human telomeres (Kipling & Cooke, 1990) due to a 
background level of telomerase expression in murine tissues (Kipling, 1997). The 
telomerase-knockout mouse (Blasco et al, 1997) provided a model system to 
study the effects of telomere dysfunction and these animals demonstrated 
features of premature ageing in several proliferative compartments (Lee et  al, 
1998; Rudolph et  al, 1999; Allsopp et  al, 2003; Choudhury et al, 2007). Although 
p53 deficiency rescued some of the phenotype it did not extend lifespan of 
these animals due to increased tumourigenesis (Chin et al, 1999). However, loss 
of p21WAF1, p53’s transcriptional target, partially extended longevity without 
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tumour development (Choudhury et al, 2007). More interestingly, in a recently 
developed mouse model endowed with a cancer-resistant background 
(Tomás-Loba et al, 2008) TERT over-expression improved fitness of proliferative 
compartments and increased lifespan, undoubtedly demonstrating the 
importance of telomere maintenance in the context of mammalian ageing. 
Finally, since telomeres have been recently characterised as specialised DNA 
structures which are both particularly susceptible to damage (Hewitt et al, 2012; 
Suram et al, 2012) and resistant to repair (Fumagalli et  al, 2012), persistent DNA 
damage capable of inducing senescence seems to mainly emanate from the 
telomeres. This occurs irrespectively of telomere length and is corrected by 
expression of telomerase. All this evidence highlights the importance of TDIS in 
the context of ageing and raises new questions on how telomere dysfunction 
contributes to human ageing.
 In addition, telomere dysfunction is not necessarily associated with TIFs or 
a DDR (Muntoni et  al, 2003; Minty et al, 2008) suggesting that signals other than 
the DDR originate from the telomere but whether these are required for 
senescence and ageing is yet to be established. Nevertheless, the markers of 
keratinocyte telomere dysfunction that I have characterised in this thesis, 
especially S100A7, may have the potential to identify cells with telomere 
dysfunction in human tissues and body fluids. 
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Future plans
 The underlying hypothesis of my thesis is that tissue- and mechanism-
specific markers of telomere dysfunction exist and that S100A7 appears to be 
such a marker. I have established that S100A7 expression does not seem to be 
induced by the main effectors of senescence, p14, p16 and p53. Indirectly, 
these findings indicate that S100A7 should also not be regulated by NF-K". 
However, since NF-K" acts downstream of DSBs, I would in future like to test 
whether other upstream activators of p16INK4a and p53 other than DSBs, such as 
TGF-", ROS and HDACs, could regulate S100A7 expression. Furthermore, since 
previous work in the D17 dysplasia suggested that S100A7 is regulated by TERT 
(Minty et  al, 2008) I would also like to show that S100A7 protein is up-regulated 
in D17 with senescence and is down-regulated by expression of telomerase in 
these cells. Finally, I would like to extend this work to clinical samples (tissue/
serum/saliva) in order to further investigate S100A7 expression in the context of 
neoplasia and ageing. I would expect S100A7 to be expressed in pre-
malignancy and ageing associated with telomere dysfunction, and to be 
down-regulated in neoplasia. 
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DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN CONNECTION WITH
THE DOWNLOADING, PROVISIONING, VIEWING OR USE OF THE MATERIALS
REGARDLESS OF THE FORM OF ACTION, WHETHER FOR BREACH OF
CONTRACT, BREACH OF WARRANTY, TORT, NEGLIGENCE, INFRINGEMENT OR
OTHERWISE (INCLUDING, WITHOUT LIMITATION, DAMAGES BASED ON LOSS
OF PROFITS, DATA, FILES, USE, BUSINESS OPPORTUNITY OR CLAIMS OF
THIRD PARTIES), AND WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF
THE POSSIBILITY OF SUCH DAMAGES. THIS LIMITATION SHALL APPLY
NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED
REMEDY PROVIDED HEREIN.
9. Should any provision of this Agreement be held by a court of competent jurisdiction to be
illegal, invalid, or unenforceable, that provision shall be deemed amended to achieve as
nearly as possible the same economic effect as the original provision, and the legality,
validity and enforceability of the remaining provisions of this Agreement shall not be
affected or impaired thereby.
10. The failure of either party to enforce any term or condition of this Agreement shall not
constitute a waiver of either party's right to enforce each and every term and condition of
this Agreement. No breach under this agreement shall be deemed waived or excused by
either party unless such waiver or consent is in writing signed by the party granting such
waiver or consent. The waiver by or consent of a party to a breach of any provision of this
Agreement shall not operate or be construed as a waiver of or consent to any other or
subsequent breach by such other party.
11. This Agreement may not be assigned (including by operation of law or otherwise) by
you without WILEY's prior written consent.
12. Any fee required for this permission shall be non-refundable after thirty (30) days from
receipt
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13. These terms and conditions together with CCC's Billing and Payment terms and
conditions (which are incorporated herein) form the entire agreement between you and
WILEY concerning this licensing transaction and (in the absence of fraud) supersedes all
prior agreements and representations of the parties, oral or written. This Agreement may not
be amended except in writing signed by both parties. This Agreement shall be binding upon
and inure to the benefit of the parties' successors, legal representatives, and authorized
assigns.
14. In the event of any conflict between your obligations established by these terms and
conditions and those established by CCC's Billing and Payment terms and conditions, these
terms and conditions shall prevail.
15. WILEY expressly reserves all rights not specifically granted in the combination of (i) the
license details provided by you and accepted in the course of this licensing transaction, (ii)
these terms and conditions and (iii) CCC's Billing and Payment terms and conditions.
16. This Agreement will be void if the Type of Use, Format, Circulation, or Requestor Type
was misrepresented during the licensing process.
17. This Agreement shall be governed by and construed in accordance with the laws of the
State of New York, USA, without regards to such state's conflict of law rules. Any legal
action, suit or proceeding arising out of or relating to these Terms and Conditions or the
breach thereof shall be instituted in a court of competent jurisdiction in New York County in
the State of New York in the United States of America and each party hereby consents and
submits to the personal jurisdiction of such court, waives any objection to venue in such
court and consents to service of process by registered or certified mail, return receipt
requested, at the last known address of such party.
Wiley Open Access Terms and Conditions
Wiley publishes Open Access articles in both its Wiley Open Access Journals program
[http://www.wileyopenaccess.com/view/index.html] and as Online Open articles in its
subscription journals. The majority of Wiley Open Access Journals have adopted the
Creative Commons Attribution License (CC BY) which permits the unrestricted use,
distribution, reproduction, adaptation and commercial exploitation of the article in any
medium. No permission is required to use the article in this way provided that the article is
properly cited and other license terms are observed. A small number of Wiley Open Access
journals have retained the Creative Commons Attribution Non Commercial License (CC
BY-NC), which permits use, distribution and reproduction in any medium, provided the
original work is properly cited and is not used for commercial purposes.
Online Open articles - Authors selecting Online Open are, unless particular exceptions
apply, offered a choice of Creative Commons licenses. They may therefore select from the
CC BY, the CC BY-NC and the Attribution-NoDerivatives (CC BY-NC-ND). The CC BY-
NC-ND is more restrictive than the CC BY-NC as it does not permit adaptations or
modifications without rights holder consent.
Wiley Open Access articles are protected by copyright and are posted to repositories and
websites in accordance with the terms of the applicable Creative Commons license
referenced on the article. At the time of deposit, Wiley Open Access articles include all
changes made during peer review, copyediting, and publishing. Repositories and websites
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that host the article are responsible for incorporating any publisher-supplied amendments or
retractions issued subsequently.
Wiley Open Access articles are also available without charge on Wiley's publishing
platform, Wiley Online Library or any successor sites.
Conditions applicable to all Wiley Open Access articles:
The authors' moral rights must not be compromised. These rights include the right of
"paternity" (also known as "attribution" - the right for the author to be identified as
such) and "integrity" (the right for the author not to have the work altered in such a
way that the author's reputation or integrity may be damaged). 
Where content in the article is identified as belonging to a third party, it is the
obligation of the user to ensure that any reuse complies with the copyright policies of
the owner of that content. 
If article content is copied, downloaded or otherwise reused for research and other
purposes as permitted, a link to the appropriate bibliographic citation (authors, journal,
article title, volume, issue, page numbers, DOI and the link to the definitive published
version on Wiley Online Library) should be maintained. Copyright notices and
disclaimers must not be deleted.
Creative Commons licenses are copyright licenses and do not confer any other
rights, including but not limited to trademark or patent rights.
Any translations, for which a prior translation agreement with Wiley has not been
agreed, must prominently display the statement: "This is an unofficial translation of an
article that appeared in a Wiley publication. The publisher has not endorsed this
translation." 
Conditions applicable to non-commercial licenses (CC BY-NC and CC BY-NC-
ND)
For non-commercial and non-promotional purposes individual non-commercial users
may access, download, copy, display and redistribute to colleagues Wiley Open
Access articles. In addition, articles adopting the CC BY-NC may be adapted,
translated, and text- and data-mined subject to the conditions above.
Use by commercial "for-profit" organizations
Use of non-commercial Wiley Open Access articles for commercial, promotional, or
marketing purposes requires further explicit permission from Wiley and will be
subject to a fee. Commercial purposes include:
Copying or downloading of articles, or linking to such articles for further
redistribution, sale or licensing; 
Copying, downloading or posting by a site or service that incorporates
advertising with such content; 
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The inclusion or incorporation of article content in other works or services
(other than normal quotations with an appropriate citation) that is then available
for sale or licensing, for a fee (for example, a compilation produced for
marketing purposes, inclusion in a sales pack) 
Use of article content (other than normal quotations with appropriate citation)
by for-profit organizations for promotional purposes 
Linking to article content in e-mails redistributed for promotional, marketing or
educational purposes; 
Use for the purposes of monetary reward by means of sale, resale, license, loan,
transfer or other form of commercial exploitation such as marketing products 
Print reprints of Wiley Open Access articles can be purchased from:
corporatesales@wiley.com 
The modification or adaptation for any purpose of an article referencing the CC
BY-NC-ND License requires consent which can be requested from
RightsLink@wiley.com .
Other Terms and Conditions: 
BY CLICKING ON THE "I AGREE..." BOX, YOU ACKNOWLEDGE THAT
YOU HAVE READ AND FULLY UNDERSTAND EACH OF THE
SECTIONS OF AND PROVISIONS SET FORTH IN THIS AGREEMENT
AND THAT YOU ARE IN AGREEMENT WITH AND ARE WILLING TO
ACCEPT ALL OF YOUR OBLIGATIONS AS SET FORTH IN THIS
AGREEMENT.
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If you would like to pay for this license now, please remit this license along
with your payment made payable to "COPYRIGHT CLEARANCE CENTER"
otherwise you will be invoiced within 48 hours of the license date.
Payment should be in the form of a check or money order referencing your
account number and this invoice number RLNK501037559.
Once you receive your invoice for this order, you may pay your invoice by
credit card. Please follow instructions provided at that time.
Make Payment To:
Copyright Clearance Center
Dept 001
P.O. Box 843006
Boston, MA 02284-3006
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For suggestions or comments regarding this order, contact RightsLink
Customer Support: customercare@copyright.com or +1-877-622-5543 (toll
free in the US) or +1-978-646-2777.
Gratis licenses (referencing $0 in the Total field) are free. Please retain
this printable license for your reference. No payment is required.
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